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INTRODUCTION. 
Since the recognition of the disease one 
hundred years ago, the treatment of leukaemia has 
passed through two main phases. During the first 
fifty years treatment was by chemical agents. A 
,large variety underwent clinical trial and some 
were found to temporarily influence the leukaemic 
process. Unfortunately many were highly toxic, 
and probably on account of this and our ignorance 
f their mode of action. they became known as 
cytotoxic agents. The discovery of x -rays in the 
early part of the Present century led to a new 
a_Dproach in treatment, and radiotherapy thereafter 
was generally accepted, by most clinicians, as the 
treatment of choice for the chronic variety of 
leukaemia. During the past decade, however, 
interest has been renewed in chemotherapy, and it 
seems likely that we are now on the threshold of a 
second era of chemotherapy. Since the Second World 
sudar a considerable amount of research in this 
subject has been carried out in the United Kingdom 
and the United States of America and to a lesser 
;extent in other parts of the world. As a result 
1 
number of chemical agents have been discovered 
which materially influence not only patients with 
chronic leukaemia but also those with the more 
rapidly fatal acute disease. Their introduction 
has come about in one of three ways: (a) the 
2. 
observation that a compound being investigated for 
other reasons has a depressant effect on 
haemopoietic tissues - for example nitrogen mustard 
and urethane; (b) the synthesis of compounds 
related chemically to substances already known to 
be effective, such as in the case of triethylene 
melamine, triethylene phosphoramide, and 1:4- 
dimethanesulphonyloxybutane (Myeleran); and (c) 
the synthesis of analogues of nucleic acid 
precursors. Much attention is now being focussed 
on the last group of compounds. It is an entirely 
new field of research in chemotherapy and is 
considered by many investigators to be a more 
rational approach to the problem. Not only have 
some, e.g. the folic acid analogues and the purine 
analogue 6- mercaptopurine, resulted in dramatic 
'remissions in patients with acute leukaemia, but 
with the aid of modern scientific techniques 
information has been obtained relating to their mode 
of action In addition their importance as a 
stimulus to research into biochemical processes 
connected with nucleic acid metabolism in the 
normal, leukaemic and neoplastic cell as a whole, 
probably outweighs their present therapeutic value. 
This thesis contains a study of the advances 
in chemotherapy which have taken place during the 
past ten years. For descriptive purposes it has 
been divided into four main sections. In the first 
3. 
the history of chemotherapy has been described. 
This is followed by a section devoted to a 
comprehensive review of modern chemotherapeutic 
agents available for the treatment of both acute 
and chronic leukaemia. Allied neoplastic disorders 
shown to be responsive to these compounds have also 
been included in the text. A third section 
describes metabolic studies in normal and 
leukaemic patients and animals. The metabolism of 
the folic acid analogue, amethopterin, with 
particular reference to the problem of drug 
resistance is principally dealt with. Studies in 
the metabolism of folic acid and the citrovorum 
factor are also included. The final section deals 
with the clinical evaluation, in fifty patients, 
of a new compound, 6- mercaptopurine. 
This thesis would not have been possible 
without the stimulus and advice of others. I am 
greatly indebted to the British Empire Cancer 
Campaign and the American Cancer Society for 
providing me with a research fellowship to study 
the problem d' chemotherapy at the Sloan- Kettering 
Institute, Memorial Centre, New York City, United 
States of America. During the tenure of this 
scholarship studies were carried out under the 
guidance of Dr. C. P. Rhoads and Dr. J. H. 
Burchenal. To them I am most grateful. I should 
also like to thank Dr. Burchenal for permission to 
include Figs. 1, 2, 3, 4, 5, and 6, Dr. Doris 
4. 
Hutchison for her help in instructing me in the 
techniques of microbiological assay and Dr. 
Georgia Waring for her technical assistance. 
Acknowledgements are also due to the 
consultant physicians of the Leeds and District 
Hospitals for their kindness in allowing me to 
study patients under their care, and also to 
Professor D. H. Collins, lately Reader in Clinical 
Pathology, University of Leeds, and Dr. W. Goldie 
and the staff of their laboratories at the General 
Infirmary and St. James' Hospital, Leeds, for 
carrying out routine blood examinations. 
Many of the materials used in the experimental 
studies were kindly provided by the Lederle 
Laboratories Division of the American Cyanamid Co. 
6- Mercaptopurine was initially supplied through 
the kindness of Dr. D. S. Searle, Medical Director, 
Burroughs Wellcome and Co. Inc., Tuckahoe, New York, 
U.S.A., and later by Dr. F. Prescott, Clinical 
Research Director, Burroughs Wellcome, London, 
England. 
I am greatly indebted to Professor R. E. 
Tunbridge for his advice and criticism throughout 
the period of this study; and finally I should 
like to express my sincere appreciation to the 
patients for their willing co- operation. Without 





One hundred and ten years have lapsed since 
Craigie (1845) published his report in the 
Edinburgh Medical and Surgical Journal describing 
a patient in which "large numbers of pus and -lymph 
cells" were observed in the blood after death. 
This description together with those of Bennett 
(1845) and Virchow (1846) are the first accurate 
accounts of the disease which Virchow named 
"Weisses Blut (Leukamie)" and which we have since 
called leukaemia. 
The malignant nature of the disease has led 
to numerous forms of therapy, none of which to the 
present day have resulted in more than temporary 
improvement in the clinical and haematological 
state. Arsenic has the reputation of being the 
oldest form of effective treatment for leukaemia 
and its use was first described by Lissauer in 1865. 
Following the administration of Fowler's solution 
(Solution of Potassium Arsenite) to a patient 
suffering from leukaemia he observed marked 
symptomatic improvement, although in the absence o 
a method for ennumerating blood cells detailed 
information relating to changes in the blood was 
not recorded. Billrath (1871) , Winiwarter (1877) 
and Morrill (1877) also commented on the efficacy 
of arsenic as a therapeutic agent in leukaemia, 
but it remained for Cutler and Bradford (1878) to 
accurately describe the effect of the drug on the 
7. 
blood cells. They showed that Fowler's .solution 
in gradually increasing doses caused a progressive 
decrease in both white and red cells. By 
substituting iron for arsenic the red cells 
increased, but a rise in the white cells occurred 
also and had, a month later, returned almost to 
their original level. Numerous publications now 
followed, (Sticker 1866; Thatcher 1889; Drew 
1892; Osler 1892 Anderson 1893; Taylor 1894; 
Campbell 1:394; White 1895; Bramwell 1899; 
i:cCrae (100) all agreeing that improvement 
followed the use of Fowler's solution or other 
preparations of arsenic in cases of chronic 
leukaemia. The reign of arsenic as first choice 
in treatment of leukaemia ended following the 
discovery by Pusey (1902) and Senn (1903) of the 
beneficial effects of X -rays, and during the next 
thirty years radiotherapy became established as the 
treatment of choice in chronic leukaemia. Forkner 
and Scott (1931) and Forkner (1932) restudied the 
effect of arsenic and demonstrated the effectiveness 
of Fowler's solution in chronic myeloid leukaemia 
in particular and to a lesser extent in chronic 
lymphatic leukaemia. Patients with acute leukaemia 
were not benefitted although in some instances the 
total white cell counts were diminished. The 
interest aroused by Forkner's observations was, 
however, only temporary, and, apart from a few 
8. 
physicians of the old school, the use of arsenic as 
a chemotherapeutic s.perit is now rarely considered. 
Arsenic is given orally in the form of 
Fowler's solution, 5 minims three times daily, 
increasing one minim per day until a maximum dose 
of 20 minims three times per day has been reached, 
or toxic symptoms have intervened. Thereafter the 
dose is gradually diminished until a maintenance 
dose of five to eight minims three times daily is 
reached. 
Although arsenic is generally considered to be 
the oldest form of treatment in leukaemia it must 
be remembered that quinine was reported by Hewson 
in 1852 as resulting in a return of an enlarged 
liver and spleen to normal size in the first case 
of leukaemia described in America. Wood (1852) 
observed a similar effect in his case. The 
diagnosis in these early cases was, however, 
uncertain. Blood studies were insufficient and the 
Possibility that the clinical picture may have been 
confused with malaria cannot be excluded. However, 
later workers such as Bramwell (1699) described 
dramatic improvement following the administration 
of quinine, with disappearance of the enlarged 
spleen and a return of the leucocytes to normal 
levels within a few weeks. Muir (1909) also 
considered quinine of value but, generally, 
inferior to arsenic. Probably because of the adven t 
9. 
x -rays, further studies of the effects of 
quinine in leukaemia have not been recorded. 
It is generally recognised that iron has no 
specific effect in leukaemia but may be of value 
sometimes in assisting haemoglobin synthesis when 
iron deficiency anaemia develops. Roberts and 
Leonard (1869), however, reported 'a cure' 
following treatment with iron, but like all the 
reported 'cures' of leukaemia the lack of 
sufficient data makes it difficult to accept their 
diagnosis. 
In 1875 Fox noted marked improvement following 
treatment of chronic leukaemia with phosphorus. In 
his account published in the Lancet and entitled 
"On the cure of leukaemia splenica by means of 
phosphorus" he reported that the white blood cells 
returned to normal, the spleen diminished in size 
and the anaemia disappeared. Broadbent (1875) and 
Gowers (1877) also described improvement following 
the administration of phosphorus in a patient with 
lymphatic leukaemia. Jenner (1876) and Moxon (187 
did not, however, observe the same beneficial 
effects. Little was heard of phosphorus as a 
chemotherapeutic agent in leukaemia thereafter and 
although the original observations of Fox, 
Broadbent and Gowers have never been substantiated 
by conte :mporary workers, the knowledge that arseni 
and phosphorus have similar chemical properties 
) 
10. 
suggest it may, like arsenic, be able to temporaril; 
bring about improvement in patients with chronic 
leukaemia. Another element closely related 
chemically to arsenic and phosphorus is antimony. 
Macfie (1920) describing a patient with both 
chronic myeloid leukaemia and malaria observed a 
marked, but temporary fall in the leucocyte count 
following the intravenous administration of tartar 
emetic. Lucia and Brown (1934a) and Lucia (1935) 
studied the effects of an antimonial compound in 
animals and human leukaemia respectively. A fall 
in the leucocyte count was observed in both, and in 
two patients with chronic myeloid leukaemia the 
splenomegaly diminished. 
Iodine was administered to patients with 
leukaemia as early as l877 by Morrill, and a year 
later by Cutler and Bradford without any beneficial 
effect being noted. Many years passed without any 
further observations being made. Then, as a 
result probably of the a,sociation of lymphoid 
hyperplasia with hyperthyroidism and the knowledge 
that the basal sedimentation rate was raised in 
leukaemia, interest was temporarily renewed. 
Friedgood (1932) reported the results of treatment 
of ten patients suffering from chronic lymphatic 
leukaemia, with Lugol's iodine solution. He was 
of the opinion that definite symptomatic, objectiv 
and haematological improvement occurred. Damashek 
11. 
et al. (1934) and Witts (1935) were unable to 
support these findings, but Israels (1935) noticed 
a reduction in the leucocyte count in two out of 
five patients with chronic lymphatic leukaemia. 
Damashek et al. (1934) performed a thyroidectomy 
in one of their patients after failure to respond 
to iodine with marked improvement in the clinical 
and blood picture. Witts (1935) was, however, 
unable to detect any improvement in a patient 
similarly treated and concluded that thyroidectomy 
did not seem justified as a form of treatment for 
leukaemia. 
The only other reported chemical agent to be 
used in the nineteenth century was ergot, which 
both Da Costa (1875) and Walker (1896) considered 
to be beneficial and able to produce a diminution 
in size of the spleen. With the turn of the Century 
came the introduction of X -ray treatment and a 
general trend away from chemotherapy. Isolated 
reports appeared, however, concerning this form of 
treatment. Drysdale (1909) observed remarkable 
clinical and haematological improvement in a 
patient with chronic myeloid leukaemia following 
treatment with naphthalene tetrachloride. Colloidal 
gold, silver, and sulphur were given intramuscular) 
to two patients with chronic leukaemia by Cawadias 
and adonpherrate (1917) with no obvious improvement 
although the leucocyte count fell. The effect of 
y 
l. 
lead was studied by Hartmann (1931) and Krebs and 
Clemmesen (1934) in man and animals, but the 
results were unfavourable. Piney and Riach (1932) 
in a paper on the treatment of chronic myeloid 
leukaemia quoted Richter and Spiro (1910) as having 
observed a favourable haematological response to 
treatment with cinnamic acid. Only one new 
substance appeared to provoke much clinical 
interest in the period 1900 -1939 and that was 
benzol, and it was largely from Germany and other 
continental countries that reports appeared of its 
use in chronic leukaemia. Following the 
observations of Selling (1910, 1911 and 1916) who 
described the toxic effects of benzol on the 
haemopoietic tissues, Korányi (1912) reported the 
first results of its use in the treatment of 
leukaemia. Chronic myeloid leukaemia appeared 
more responsive to treatment than chronic lymphatic 
leukaemia and a delay of approximately two weeks 
was observed before the drug became effective. 
Toxic manifestations were, however, common, 
especially gastro- intestinal upsets. Királyfi (191 
treated six cases of leukaemia and one with 
polycythaemia with definite benefit. Klein (1913) 
and Piney and Riach (1932) also found benzol an 
effective choice of treatment, while Kalapos (1935) 
in the most recent review of the subject concluded 
that from a study of over two hundred leukaemic 
13. 
patients treated with a variety of agents over a 
t:enty year period, benzol was quite as effective 
as radiotherapy. The same author believed that the 
dangers of benzol poisoning had been greatly 
overestimated because of the results of animal 
experiments where excessive doses were given. 
Injudicious treatment with benzol, he pointed out, was 
dangerous as it might lead to aplastic anaemia and 
damage to the liver and kidneys, but on the other 
hand, as he so correctly stated, X -rays might also 
lead to serious complications if not properly 
handled. Forkner (1938) was unable to find any 
evidence to incriminate benzol as a dangerous drug 
and although he considered Fowler's solution, at 
that time, probably the most reliable form of 
treatment, he felt that benzol was a useful 
chemotherapeutic agent. 
Benzol is usually administered in doses of 
4 ces. daily, b7,- mouth, in olive oil. 
Apart from occasional publications such as 
those of Forkner and Scott (1931), Forkner (1932) 
and Kalapos (1935) which attempted to recreate 
interest in the values of arsenic and benzol, 
chemotherapy of leukaemia was not seriously 
considered again until after the Second World War. 
Renewed interest in this subject then occurred. 
The reason for this is not too certain. One must 
assume that it was related to the War at least in 
14. 
some measure. Undoubtedly one group of drugs, the 
nitrogen mustards, appeared as a result of the 
interest surrounding mustard gas and its 
derivatives, as a direct consenuence of war. 
Although Krumbhaar and Krumbhaar (1919) first 
described the effect of mustard gas derivatives on 
the blood and bone marrow it was not until the 
clinical trials carried out in the United Kingdom 
initially by Wilkinson and Fletcher (1947) and in 
the United States of America by Rhoads (1946) and 
Goodman et al. (1946), using methyl -bis (B- chloreth 
amine hydrochloride and tris (B- chlorethyl) amine 
hydrochloride, that these derivatives were found to 
.be effective, when given intravenously, in chronic 
leukaemia and in certain related diseases, 
particularly Hodgkin's disease. In an attempt to 
find a nitrogen mustard with a more selective effec 
on tumour tissue and less toxic and more convenient 
to administer, many new compounds were synthesised 
and tested initially against various animal tumours 
including leukaemia (Burchenal et al. 1948) and 
later, those considered suitable, against human 
leukaemia. The result was the introduction by 
H:' ddow, Ktn and Ross (1948) of a nitrogen mustard 
derivative (B naphthyldi -2- chloroethylamine; R 48), 
which possessed nitrogen -mustard -like activity and 
was effective when given by mouth in inhibiting the 




and later other investigators, revealed that it 
Produced temporary relief in chronic leukaemia and 
Hodgkin's disease. In the United States Karnofsky 
et al. (1951) reported on the effectiveness of 
triethylene melamine (T M) as an oral nitrogen 
mustard. Other similar preparations have since 
been tested and in 1953 Haddow and Timis describe 
1:4 Dimethanesulphonyloxybutane, or Myeleran, 
which Dalton (1953, 1955) found to be effective 
in chronic myeloid leukaemia. A compound allied 
to TEM, triethylene thiophosphoramide (thio -TEPA) 
has also recently been described by Shay et al. 
(1953) and Zarafonetis et al. (1955) and found to 
be useful in the treatment of the dhronic 
leukaemias. 
About the time the clinical effectiveness of 
nitrogen mustard was being described, Haddow and 
Sexton reported in 1946 on the inhibiting effect of 
ethylcarbamate, ethyl phenylcarbamate, and isopropyl 
phenylcarbamate on tumours in ;mice. Subsecjuently 
Paterson and her colleagues (1946) reported the 
beneficial effect of ethyl carbamate (Urethane) in 
patients with chronic leukaemia. Since. then many 
similar reports have appeared. 
Colchicine derivatives have recently been the 
centre of much interest although it was as long ago 
as 1908 that Dixon and Malden described the 
influence of colchicine on leucocytes and the bone 
10. 
marrow. Dustin (1934) showed colchicine to be 
an effective inhibitor of mitosis but it was not 
until 1953 that Santavy and Reichstein isolated a 
new alkaloid, deacetyl methylcolcilicine (Colcemid; 
domecolci!e), of low toxicity but effective in 
chronic leukaemia (Moeschlin et al. 1953; 
Wilkinson 1955). 
The chemotherapeutic agents described above 
have been generally found effective only in chroni. 
leukaemia. However, during recent years iriroortant 
advances have been made in the chemotherapy of 
acute leukaemia. In 1948 Farber published the 
remarkable observation that two folic acid 
conjugates, pteroyldiglutamic acid and 
pteroyltriglutamic acid, when given to children 
with acute leukaemia produced a rapid progression 
of the disease. Heinle and Welch (1948) suti orted 
this finding. This was the impetus to considerable 
research and one cannot help but feel that the 
introductioh of the folic acid antagonist, 
4- aminopteroylglutamic acid (aminopterin), and 
later 4- amino -N 10- methyl pteroylglutamic acid 
(amethopterin), together with Farber et als 
(1945) account of the beneficial effects of 
aminopterin in acute leukaemia, was probably the 
stimulus for the immense intere in the subject 
of leukaemia chemotherapy which followed. Numerous 
analogues of nucleic acid precursors have been 
17. 
synthesised and tested for anti- tumour activity at 
such centres as the Sloan -Kettering Institute, 
New York, U.S.A., where a large tumour screening 
programme has been in progress since 1942. 
2, 6- diarninopurine (Burchenal et al. 1951), 
2, 4- diamino -5 (3' 4'eichlorpheny1) 6- methylpyririidi 
(Murphy et al. 1954) and other compounds such as 
the dihydrotriazines (Modest et al. 1952; Farber 
et al. 1953) have all been shown to have anti - 
leukaemic properties, and able to produce occasion 
temporary remissions in acute leukaemia. One 
compound, 6- mercaptopurine (Burchenal 1953; 
Fountain 1954, 1954a, 1955) has been found to be 
effective in both acute leukaemia and chronic 
myeloid leukaemia. This form of chemotherapeutic 
research would a pear to have a more rational 
basis, and may lead to an increase in our 
kno- ledge of the metabolism of mucleic acid and to 
the understanding of the metabolism of the 
neoplastic cell as a whole. In addition to the 
folic acid antagonists and 6- mercaptopurine, 
adrenocorticotrophic hormone and cortisone were 
described in 1949 by Pearson et al., and later by 
numerous other investigators as being able to brin 
about complete clinical and hematological 
remission in children, and occasionally in adults, 
with acute leukaemia. Unfortunately like all the 
other agents used in the treatment of leukaemia 
ne 
18. 
in the past one hundred and ten years the resonse 
is only temporary and the ultimate prognosis 
remains the same. 
19. 
RTTIFIV OF THE LITERATUR 
A . ACUTE LEUKAEMIA. 
20. 
Whereas certain chemical agents have been 
known for many years which favourably affect the 
course of chronic leukaemia, the treatment of acut 
leukaemia with such agents has come about within 
the past ten years. Although, as yet, of only 
limited therapeutic value the discovery of these 
compounds has stimulated much research in this 
field and has resulted in important advances both 
in therapeutics and in the understanding of the 
metabolism of the malignant cell. 
The introduction of the folic acid 
antagonists is probably one of the most important 
fundamental advances in the treatment of neorlasti 
disease. The use of these antimetabolites as 
chemotherapeutic agents in acute leukaemia 
represents a -biological approach to the treatment 
of what is generally considered to be a neoplastic 
disease, and is based on a .i nGv ledge of the 
metabolism of the leukaemic cell. Before the 
introduction of the folic acid antagonists, the 
natural course of acute leukaemia was one of 
continuous regression and death, usually within 
four or five months. A few patients had 
spontaneous remissions but such occurrences were 
unusual. To -day, with chemotherapeutic agents suc 
as the folic acid antagonists, cortisone and ACTH, 
and more recently 6- mercaptopurine, remissions in 
children are to be expected in more than 50 per ce t 
21. 
of patients treated. 
The ability of these agents to produce 
remissions during which the patient is apparently 
normal, both clinically and haematologically, is 
probably of more fundamental importance, in our 
present state of knowledge, than the fact that the 
average survival time of children with acute 
leukaemia is now longer than in previously 
untreated patients. In addition their importance 
as a stimulus to research into biochemical 
processes connected with nucleic acid metabolism 
in the normal, leukaemic, and neoplastic cell as a 
whole, probably far outweighs their present 
therapeutic value. 
In 1948 (Farber et al. 1948) during the course 
of clinical trials of a variety of incurable 
neoplastic conditions with two folic acid 
conjugates, pteroyl- diglutamic acid and pteroyl- 
t riglutamic acid, gave them to eleven children with 
acute leukaemia. He observed in each case a rapid 
progression of the clinical course of the disease, 
what he termed an "acceleration phenomenon ". A verb 
rapid extension of the disease in the viscera and i 
the bone marrow occurred in comparison with untreat 
patients. Heinle and Welch (1948) also observed 
hat a rapid clinical and haematological relapse 
ccurred in three cases of chronic myeloid leukaemi. 
.iven large doses of folic acid (pteroylglutamic 
d 
22. 
acid; PGA) . 
Such evidence that folic acid and its 
conjugates could induce apparent stimulation of 
abnormal leucocyte production led to the 
hypothesis that folic acid was an essential 
metabolite for leucopoiesis. It was this 
rationale that instituted the trials with the 
analogues of folic acid, commonly termed the folic 
acid antagonists, in patients with leukaemia. 
Numerous analogues of folic acid have been 
prepared of which it is necessary to mention only 
few. The first to show any effect on the leukaemi 
process was pteroylaspartic acid (Anfol A) prepare 
by substitution of aspartic acid for the glutamic 
acid residue of the folic acid molecule. N'0 
methyl- pteroic acid (Metfol B) also had some 
beneficial effect and led to the development of 
more potent antagonists of folic acid. The 
antagonist activity was found to be markedly 
increased by the replacement of the hydroxyl group 
by an amino group in position 4 of the pteridine 
ring, with the formation of 4- aminopteroylglutamic 
acid or as it is generally known, aminopterin 
(Seeger et al. 1947). Another analogue with 
similar activity was prepared by substituting a 
methyl group for a I3 atom in position 10 of the 
aminopterin molecule with the formation of 
4- amino -N10- methyl pteroylglutamie acid (Amethopter in) 
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(Franklin et al. 1949, Seeger et al. 1949, Jukes 
et al. 1950). The presence of a methyl group in 
the latter compound modified the toxicity in chicks 
but the anticipated reduction in toxicity in human 
subjects was not fulfilled. 
Many more analogues of folic acid have been 
synthesised but aminopterin and amethopterin have 
proved to be the most effective for the treatment 
of acute leukaemia. Farber et al. (1948) in their 
initial report stated that of sixteen infants and 
children treated with aminopterin, ten showed 
clinical and haematological evidence of 
improvement. This observation was the stimulus 
which started large scale clinical trials of the 
folic acid antagonists throughout the United States 
of America and to a lesser extent in the United 
Kingdom and other parts of the world. 
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THE BIOLOGICAL ACTIVITY 
OF THE FOLIC ACID ANALOGUES 
For the satisfactory understanding of the 
role of folic acid in neoplastic tissue it is 
necessary to consider the manifestations of folic 
acid deficiency in normal tissues. 
It is we1.1 established that folic acid is an 
essential growth factor for a variety of lacto- 
bacilli (Jukes and Stokstad 1:48), a ciliated 
protazoon Tetrahymina Geleii (Kidder 1946) and for 
the development of the pupae of the mosquito Aedes 
Egypti (Goldberg et al. 1944) and other insects 
( Fraenkel and Blewett 1947, Grob and Brunner 1946). 
In the absence of folic acid growth is prevented 
and hence the value of Streptococcus faecalis R. 
and Lactobacillus casei in mocrobiological assay 
procedures for folic acid. 
Folic acid is also an essential metabolite for 
the growth of myeloid and erythroid tissues and in 
man it is now recognised that a deficiency is 
associated with the development of a megaloblastic 
anaemia. In monkeys, by feeding folic acid 
deficient diets, May and his associates have 
produced classical megaloblastic erythropoiesis 
associated with leucopenia, diarrhoea and lesions 
of the buccal mucosa (May et al. 1951, Sundberg 
et al. 1952). Similar observations described 
previously by Wills and Stewart (1935) as a 
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deficiency of Vitamin M are now generally 
recognised to have been due to folic acid 
deficiency. Folic acid deficient diets given to 
chicks in addition to inadequate growth and poor 
feathering led to anaemia, leucopenia and 
thrombocytopenia (Campbell et al. 1944, Hogan and 
Parrott 1940, Pfiffner et al. 1943). Rats 
receiving "purified" diets supplemented by 
sulphonamide drugs to suppress the biosynthesis of 
folic acid in the intestine, developed anaemia and 
granulocytopenia (Endicott et al. 1945, Spicer 
et al. 1942, Thiersch and Phillips 1949). In these 
few instances it is obvious that the cardinal 
feature of deficiency of folic acid is a derangement 
of haematopoiesis. In all cases when deficiency 
is produced by dietetic means a reversal to normal 
can be produced by administering folic acid or its 
conjugates, pteroyldiglutamic acid, pteroyltriglu- 
tamic acid or pteroylheptaglutamic acid (Endicott 
et al. 1945, Wright and Welch 1943, Daft et al. 
1946, Hutchings et al. 1944, Suarez et al. 1946, 
Frost et al. 1946). 
The use of folic acid analogues results in 
similar manifestations of folic acid deficiency. A 
crude methyl -substituted derivative of folic acid, 
referred to as X- methyl folic acid, was the first 
analogue found to antagonise the Vitamin in mammals. 
Characteristic signs of deficiency can he produced 
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ih mice (Weir et al. 1948), rats (Franklin et al. 
1947), chicks (Franklin et al. 1947a), and pigs 
(Cartwright et al. 1948) by feeding this compound. 
In pigs, a syndrome resembling the spnue syndrome 
resulted with the development of diarrhoea, loss 
in weight, a macrocytic anaemia and leucopenia. 
The manifestations of deficiency produced by this 
product are, similar to the dietary- induced 
deficiency, prevented or reversed by increasing 
the dietary level of folic acid. Aminopterin has 
been shown to produce a similar sprue -like syndrom 
in dogs (Thiersch and Phillips 1949a) with a 
characteristic megaloblastic bone marrow. By 
injecting guinea -pigs with 0.25 mgin. of aminopteri 
daily, Girdwood (1950) produced a moderately 
severe normoblastic anaemia. Evidence of folic 
acid deficiency induced by aminopterin has been 
recorded in other animal species by several 
investigators (Minnich and Moore 1948, Franklin 
et al. 1948, Swendseid et al. 1948, Oleson et al. 
1948). One of the interesting features of the 
aminopterin- or amethopterin -induced deficiency is 
the fact that it is not readily prevented or 
reversed by folic acid, suggesting that these 
compounds are not true, competitive antagonists 
of folic acid. 
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THE MODE OF ACTION OF THE FOLIC ACID ANALOGUES 
It may be said that an antimetabolite function 
by replacing the metabolite in its particular 
enzyme system (Woolley 1952). Thus the folic acid 
analogues combine with folic acid enzyme systems, 
Presumably because of their similar chemical 
structure. However, in view of the structure not 
being identical to that of the metabolite, they 
are unable to proceed through the remainder of the 
cycle of metabolic reactions. The end result is a 
blockage of the enzyme system and hence of the 
utilisation of folic acid. The degree of blockage 
of the enzyme system is dependent on the analogue 
in question and the presence of an amino group in 
Position 4 of the folic acid molecule seems to be 
the most effective in preventing folic acid 
utilisation. 
Various workers including Lampen et al. (1946) 
and Rogers and Shive (1948) have shown that the 
metabolic function of folic acid appears to be 
concerned with the synthesis of thymine and purine 
bases, which in turn enter into the metabolism of 
the nucleic acids, in particular the synthesis of 
desoxyribonucleic acid (Stokes 1944). Deficiency 
of folic acid results in an impaired formation of 
desoxyribonucleic acid (Prusoff et al. 1948) while 
excess of the metabolite enhances its formation 
s 
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(Rege and Screenivasan 1950). Inhibition of 
nucleic acid formation by aminopterin and 
amethopterin would therefore appear to be due to 
blocking' the synthesis of essential purine bases 
(Skipper et al. 1950, 1951, 1951a) . 
The action of folic acid antagonists cannot, 
however, be explained solely on the basis of an 
interference with the metabolism of folic acid. 
Studies by Franklin et al. (1948, 1949) indicate 
that folic acid can prevent the toxicity of 
aminopterin and amethopterin only when the 
analogues are administered near the minimal lethal 
dose. At higher doses of the analogues folic acid 
is ineffective. Since the demonstration of 
citrovorum factor (5 formyl, 5, 6, 7, 8- tetrahydro- 
pteroylglutamic acid.; Leucovorin; Folinic Acid 
S.F.; C.F.), which has a close biological 
relationship to folic acid and is essential for 
the growth of the organism Leuconostoc citrovorum 
8081, several workers have shown the more potent 
effects of this compound in reversing the toxic 
effects of the folic acid analogues. Thus 
Burchenal and Babcock (1951) have demonstrated the 
ability of C.F. to prevent the toxicity of massive 
doses of amethopterin in mice. similarly C.F. has 
been found to be more effective than folic acid in 
preventing the growth inhibition of S. faecalis R. 
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(Broquist et al. 1950) and L. citrovorum 
(Sauberlich 1949) by aminopterin. It appears, 
therefore, that the 4 amino- analogues of folic aciC 
act as competitive antagonists with respect to C.F. 
They also appear to act as non- competitive 
antagonists in relation to folic acid, such a 
mechanism being suggested by the work of Nichol 
and Welch (1950) who showed that aminopterin ad,_Led 
to rat liver slices blocked the conversion of 
folic acid to C.F. 
One of the interesting features of the actions 
of aminopterin and amethopterin is that their 
incorporation in folic acid enzyme systems apears 
to be almost irreversible. By injecting mice with 
amethopterin it can be readily shown with the aid 
of a plate assay technique (Burchenal et al. 1951a) 
that this compound becomes concentrated in tissues 
containing C.F. and folic acid, mainly the liver 
and kidney (Fountain et al. 1952). 
Here it remains at almost the same concentrati.n 
for a considerable .period and is not readily 
replaced by either folic acid or C.F. at high doses 
(Fountain et al. 1953). Similarly human volunteers 
( Burchenal et al. 1951) showed that only 40 -57 per 
cent of a 5 mg. oral dose of amethopterin was 
excreted in twenty -four hours, the majority within 
six hours. Using a modified technique a delay in 
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excretion of amethopterin was observed in twenty 
seven patients with acute leukaemia (see page 179) 
The serum level pattern and rate of excretion did 
not however show any obvious difference to those 
found in a limited series of control subjects. 
Swendseid et al. (1952) have also shown in patients 
with acute leukaemia that, following the adminis- 
tration of aminopterin, considerable although 
variable amounts are retained in the tissues. 
The same investigators have in addition demonstrate 
in human subjects suffering from leuk.aemia treated 
with aminopterin, that following a single oral dose 
of folic acid, larger quantities of the metabolite 
were excreted than would have occurred in patients 
not receiving aminopterin. The deduction is that 
the folic acid analogues are possibly retained in 
human tissues in a manner similar to that 
observed in experimental animals, and that A. the 
utilisation of folic acid is prevented by the 
blockage of the folic acid enzyme systems by the 
analogue, and B. the incorporation of the 
antimetabolite in these systems is almost wholly 
irreversible. 
Other workers (Dougherty and Dougherty 1950, 
Higgins and Woods 1949) have suggested that a 
further action of aminopterin and amethopterin may 
be mediated by the adrenals, although in mice the 
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antileukaemic properties of these compounds do not 
appear to be prevented by adrenalectomy (Law et al. 
1949). Hanlon et al. (1950) found no evidence of 
adrenocortical stimulation in leukaemic subjects 
treated with aminopterin. 
That the folic acid antagonists do not wholly 
exert their influence through interference with 
folic acid enzyme systems in the viscera has been 
shown by experiments in which changes in the bone 
marrow of the rat have been observed in the absence 
of the abdominal viscera including the liver, 
kidneys and adrenal gland (KarnofsKy et al.). 
This suggested a direct action on the haemopoietic 
tissues, and the possibility that the folic acid 
antagonists might in addition be cytotoxic agents. 
The experimental data which conclusively demonstrat: 
their antifolic activity, the ability of C.F. to 
reverse the antileukaemic effect of ameth.onterin in 
leukaemic mice (Burchenal et al. 1950, Burchenal 
et al. 1::49), the prevention of toxicity in human 
subjects with C.F. (Burchenal 1952) and the 
appearance occasionally in patients undergoing 
treatment, of evidence of folic acid deficiency in 
the form of megaloblastic erythropoiesis, indicates, 
however, their main action to be antagonists of 
folic acid. 
Recently Jacobson (1954, 1954a, and 1954b) has 
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shown that one of the principal modes of action of 
folic acid antagonists is to interfere with the 
function of C.F. in the growth of both normal and 
pathological cells. C.F. was demonstrated to play 
an essential part during mitotic division and 
without this factor during treatment with 
aminopterin, bone marrow cells from acute human 
and mouse leukaemia, which had entered mitosis, 
were unable to advance beyond the metaphase stage. 
Similar observations were made on the normal 
intestinal epithelium of the mouse. The same 
author also made the interesting observation that 
aminopterin was inactivated when cultured with 
various tissues including mouse and human leukaemic 
cells, but the mechanism of inactivation was 
obscure. 
In patients with acute leukaemia rapidly 
proliferating leucocytes have been shown to have a 
content of C.F. approximately five times that of 
the normal leucocyte (Swenseid et al. 1951). The 
same investigators (Swenseid et al. 1952a) also 
ESp0rted that leukaemic patients excreted less of a 
test dose of folic acid as folic acid than did 
normal individuals. The latter observation has 
been sup ported by Girdwood (1953) . These findings 
suFgest that the primitive leucocytes concentrate 
C.F. because of their relatively high metabolic 
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requirements and it has been postulated that on 
this basis they would be more susceptible to the 
action of the folic acid antagonists and so 
provide a rational basis for the use of these 
compounds in the treatment of acute leukaemia. 
Similar studies, however, carried out by the 
author in collaboration with Drs. Burchenal, 
Murphy, Ellison and Hutchison failed to reveal any 
difference in the demands for exogenous C.F. 
between the leukaemic and non- leukaemic subject. 
THE CLINICAL APPLICATION 
OF THE FOLIC ACID ANTAGONISTS 
I'7 THE TREATMENT OF ACUTE LEUKAEMIA. 
Initially the 4 -amino derivates of 
pteroylglutamic acid were given intramuscularly, 
but it has now been shown that both aminopterin 
and amethopterin are equally effective by mouth. 
Absorption of amethopterin has been demonstrated 
to be equally rapid by the oral or intramuscular 
route (Burchenal et al. 1951a). If a 5 mgm. dose 
of amethopterin is administered to a normal 
individual on a fasting stomach, appreciable levels 
of the drug can be detected in the serum fifteen to 
thirty minutes later with a rapid disappearance 
from the blood in three to twenty -four hours. Only 
where there is impaired real function, as may occur 
in the later stages of acute leukaemia, are 
detectable amounts of amethopterin found in the 
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serum after twenty -four to forty -eight hours. It 
is when renal excretion is impaired that great care 
must be exercised, as serious toxic manifestations 
are likely to occur. 
The initial dose of amethopterin for a child 
is 2.5 or 5.0 mgm. (half to one tablet) depending 
on the age. The equivalent dosage of aminopterin 
is 0.5 or 1 mgm. (half to one tablb) . In adults 
up to 10 mgr. of amethopterin and 3 mgm. of 
aminopterin may be administered daily. 
Both compounds a_opear to be equally effective 
in producing remissions, the only advantage of 
amethopterin being that the dose is higher and 
therefore more easily regulated. 
Whether or not patients are treated in 
hospital or as out -patients is dependent upon 
their general condition, the presence or absence of 
high fever, severe haemorrhage or infection, etc. 
In the author's experience at the Memorial Centre, 
New York City, all patients whose immediate 
prognosis was good were treated as out- patients. 
They were seen twice weekly when full clinical and 
haematological examinations were carried out, 
excepting bone marrow examination, which was usually 
performed at fortnightly intervals. During periods 
of remission patients were seen at less freciuent 
-intervals. Patients requiring blood were 
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transfused in the out- patient clinic and in the 
absence of haemorrhage were usually allowed to 
return home. Fever necessitated the use of 
antibiotics (penicillin, aureomycin, terramycin, 
etc.), which were prescribed for out -patients by 
the family doctor. 
The usual plan of therapy in children is to 
prescribe 2.5 mgm. of amethopterin daily (or an 
equivalent dose of aminopterin) at the outset. Thi 
is continued until a remission occurs as evidenced 
by a return of the bone marrow to normal function. 
Regulation of the dosage is dependent on the state 
of the patient's bone marrow, the peripheral white 
count and whether or not toxic manifestations occur 
A failure to respond, as shown by a deterioration 
in the patient's general condition, a stationary or 
rising leucocyte count, a failure of the number of 
leukaemic cells in the bone marrow to fall, and an 
enlarging spleen or increasing lymphadenopathy, is 
an indication to increase the dose of amethopterin. 
A low platelet count when secondary to the disease, 
with or without associated haemorrhage, is not a 
contra -indication to treatment, for it is only by 
suppressing the leukaemic process that haemorrhage 
can be controlled for any length of time. 
The appearance of a remission as evidenced by 
a return of the patient to apparently normal health 
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with a normal or greatly improved haematological 
status, may occur at varying intervals after the 
onset of therapy. It may be necessary to continue 
treatment for only two or three weeks, while in 
other instances evidence of a remission may not 
occur for as long as three months. 
When a remission results therapy is sometimes 
withheld until signs of relapse occur. Such 
intermittent therapy has been advocated in the 
hope that premature drug resistance might be 
prevented. Farber (1951), however, maintains that 
treatment should be continued during a remission 
in an attempt to delay a relapse.. It is doubtful 
whether either regime holds any significant 
advantage over the other. 
Contra -indications to increasing the dosage o 
the antagonist are the presence of renal dysfuncti 
and the onset of signs of toxicity. As there is 
marked individual variation in the tolerance to 
these compounds it is essential that signs of 
developing toxicity should be watched for in all 
patients. With the onset of toxic symptoms 
treatment is suspended temporarily until they 
subside, after which treatment is restarted, usual: 
at a lower dosage. In many instances the folic 
acid antagonists must be given until toxic 
manifestations develop, as not infrequently the 
onset of toxicity precedes a remission. 
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FIG. 1. Prolonged improvement, in a child with 
acute leukaemia following, treatment 
with folic acid antagonists. 
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TOXIC 1IANIFESTATIONS 
The earliest sign of toxicity of amethopterin 
nd aminopterin may occur at any time from two days 
o months after the commencement of therapy and is 
sually in the form of ulceration of the buccal 
ucosa. These ulcers take the form of a white or 
yellow necrotic area, in the early stare the size o 
a ;yin head, surrounded by a painful reddened mucosa. 
o the experienced observer there should be no 
difficulty in differentiating these lesions from 
those due to the leukaemic process. Temporary 
cessation of therapy usually results in rapid 
healinE, but continuation of treatment may lead to 
ulceration further down the gastro -intestinal tract 
with vomiting, diarrhoea and bleeding per rectum. 
Aplasia of the bone marrow may occur with 
pancytopenia and resulting haemorrhage, severe 
anaemia, infection and high fever. 
Alopecia is a later sign and may not be 
recognised in the early stages. Skin rashes may 
develop, but these are usually evidence of 
sensitivity to the drug- and not infreouently respon 
to treatment with antihista:_ine drugs. 
Megaloblastic erythropoiesis indicative of 
folic acid deficiency is not uncommonly found, and 
although not necessarily associated with toxic 
manifestations elsewhere is an indication to 
discontinue or reduce-the dosage of the antagonist. 
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:y withholding treatment at the onset of toxicity, 
ogether with the institution, if necessary, of 
.food transfusions and antibiotics, recovery is the 
°ule in the majority of patients. 
There seems to be no advantage in giving folic 
ecid or C.F. once the toxic manifestations have 
_eveloped. Experiments in animals have shown that 
.F. will prevent the toxicity of amethopterin if 
given immediately prior to the antimetabolite 
(Burchenal and Babcock, 1951) . No significant 
rotection is afforded when a similar dosage of 
C.F. is given four or more hours after the 
administration of amethopterin. That C.F. is 
capable of preventing toxicity in human subjects 
iia.s been shown by Burchenal (1952) . In a patient 
extremely sensitive to amethopterin who developed 
sip= of toxicity after amethopterin 2.5 mgm. daily 
for eight days, 3 mom. of C.F. were given at the 
same time as the antagonist and the patient was the 
able to tolerate up to 60 mgm. of amethopterin dail 
for twenty -one days. Schoenbach et al. (1950) 
recorded a somewhat similar observation on two 
patients. 
It was hoped that with the introduction of C.F 
toxicity might have been prevented without interfer 
with the chemotherapeutic action of the folic acid 
antagonists. It has been shown in mice that the 
antileukaemic effect of amethopterin is prevented 
ng 
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._g_y C.F. (ï3urchenal et al. 1950, Burchena l et al. 
1949) and although a similar effect seems likely 
in human subjects it has not yet been conclusively 
demonstrated. Several observers believe C.F. to 
hasten the leukaemic process in man, and the 
consensus of opinion is that it holds no place in 
the treatment of acute leukaemia with the folic 
acid antagonists. 
EVALUATION OF r2HE RESULTS OF TREATMENT 
OF ACUTE L,UK!'L E_-_IA 71ITH THE FOLIC ACID ANTAGONISTS. 
Many clinicians consider that every patient 
with neoplastic disease should be given the 
0 ortunity of any new therapy, and for this reason 
presumably a therapeutically, controlled series is 
rarely available. Untreated acute leukaemia with 
its unpredictable course, renders the evaluation 
of results of therapy extremely difficult, a 
problem which is made more complex by the absence 
of a satisfactory series of controls. Before 
evaluating the results of antifolic treatment one 
must take into account other factors which may 
influence the course of the disease, and the 
incidence of spontaneous remissions. 
Spontaneous Remissions in Acute Leukaemia 
It is well recognised that temporary 
spontaneous remissions may occur during the course 
of acute leukaemia. Evidence of such remissions 
extends back as far as 1876 when Eisenlohr reported 
regression of organ enlargement together with a fal 
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in the _leucocyte count in a male adult. IIeuc_L (13'79) 
reported a similar remission and in :.ore recent 
years the subject of spontaneous remissions has 
been reviewed by Forkner (1938), Dreyfus (1948), 
Birpe et al. (194c), Jimenez de Asua (1951), Southal 
et al. (1951) and Tivey (1954). 
An analysis of the reported cases of 
spontaneous remissions in many instances is made 
difficult by the lack of necessary haematological 
data, in particular studies of bone marrow cytology 
As Southam et al. (1951) stress in the discussion o 
remissions in acute leukaemia, a precise definition 
of terms is essential. The term remission is 
sometimes loosely applied to any improvement in the 
general clinical status such as might frequently 
follow blood transfusion. This seems undesirable 
as in the vast majority of instances no change in 
the basic pathological state occurs. It is now 
generally recognised, since the introduction of 
chemotherapeutic aEents able to favourably alter 
the haematological status in acute leukaemia, that 
a remission infers a reversal of the - peripheral and 
pone marrow blood picture towards normal - complete 
or partial depending on the degree of improvement - 
in addition to clinical improvement. With such 
criteria Southam et al. (1951) in an excellent revi:w 
of patients treated at the Memorial Centre, New Yori, 
prom 1926 -48, were able to detect only two instance 
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of complete spontaneous remissions in their 
series of one hundred and fifty cases, both being 
in children, although from the data available a 
total of 8,7 per cent spontaneous remissions of 
varying degree was assumed, 4.0 per cent of which 
a_ 2 Deared to be complete. 
From a study of the literature spontaneous 
remissions appear to be rare, and the variation in 
their reported incidence seems probably due to some 
fundamental differences in definition of the term 
remission. Diamond and Lubby (1951) found that 
8.6 per cent: of thre hundred children observed 
prior to 1947 exhibited evidence of a partial or 
complete remission. Dante et al. (1951) noted one 
in thirty -seven childrenl, Jersild and Mehlsen (1951,' 
two in sixty cZiildren, Zuelzer (1949) eighteen in 
seventy -five childre -, Smith and Bell (1950) three 
in seventy -four criildre:i, Rodgers et al. (1951) 
none in one hundred and forty childre,L. Including 
the figures reported by Southam et al. (1951) the 
above publications comprise nine- hundred and t7enty- 
one cases of acute leukaemia in children of which 
sixty -two (6.7 per cent.) showed evidence of 
spontaneous remissions of varying degrees (Table 1) 
Reports of the incidence of spontaneous remissions 
in adults are few. Rosenthal (1950) noted six in 
two thousand patients, while Damashek et al. (1950) 
auóted figures of 1 -2 per cent. Ross (1950) stated 
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Investigators No. of Patients 
Spontaneous Remissions 
No. Per Cent. 
Southam et al. (1951) 83 12 14.4 
Diamond and Luhby (1951) 300 26 8.6 
Darte et al. (1951) 37 1 2.7 
Jersild and Mehlsen (1951) 60 2 3.3 
Zuelzer (1949) 75 18 24.0 
Smith and Bell (1950) 74 3 4 
Rodgers et al. (1951) 152 Nil - 
Brandberg (1943) 140 Nil - 
Total 921 62 6.7 
TABLE 1 Incidence of pontaneous Remissions reported in 
Children with Acute Leukaemia. 
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that they never occurred. Southan et al. (1951) 
detected one in sixty -seven cases but the same 
author in a review of fifty -one cases of 
spontaneous remissions, thirty -eight of which had 
been previously reported in the literature, twenty - 
one were over the age of nineteen years. Tivey 
(1954) analysed one hundred and two cases of 
spontaneous remissions from the literature, fifty - 
one of which were those previously examined by 
Southam et al. (1951). He noted the age and sex 
incidence to be a .,proximately equal, suggesting 
that such remissions when they occur are as likely 
to be seen in adults as in children. Another 
finding; of interest was that remissions occurred 
in all morphological varieties of leukaemia. Of 
seventy -nine cases where the type of leukaemia was 
recorded, forty occurred in the lymphoblastic, 
twenty -five in the myeloblastic and fourteen in 
the monocytic variety Thirty -four of the 
remissions in those with lymphoblastic leukaemia 
occurred in children while twelve of the fourteen 
patients with monocytic leukaemia developing 
spontaneous remissions were adults. It seems 
likely -that such a distribution is to a large 
extent due to the fact that lymphoblastic leukaemia 
is more common in children, while monocytic 
leukaemia is usually seen in adults. 
In several of the reported cases, remissions 
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were preceded by one or more factors, which have 
led many to suspect that such remissions may not 
in fact be truly spontaneous. It has for long been 
a common supposition that remissions generally are 
causally related to an infectious process. 
Diamond and Luhby (1951) reported that 75 per cent. 
of children with remissions had severe acute 
infections immediately preceding the onset. Tivey 
(1954) considered that pyogenic infection was an 
associated factor in about one third of his series,, 
and in 50 per cent. remission was preceded by a 
febrile illness. Southam et al. (1951) could find 
no relationship of remissions to preceding infection. 
Eisenlohr (1878) and Heuck (1879) in their early 
reports observed a relationship of infection to 
spontaneous remissions. The former author 
observed a case in which typhoid fever occurred. 
,During the acute illness the clinical and 
haematological evidence of leukaemia regressed only 
to re- appear three weeks after recovery from the 
fever. In Heuck's cases the occurrence of empyema 
was associated with a decrease in the leucocyte 
count and diminution in size of the spleen. 
Marischler (1896), Neutra (1903) and Dock (1904) 
reviewed the early cases and suggested that a 
variety of infections mig-ht be the forerunners 
of a temporary improvement in the leukaemic state. 
Recently, Tivey (1954) has, ih addition, 
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associated virus diseases, including chicken pox, 
measles and infectious mononucleosis with 
"spontaneous" remissions. Wintrobe (1951) has 
occasionally observed temporary improvement 
following virus and coccal infections but he 
considers it a rare and unusual occurrence. 
Taylor (1953) reported remissions in cases of 
acute monocytic leukaemia who developed glandular 
fever. Jaffe (1932) is of the opinion that the 
response to infection depends on the persistence 
of sufficient functioning myeloid tissue to produce 
mature polymorphonuclear cells. 
Considerable differences of opinion exist 
regarding the relationshi: of infection to 
remissions. Southard (1951) stated that the 
evidence seemed to be only circumstantial and 
found it difficult to accept a causal relationship 
between infection and remission in a disease 
characterised by marked susceptibility yet rarely 
showing evidence of remissions. Such is the 
opinion of many and although the personal 
observations of others must be considered, more 
conclusive evidence seems desirable before 
infection per se can be accepted as the factor 
responsible for spontaneous remissions. 
Other factors have been described as being 
associated with remissions. These include non- 
specific trauma, various extracts including those 
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of urine and faeces (myelokentric and lymphokentric 
acids) (Miller et al. 1947) and blood transfusions. 
In the evaluation of treatment of acute leukaemia 
with chemotherapeutic agents only the latter has 
to be seriously considered. 
It seems probable that the more liberal use 
of sunnortive measures such as blood transfusions, 
antibiotics, the maintenance of a normal acid base 
equilibrium, etc., as well as the increased skill 
in caring for these patients may have also affected 
the natural course of the disease. Southam et al. 
(1951) were of the opinion tht repeated blood 
transfusions and the use of antibiotics in the 
treatment of patients at the Memorial Centre, New 
York, during the years 1946 and 194'7 had no effect 
in inducing remissions, although there was some 
evidence of a slight but significant increase in 
survival time. Bierman (1950) also found that 
blood transfusion and antibiotics increased the 
survival time in children from 5.6 to 8.9 months, 
in an untreated control series, to 8.9 months. 
Tivey (1954) found in his analysis of one hundred 
and two cases of spontaneous remissions that blood 
transfusion may have been an associated factor in 
thirteen instances. Hayhoe and Whitby (1955) are 
of the opinion that simple transfusion alone is 
likely to lead to a remis :ion of greater or lesser 
degree in aproximately one third of patients, 
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the outcome of treatment being usually manifest 
within a week. They also believe that second 
remissions may be induced by these means and only 
recommend hormonal or chemotherapeutic methods 
when it is clear that blood transfusion is not 
being effective. In their series, fourteen of 
forty -one patients were considered to have develope 
remissions following blood transfusion alone, and 
it was observed that the lymphoblastic type of 
leukaemia respond more frequently than the other 
varieties. Evidence of definite haematological 
impprovement was, however, not recorded conclusively 
and in only one instance was definite improvement 
in bone marrow cytology observed. It is also of 
interest that the majority had received considerabl 
quantities of transfused blood. The opinion of 
Whitby and Hayhoe is not that of others, and in the 
author's present series of twenty -eight patients 
with acute leukaemia there was no indication that 
haematological remissions were in any way related 
to routine blood transfusions, although symptomatic 
improvement was frequently observed. 
French workers have stressed the role of 
blood transfusions in the causation of remissions 
and have used exsanguino- transfusion as a form of 
therapy (Bernard and Bessis 1948, Bessie and 
Bernard 1947 and 1948). In a clinical study of 
sixty patients receiving this treatment Bessis and 
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Dausset (1950) noted clinical improvement with 
regression of enlarged organs in approximately 50 
per cent., while a significant number (20 per cent. 
showed haematoloEical improvement of some degree. 
Improvement was observed to occur largely in 
children, adults not being affected to the same 
extent. Dreyfus (1948) in reviewing the literature 
found that in twenty -two examples of spontaneous 
remissions blood transfusions were the only constan 
form of therapy and had been given in nineteen. 
The findings of the French investigators led to 
the suggestion that normal blood or plasma 
contained a blood -cell maturation factor absent or 
deficient in patients with leukaemia (Bernard and 
Bessis 1948; Dreyfus 1948) which has gained suppor 
from Schwind (1947) who noted partial maturation of 
leukaemic myelobïasts following fresh plasma 
transfusions. Further studies relating to the 
fundamental mechanism of the remissions in these 
patients seems, however, desirable. 
In view of the variety of factors which have 
been considered to predispose to remissions one is 
led to consider the :possibility of a common basic 
mechanism. As remiss ions in a percentage of 
patients follow the administration of adrenocorti- 
cotrophic hormone (ACTH) or cortisone the 
possibility that the rare spontaneous remission may 
be -due to adrenal stress might be postulated. Tive 
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(1954) also supported such a mechanism and 
considered that exchange transfusions might act in 
this way or even result in á direct transfer of 
ACTH and /or cortical steroids. 
The duration of spontaneous remissions is 
variable. Diamond and Luh y (1951) found them to 
be less than ten weeks while Tivey (1954) in his 
series which included those of Southam et al. (1951 
found the median duration in fifty -four children to 
be 5.2 weeks and in forty -eight adults 9.4 weeks. 
Individual remissions lasting as long as four years 
h--ve, however, been described (Fauvert et al. 1948, 
Schiro and Weiss 1946). Rarely has more than one 
spontaneous remission been observed but Birge et al 
(1949), Rappoport and Kugel (1947) and Whitby and 
Christie (1935) have reported such an occurrence 
while Miller et al. (1947) described partial 
remissions on two occasions in each of three pat ien 
treated with crude myelokentric acid. Bassen and 
Kohn (1952) reported four separate spontaneous 
remissions in the same individual. 
The average survival time of patients 
developing s..pontaneous remissions seems to be 
appreciably longer than those who do not ( Southam 
et al., 1951). 
In summary it may be said that whereas so -call 
spontaneous remissions occasionally occur they woul 




doubtful but from the reports examined comprising 
almost one thousand children with acute leukaemia, 
not treated with modern chemotherapeutic agents 
such as folic acid antagonists, some evidence of 
clinical and haematological improvement occurred in 
6.7 per cent. of cases_, Blood transfusions when 
massive may predispose to remissions but Hayhoe and 
Whitby's (1955) su.gestion that one third of adult 
cases of acute leukaemia have true remissions 
following transfusion is not accepted by the author 
The variety of infections described as leading to 
remissions suggests that the organism is not 
directly responsible for the remission. Many 
factors have been described as associated with such 
remissions which throws some doubt as to their true 
spontaneity and leads to the suggestion that all 
these factors may lead to a common basic mechanism 
and that remissions in patients not treated with 
chemotherapeutic agents may be the result of adrena 
stress in the susceptible individual. Remissions 
may o; cur irrespective of age, sex and morphologica 
type of leukaemia but in view of the incidence of 
the particular types varying with age, remissions 
are more likely to be observed in acute lymphoblast 
leukaemia in childre n, while remissions in monocytii 
leukaemia and to a lesser extent myeloblastic 
leukaemia are generally to be seen in adults. 
Spontaneous remissions resemble those followin' 
53. 
treatment with the folic acid antagonists in certaif. 
respects, including the variable but generally 
relatively thort duration and the a sHociated 
significant increase in survival time. 3assen and 
:«oi (193 2) observed an initial period of 
leucopenia before the onset of spontaneous 
remission in their patient and suggested the 
similarity between s-Dontaneous and drug induced 
remission. Although accurate statistics of the 
incidence of spontaneous remissions in adults is 
lacking, the reported remissions appear to equal 
those in children. Remissions in adults following 
treatment with aminopterin or amethopterin are on 
the other hand extremely uncommon. Similarly 
antifolic treatment seems to affect mainly 
lyr?phoblastic leukaemia whereas s_.onta.neous 
remi sc ions may develop in any variety of leukaemia. 
There would therefore a,,pear to be certain 
differences, as well as similarities, between the 
spontaneous and drug induced remissions. 
In conclusion it may be stated that supportive 
treatment may account for some increase in survival 
time, and that occasional spontaneous remissions 
may occur. Neither of these factors are however 
likely to interfere with the evaluation of present 
day chemotherapeutic agents to any extent. 
Comparison of a series of patients treated with the 
folic acid antagonists at the Memorial Centre, New 
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York, between 1948 -51 with Southam et al's. (1951) 
series of untreated cases is interesting (Burchenal 
1952a). Of one hundred and thirty -six cases 
treated with the folic acid antagonists thirty - 
eight survived more than one year and there was an 
overall remission rate of over 50 per cent. In one 
hundred and fifty untreated cases only two survived 
more than a year and the overall remission rate was 
8.7 per cent. Although the folic acid antagonists 
appear to have played the major therapeutic role 
in the induction of remissions, with regard to the 
survival time account must be taken of the 
su T ortive treatment as well as the effect of the 
chemotherapeutic agents. Thus Farber (1951) now 
speaks of "Total Care ", to infer a combination of 
all the available means to increase the comfort, 
well -being and survival time of the patient. 
RESULTS OF TREATMENT OF ACUTE LEUKAEMIA 
WITH THE FOLIC ACID ANTAGONISTS. 
At the Second Conference on the Folic Acid 
Antagonists in the treatment of Leukaemia, held in 
February, 1951, at Boston (Proceedings of the Secon 
Conference on Folic Acid Antagonists in the 
Treatment of Leukaemia, 1952), it was reported that 
68 per cent. of four hundred and twenty -five 
children with acute leukaemia had been improved by 
therapy with the folic acid antagonists. At the 
Memorial Centre, New York, forty -four out of one 
hundred and nineteen children developed complete 
U 
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.remissions but only one out of thirty -six adults 
(Burchenal 1952a). The poor resonse in adult 
patients is now generally recognised and the value 
of aminopterin and amethopterin is almost confined 
to the treatment of acute leukaemia in children. 
The evaluation of theca y by various 
investiFa.tors in the United States of America is 
shown in Table 2. The detailed criteria of 
complete and partial remissions tend to vary. 
F..rber (Proceedings of the Second Conference on the 
Folic Acid Antagonists, 1952) considered a complete 
remission to be _present when the patient returned t 
tei - oorary normal health, with the presence of less 
than 7 per cent. blast cells in the bone marrow. A 
Partial remission was indicated by a reduction of 
blast cells in the bone marrow to less than 30 per 
cent. Burchenal, at the sane Conference, stated 
that a remission was complete when the bone marrow 
contained 20 per cent. or fewer stem cells or 
lymphocytes, as frequently there was difficulty in 
differentiating between stem cells and young 
lymphocytes. In a more recent publication (Burchenal 
et al. 1953) this figure was changed to 30 per cent. 
In some instances clinical improvement occurs 
without any noticeable change in the haematological 
status. Whether this is a consequence of treatment 
with the folic acid antagonists alone is Questionable. 






















































































































































































































































































































































































































































































































































































































































































































































































































































institution to another is probably accounted for in 
part by the different interpretation as to what 
constitutes a complete and partial remission, 
although there is no doubt that higher remission 
rotes are obtained by those most experienced in the 
use of these compounds. 
Many other reports have been published 
concerning the ability of the folic acid antagonist 
to bring about clinical and haematological 
remissions in acute leukaemia. In the United 
Kingdom Dacie et al. (1950) noted nine remissions i 
thirteen patients treated with aminopterin, of whic 
seven occurred in children. Wilkinson (1948 and 
1953) and WiLnimson and Gardikas (1951) reported 
remissions of varying degree in ten out of thirty - 
eight patients of various ages. Other investigator 
included Pierce and Alt (1948), Jacobson et al. 
(194) , Stickney et al. (1949), Weber et al. (1950) 
Damashek et al. (1950), Meyer et al. (1950), Bruton 
and Price (1952), Poncher (1952) and Dresner and 
White (1952). All agree that remissions are more 
likely to develop in children and in the 
lymphoblastic type of leukaemia. 
The duration of individual remissions is 
extremely variable. They may last only a few weeks 
or many months. Damashek (1950) has noted 
individual remissions lasting thirteen months while 
Burchenal et al. (1951b) reports a range of four to 
58. 
ninety -six weeks, the majority lasting five to 
eight weeks. Second remissions are generally 
accepted as being less common, although Burchenal 
et al. (1951 b) found that only two of twenty 
Patients, in whom treatment had been discontinued 
during the period of complete remission, failed 
when relapse occurred to respond to a second course 
of treatment. Eventually, however, the disease 
ecomes refractory to the folic acid antagonists, 
lthough individual cases of multiple remissions 
re known. 
RESISTANCE TO THE FOLIC ACID ANTAGONISTS 
IN ACUTE LEUK ' EhiIA. 
It has been shown that a substantial percentage 
f children with acute leukaemia develop evidence 
f a partial or com-_aete remission following 
-reatment with aminopterin or amethopterin. The 
crying response may in part be dependent on the 
ell type, as most observers agree that the 
mrhobi<stic variety of acute leukaemia responds 
est, fewer remissions occurring in the myeloblastic 
ype, while acute monocytic leukaemia appears to be 
naffected b :: these compounds. 
In many instances it seems likely that the 
eukaemic cells rapidly acquire resistance to the 
olic antagonists. Experience has shown that all 
atients ultimately become resistant and it is 
xpected that a child who has responded once or even 
wo or three times will eventually fail to benefit 
59. 
from further therapy. 
An attempt at explaining the development of 
resistance to the 4 -amino analogues of folic acid, 
a circumstance of major importance, has been 
undertaken by several investigators. By passing 
leukaemic cells, generation after generation, 
through mice treated with amethopterin, a strain 
of leukaemia resistant to amethopterin has been 
produced (Burchenal et al. 1950a). Passage of 
resistant cells through untreated mice failed to 
show any reduction in the degree of resistance, 
suggesting that it was a true mutation. If such 
animal studies could be aplied to human leukaemia, 
which is open to doubt, it would suggest that 
resistance does not appear to be due to tolerance 
r 
on the part of the patient as a whole, but to the 
acquisition of tolerance specifically by the 
abnormal leucocyte. Animal studies by Burchenal 
et al. (1951e) have shown that although the 
leukaemic cells were originally exposed only to 
amethopterin a cross resistance to all the 4- amino- 
analogues of folic acid was observed. However, the 
same investigators (Burchenal et al. 1951d) have 
demonstrated that a strain of mouse leukaemia 
highly resistant to the 4 -amino analogues of folic 
acid is suppressed by 9- methyl -folic acid suggestin 
that this particular leukaemic cell does not 
develop an alternative metabolic pathway allowing 
60. 
it to survive without the need for folic acid. 
Lack of cross resistance to cortisone (Burchenal 
et ai. 1951e) and a purine antagonist, 2, 
6- diaminopurine (Burchenal et al. 1951e), in the 
amethopterin resistant strain of mouse leukaemia 
has also been observed Law and Boyle (1950) and 
Law (1951) have also developed a transplantable 
lymphoid leukaemia in mice resistant to the folic 
acid antagonists and showing an ability of the 
leukaemic cells to utilise the antagonist. flaw 
(1954) has reviewed the phenomena of resistance and 
dependence. The results of these two groups of 
workers suggested the possibility that the leukaemi 
cell rapidly acquires or develops an ability to 
metabolise the 4- amino -analogues of PGA. Support 
for this concept was obtained by Burchenal and his 
colleagues who after developing a strain of 
streptococcus faecalis highly resistant to 
amethopterin, designated S. faecalis /A, (Burchenal 
et al. 1951f) showed that S. Faecalis /A was capable 
of maximum growth on aminopterin and amethopterin i 
the absence of a folic acid supplement (Hutchison 
and Burchenal, 1952) . Further study, however, 
indicated that these folic acid analogues contained 
varying amounts of folic acid as impurity (Hutchiso 
and Burchenal, 1953) so the initial suggestion that 
the resistant organism might be metabolising the 
antagonists was probably incorrect. A similar 
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explanation may account for the suggestion by Kidde 
et al. (1951) that aninopterin can substitute for 
folic acid in promoting the growth of Tetrahymena °e eii 
and so disprove the thesis that conversion of the 
analogues to form folic acid occurs (Hutchison and 
Burchenal (1952)). Experiments in mice previously 
given amethopterin have shown that no apreciable 
diminution in concentration of the antimetabolite 
follows implantation of resistant (Á:'14R) leukaemic 
cells (page 166), again sugFesting that the resistan 
cell fails to metabolise amethopterin at least in 
assayable quantities. 
In adJition to the theory that the resistant 
leukaemic cell may convert aminopterin to utilisabl 
folic acid, resistance to amethopterin has also bees 
suggested to be due to deaiimation to form a weaker 
antagonist, N10- methylpteroylglutamic acid 
( methopterin). It has been demonstrated that 
amethopterin is not deam_inated in normal mouse 
tissues (Fountain et al. 1953) and the indication i 
that the animal with resistant leukaemia also fails 
to do so (Page 202) 
Resistance has been considered by some as 
possibly due to an increased synthesis of folic 
acid and C.F. by the resistant cell. Studies by 
the author (ease 224), suggest no appreciable 
difference in total C.F. and folic acid concentration 
in the livers of mice with ÁK4 ( amethopterin'. 
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sensitive) and AK4R (amethopterin resistant) 
leukaemia. C.F. has ben found to be ineffective in 
influencing the growth of sensitive and resistant 
cells and indeed Law and Boyle (1951) have 
indicated that C.F. may interfere with the 
utilisation of amethopterin. i;;ichol (1954) found 
that suspensions of lymph nodes and spleens from 
leukaemic _mice formed C.F. from synthetic folic 
acid when incubated in a medium containing glucose, 
ascorbate and serine or formete. The enzymatic 
formation of C.F. in this system was inhibited by 
amethopterin. Ametiooterin resistant (Line 1 /A) 
leukaemic tissue, however, did not utilise folic 
acid more efficiently for the formation of C.F. 
than the corresponding.sensitive lines. In this 
respect resistant leukaemic cells differ from 
the amethopterin resistant strain of S. faecalis 
which has the ability to form more than one hundred 
times as much C,F. from folic acid as the parent 
antagonist - sensitive strain (Broauist flt al. 
1953, Hutchison and .urchenal 1952a, Nichol et al. 
1953). Hutchison and Burchenal (1954) are also of 
the opinion that resistant leukaemic cells are 
unable to form more C.F. from exogenous folic Ecid 
than the sensitive cells. However, their 
experiments suggested a higher concentration of 
both total and free C.F. in the spleens of mice wit - 
resistant (Line 1 /A) leukaemia as compared with tho e 
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with the arnethoPterin sensitive (Line /1) leukaemia. 
In addition their results sugested that the 
resistant cell liberates the conjugated C.F. more 
readily. 
Other theories such as m_ethylatìon, 
acetylation or esterification of the 4 -amino group 
or alteration in the -permeability of the cell 
membrane have been su gesteed ( :3urchenal et al. 
1951F). Nichol (1954a) wor Ling with the resistant 
strain of Se faecalis has also some evidence that 
the cell walls may be less permeable to 
amethorterin. 
In summary, several Possible explanations 
have been put forward rega ding the mechanism of 
resistance to the folic acid antagonists. 
Alternate metabolic pathways, conversion of the 
antifolics to less potent antagonists or to 
utilisable folic acid or an increased synthesis of 
citrovorum factor have been suggested. In 
addition the pcssibility that the resistant 
leukaemic cell is unable to readily absorb the 
antagonist has to be considered in addition to the 
more clinical approach that nests of leukaemic cell 
may be resistant from the outset and gradually 
replace the sensitive ones destroyed by anti -folic 
treatment. The -possibility that the terminal 
failure of the leukaemic patient to respond to the 
folic acid antagonists may not be due to drug 
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resistance in the accepted meaning of the term 
cannot at this stage be altogether excluded. J ny 
patients failing to benefit from antifolic therapy 
show a decline in the leucocyte oount but without 
improvement in the differential cell count, 
haemoglobin or platelet level, suggesting treatment 
is eliminating leukaemic cells but normal 
haemopoietic development is suopressed. A 
possible explanation of the development of a 
remission and eventual resistance can be summarised 
as follows:- (a) Remission in acute leukaemia 
results from suppression of the leukaemic process 
followed by regeneration of normal blood cells from 
functioning haemopoietic tissue; (b) "Resistance" 
results when the bone marrow fails to regenerate 
after the inhibition of growth of leukaemic cells. 
"Resistance would therefore be a part of the 
natural history of leu kaeia and due to a 
fundamental defect in normal haematopoiesis in 
turn brought about by the leukaemic process. 
Although this may be an explanation of "resistance" 
in human leukaemia, in animals and bacteria cells 
resistant to amethopterin have been developed. It 
is therefore essential that work in this field be 
continued in the hope that it will help to 
elucidate this problem. 
Adrenocorticotrouhic Hormone (ACTH) and Cortisone 
in the Treatment of Acute Leukaemia, 
Since 1950 several reports have appeared 
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relating to the effectiveness of ACTH and Cortisone 
in producing tepora.ry remissions in acute leukaemi 
s early as 1942, Heilman and Kendall had observed 
temporary regression of lymphoid tumours in mice 
administered cortisone (comr,ound E) although this 
work was not published until 1944. Murphy and 
Sturm (1944) also demonstrated the effectiveness of 
CTH and adreno- cortical hormones in protecting 
gainst transplanted leukaemia in rats. In the sama 
rear, Dougherty and White (1944) showed the effect 
of these hormones on lymphoid tissues and the 
epressive effect on circulating lymphocytes. 
Valentine, Craddock and Lawrence (1948) reviewed th 
subject of the relationship of the hypophyseo- adren.1 
oortical system to lymphoid tissue structure but 
themselves at that time were unable to demonstrate 
leer cut association. In animals and in human 
ubjects (Hills et al. 1948) the administration of 
CTH is followed by an increase in circulating 
neutro_,hils and a diminution in lymphocytes and 
osinophils. Later workers (Burchenal et al. 1950b) 
-ugU.ra et al. 1950) showed some deree of regression 
f malignant processes in animals. The vast amount 
f experimental work showing the effect of the 
dreno- cortical hormones on haemo9oietic, and in 
articular lymphoid tissue, naturally led to its 
rial in the treatment of leukaemia. 
ACTH and cortisone appear to be equally 
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effective in their action on the leukaemic process, 
although ACTH stimulates the patient's adrenal 
glands to secrete several steroids whereas cortison 
merely su-,'plies an excess of a single adrenal 
hormone. The dosage of the hormone varies to a 
certain extent with the age of the patient but it 
should be stressed that if remissions are to develo 
adequate dosage is essential, in children up to 
200 mgm. daily of cortisone by mouth and twice this 
dosage if necessary in adults. ACTH is given 
intramuscularly, usually four times daily, for a 
total dose of 100 mgm. in children and 200 mgm. in 
adults. 
The intravenous administration of ACTH is 
highly satisfactory and in children 25 -40 mgm. may 
oe given in an intravenous infusion over a period 
of eiç-ht to twelve hours. This method of 
administration is occasionally dramatic. Within a 
ay or two the bleeding completely ceases, 
ormoblasts and granular cells replace the 
Ieukaemic cells in the bone marrow, which usually 
ecomes hypocellular, associated with a 
ieticulocytosis and rise in haemoglobin. Platelet 
roduction increases and normal white cell 
maturation a_pears. The lymph glands and spleen 
ecrease in size and the patient, within seven to 
ourteen days, regains a_;pa.rent normal health. 
ortisone and intramuscular ACTH may produce the 
67 .. 
same effect but usually not so rapidly. Treatment 
with oral cortisone may have to be continued for 
several weeks in order to produce a remission, but 
if undesirable side effects should occur, such as 
severe hypertension and metabolic upsets, therapy 
is usually suspended. Cushing's facies, hirsutism 
and acne usually clear rapidly when treatment is 
sto:ped and are therefore not dangerous. It is 
the author's impression that if a child with acute 
leukaemia is going to respond to hormonal therapy, 
a response will usually occur soon after therapy 
is started and before the onset of unpleasant side 
effects. 
Results of Treatment with ACTH and Cortisone 
Pearson et al. (1949) in a preliminary report 
showed that in six patients with neoplastic disease 
of lymphatic tissue, including chronic lymphatic 
leukaemia, a marked decrease in size of lymph 
glands, spleen and other evidence of disease 
followed treatment with ACTH and cortisone. The 
same group of workers in 1950 demonstrated the 
effectiveness of these adrenal- cortical hormones 
in inducing remissions in patients with acute 
leukaemia. Numerous publications supporting these 
observations followed. Farber et al. (1950) noted 
ten remissions, of which five were described as 
complete, out of a total of seventeen children, the 
duration of the remissions being less than ten weeks 
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FIG. 2. Complete remission in a child with acute 
leukaemia following_ treatment with ACTH 
and cortisone. A second remission was 
induced later by 6- chloropurine and 
6- =mercaptopurine. 
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in all cases. Wintrobe et al. (1950), Stickney 
(1950), Spies et al. (1950), Snelling et al. (1951) 
chulman et al. (1951) and Rosenthal et al. (1951) 
reported similar observations. At the Second 
finical ACTH Conference held in December, 1950, at 
hicago (Proceedings ACTH Conference 1951) it was 
hown that eighty of :..one hundred and seventy -five 
hildren and fourteen of forty -six adults developed 
;ood clinical and haematological remissions. 
osenthal et al. (1951) stated that 69 per cent. 
hildren with acute lymphoblastic leukaemia in his 
eries showed a good remission Statistics vary 
ut an average remission rate of 50 per cent. in 
hildren would probably be generally accepted. 
urchenal (1952a) reviewed the treatment of acute 
eukeemia with cortisone and ACTH. The Medical 
esearch Council Panel report (1952), however, only 
entioned improvement in six out of twenty children 
lith acute leukaemia, and three out of sixteen 
dults. A second report (1953) showed improvement 
o have occurred in three of a further sixteen 
a.tiente. Damashek (1952) criticised the dosage use 
n this group of patients and stated that good 
emissions were generally observed in 50 -60 per cent 
f cases of lymphoblastic leukaemia in children and 
hen ACTH or cortisone was given simultaneously with 
minopterin of which he had observed fifteen cases a 
emission may be induced in almost every case. 
70. 
Hayhoe and Whitby (1955) observed five remissions 
in their series of ten adult patients, three of 
the remissions being complete. Wilkinson (1955a) 
reports a remission rate of 31.5 Per cent. in his 
series of seventy -six patients of various ages. 
Remissions are generally accepted as being 
less common in adults than in children, although 
more likely to occur than if treated with the folic 
acid antagonists. Acute lymphoblastic leukaemia is 
more responsive than other types to hormone therapy 
as is expected in view of the known effect on 
lymphoid tissue (Dougherty and White 1944) . Acute 
monocytic leukaemia invariably fails to show any 
form of response to ACTH or cortisone (Pearson 
et a .l. 1950, Burchenal 1952a, Hayhoe and Whitby 
1955). ACTH and cortisone induced remissions 
generally last from a week to three months, the 
majority of investigators agreeing that the average 
duration of a remission is rather less than that 
obtained with the folic acid antagonists. Second 
remissions may occur in children but adults usually 
fail to respond a second time. Resistance to 
therapy occurs sooner or later in all -cases and 
the eventual outcome is the same as that which 
follows treatment with the folic acid antagonists. 
An interesting and important feature in this respec 
is the apparent absence of cross resistance betwen 
the steroids and the folic acid antagonists (Kingsl y 
71. 
Piliers et al. 1952) suÉresting that ACTH And 
cortisone have a different primary mode of action 
on the leukaemic process from that of the folic 
acid antagonists. These workers were of the 
opinion that the two series of compounds were 
effective in producing further remisions in 
approximately 50 per cent. of patients showing 
resistance to one type of therapy. The suggestion 
by DamasheK (1952) that remissions in acute 
leukaemia in children may be expected in almost 
every case when a combination of aminopterin and 
hormones was used tends to support this finding. 
Farber (1950), Marie and his co- workers (1951) 
and Bernard and Mathé (1952) have also recommended 
"combination therapy" and an apparent synergistic 
effect together with a lower degree of toxicity has 
been sugpested by the French workers. Kelty and 
Beard (1953) and TYiaguin (1953) also considered 
combined therapy to be advantageous. Others agree 
that a higher initial percenta -e of remissions are 
likely to occur in children but prefer to use 
sequential t__erapy as they believe that resistance 
to both compounds is likely to occur earlier when 
used in combination. Nevertheless it is accepted 
that combination therapy in adults is no 
improvement on ACTH or cortisone alone. Since the 
folic antagonists alone are rarely of value in 
adults it would be remarkable if the combination 
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produced more favourable results, and indeed would 
indicate a true synergistic relationship.,. 
The mode of action of cortisone and ACTH in 
leukaemia is unknown. As has been suggested, the 
absence of cross resistance (Kingsley- Pillers 
et al. 1952) suggests it is different to that of 
the folic acid antagonists, although as mentioned 
previously there is some evidence that the 
antagonists may in part act via the adrenals. 
Chemical studies by Pearson et al. (1949 and 1950) 
and Snelling et al. (1951) showed a relative increa-e 
in excretion of uric acid and creatine which 
appeared to be proportional to the disa::pearance of 
leukaemic cells. Whatever the mechanism may be 
this suggests a dissolution of leukaemic tissue. 
'he clinical findings of diminished cellularity of 
the bone marrow during treatment coincident with a 
decrease in the proportion of blast cells and a 
subsequent re- appearance of normal marrow 
onstituents points to this being the case, as does 
he absence of any evidence of maturation of the 
frhile cell precursors. 
urvival Time of Treated and Untreated Acute Leukaemia 
One of the most objective single measurements 
the effectiveness of chemotherapy in acute 
eukaemia is probably the duration of survival, 
lthough the number and duration of remissions and 
he symptomatic benefit afforded by treatment must 
73. 
also be considered when assessing the value of a 
chemotherapeutic ac.ent. 
Survival time in a disease such as acute 
leukemia may be measured from the time of 
diagnosis or from the onset of the first symptoms. 
Both methods are open to obvious criticism and are 
likely to be only a rough approximation. The 
duration from the time of diagnosis when examining 
a series of cases from a single clinic seems to the 
author to be more accurate, at lea t for comparativ 
purposes, than relying upon the patient's 
judgement as to the onset of definite symptoms of 
leukaemia. 
Warren (1929) found that only two patients in 
his series, out of a total of one hundred and 
thirteen, survived longer than six months, and that 
74 per cent. were dead within two months. More 
recent figures relating to survival time in 
patients not receivinv chemotherapy have been 
reported by Dale (1949). Of a total of thirty -six 
only one survived longer than one year and 75 her 
cent. were dead within six months. Southam et al. 
(1951) in a comprehensive study of one hundred and 
fifty patients found an average duration from the 
onset of the first symptoms of just over twenty 
weeks. Theyreorted 50 per cent. as being dead 
by the seventeenth week and 75 per cent. by the 
twenty -eighth week. Only two survived longer than 
74. 
one year. The same workers noted a gradual increas 
in the survival time over the years between 1926 
and 1948. This they considered due to su_Dportive 
measures such as blood transfusions, suî._nonamides 
and later penicillin and other antibiotics. Deep 
x-rays, radioactive phosphorus, urethane and 
nitrogen mustard had no influence on survival time. 
:Bierman (1950) ^lso found an increase in survival 
time, from 5.6 to 8.9 months, in patients 
receiving supportive treatment . A recent 
statistical analysis by Tivey (1952) of four 
hundred and twenty-eivht cases recorded in the 
-_its; L-atu e _; o; e 1 that 30 per cent. cried within 
our ,,onth; of the first sylaptoms ari oily 5 er 
cent. survived ati_ong as one year. 
Little information of statistical 
significance has been published concerning the 
effect of chemotherapy on survival time. Ponchor 
et al. (1952) reported an increase in the mean from 
twenty-three to forty weeks as a consequence of 
treatment with folic acid analogues. Colebatch 
and Williams (1950) also noted an increase in life 
expectancy, and in his small series found the 
survival time almost doubled as a result of 
chemotherapy. On the other hand, Haut et al. (1955 
who analysed statistically the results recorded in 
the literature and included one hundred and three o 
their own patients were of the opinion that 
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reatment with the folic acid antagonists, ACTH 
nd cortisone and 6- mercaptopurine had not 
significantly increased the total survival time. 
hey did, however, find that in those patients who 
achieved at least one remission, the median survival 
eras enhanced from four and a half to eight months. 
There seems little doubt that in many 
instances life has been prolonged as a result of 
ghat might be termed (a) sup ortive measures and 
(b) specific chemotherapeutic agents, but it seems 
doubtful whether the survival time in the group 
vhich fail to show haematological improvement as a 
result of treatment, is materially affected. A 
comparison of Southam et als (1951) figures prior 
to 1948 and those obtained from the Memorial Centre, 
few York, between 1948 -51 after the institution of 
specific chemotherapy is of interest. Of one 
iundred and thirty -six patients treated with the 
folic acid antagonists, thirty -eight (28 per cent.) 
survived more than a year. In the group of one 
aundred and fifty not receiving treatment only two 
(1.3 per cent.) survived more than a year. 
Similarly in the untreated group of leukaemic 
children reported by Tivey (1952) only 5 per cent. 
survived as long as one year. Since the 
introduction. of 6- mercaptopurine Burchenal et al. 
(1954) have observed that by the sequential use of 
agents known to favourably influence the leukaemic 
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process, the number of patients surviving longer 
than a year has risen. to 52 per cent. 
The increase in survival time as a consequence 
of therapy, is a positive indication that agents 
such as the folic acid antagonists, ACTII and 
cortisone and 6- mercaptopurine can temporarily 
arrest the leukaemic process. When viewed as a 
[whole, the increase is depressingly small, but the 
knoz;led :e that in a percentaf:e of patients 
rolonged remissions with complete freedom from 
symptoms may occur, gives added impetus to further 
research. 
_ecent Trends in Chemotherapeutic Research 
Although the need for fundamental biochemical 
information is of prime importance, the lack of 
uch knowledge led to a new approach in cancer 
herapy. At several Centres in the United States of 
A lerica large tumour screening programmes are in 
rogress (Stock (1950), Considerable numbers of 
heroical compounds are tested annually for growth 
inhibitory properties in animal tumours, including 
mouse leukaemia. Those found effective, and of low 
oxicity are tested for therapeutic properties in 
atients with various neoplstic diseases including 
Leukaemia. This type of research in many instances 
s largely empirical, but many compounds are chosen 
.n a more rational basis. With the knowledge that 
Colic acid was essential for the synthesis of 
77. 
nucleic acid and that the folic acid antagonists 
were effective in the treatment of acute leukaemia, 
analogues of other essential metabolites have been 
prepared and tested. Several analogues of adenine 
and guanine have been synthesised of which one, 
2, 6- diaminopurine has resulted in remissions in 
five patients out of a series of twenty -five 
treated with this compound (Burchenal et al. 1951b) 
Azaguanine has not been found to be of any 
material benefit in the human subject although in 
animal leukaemia it has been found to strikingly 
influence the disease when given in conjunction 
with the folic acid antagonists (Goldin et al. 
1952; Law 1952). The most effective purine 
antagonist to be prepared and tested up to the 
resent is 6- mercaptopurine. This compound has 
een shown to bring about remissions in a high 
Dercenta Fe of children with acute leukaemia and 
.lso occasionally in adults with this disease 
( Burchenal et al. 1953; Fountain 1954, 1955). 
5-Mercaptopurine is considered in detail later 
page 
6- Mercapto- 2- aminopurine (thioguanine), 
. ynthesised by Elion et al. 1952, and 6- chloropurine 
. ynthesised by Bendich et al. have both brought 
bout remissions in chronic myeloid leukaemia 
without any evidence of toxicity ( Burchenal, 1954) 
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FIG. 5. Complete remission, in a child with acute 
leukaemia) folloyrinu treatment with 
6- Chloropurine. 
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occasionally in acute leukaemia (Figs. 4 and 5). 
Compounds containing the 2:4- diaminopyriidine 
moiety including those with antimalarial activity 
(Falco et al. 1949) are competitive antagonists of 
folic acid in the growth of lactobacillus casei 
(Iïitchings et al. 1952). In animals they produce 
states indicative of folic acid deficiency and 
with this in mind the possibility was suggested 
that such conroounds might be effective in acute 
leukaemia. Several have been synthesised' and one, 
2, 4-diamino-5-(3'4'-dichlorophenyl)-6-methylpyri- 
midine (DDI .P) was found to exhibit inhibitory 
effects on animal tumours (Clarke et al. 1952) and 
mouse leukaemia (Burchenal et al. 1952). At a 
later date it was reported as producing 
haematological improvement in three of twelve 
children with acute leukaemia (Murphy et al. 1954). 
Toxic effects similar to those associated with the 
folic acid analogues was.noted, including the 
conversion to niegaloblastic erythropoiesis. DDMP 
seems to differ from amethopterin, however, in that 
it has a more ;prolonged toxic effect. 
A related group of compounds, the 
dihydrotrin_zines have been shown by Farber et al. 
(1953) to have a temporary antileukaemic activity 
in children. Undesirable side -effects preventing 
them from being of practical value at the present 
time have, however, been observed. 
82. 
Another antimetabolite, 0-diazo- acetyl -L- 
Serine (azaserine) (Bartz et al. 1954; Ehrlich 
et al. 1954; Stock et al. 1954) has been found to 
occasionally ,produce temporary haematological 
improvement in children, but relapse tends to 
follow after a short interval (Ellison et al. 1954) 
Pyridoxine deficiency in mice, produced by 
administering the analogue desoxypyridoxine, has 
been shown to result in l miphopenia and 
granulocytosis (Weir et al. 1949; Weir and Heinle 
1950) and its action has been compared with that of 
cortisone. Desoxypyridoxine has been tested in 
human leukaemia but no evidence that it produces 
any material benefit has been recorded. 
Apart from possible antimetabolites, and more 
specifically substances which may interfere with 
nucleoprotein metabolism, com_ounds related in 
chemical structure to the compounds already known 
to affect the leukaemic process e.g. the nitrogen 
mustards, form a basis for testing for antileukaemi 
activity. 
Burchenal (1954) has suggested that until more 
than aua.ntitative differences are discovered betwee 
the normal and leukaemic cells, it is doubtful 
whether any single agent will have sufficient 
specificity to control the disease. Until more 
undamentai knowled e be known concerning the 
let_abolic derangement in leukaemia, a combination 
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:f several compounds able to produce inhibition at 
-ifferent levels of a single metabolic pathway 
ecessary for the leukaemic cell, may yield more 
satisfactory therapeutic results. Such "combined 
he.rapy" has, of course, been used with success in 
he treatment of infectious diseases, particularly 
uberculosis. 
Various investigators have reported on the 
additive effects of a combination of drugs in the 
leukaemic animal. Goldin, Greenspan and Schoeizbach 
(1952), using a combination of aminopterin and 8- 
azaguanine observed an increased survival time in 
leukaemic mice. Amethopterin and 8- azaguanine were 
also found by Law (1952) to have striking 
Potentiating effects in mouse leukaemic while Nadel 
and Greenberg (1953) observed a synergistic 
inhibitory action of amethopterin and the 
diaminopyrimidine, 2, 4- diamino- 5- (3'4'- dichlorophei_yl) 
6- Methyïpyrimidine (DDMP), upon leukaemia L 1210 in 
,lice, with an increase in survival time of 92 per 
cent. Various combinations of amethopterin, 
itrogen mustard, a nitrogen mustard derivative, 
triethylenemelamine, and erythromycin were found by 
i; arvick and Goodson (1954) to reduce the tumour 
growth and increase the survival time of mice with 
sarcoma lJ0, and as early as 1949 Skipper presented 
data suggesting a possible antileukaemic synergism 
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FIG. 6. Complete remissions in a child with acute 
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6- mercaptopurine alone cannot be excluded. 
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is (B- chloroethyl) amine. 
Up to the present time few reports have been 
published concerning the effectiveness of combined 
therapy in human leukaemia. Burchenal (1954a) has 
found no evidence of synergism between amethopterin 
and cortisone, or amethopterin and 6- mercaptopurine . 
ithough certain investigators (Damashek 1952; 
arber 1950; 1\Iarie et al. 1951; Bernard and Mathe 
1952; ñelty and Beard 1953; Maguin 1953) consider 
he initial response of children with acute leukaemia 
is better when a combination of cortisone and a folic 
acid antagonist is given, this does not necessarily 
indicate a synergistic effect.. Kingsley- Pillers 
t al. (1952) have shown an absence of cross 
esistance between these two compounds and it eems 
ikely that seouential therapy would produce just as 
ood if not better results than combined trest ment. 
he French workers, however, are of the opinion that 
synergistic effect does exist. Azaserine and 
-merca»to-purine although resulting in striking 
dditive effects in animals (Clarke et al. 1954) hav 
Dho`-rn .Little effect when given to children with 
eukaemia. Innes and Rider (4.955) have recently 
eported evidence suggesting a synergistic 
elationship between urethane and a nitrogen mustard 
eriva.tive, napthyldi- 2- chloropropylamine, 
esip`nated R151, in the treatment of multiple 
yeloma, which provides a further stimulus in the 
86. 
earch for more effective combinations for the 
Lana cement of Patients with leukaemia. 
In the search for new chemotherapeutic agents 
or acute leukaemia it seems probable at the Present 
,ay that the main ttention will be focussed on 
zucleic acid synthesis. It is, however, also 
ssential that studies relating to the mode of 
ction of cortisone and ACTH and the mechanism of 
esistance of the leukaemic cell to these hormones 
',nd other chemotherapeutic agents, be pursued. 
Although disappointment followed the encouraging 
arly results with the folic acid antagonists, the 
important developments in the chemotherapy of acute 
eukaemia in the space of only a few years leads 
'ne to believe that further advances may be looked 
"orwarä_ to with optimism. 
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B. CHRONIC LEUKAEMIA . 
88. 
NITROG N T..iUSTARDS - JD RELATED COMPOUNDS 
The effects of mustard gas derivatives on 
haemop oietic tissue was first reported after the 
first world war. Krurrïohaar and Krumbhaa.r (1919) 
described the action of these compounds on blood 
and bone marrow and their cytotoxic action was 
reported by Pappenheimer and Vance (1920). About 
the same time Lynch et a1. (1918) and Warthin and 
Weller (1919) published accounts of the medical 
aspects of mustard gas poisoning and its general 
systemic effects, while Flury and Wieland (1921) 
studied the effects of these compounds on the 
Ea tro- intestinal tract and on the normal 
electrolyte and fluid balance. 
The _possible value of mustard gas in the 
local treatment of cancer was reported by 
Beremblum in 192x;. He observed that the induction 
of warts in mice by the repeated application of tar 
could be almost completely prevented by the 
addition to the tar of 0.1 per cent. mustard gas. 
Adair and Bagg (1931) showed that tar cancers in 
mice could be controlled by the surface a-.:)plication 
of mustard gas in absolute alcohol and in human 
subjects good therapeutic results were obtained in 
cases of siLin cancer. It was not until 1935 that 
this particular therapeutic application of the 
mustards was pursued further. Berenblum in that 
-year found that several compounds closely related 
89. 
to mustard gas were able to produce pronounced 
inhibition of t rnour induction in mice. Three 
years later Maier (193:0 described the depressant 
effects of mustard gas on the leucopoietic tissues 
which were followed in 1939 by a similar report by 
Drees. 
With the advent of the second world war, 
V- 
intensive interest in the subject of Aatrogen 
mustard derivatives was developed in both the 
United Kingdom and the United States of America. 
Wilkinson, as early as 1942, observed that certain 
B- halogenated alkylamines had marked depressant 
effects on ha.emotopoiesis. Leucopoiesis appeared 
to be affected earlier than erythropoiesis and a 
rapid improvement was seen to follow the withdrawal 
of these toxic agents (Wilkinson and Fletcher 1947) 
Such an observation led to the consideration of the 
possible therapeutic effects of these substances in 
both chronic lymphatic and chronic myeloid leukaemi 
and later to acute leukaemia, Hodgkin's disease and 
polycythaemia. Wilkinson and Fletcher (1947) 
reported the effects of two derivatives, methyl -bis 
(B- chlorethyl) amine hydrochloride and tris 
(B- chlorethyl) amine hydrochloride in these 
conditions. When given intravenously they found 
these nitrogen mustards to be most beneficial in 
chronic myeloid leukaemia, in one patient a 
remission of eight months following treatment. 
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Dramatic improvement was also seen to armour in 
Hodgkin's disease but less satisfactory results 
were observed in chronic lymphatic leukaemia. 
The nitrogen mustards were introduced into 
medical practice in the United States of America 
in 1946 for the palliative treatment of leukaemia 
and other malignant diseases of the reticulo- 
endothelial syster:L. Rhoads (1946) investigated the 
therapeutic properties of the same two compounds as 
used by Wilkinson, in a series of one hundred and 
sixty patients suffering from neo- clastic disease, 
chiefly leukaemia, Hodgkin's disease and related 
disorders. Good results were obtained in patients 
with Hodgkin's disease but X -ray therapy was still 
considered advisable in the early, slowly 
progressive case with localised disease. Nitrogen 
mustards were concluded to be of most value in 
producing symptomatic relief when the disease 
became widespread and systemic effects, such as 
fever, were present. Some patients with lympho- 
sarcoma and chronic lymphatic leukaemia were 
improved as were those with chronic myeloid 
leukaemia. The effects of the nitrogen mustards 
in other forms of cancer were not encouraging. 
Goodman et al. (1946) published detailed clinical 
reports of the therapeutic results obtained in this 
series of patients. Following these initial 
observations numerous reports have appeared in the 
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literature substantiating, the findings of those 
early workers and indicating that the nitrogen 
mustards have a place in the management of 
malignant disease of the reticulo- endothelial 
system. 
The chemistry, mechanism of action and 
pharmacology of the nitrogen mustards has been the 
subject of intensive research and has been reviewed 
at length by Gilman and Philips (1946) and Philips 
(1950). The two mustard gas derivatives which have 
been found most satisfactory for clinical purposes 
are those described by Wilkinson and Fletcher (1947; 
and Rhoads (1946) and. are:- 
l Di- (B- chloroethyl) methylamine 
hydrochloride, the 'bis' compound 
,CH2 - CH2 - Cl 
CH3 - id` 
CH2 - CH2 - Cl 
and (b) Tri -(B- chloroethyl) amine 
hydrochloride, the 'tris' compound 
72 - CH2 - Cl 
Td CH2 - CH2 - Cl 
\CH2 - CH2 - Cl 
The 'bis' compound has been most widely used 
as most observers have claimed it to be less toxic. 
Wilkinson (1953), however, considers the 'tris' 
compound to be better and less likely to give rise 
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to phlebosclerosis. It seems probable th ̂.t both 
compounds have identical therapeutic properties. 
The two nitrogen mustards are very soluble in 
water in which they undergo a distinctive intra- 
molecular transformation (Fig. 7 ), with release of 
halide ion to form cyclic ethylenimonium 
derivatives which are the intermediates responsible 
for chemical reactivity of nitrogen mustards 
(Philips 1950) and which produce powerful nucleo- 
toxic and cytotoxic effects on enzyme systems and 





CH 3 - ï 
./ 
CH2 - CH2 - Cl 
Fig. 7 
Eth lenimonium transformation of 
Di- B-chloroethyl methylamine> 
This chemical re- arrangement of the nitrogen mustar 
molecule in aqueous solution is to some extent 
reversible, but more important is the hydrolysis 
which these intermediate derivatives undergo in 
aqueous solution to form chlorohydrims which are 
relatively inactive. For this reason solutions of 
the nitrogen mustards should be prepared 
immediately before administration otherwise much 
of their potency will be lost through hydrolysis. 
The exact mode of action of the nitrogen 
nustards in destroying growing cells is unknown. 
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Philips (1950) comments on the similarity in 
actions of these comoounds and those of ionizing 
radiation, a view put forward by others including 
Boyland (1948) who has used the term 'radiomimetic` 
to describe the biological properties of these 
chemical ap:ents. The susceptibility of cells 
seems dependent on their proliferative activity 
and the site of action is the nucleus. Skipper 
et al. (1951) have observed inhibition of nucleic 
acid synthesis following administration of nitrogen 
mustards, while tustin (1948) noted that mitotic 
poisons, like radiation, caused depolymerisation 
of the nucleoproteins. 
In spite of their high vesicant properties 
these two nitrogen mustards can be given safely 
intravenously. The usual mode of administration is 
to inject the solution of nitrogen mustard into the 
rubber drip tube of a saline infusion. By such a 
method extravasation into the subcutaneous tissues 
with local inflammation, pain and necrosis may be 
Prevented and venous thrombosis possibly lessened. 
The dosageschemes of nitrogen mustards vary 
widely. The initial recommendation was 0.1 to 0.2 
mg. per kg. of body weight administered on 
consecutive or alternate days until between three 
and six doses had been given. The maximal single 
dose advised was 8 mg. In selected cases larger 
oses of 0.2 to 0.3 mg. per kg. have been given in 
two injections, twenty-four to forty -eight hours 
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hours apart (ApThomas and Cullumbine 1947). 
Wilkinson (1953) advised the use of a standard dose 
of 3 mfg. in adults which was repeated two or three 
days later or at longer intervals depending on the 
leucocyte count and response of the patient. 
Sensitivity to the nitrogen mustards varies 
considerably in different subjects which must alway 
be a consideratioli when estimating the dose of the 
drug to be employed. In the author's experience 
the scheme suggested by Wilkinson (1953) is highly 
convenient and is a satisfactory standard method of 
prescribing these compounds. In view of the effect 
of the nitrogen mustards on the bone marrow it does 
however, seem advisable to refrain from repeating a 
course of treatment until six to eight weeks has 
passed since the last course. 
One of the adverse criticisms of nitrogen 
mustard therapy is the toxic side- effects which are 
liable to occur. 
When injected into animals in toxic doses then 
compounds have been shown to provoke an early 
transient rise in the haemoglobin level and 
erythrocyte count followed by a rapid development o 
anaemia and leucopenia (Cameron 1942). Loss of 
weight and diarrhoea occurred and at post- mortem 
scattered haemorrhages in the gut were seen. 
Examination of the bone marrow revealed that the 
white cells were more depleted than the red. 
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Cameron and Rydon (1942) showed that the 
leucotoxic action was mainly on the polymorpho- 
nuclear cells and their precursors, while the 
lymphocyte series was affected to a lesser extent. 
In higher doses, Philips (1950) observed marrow 
aplasia together with a rapid shrinkage of i ynnhoi 
tissue which became devoid of lymphocytes. 
It is usual for human subjects to experience 
nausea or vomiting within the first four to 
eight hours of injection. Attempts to counteract 
the severity of this effect have been made. 
Shullenberger et al. (1949) suggested the 
simultaneous administration of 150 to 200 mg. of 
pyridoxine hydrochloride (vitamin B,) . Craver 
(1948), however, considered that pyridoxine should 
be administered intramuscularly ten to thirty 
minutes after the nitrogen mustard to avoid 
chemical interaction between the two substances. 
Wilkinson (1953) found that anti- histamine drugs 
given at the time of injection and repeated four 
hours later controlled or reduced the severity of 
these symptoms. Other workers (Wintrobe and 
Huguley 1948; Kennedy and Aub 1949) recommended 
the use of sedatives, e.g. opiates or barbiturates 
to minimise the gastro-intestinal reactions. 
The effect on the haemopoietic system may be 
marked but at the dosage level used therapeutically 
Gellhorn and Jones (1949) found that depression of 
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haematopoiesis was usually reversible, and 
thronibocytopenia of a degree to produce serious 
haemorrhagic manifestations has been rare 
(Wintrobe and. Huguley 1948) . 
Depression of all elements of the blood 
forming tissuesfoilows the administration of 
nitrogen mustard, but the effect on the leucocytes 
is the most pronounced. The fail in granular cell 
is more marked than that of the lymphocytes and 
usually reaches its maximum in two to three weeks. 
The level of lymphocytes in the peripheral blood 
falls during the first week reaching its maximum 
in about six to eight days, while thrombocytopenia 
may not reach its maximum until the third week 
after treatment. Within six weeks of treatment 
the white cells and platelets usually return to 
normal, the presence of a few myelocytes in the 
peripheral blood and monocytosis heralding the rise 
in the polymorph count, as frequently seen in 
patients recovering from acute agranulocytosis. A 
mild reduction in the volume of packed erythrocytes 
may occur reaching its peak, in about three weeks 
but occasionally anaemia may be improved by the 
effect of nitrogen mustard on the neoplastic 
process. Depression of both mature and primitive 
cells in the bone marrow occurs but marrow 
regeneration has been stated as usually following 
within a period of six weeks. (Spurr et al. l47) 
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Haemorrhagic manifestation associated with 
a Prolonged clotting time and the appearnce of 
heparin -like anticoagulant in the blood have been 
described (Smith et al. 1943) . A similar 
coagulation defect has been induced in 
experimental animals by toxic doses of nitrogen 
mustard or x -rays (Jacobson et ai. 1948; Allen 
et al. 1948) 
Although a return of the bone marrow, 
leucocyte and platelet counts to normal is 
generally considered usual following a course of 
nitrogen mustard, the author has found that marrow 
aplasia with cytopenia and bleeding is more 
prominent in those having received nitrogen mustard 
therapy. An analysis by the author of the terminal 
blood __ ictures at the Memorial Hospital, New York, 
of eighty patients h<'.ving died of Hodgkin's disease 
many of which had received several courses of 
nitrogen mustard, or a nitrogen mustard derivative, 
tried rlene melamine, indicated the hazard of 
intoxication following their administration. 
Table 3 indicates the last recorded haemoglobin 
levels, leucocyte and platelet counts before death. 
The interval between blood examination and death 
was less than two weeks in over 75 per cent. of 
patients, the vast majority actually being within 









60 - 79% 40 - 59% Below 40% 
76 to (13%) 22 (29 %) 36 (48 %) 8 (10 %) 
Na. Over 10 - 4 - 1 - Under 
15,000 15,000 10,000 4,000 1,000 
77 9 (11.5 %) 8 (10.5 %) 12 (15.5 %) 32 (41.5 %) 16 (21%) 
Na. Over 100 - 50 - Below 
150,000 150,000 100,000 50,000 
6o 13 (21.7;) 5 (8.3 %) 12 (20%) 20 (50%) 
TABLE 3, Haemoglobin., Leucocyte and Platelet Levels in Patients in 
the Terminal Stage of Hodgkin's Disease 
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7:ost patients received blood transfusions late 
in the disease and the haemoglobin levels as a 
result did not reflect the true degree of anaemia. 
Sevare anaemia was, however, observed in 
-jroTimate-ly 30 per cent. of patients irrese)ective 
transfusions. More revealinQ:, however, 
th,-, profound leucopenia, in 21 per cent. the 
leucooto count beinF under 1,000 per c.mm., while 
:F.2.5 Ter cent. llad counts below 4,000 per c.rim. 
Platr-Tats were also greatly reduced in 50 per cent. 
of -oatients in 7hich counts were carried out in the 
-,,t7e7_, the disease, the count being below 
_ :er c r7lirombocytopenia was associated 
1-,.ael:n-rb,a.7:e in twenty-seven patients (i.e. 
per -oleedinp- being confined, as would 
be excted, :_ainy to the group of patients whose 
latelet counts were below 50,000 per 
(Table 4. ). 
In a condition such as Hodgkin's disease where 
the accepted forms of treatment, irradiation and 
otherapy, have a toxic, inhibitory effect on 
fer-ation, the therapeutic agent is usually 
incrirnated as the cause of the low leucocyte or 
H.21telet count. It should be remembered, however, 
that the clio,ear::e itself may in part predispose to 
6.eression of hoeffatopoiesis. In the series under 
discussion on_Ly five patients received no treatment. 
Two of these Patient3 had blood pictures characteristic 
* 
Platelets in patients 
No. No. 




Normal 50-100,000 <50,000 
6o 30 27 1 2 22 
TABLE 4 Incidence of Thrombocytopenia and Haemorrhage in 
Patients with Terminal Hodgkin& Disease. 












71 10 IZ 37 12 














71 10 44 5 12 
TABLE 6. Incidence of Bone Marrow Invasion by 
Hodgkin's Disease. Autopsy Figures. 
A. Leucopenia 
Patients treated 
with x -rays alone 




with x -rays and 
nitrogen mustard 
No. with leucopenia 
W.B.C.'s <4,000 
per c.mm. 
25 8 (32 %) 50 37 (74%) 
B. Thrombocytopenia 
Patients treated 
with x -rays alone 
No. with platelets 
<150,000 per c.mm. 
Patients treated 
with x -rays and 
nitrogen mustard 
No. with platelets 
<150,000 per c.mm. 
10 7 (70 %) 48 40 (83.) 
TABLE 7. Incidence of (A) Leucopenia and (B) Thrombocytopenia following 
X-rays and Nitrogen Mustard in Patients with Hodgkin's Disease 




with x -rays 
Leucopenia after 




with x -rays and 
nitrogen mustard 
Leucopenia after 
x -rays and 
nitrogen mustard 
63* 15 (24.5 %) 50 37 (74%) 
B. Thr omb ocytopenia 
Patients treated 
with x -rays 
Thrombocytopenia 




with x -rays and 
nitrogen mustard 
Thrombocytopenia 
after x -rays and 
nitrogen mustard 
* 
45 15 (30 %) 48 40 (83%) 
TABLE 8. Incidence of (A) Leucopenia and (B) Thrcvbooytopenia following 
X -ra's and Nitrogen Mustard in Patients with Hod . in's Disease 
(where Blood Counts available for analysis 
12 patients who had combined x -ray and nitrogen mustard therapy are not 
included. 
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of aDlastic anaemia and the bone marrow at autopsy 
was found infiltrated by disease. It was 
interesting to observe that in 70 per cent. of 
cases the bone marrow taken at autopsy from four 
sites (sternum, rib, vertebra and ilium), showed 
infiltration by the disease (Table 6 ). In 
addition the bone marrow was found to have a 
reduced cellularity in 70 per cent. of c ses 
(Table 5 ). 
How much x- rays play a part in producing 
depression of bone marrow activity is difficult to 
say but there is no doubt that excessive doses of 
nitrogen mustard may lead to a profound leucopenia 
and thrombocytopenia. Comparison of the blood 
pictures in patients receiving x -rays alone and 
those receiving x -rays and nitrogen mustard 
(Tables 7 and 8 ) showed clearly that the 
wain cause of the high incidence of hypoplasia or 
aplasia of the bone marrow was due to nitrogen 
custard, but probably in 25 to 30 per cent. of 
ases, x -rays and bone marrow replacement by disease 
nay have been the predisposing factors. 
linical A :plication of the ïitro en Mustards. 
Since the original reports of Rhoads (1946) 
oodman et al. (1946) and Wilkinson and Fletcher 
1947) a voluminous literature has collected on the 
.ubject. Most of the reports of their therapeutic 
clue concerns the treatment of Hodgkin's disease 
nd related lymphomns, but a number of investigators 
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have published accounts on their experiences with 
the nitrogen mustards in the treatment of the 
leukaemias. In the United Kingdom Wil`Anson (1953) 
has presented his results of treating one hundred 
and twenty -six cases of chronic leukaemia with 
tri- (B- chlorethyl) -amine hydrochloride. In 74 per 
cent. of the patients, clinical and haematological 
improvement followed treatment. In 54 per cent. t 
duration of the remission was, however, less than 
three months, 36 per cent. had improvement lasting 
from four to twelve months while in 10 per cent. 
the remission exceeded one year's duration. 
Comparing the survival time of patients with 
chronic leukaemia treated with x -ray irradiation 
and those receiving nitrogen mustard therapy 
WiLinson observed that the latter group compared 
extremely well and were by no means inferior. In 
general, he considered the indications for 
treatment of chronic leukaemia with nitrogen 
mustard were deteriorating health, anaemia, a 
rising leucocyte count, loss of weight, sweating, 
increasing splenomegaly and glandular enlargement. 
No beneficial effects were observed in patients 
with acute leukaemia except in a few where the 
leucocyte count was high. In these instances a 
fail in the leucocyte count rapidly followed 
treatment but no improvement in the distribution 
of white cells or in platelet or red cell 
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production was noted. This is in agreement with 
the author's experience that nitrogen mustards have 
no specific effect on the acute leukaemic process 
and are on the whole not to be recommended. 
Goodman et ai. (1946) found that nitrogen mustard 
therapy was of no value in the terminal stages of 
chronic leukaemia but in others the results of 
treatment were comparable with those obtained with 
x -ray therapy. Spurr et al. (1948) found that 
remissions in patients with chronic myeloid 
leukaemia were rarely longer than three months and 
concluded that they were no longer than those 
induced by x-ray therapy. Burchenal et al. (1949a) 
analysed the results of treatment of thirty -eight 
patients with leukaemia. In those with acute 
leukaemia no consistent clinical remissions were 
seen, but occasional temporary symptomatic relief 
occurred. They concluded that the results 
obtained in chronic myeloid leukaemia were similar 
to those with irradiation and that in chronic 
lymphatic leukaemia only those patients in good 
condition before treatment did well, those with far 
advanced disease generally responding poorly. 
Craver (1948) considered that as a rule longer 
remissions and one accompanied by greater reduction 
in the splenomegaly can be produced at least 
initially by x -ray treatment. In his experience 
nitrogen mustard induced remissions were short live 
and lasted only a month or so. Goldman et al. 
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(1948) noticed temporary benefit from treatment in 
both patients with chronic myeloid and chronic 
lymphatic leukaemia. Bauer and Lrf (1950) 
considered nitrogen mustards of no real asset in 
the treatment of leukaemia and was probably contra- 
indicated. Other reports have a-_peared concerning 
the treatment of leukaemia with these compounds 
including those by Karnofsky et al. (1947) , Wintrob 
And Huguley (1948) and Damashek (1949). Wintrobe 
and Huguley (1948) found that seven out of eleven 
patients with chronic myeloid leukaemia showed a 
good response to nitrogen mustard, but when the 
disease became refractory to x -ray therapy, 
nitrogen mustard also usually failed. Karnofsky 
and his colleagues concluded that nitrogen mustard 
did not produce any therapeutic effects which 
could not be accomplished with x -rays. 
Most observers agree that remissions follow 
treatment in the early cases. The remissions, 
however, are generally of short duration and are no 
longer than those following x -ray treatment, 
although nitrogen mustard, as Wilkinson (1953) has 
:.pointed out, may result in the survival time being 
equal to that of the patient receiving radiotherapy 
it has no real advantage over x-rays, and because 
of this, their mode of administration and of their 
less readily controlled toxicity, few physicians 
are now using this method of treatment of chronic 
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leukaemia. 
Treatment of diseases other than Leukaemia with 
Nitrogen Mustard 
Hodgkin's disease 
Goodman et al. (1946) studied the results of 
nitrogen mustard therapy in twenty-seven patients 
with Hodgkin's disease, most of which were 
advanced or had become resistant to x -rays. 
Nitrogen mustard ccused a partial or complete 
disappearance of the tumour masses, a fall in 
temperature, and an increase in both appetite and 
weight; this was followed by symptom -free 
remissions of from two weeks to seven months. 
Since response to subsequent courses of nitrogen 
mustard was unsatisfactory, it was considered that 
the main indication for its use was in the later 
stages of the disease, particularly when resistance'. 
to therapeutic doses of x -rays developed. Wintrobe 
et al. (1947) and Karnofsky et al. (1947) agreed 
that nitrogen mustard was particularly likely to be 
of benefit in the x -ray resistant case of Hodgkin's 
.disease. ApThomas and Cullimbine (1947) working in 
'Manchester, England, reported the first comprehensive 
account in the United Kingdom of the effect of this 
form of treatment in patients with Hodgkin's 
disease. They concluded that it was a useful agent 
in the palliative treatment of extensive disease 
and pointed out that symptoms could still be 
alleviated by nitrogen mustard in cases where 
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radiotherapy had been abandoned. Bone marrow 
depression was considered a limiting factor as far 
as dosage was concerned and leucopenia and 
thrombocytopenia appeared to be more severe after 
the 'tris' compound. Both the 'bis' and 'tris' 
forms of the drug seemed to have identical clinical 
effects on the disease. Radiotherapy was considere 
the choice of treatment initially because (1) the 
mean period of remission after x -rays was longer; 
(2) vomiting was less troublesome; (3) leucopenia 
was certain and sometimes severe after nitrogen 
mustard therapy. Wintrobe and Huguley (1948) 
reported that in seventeen out of thirty -two 
patients with generalised Hodgkin's disease the 
results were good, and that thirteen had survived 
for an average of over fifteen months. Craver 
(1948), based on an experience of treating one 
hundred and two patients, concluded that in the 
presence of generalised disease with associated 
symptoms, viz. fever, night sweats, pruritus, etc., 
nitrogen mustard was the treatment of choice. 
nitrogen mustard did not, however, replace x -rays 
in those patients with localised disease. Goldman 
et al. (1948) carne to similar conclusions and 
reviewing the literature found that over 90 per 
cent. of the reported cases of Hodgkin's disease 
who had received mustard therapy obtained benefit. 
Nabarro (1949) was also of the opinion that in 
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generalised Hodgkin's disease nitrogen mustard 
was more effective than x -rays. In his series of 
twenty -one patients only five, however, responded 
satisfactorily to treatment. Erf and Bauer (1949) 
demonstrated the brevity of the remissions which 
may follow treatment. Of their forty -three 
patients only seventeen remained in remission six 
weeks after treatment. In a later publication 
these workers (Bauer and Erf, 1950) reported good 
immediate results in all but two of fifty -nine 
cases. 
Hodgkin's disease involving bone has been 
reported by Dsióshek et al. (1949) to be unaffected 
by nitrogen mustard. hamofs y et al. (1947) have 
also colmiented on the lack of radiological 
improvement in osseous lesions but found that pain 
may be relieved. Wintrobe and Huguley (1948) 
however observed healing in some instances of 
spinal involvement, and relief of backache in 
other cases without radiological evidence of 
vertebral lesions. 
Many other reports have been published 
relating to the value of nitrogen mustard in 
Hodgkin's disease including those by Reinhard 
et al. (1950), Alpert (1950), Spurr et al. (1950) 
and Bethell et al. (1950). The consensus of opinio 
suggests that it is a valuable additional 
therapeutic agent but radiotherapy is still the 
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treatment of choice in the early stages. Nitrogen 
nustal°d therapy aTipears to be most suitable 
indicated in the following clinical types of 
iodgkin's disease: 
1) Advanced cases which fail to respond to 
therapeutic doses of x -rays, i.e. "radio- resistant" 
isease. 
2) Where the disease is wides-oread and 
associated with marked constitutional symptoms 
(fever, sweating, pruritus, weight loss, etc.) 
3) Those with fever but without demonstrable 
-nlarged lymph nodes, 
and 4) Pati.:nts with visceral involvement, 
pleural effusion and ascites. 
Irrespective of the dramatic improvement, 
ahich may occasionally be observed in patients with 
dvanced Hodgkin's disease following nitrogen 
custard therapy, there seems to be little effect on 
he survival time of patients as a whole. Boland 
(1951) compared the survival time of (A) one hundre 
nd five patients treated with irradiation alone 
°een betTeen 1940 -1944, with (B) a group of eighty- 
even patients first seen during; 1946-47. Twenty- 
even of the latter group had nitrogen mustard at 
sometime during their illness. The three year 
survival time rate in (A) was 33 per cent. and in 
(B) 40 per cent. The average duration of life was 
hree months longer in Group (B) and the author 
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three to eighteen months in four out of six 
patients with lymphosarcoma. Rhoads (1946) was of 
the opinion that the highly aggressive and rapidly 
crowing type of lymphosarcoma did not seem to be 
significantly affected even by maximal doses. 
Wintrobe and Huguley (1946) found that only three 
of their series of eleven patients with lympho- 
sarcoma responded well. Justin -Besancon et al. 
(1948) concluded that only a certain percentage of 
cases were sensitive to this treatment and the 
results on the whole were less encouraging than 
those of Hodgkin's disease. Ben -Asher (1949) and 
Reinhard et al. (1950) came to similar conclusions. 
Herve (1948) and Spurr et al. (1950) were, however, 
more favourably impressed. 
The indications for nitrogen mustard therapy 
in lymphosarcoma would appear to be similar to 
those in Hodg :tin's disease. Whereas many 
clinicians consider lymphosarcoma and especially 
the more rapidly growing form to respond less 
readily than Hodgkin's disease to nitrogen mustard, 
symptomatic relief may follow in the later stages 
of the disease and it is therefore worthy of trial. 
Polycythaemia Vera. 
Treatment with nitrogen mustard may result in 
a remission of symptoms and a return of the blood 
picture to normal. Jacobson (1946), in an early 
report, stated that in all five patients he treated 
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symptomatic and haematological improvement occurred 
and in some cases improvement was maintained for 
over a year. Di Guglielmo (1949) found that a 
four -day course of nitrogen mustard usually 
resulted in the erythrocyte count returning to a 
normal level. A delay of up to two months was 
observed before the maximum effect of therapy 
occurred. Craver (1948); Goldman et al. (1948); 
saloon and Gorham (1948) also reported beneficial 
effects of nitrogen mustard therapy, but concluded 
that the results were no more favourable than 
could be expected from x -ray therapy. Spurr et al. 
(1950) treated a group of ten patients with 
nitrogen mustards. A total of fifteen courses was 
_iven and the range of remissions varied from two 
to thirty months. In eight cases, remissionE of 
five months or more were produced and in two the 
remission lasted three months or less. Bauer and 
Erf (1950), however, considered it dangerous to use 
nitrogen mustard for the treatment of polycythaemia 
in case vomiting caused cerebral haemorrhage. 
Although only small groups of patients with 
olycythaemia have been treated and, therefore, a 
omplete evaluation of nitrogen mustard therapy has 
of been obtained, most observers agree that its 
ffect is no better than that of other forms of 
reatment - especially x -rays. The toxic side 
xffects encountered with nitrogen mustard therapy 
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are also against this form of therapy, while the 
ease of administering treatment with x -rays, and 
in the author's opinion, radioactive phosphorus 
(P32) in particular, must also be considered when 
considering the assets of the various therapeutic 
agents. In a series of thirty patients treated by 
the author at the Leeds General Infirmary during 
the past four years, twenty -four have developed 
remissions following P32 of over nine months 
duration, and only four responded unsatisfactorily. 
The good therapeutic results and the absence of 
side -effects suggest that P32 is still more 
satisfactory than present day chemotherapy. 
Mycosis Fungoides 
Craver (1948) treated four patients with this 
disease and suggested that the chronic type of case 
without bulky tumours of the skin may do fairly 
well but that in the advanced or aggressive cases, 
while striking rapid, partial remissions may occur, 
they will probably be follarr ed by rapid relapses. 
There is, however, little evidence that nitrogen 
mustard is more effective than radiotherapy in the 
treatment of this disease. Block and Murphy (1948) 
noted improvement in one patient with mycosis 
fungoides and showed that the lesions, although 
becoming acellular, still retained the characterist 
of the disease following treatment. Philpott et al 
(1947) also obtained good results with nitrogen 
cs 
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mustard in one patient and Schafer and Le filer (1949; 
published an account of a case which responded well 
to nitrogen mustard when other forms of therapy 
had failed. lienstall et al. (1947) noted dramatic 
improvement in one patient followings nitrogen 
mustard therapy, and Herve (1948a) observed a 
complete regression of all tumours within thirty 
days of treatment with marked symptomatic 
improvement. Local relapse occurred three months 
aftr the injection of nitrogen mustard. 
In certain instances nitrogen mustard would 
appear to be beneficial in patients with mycosis 
fungoides and must be considered as an available 
therapeutic agent in the management of this disease. 
With the knowledge that the skin lesions are in the 
early stales are highly radio- sensitive, x -rays 
should be considered the treatment of choice at 
that stage, for it has not been demonstrated that 
remissions following nitrogen mustard are ever an 
improvement on those obtained by x -rays. 
Miscellaneous Diseases, 
Various diseases apart from the reticulosis 
have been treated with nitrogen mustard. Diaz 
et al. (1951) reported favourable results in 
rheumatoid arthritis, but this was not substantiated 
y Cohen et ai, (1958). Snider (1948) reported 
improvement in four cases of sarcoidosis and 
oodman et al. (1946) considered that some benefit 
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followed the administration of nitrogen mustard in 
cases of melanosarcoma. As a result of the 
beneficial effects in leukaemia and Hodgkin's 
disease, nitrogen mustard has been given to a wide 
variety of neoplastic diseases in the hope that it 
may produce at least symptomatic relief. The only 
form of cancer in which definite improvement has 
consistently been reported is bronchogenic carcinorr. 
Boyland and Warwick (1947) in the Twenty- Fourth 
Annual Report of the British Empire Cancer Campaign 
reported good responses with nitrogen mustard in 
several cases of bronchial cancer as evidenced by 
alleviation of pain and cough, and absorption of 
pleural exudates. Similar results have been 
reported by other workers including Rhoads (1946) 
and Karnofsky et al. (1948). Karnofsky and his 
colleagues reported symptomatic improvement lasting 
from two weeks to two months in 74 per cent, of 
thirty -five patients with inoperable cancer of the 
lung. Objective evidence of disease such as those 
associated with superior mediastinal obstruction, 
metastatic lesions and pleural effusion diminished 
following nitrogen mustard. In the rapidly growing 
anaplastic lung cancer improvement was noted to 
frequently follow treatment and these authors 
considered that nitrogen mustard may be more 
effective and possibly less hazardous than x -ray 
treatment. The combination of x -rays and nitrogen 
a. 
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mustard did not produce more satisfactory results. 
Skinner and his fellow- workers (1948), however, 
considered that inoperable lung cancer was best 
treated by nitrogen mustard combined with x -rays. 
Craver (1948) treated thirty -three cases of 
carcinoma of the lung and observed occasional 
dramatic improvement, while Lynch (1950) analysing 
his series of sixty patients noted that in 69 per 
cent. subjective improvement occurred while in 
over 50 per cent. there was definite objective 
evidence of improvement. 
Although the results are only of a temporary 
nature, and the response to a second course of 
treatment poor (Karnofsky et al. 1948), nitrogen 
mustard would seem to hold a place in the pailiativ- 
treatment of lung cancer. If x -rays are contra- 
indicated, and if pain, dyspnoea, pleural effusion 
or other distressing symptoms are present a trial 
should be given to nitrogen mustard. 
ORAL NITROGEN MUSTARD DERIVATIVES. 
Following the successful clinical trials of 
the intravenous nitrogen mustards, research was 
directed towards finding a nitrogen mustard with a 
greater selective effect on tumour as compared with 
the normal tissue, and therefore with less toxic 
side effects. In addition new derivatives have been 
sought for which are active when taken orally. The 
former efforts have, thus far, not been successful 
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but progress has been made towards a more 
convenient method of nitrogen mustard therapy 
through the discovery of the tumour- inhibiting 
effects of 
A. B- naphthyldi -2- chloroethylamine (R.45), 
followed later by a similar preparation, 
B- naphthyldi -2- chloropropylamine (R.151). 
B. 1:4- Dimethanesulphonyloxybutane (Myleran: 
GT 41) . 
C. Triethylene melamine (TEM) 
D. Triethylene phosphoramide (TEPA) and 
Triethylene thiophosphoramide (thio TEPA) 
A. B- naphthyldi- 2- chloroethylamine (R. 48) 
Haddow et al. (194o) studying the inhibitory 
effects on tumours of a variety of aromatic nitrog 
mustards, selected two for clinical trial. 
Preliminary investigations (Haddow1948), however, 
revealed that one of these compounds, bis 
(B- chloroethyl) aniline (R 74) had a marked 
depressant effect on the bone marrow. More 
encouraging results were obtained with 
B- naphthyldi- 2- chloroethylamine (R 48) which led 
to clinical trials by several groups of workers 
through the Medical Research Council. Matthews 
(1950) was the first to publish his results. Five 
patients with Hodgkin's disease all showed some 
improvement but this was of short duration (four 
to eight weeLs) and further treatment was less 
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effective. Three cases of chronic myeloid 
leukaemia were treated and remiss -:ions lasting 
aTproximately three months occurred in two. A 
further two remissions of similar duration occurred 
in one following repeated courses of treatment. 
Two out of four cases of chronic lymphatic 
leukaemia were benefited and a prolonged remission 
was also observed in a patient with polycythaernia. 
Patients with acute leukaemia and reticulosarcoma 
were not effected. Toxic symptoms were mild and 
generally consisted of gastric disturbance. One 
patient developed cystitis. Leucopenia and a fall 
in ?platelets was, however, usual. The effective 
dose of the com pound Ms large 300 to 400 mg. 
-per day - and the patients wire hospitalised during 
the early part of treatment. G- xmikas and 
Wilkinson (1951) and Wilinson (1953) also reported 
their results with this compound. The daily dosage 
employed varied between 50 to 800 mg. given orally 
in divided doses, the usual Quantity being 100 - 
300 mg. Symptoms suggesti -e of cystitis, viz. 
dysuria and haematuria also occurred in some of 
their patients, other toxic features being purpura 
and occasional nausea and diarrhoea. The amount of 
the drug prescribed did not seem to bear any 
relationship to toxic phenomena. Good responses 
were observed in three out of ten patients with 
chronic myeloid leukaemia, three showed only 
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moderate responses and four failed to benefit at 
all. Seven of twelve patients with chronic 
lymphatic leukaemia shared variable degrees of 
improvement, as did thirteen out of nineteen 
patients with Hodgkin's disease. Acute leukaemia 
and lym1Dhosarcoma were unaffected. Wilkinson 
concluded that the results with R 48 were inferior 
to those obtained with the original intravenous 
nitrogen mustards. i.cWhirter (1951) observed 
improvement in six of fifteen patients with 
chronic myeloid leukaemia and four of eleven 
-patients with "idiopathic reticuloses ". Nabarro 
(1951) obtained disappointing results with R 46 
given in doses of up to 400 mg. per day. Of a 
total of twenty -two patients with leukaemia, 
Hodgkin's disease, myelomatosis and mycosis 
fungoides only five showed a moderate degree of 
improverr_ent . He concluded that it should be only 
used if intravenous nitror en mustard for any reason 
was contra -indicated. Gallon (151) also 
considered R 48 to be is active than nitrogen 
mustard. 
N 
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A similar derivative to R 48, known as R 151 
( B- naphthyldi- 2- chloropropylamine) (Everett and 
Ross 1949) has also undergone clinical trials. 
McWhirter (1951) considered that although similar 
toxic effects may occur, they were generally less 
marked than those with R 48. The results obtained 
with R 151 in a series of twenty -nine patients 
suggested that this new compound may be rather more 
effective than R 48, eleven out of twenty -nine 
Patients responding favourably as compared with 
eleven out of fifty -two treated with R 48. The 
dosage of R 151 employed was 50 to 100 mg. daily 
initially, reduced later to 25 - 50 mg. Used in 
conjunction with urethane, R 151 has been shown to 
be of value in the palliative treatment of multiple 
my elomato'sis (Innes and Rider 1955) .. Although it 
might be argued that urethane alone may benefit 
patients with myelomatosis, the daily dose used 
(1 G:: urethane and 50 mg. R 151) by these 
investiators, was so small that it suggested a 
synergistic action between the two drugs. 
B. 1:4 Bimethanesulohonyloxybutane - Myeleran; GT 41 
Haddow and Timis (1953) , as a result of 
investigating the tumour inhibiting effects of a 
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series of sulo?honic acid esters, discovered one 
member, 1 4 - climethanesu1 :ohonyloxybutane 
('Myeleran' or 'GT 41') to have an intense 
inhibitory effect on the growth of the Walker rat 
carcinoma 256, and a depressant effect on 
granulopoiesis, but not lymphopoiesis, both in 
animals and man, at a lower dose than other members 
of the series. Preliminary clinical trials (British 
Empire Cancer Campaign Annual Report, 1950) 
demonstrated it to be much :less toxic than nitrogen 
mustard an.d that it had a favourable effect upon 
patients with chronic myeloid leukaemia. 
Galton (1953) in a more detailed account 
showed that acute leukaemia was unaffected but 
nineteen patients with chronic leukaemia 
all showed an initial response. Nine relapsed 
within six months and eight patients obtained 
clinical and haematological remissions varying from 
six to twenty -one months. 
Toxic symptoms were not encountered but the 
danger of thromoocytopenia was stressed and 
platelet counts below 100,000 per c.mm. were 
considered to be a contra -indication to Myeleran 
therapy. The dose of Myeleran suggested for adults 
was either (a) a course of 4 to 10 mg. daily up to 
a total of 200 to 500 mg.; (b) one or more short 
courses in which 100 to 150 mg. was given in one 
to six days. 
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-Li a later Raper ( Galton and Till, 1915), the 
short intensive course was considered unwise 
because of the danger of bone marrow aplasia, and 
the dosage advised was 0.06 mg. per Kg. of body 
weight daily, i.e. approximately 4 ins. In some a 
maintenance dose of 0.5 to 4.0 mg. daily was 
prescribed, and the results compared with interrupt 
therapy. No definite conclusion was arrived at as 
to which was the best method of treatment. In a 
four year trial thirty -one patients with chronic 
myeloid leukaemia were treated with r elief of 
symptoms, splenic regression, a reduction in 
leucocytes and a rise in haemoglobin, of various 
degree and duration. Patients on maintenance thera 
were maintained satisfactorily for up to a period 
of two years. An important finding was that 
Myeleran may be beneficial when radiotherapy has 
become ineffective. Galton was of the o-_inion that 
Eyeleran was su-oerior to Urethane, benzene and 
arsenic because of the absence of side- effects, the 
response being less erratic and the remissions 
longer. Ledlie (1953) has referred to the 
effectiveness of Myeleran in chronic myeloid 
leukaemia and stated that it was now the only 
chemotherapeutic agent used at the Royal Cancer 
Hospital, London. Petrakis et al. (1954) 
considered Myeleran a promising therapeutic agent 
in this disease. In their series of eleven patient 
y 
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given maintenance therapy, eight shaved clinical 
and haematological improvement, and one patient 
continued in remission nineteen months after the 
start of treatment. Acute leukaemia and multiple 
myeloma were not benefited by treatment. 
Wilkinson (1953) giving 25 mg. orally for three to 
five days f olla ed two to three weeks later when 
the full effects had developed by a maintenance 
dose of 2 to 4 mg. daily or on alternate days, 
found a good initial response in eighteen patients 
with chronic myeloid leukaemia and remissions 
varying from five to fifteen months in fifteen. 
The danger of bone marrow depression with 
conseouent apla stic anaemia, thrombocytopenic 
purpura and agranulocytosis was pointed out. 
Bollag (1953), Hansen (1954) and Turesson (1953) 
also considered Myeleran an effective palliative 
treatment in chronic myeloid leukaemia. 
There is no doubt in the author's mind that 
Myeleran is a highly satisfactory ,chemotherapeutic 
agent. It is of low toxicity and not associated 
with uamleasant side -effects such as may our 
with intravenous nitrogen mustard or triethylene 
melamine, it has a selective action on myeloid 
cells and may result not only in prolonged 
remissions but may sometimes benefit patients who 
have become resistant to therapeutic doses of 
x -rays. If radiotherapy is unavailable, as is the 
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case in many countries, Myeleran would at least be 
a satisfactory substitute. Whether Myeleran can, 
however, replace radiotherapy as a first choice 
of treatment remains to be seen, for only by a 
properly controlled trial can this answer be 
achieved. 
C. Triethylene melamine: (2, 4, 6 triethylenimino 
s- triazine: T.E.I._. ) 
The encouraging results of Haddow et al. (1948) 
in the search for a compound with nitrogen mustard - 
like activity which could be administered orally 
led to research in this field by other groups of 
workers. At the Sloan Kettering Institute, New 
York, several compounds were synèhesised and teste 
against animal tumours including mouse leukaemia 
(Burchenal et al. 1948). One, a methoxypyridoxine 
derivative of nitrogen mustard was found to produce 
inhibition of a variety of transplantable mouse 
and rat tumours (Stock 1950) but in human subjects 
disagreeable side- effects including nausea, 
vomiting and a foul taste, led to it being discarde 
as a :'ossible therapeutic agent. Another compound, 
triethylene melamine with a structural formula 
shown in Fig. 8 was investigated independently at 
the Sloan Kettering Institute and in England at 
the Research Laboratories of the Imperial Chemical 








It was found to be more satisfactory, being 
effective both orally and intravenously in man, 
less toxic than the previous com_Dound, but liable 
to result in similar side -effects as the original 
nitrogen mustards. The pharmacological 
characteristics of T'E\1 have been described by 
Philips and Thiersch (1950). The ethylenimino 
groups will be observed to be similar to the 
ethylenimonium transformation product of the tri 
and di - (2- chiorethyl) methylamines, which as 
has been Pointed out earlier is the reactive form 
of the molecule. Various investigators have 
described its effect upon a wide variety of 
bioloFical materials. Lewis and Crossley (1950) 
remarked on its ability to cause tumour retardation 
in mice when added to their diets in amounts of 
0.001 - 0.15 per cent. by dry weight. Burchenal 
et al. (1950c and 1950d) observed that TL_ when 
given intraperitoneally prolonged the survival time 
of mouse leukaemia. Suguira (1950) and Buckley 
(1950) noted its inhibitory effect on a variety of 
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rat and mouse tumours and on Sarcoma 180 
respectively. Variable results in animal tumours 
were obtained by Paterson and Boland (1951). 
Toxic doses of TEM.I, close to the LD50, 
resulted in pathological changes in rats and dogs 
similar to those observed following the 
administration of the nitrogen mustards, viz. 
nancytopenia in the peripheral blood, atrophy of 
haematopoietic elements in the bone marrow and in 
all lymphoid tumours, and mucosal oedema with 
desáuamation of intestinal epithelium and 
ulceration (Philips and Thiersch 1950). When give 
by mouth to dogs it was found that TEM was 
approximately half as toxic as when given by 
intravenous injection. A considerable variation 
in r_esponse to the drug occurs when administered 
orally compared with the intravenous route, due 
probably to inactivation by the acid gastric conten 
This may explain the erratic response and diminishes 
toxicity to oral dosing in animals (Rose et al. 
1950; Philips and Thiersch 1950) and in part to 
the variable response in man. 
The first clinical reports relating to the 
effectiveness of TEM in the treatment of human 
neo-olastic disease were by Karnofsky et al. (1951) 
and in the United States of America, and Paterson 
and Boland (1951) in England. The former group 
observed its effect when administered orally in 
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fifty -eight patients with a variety of malignant 
diseases, and in a further thirty -six patients 
when given intravenously. When administered 
intravenously in doses of 6 to 8 mg., in daily 
doses of 2 to 3 mg. diluted in normal saline to a 
concentration of 0.5 mg. /ml., the results in 
patients with Hodgkin's disease, lymphosarcoma 
and chronic leukaemia were found to be no better 
than those expected to fo_..low nitrogen mustard 
therapy. No benefit was recorded in patients 
refractory to irradiation or nitrogen mustard. 
Although nausea and vomiting were less common 
following intravenous TEM, depression of the bone 
marrow was liable to occur and bleeding as a 
consequence of thrombocytopenia was recorded. They 
concluded that nitrogen mustard was still the drug 
of choice for intravenous use. The dosage scheme 
advised for oral use was 5 to 10 mg. (2.5 or 5 mg. 
as a single dose per day) during the first week. 
If no reduction in the leucocyte count was 
observed a further 5 to 10 mg. was given folloved 
by further courses at weekly intervals, depending 
on the white cell count, haemoglobin level, the 
Platelet count and the ,patient's clinical condition. 
Improvement usually appeared within two to three 
weeks and there seemed little indication to 
continue treatment after three to four weeks. 
Occasional nausea and vomiting was observed and les. 
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commonly diarrhoea. Bone marrow depression also 
occurred similar to that following intravenous use, 
and on the ,:!hole seemed more severe and more 
prolonged. This latter observation is in contrast 
to the findings of Philips and Thiersch (1950) in 
dogs and is probably related to the variability in 
response to the drug. 
Karnofsky and his colleagues suggested that 
the most useful application of TEM was in the 
treatment of advanced Hodgkin's disease where it 
Produced relief of itching, fever, weakness and 
regression of enlared lymph nodes. Twenty out of 
twenty -five patients with Hodgkin's disease were 
reported as obtaining temporary benefit from 
TEIvi lasting two to fourteen weeks. Improvement 
was observed in patients with chronic lymphatic 
leukaemia and remissions in chronic myeloid 
leukaemia occurred lasting four to ten weeks. Some 
cases of mycosis fungoides were reported as 
benefiting from TEM. Advanced lymphosarcoma 
failed to respond to oral TEM, and various other 
forms of cancer, including bronchial carcinoma, 
also showed no improvement. 
Paterson and Boland (1951) published their 
results of treating seventeen patients. They gave 
the drug intravenously in doses ranging from .09 
to .22 mg. per Kg. of body weight, the total dose 
being spread in the majority of instances, over 
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three days. All patients had advanced disease or 
were unsuitable for x -ray treatment. In patients 
with leukaemia, polycythaemia and Hodgkin's disease 
and in one case of multiple myeloma improvement 
was noted, "about equal to the established methods 
of treatment ". The absence of troublesome gastric 
upsets following treatment suggested that it might 
be a pleasanter alternative to nitrogen mustard. 
Since these early papers, many reports of othe 
investi'ators have been published. Hansen and 
Eichel (1951) observed oral TEM to be an effective, 
although temporary palliative in seven out of nine 
patients with Hodgin's disease and in one of two 
patients with chronic lymphatic leukaemia. Bayrel 
(1952) treated thirty -eight patients, using a 
similar oral dosage as Karnofsky et al. (1951). 
Good results were obtained in chronic lymphatic 
leukaemia and chronic myeloid leukaemia, with 
symptomatic improvement, a fall in the leucocyte 
count, improvement in haemoglobin concentration and 
regression of the enlarged spleen, lymph nodes, etc 
Remissions lasted from three to elevenweeks 
following the initial course of therapy. Four 
patients with Hodgkin's disease showed considerable 
improvement, the remissions varying from three to 
twelve weeks duration. One third of patients were 
troubled with vomiting and twenty -five per cent. 
developed leucopenia or temporary bone marrow 
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aplasia, while in two instances TEM probably 
contributed to death. Rundles and Barton (1952) 
in a comprehensive study of one hundred and thirty - 
four patients given oral TEM, reported excellent 
or good results in twenty -four of forty -five 
patients with Hodgkin's disease, eighteen of 
twenty -three with chronic lymphatic leukaemia and 
four of six with chronic myeloid leukaemia. Other 
neoplastic diseases were unaffected. Using a 
maintenance dose they considered TEIVi as possibly 
the treatment of choice in chronic lymphatic 
leukaemia. Bond et al. (1953) also obtained good 
results with TL when administered oral-!y at 
intervals in patients with chronic leukaemia but 
their results with Hodgkin's disease were -Jess 
Promising than suggested by other investigators. 
Symptomatic haemolytic anaemia was controlled in 
two patients by TEM. Meyer et al. (1952) thought 
that Hodgkin's disease was benefited but the best 
results occurred in chronic leukaemia. Acute 
leukaemia was unaffected and five cases of multipl: 
myeloma showed no improvement after treatment. 
Wilkinson and Gardikes (1951) treat ed twenty 
patients with TEIl with disappointing results, only 
one patient out of six with chronic myeloid 
leukaemia responding well. Three patients 
developed aplastic anaemia. Wilkinson considered 
TEI,i to be highly toxic and he did not recommend it 
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for clinical use on this account, and because of it 
unpredictable effect and variation in individual 
tolerance. In the published papers mention is made 
of the variability of res-.monse to oral TE1v of 
individual patients and it is pointed out that 
dosage must be calculated according to the 
individual's needs. Gellhorn et al. (1952) in an 
attempt to obtain a more uniform response from oral 
administration have reccomendeä the use of sodium 
bicarbonate with TEE to neutralise gastric acid. 
Paterson et al., for similar reasons, have prescrib 
enteric coated tablets of TE'M to dogs and showed 
that such a preparation had a more consistent effec 
The same authors dec cribed the effect of this 
preparation in forty -four patients. A dose of 0.2 
to 0.3 mg. /Kg. was given to twenty-two patients 
with Hodgkin's disease and in over two- thirds a 
satisfactory remission of symptoms was obtained 
with diminution in objective evidence of disease. 
They stressed that treatment should only be repeate 
when the polymorDhonuclear leucocyte count was 
re2tored. A dose of 0.1 to 0.2 mg. /Kg. was given 
to fourteen patients with chronic leukaemia of 
either myeloid or lymphatic type, with definite 
benefit in seven. The response in lymphoid 
leukaemia was better than in the myeloid type. The 
ntutïbers were, however, small and the patients with 
myeloid leukaemia had advanced disease. They 
u 
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concluded that the simplification of dosing by 
enteric coated_ tablets seemed worthwhile but 
adequate haematological control was still essential 
Walsh et al. (1954), Silverburg and Damashek 
(1952) , Gellhorn et al. (1952) and Wright et al. 
(1952) agree with other reported observations that 
TEE is a useful agent in treating Hodgkin's disease 
chronic leukaemia and lympriosarcoma, and again 1poin 
out the dangers of irreversible pancytopenia. Wals 
et al. (1954), Ellison et al. (1953) and Rosenthal 
and Rosenthal (1952), have reported on the 
effectiveness of TIT in polycythaemia vera. The 
latter authors followed thirty patients with this 
disease, for over a year. Twenty showed satisfacto 
symptomatic nâ haematological remissions with a 
mean duration of eight to nine r:-_onths, following an 
average course of 30 mg. TEM. 
The advent of TEM has been another contributio 
to the palliative treatment of certain chronic 
malignant diseases. Its effects as most agree, and 
as one would expect from its chemical structure, ar 
similar to those of the nitrogen mustards. Its 
advantage lays in the fact that it may be 
administered orally and patients may therefore be 
treated as out- patients. A drawback is the 
variability of response in individual patients whic 
may lead to serious toxic manifestations. The 
attempt to produce more consistent effects by 
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rescribing alkalies with T_;L, or using enteric 
,oated capsules has not, in the author's experience, 
altogether corrected this difficulty. Although 
oxic symptoms are less than the nitrogen mustards, 
'EM is a powerful Lone marrow depressant, and in 
inexperienced hands is likely to result in marrow 
aplasia, with consequent infection and bleeding. 
egular blood examinations must be carried out 
'urine- treatment and further courses of TEM must not 
given until the total leucocyte count is normal. 
In view of the existence of equaily satisfactor 
and less toxic compounds, it is unlikely that TEM 
:;rill be used in the treatment of chronic myeloid 
eukaemia. Similarly the treatment of _)olycythaemia 
rera with x -rays, including radio- active -- phosphorus 
(P 32) is not likely to be displaced by TEM. WhethAr 
r not patients with advanced Hodgkin's disease, 
ymphosarcoma or chronic lymphatic leukaemia should 
treated with TEE.. or the original nitrogen mustards 
emends upon the preference of the individual 
hysician. The author suggests that the methyl -bis 
TLi roger mustard given intravenously is probably 
till the treatment of choice in advanced Hodg An's 
,isease, especially when a rapid therapeutic res_;onse 
s required. Chronic lymphatic leukaemia failing to 
espond to irradiation satisfactorily, in the 
resence of weight loss, anaemia, and a rising 
eucocyte count may be benefited by TEM Ahli5 this ma 
y 
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Tell be There the main usefulness of TEM lies. 
. Diethylene rhosrhoramide (DFPAL triethylene 
-^hosphoramide, and triethylene thio; hosphoramide. 
The encouraging results obtained with triethylene 
melamine in the treatment of leukaemia and related 
lisorders led to the synthesis and testing against 
-.nimal tumours of a number of other ethylenimine 
lerivatives with nitrogen mustard -like activity. 
ncluded in this series were the phosphoramides, 
d iethylene Dhosphoramide (DEPA) , and triet hylene 
nhosphoramide (TPA) . Because of their ability to 
inhibit the growth of transplantable mouse leukaemi 
(Burchenal et al. 1952 a) and mouse and rat tumours 
(Buckley et al. 1951 Stock et al. 1952; Suguira 
nd Stock 1952) , and as the growth of these animal 
tumours were inhibited at smaller fractions of the 
LD 50 as compared with triethylene melamine, they 
riere selected for trial against human neoplasma. 
reliminary pharmacological and pathological studie 
of the effect of these phosphor amides in various 
animals demonstrated a close similarity between 
their effects and those produced by triethylene 
nelamine viz. bone marrow depression, lymphoid 
ypoplasia and dam ge to the intestinal mucosa. In 
view of their similarity in structure to triethylen 
nelamine this is not altogether surprising. 
(Fig. 9) 
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Sykes et al. (1953) have described their 
clinical experiences with these two compounds. 
DEPA was given to nine patients with a variety of 
neoplastic diseases. The preparation was given 
intravenously in doses of 10 mg. daily up to an 
average total of 90 mg. (mg./Kg.) over a period of 
approximately three weeks. Patients with acute 
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leukaemia, chronic myeloid leukaemia and lympho- 
sarcoma showed no substantial benefit and only a 
single patient with far -advanced Hodgkin's disease 
showed definite, but only transient, improvement. 
The limiting factor in treatment was haematological!, 
and in one patient severe bone marrow depression 
occurred. 
TEPA was given intravenously in pea -nut oil at 
an average dose of 80 to 120 mg. (1.2 to 2.0 mg. 
per kg.) given in four to six divided doses over a 
two week period, to twenty -eight patients. Results 
were generally disappointing. Definite subjective 
improvement was, however, observed in two patients 
with chronic lymphatic leukaemia, associated with a 
fall in the leucocyte count, a rise in haemoglobin 
level and some shrinkage in size of enlarged lymph 
nodes and spleen. The authors concluded that 
neither DEPA or TEPA, in their limited series, 
showed any advantage over the nitrogen mustards 
or TEM. 
Farber et al. (1953 a) treated sixty -nine 
patients with TEPA. Those with acute or chronic 
leukaemia were not materially benefited and only 
one patient with Hodgkin's disease was improved. 
Occasional temporary improvement was recorded in 
patients with neuroblastoma and malignant melanoma. 
The clinical results with DEPA and TEPA have 
shown them to be disappointing as chemotherapeutic 
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agents. More encouraging results, however, have 
been reported recently using another phosphoramide, 
triethylene thiophosphoramide (Thio -TEPA). This 
compound with a chemical structure shown below 
(Fig.10 ) was found to suppress the activity of 
experimental rat leukaemia (Sparks et al. 1953, 
Shay et al. 1954) and to have a similar 
pharmacological action as nitrogen mustard, TEM, 
DEPA and TEPA. In a preliminary report Shay et al. 
(1953) shared thio -TEPA to produce effective 









Triethylene thiophosphoramide (Thio-TEPA) 
Fig. 10 - 
No nausea or vomiting or local reaction 
followed its intramuscular or intravenous 
administration. The usu -.l parenteral dose was 2 to 
10 mg. daily diluted in 10 mis. sterile saline when 
given intravenously, the total dose depending on 
the condition being treated as well as upon the 
haematological response. Over dosage resulted in 
bone marrow depression comparable to that observed 
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following treatment with other ethylenimines. Shay 
and his colleagues, however, found that such 
(lenression was readily reversed by withholding the 
drug. Thio -TEPA did not bring about remissions in 
acute leukaemia and lymphosarcoma was not materiall 
benefited. One patient with Hodgxin's disease was 
much improved following Thio -TEPA. In both chronic 
myeloid and chronic lymphatic leukaemia a fall in 
leucocyte count with diminution in size of the 
spleen together with symptomatic improvement was 
shown to occur in ten out of the fourteen patients 
treated. By giving occasional maintenance doses of 
Thio -TEPA the patients clinical condition was 
satisfactorily maintained. This original report by 
Shay et al. (1953) represented a clinical 
experience of only six months' duration. In a 
recent publication, (Zarafonetis et al. 1955) the 
same group of workers described the effect of Thio- 
TEPA in a further nine cases of chronic myeloid 
leukaemia and two cases of chronic lymphatic 
leukaemia. One patient with chronic myeloid and on- 
with chronic lymphatic leukaemia had been maintaine 
in remission for approximately twenty- months, while 
three additional cases of chronic myeloid leukaemia 
had been under treatment for over a year with 
excellent clinical and haematological results. The 
remainder showed good initial responses but three 
terminated in an acute myeloblastic phase within a 
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few months of the start of treatment. 
One of the drawbacks of Thio -TEPA at the 
outset was that it had to be administered 
-oarenterally. Zarafonetis et al. (1955) have now 
described their results using an oral preparation 
in doses of 5 to 10 mg. daily as being just as 
effective. Results on a larger series of patients 
and the opinion of others using this new compound 
are awaited with interest. These early studies 
suggest it may be a useful compound_ in the 
management of patients with chronic leukaemia, 
and the absence of side -effects in contrast to the 
other members of this group of compounds, is an 
important additional recommendation. 
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URETHANE 
Urethane (ethyl carbamate) 
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Urethane, first synthesised by Dumas in 1834, 
belongs to a group of carbamic esters .Known 
collectively as urethanes because of their 
structural similarity to urea. The term urethane 
has, however, been generally applied to ethyl 
carbamate itself. The commonly known pharmacologic 
properties of urethane are those concerned with 
anaesthesia. Schmeideberg (1885) originally studie 
its narcotic properties in dogs, while Jolly was 
apparently the first to note the effectiveness of 
urethane as a hypnotic in clinical medicine. It, 
however, only enjoyed brief popularity as a 
hypnotic towards the end of the nineteenth century 
and was later replaced by the more dependable 
barbiturate group of drugs. 
Urethane appeared as a chemotherapeutic agent 
as a consequence of experimental work on the growth 
inhibiting effects of various carbamic esters on 
animal tumours carried out by Haddow and Sexton 
(1946). Urethane having the most potent tumour 
inhibiting properties was selected for therapeutic 
trial in advanced cases of human malignant disease. 
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These clinical trials were begun in 1943, and were 
carried out initially at the Royal Cancer Hospital, 
London, and later at the Christie Hospital and Holt 
Radium Institute, Manchester. An incidental 
observation during these studies was niade by 
Paterson who noted a fall in the leucocyte count 
during urethane therapy. This suggested its trial 
in patients with leukaemia. It should be mentioned 
however, that the effect of urethane on the 
peripheral blood had been observed some years 
previously by Hawkins and Murphy (1925), during 
preliminary studies prior to determining the effect 
of X -rays on the leucocytes of rats and rabbits, 
using urethane as the anaesthetic. They demonstrat d 
a fall in the circulating lymphocytes and an increa.e 
in polymorphonuclear cells following its injection 
into these animals, and suggested this effect of 
urethane may have been responsible for the difference 
of opinion concerning the effect of X -rays on 
lymphocytes, since many investigators at that time 
used urethane anaesthesia. In contrast to these 
observations in animals, Paterson et al. (1946) 
found in human subjects with breast carcinoma that 
the cells of the polymorphonuclear series were 
vainly affected. 
The mode of action of urethane remains 
nknown. Paterson et al. (1947) has described it i 
he broadest sense as being related to "mitotic 
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disturbances induced in_the leukaemic cells." 
Haddow and Sexton (1946) suggested it interfered 
with purine metabolism while Kirschbaum and Lu 
(1947), experimenting with leukaemic mice, 
suggested that urethane interfered with mitosis in 
the blast cells. Johnston (1942) had earlier note 
that urethane had an anti -sulphanilamide effect 
similar to that of Para- aminobenzoic acid and 
suggested the growth inhibiting properties of 
urethane were due to interference with utilization 
of some natural amine in cellular metabolism. 
Interference with cellular dehydrogenases or other 
enzyme systems has also been suggested, while 
Osgood and Chu (1948) studied the action of 
interference in marrow culture. An early increase 
in mitosis followed by nuclear fragmentation in th- 
granular cells was observed. 
Urethane has been shown to produce prolonga.tioi 
of survival time in both mouse and rat leukaemia 
(Engstrum et al. 1947; Murphy and Sturm 1946; 
Burchenal et al. 1948) 
Paterson et al. (1946) first published the 
results of urethane therapy in human leukaemia. 
The initial dosage of the drug varied but was 
generally 3 - 4 Gm. daily, given orally, in a 
solution of chloroform water and syrup of orange. 
Nineteen cases of myeloid leukaemia were described .f 
which eighteen were chronic, the symptoms having 
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been present from one to thirty -three months. The 
other case was regarded as one of acute myeloblasti 
le=emia. The mean -period of observation was six 
months and six patients subsequently received x -ray 
treatment. The leucocyte count generally fell to 
20,000 per c.riim. in eleven to thirty -six days. The 
differential leucocyte count improved as the total 
white cells diminished in number and the haemoglo bi 
value rose by an average of 16.6 per cent. in ten 
out of thirteen ?patients. Marked diminution in siz 
of the spleen was observed, but anorexia, nausea, 
drowsiness, vomiting and occasional diarrhoea were 
unpleasant side- effects. Bone marrow depression 
was as serious complication of 
urethane therapy, and one patient was reported as 
dying with signs and symptoms of aplastic anaemia. 
Clinical and haematological remissions were 
rraintained for periods of two to six months. The 
response of chronic lymphatic leukaemia to urethane 
was less satisfactory and much more variable. This 
variation was shown not only in the dose required, 
but also in the time necessary for an adequate 
reduction in the white c,-11 count. The sr a le = i; 
total dose given j G., which lowered the white 
cell count from 48,000 to 7,000 per c.mm. in nine 
days. At the other extreme, however, 360 G. failed 
to reduce a white cell count of 750,000 per c.mm. 























white cells with an associated improvement in the 
distribution of white cells in the peripheral blood. 
Excessive dosep,e in either disease was again pointe 
out as liable to lead to bone marrow aplasia. 
The initial observations by Paterson and her 
olleagues were verified by several other workers. 
reskoff et al. (1948) administered 4 G. of urethane 
aily to twenty -four patients with leukaemia. 
hronic myeloid leukaemia was benefited more than ti - 
lymphatic variety and acute leukaemia was found to b- 
ninfluenced by the drug. Nausea was the commonest 
oxic symptom, occurring in 50 per cent. of patients . 
omiting, drowsiness, sweating and diarrhoea also 
eca.sionally occurred. Two patients developed bone 
-farrow aplasia. Intravenous administration of 
rethane was described as being both highly effectiv 
nd more agreeable in that nausea was prevented. 
Watkins et al. (1948) also noted temporary 
remissions in patients with chronic myeloid leukaemia, 
similar to those occurring after radiotherapy. 
Maintenance therapy was recommended in an attempt 
to prolong remissions, the daily dose being highly 
variable but in some 0.5 to 1.0 G. was found adeauat,e. 
The longest period of observation was eight months. 
Gastro - intestinal symptoms were the main toxic 
side -effects, the severity of which were found to 
be associated with the size of dose administered. 
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urethane was of value in myeloid leukaemia stressed 
the dangers of aplastic anaemia and recorded a 
fatality due to same. Leucutia (1948), Bedinger 
t al. (194'), Heilmeyer (1948) and Hoeschlin (1947) 
lave also made contributions to the literature on 
the subject of urethane treatment of leukaemia. 
Ieilmeyer claimed occasional good responses in 
atients with acute leukaemia and observed a 
emission l sting two years in one patient with 
acute myeloblastic leukaemia. Wilkinson (1953) 
onsidered that urethane was inferior to either 
rradiation treatment or nitrogen mustard in the 
reatment of chronic leukaemia, and stressed that 
deauate haematological control was necessary on 
ccount of the dangers of aplastic anaemia, 
granulocytosis and thrombocytopenic purpura. 
Loge and Rundles (1949) treated four patients 
lith multiple myeloma with urethane for eight to tel 
eeks in total doses of 120 to 290 G., with striking 
enefit. A decrease in myeloma cells occurred and 
he characteristic biochemical abnormalities became 
ess pronounced or disappeared. Serial x -rays of 
he skeleton shaed no progression in the destructive 
esions but there was little evidence of 
ecalcification during the four months following 
reatment. In a later report, Rundles and Reeves 
1950) described the effect of urethane in a series 
f twenty -four patients observed over a two year 
149. 
period. In addition to a disa- opearance of pain, 
fever and acute symptoms and a decrease in anaemia, 
recalcification in bones was occurring in some 
patients by the sixth month after institution of 
therapy. Harrington and Moloney (1950) found 
urethane to be more beneficial in patients with a 
more chronic type of multiple myeloma. In six of 
their eleven cases both clinical and biochemical 
improvement occurred coinciding with a diminution 
of myeloma cells in the bone marrow. They 
recommended a daily intake of 3 to 6 G. of urethane 
for the majority of patients although individual 
variability accounted for a dose range of 1 to 12 
G. daily. Wilidnson (1953) has also reported 
beneficial effects in multiple myelomatosis after 
urethane therapy and more recently Inns and Rider 
(1955) have obtained good results using R 151 in 
conjunction with urethane, and suggested a 
synergistic action between the two compounds. 
The main usefulnessof urethane has undoubtedly 
been in the chemotherapy of chronic myeloid leukaemia, 
and to a lesser degree in chronic lymphatic leukaemia. 
'kith initial doses of 3 to 4 G. per day followed 
when the leucocyte count has fallen to 40 to 50,000 
ier c.mm. by a maintenance dose of 0.5 to 2 G. daily, 
rolonged remissions have resulted in many ;patients 
ith chronic myeloid leukaemia. An important 
çivantage of urethane is its ready availability and 
150. 
low cost. It has, however, several disadvantages. 
he remissions are of course only temporary and 
rethane is of little value in the late, terminal 
stage of the disease. It causes nausea in at least 
50 per cent. of patients and may give rise to 
psetting vomiting and other alimentary disorders. 
More serious are the effects on the bone marrow and 
several fatalities due to marrow aplsia are 
recorded. On this account, regular blood examinati 
is essential during treatment. Urethane administerE 
intravenously as a 20 per cent. solution may result 
in fewer side effects, but is generally impracticab 
although urethane is still widely used it seems 
likely that newer and less toxic preparations such 
as myeleran and -possibly 6- mercaptopurine will 
gradually replace it. 
Only isolated reports of the n rits of urethan 
in carcinoma have appeared and these mainly relate 
to prostatic cancer. It is now accepted that 
rethane does not hold any significant place in 
cancer therapy. 
One glace in therapeutics urethane is likely t 
hold, harever, is in the treatment of multiple 
myeloma. Subjects with dimmeminated disease, genera: 
so refractory to treatment, have been shown to obtai 
relief from large doses of urethane. Symptoms 
disappear, fever settles, and biochemical 






diminish in number. In some recalcification of 
bone has been described (Rundles and Reeves 1950). 
There seems little doubt that urethane has obtained 
a place along with radiotherapy, stilbamidine and 
pentamidine in the management of patients with 
multiple myeloma. 
152. 
D± ;ACETYi,METHYL- COLCI-iICIïdE 
(Demecolcine; Colcemid) 
One of the most recent chemical agents to be 
used with some success in the treatment of myeloid 
leukaemia is a derivative of colchicum, 
deacetylmethyl- colchicine, now marketed in Great 
Britain as Colcemid. 
Colchicine has for several years been known to 
arrest mitotic division of cells in general in the 
metaphase (Lits 1934; Brues and Cohen 1936; 
Ludford 1937) and to inhibit the growth of certain 
animal tumours (Lits et al. 1938; Ludford 1945). 
The action on normal cell division and the upsettin 
side effects associated with its administration hav 
gone far in preventing the therapeutic use of 
colchicine in human malignant disease. In 1950 
Santavy and Reichstein isolated a series of new 
alkaloids, from the seeds, blossoms and bulbs, of 
the meadow saffron = Colchicum) which were less toxi 
This decrease in toxicity they observed was also 
accompanied by a diminution of the antimitotic 
rction. One of these compounds, named by Santavy 
and Reichstein as "Substance F ", was investigated b 
Bock and Gross (1953) who noticed that it had a 
selective action on myeloid cells and in chronic 
myeloid leukaemia resulted in a fall in white cells 
associated with an increase in the number of 
metaphases. Ivioeschlin, Meyer and Lichtman (1953) 
showed in animal experiments that this compound, 
153. 
"Substance F ", ._or now known as Demecolcine, was 
thirty times less toxic than colchicine and 
supported the observations of Bock and Gross (1953) 
that it had a marked elective ; eDres _er effect on 
granulocytes. They also found it to be effective 
in chronic myeloid leukaemia and by the use of a 
daily maintenance dose were able to maintain the 
blood picture satisf?ctorily. Chronic lymphatic 
leukaemia did not respond so well and no success 
was obtained in patients with multiple myeloma, 
E_od :in's disease, 17mphosarcoma, carcinoma and 
sarcoma. Bock and Gross (1954) reported their 
results of treatment in twenty -seven pat Tents with 
leukaemia or malignant tumours. Chronic myeloid 
leukaemia was the only disease to show a good 
response to treatment and acute leukaemia and chronic 
17m ha.tic le=aemia were not benefited. They 
observed no subjective complications but transient 
loss of hair, and, in five patients, a temporary 
herpetiform stomatitis developed following a 
marked drop in the leucocyte count. Piney (1955) 
reported a Mood response in one patient. He also 
observed a loss of hair during treatment but 
regrowth occurred in site of continued therapy. 
Wilkinson (1955) also observed good results in five 
patients out of seven. 
The usual dosage of Demecolcine or Colcemid 
reco__mended is 5 to 10 mg. daily at the outset 
154. 
as the leucocyte followed later count approaches 
normal, by 2 to 5 mg. daily as maintenance therapy. 
The improvement noted has been not only 
haematological but also clinical. The general 
condition improves, the size of the spleen 
diminishes and other evidence of the disease also 
regresses. Larger groups of patients must be 
studied, however, before the value of this new 
compound can be fully assessed. 
SUMMARY. 
1. The historical background to the chemotherapy 
of leukaemia has been reviewed. 
2. A comprehensive review of the chemotherapy of 
acute leukaemia has been presented. The folic acid 
analogues, ACTH and cortisone, and other analogues 
of nucleic acid precursors have been discussed. 
3. The subject of spontaneous remissions with 
reference to incidence, age, type of leukaemia, 
duration and the possible relationship of 
predisposing factors has been investigated. The 
possibility that spontaneous remissions may follow 
adrenal stress was suggested. The occurrence of 
spontaneous remissions is rare and therefore shoul . 
not interfere with the evaluation of chemotherapeut 
agents. 
4. Possible mechanisms of the development of 
resistance to the folic acid analogues have been 
discussed. 
155. 
5 Recent trends in the search for new agents 
effective in acute leukaemia have been reported. 
6. The chemical compounds available for the 
treatment of chronic leukaemia and allied disorders 
have been reviewed. 
'7. The toxic effects of the nitrogen mustard 
group of compounds on haemopoiesis have been studied 
in eighty patients with Hodgkin's disease. X -rays 
and the disease itself were found to produce 
terminal bone marrow depression, but the nitrogen 
mustards were the main cause. 
8. From a personal study of thirty patients with 
polycythaemia vera, treatment with radio- active 
phosphorus yielded good results, and the absence 
of side effects suggested that P32 was still more 




STUDIES IN THE METABOLISM OF 
4 A ,,,_:rNo -N10 METHYL PT EROYL- GLUTAMIC ACID 
(AMETIIOPTERIN) IN NORMAL AND LEUKAEMIC MICE 
A. Tissue distribution of Amethopterin in Normal 
Mice following Intravenous Injection. 
Probably as a result of the initial lack of a 
satisfactory simple method for assaying amethopter 
directly little has been reported on the fate of 
this compound following its administration either 
to human subjects or to the experimental animal. 
Swendseid (1952) using a back titration modificati 
of the standard method for microbiological assay o 
folic acid (PGA) has reported on the excretion of 
aminopterin (4- amino- pteroylglutamic acid) during 
treatment of leukaemic patients. The development 
by Burchenal et al.. (1951a) of a simple disc metho 
for determining the concentration of amethopterin 
in blood and urine suggested that such a technique 
might be of assistance in the study of the 
metabolism of this compound in animal tissues. As 
a preliminary to these studies, it was decided to 
attempt to determine the distribution of 
amethopterin in the tissues of the normal mouse 
following intravenous injection. 
Materials and Method 
Young mice of the inbred A.M stock, weighing 
approximately 20 G. each, were used. All the mice 




Laboratory Chow prior to and during the 
experiment. Water was allowed ad libitum 
throughout the experimente Each mouse was given a 
single injection of amethopterin at a dose of 
0.5 mg. /kg. by the intravenous route (into the tail 
vein). This was considered an optimum dose, 
producing. as demonstrated later, readily assayabl: 
amounts in the tissues and yet being well below 
the maximum tolerated daily dose, and approximatel 
1 /200th of the acute i.ä50 dose tri-erguson et al. 
1950). Mice were sacrificed at 15, 30, 60, 120, 
180 and 240 minutes after injection. under ether 
anaesthesia, blood was collected in a heparinised 
syringe by severing the axillary ves -els, the 
animal being finally killed by decapitation. In 
those mice injected one, two, and four hours 
previously the liver, spleen, kidneys and lungs 
were then removed and a sample of muscle taken 
from the hind leg. Each specimen was weighed and 
homogenised in distilled water (10 or 20 mis. 
depending on size) immediately after removal. 
Assay of Homogenate for. Ametho»terin Content. 
The samples were divided into two groups, 
(A) and (B); Sample (A) was unboiled, and (B) was 
boiled immediately for five minutes to destroy 
autolytic enzymes. The samples from group (B) were 
centrifuged and the supernatant assayed. In Group 
(.) the whole homogenate was assayed. Suitable 
159. 
dilution was carried out in both groups, following 
which 0.09 ml. was delivered to paper discs 
(Schleicher and Schuell penicillin assay discs, 
12.7 mm, diameter) placed on Difco folic assay 
medium containing 1 mY /ml. of PGA and inoculated 
with Streptococcus faecalis (A1TCC 6043) in a Petri 
dish. Following incubation over -night the zones o 
inhibition were measured and calculated against 
standard zones of known concentration of 
amethopterin. 
Details of Preparation of Assay Medium, 
Amethopterin Standards and Assa of Test Solutions 
(After _-urchenal et al. 1951a 
'r5 G. of Difco Folic Acid Assay medium, 30 G. 
agar, and 2,t E. of crystalline pteroylglutamic aci 
.:.ere added to 2,000 ml. of distilled water. This 
was heated to dissolve the agar, autoclaved 15 
minutes at 15 lb. pressure, cooled to 45 °C. in a 
water bath, and inoculated with 2 ml. of a twenty - 
four hour old broth culture of Streptococcus 
faecalis (ATCC 8043). After shaking thoroughly to 
mix the organisms throughout the media, 20 ml. 
aliquots were pipetted into 100 specially pressed 
flat bottom Petri dishes, arranged on a level 
surface, and allowed to solidify. These plates 
were then stored in the refrigerator at 4 00. and 
used when required one to ninety -six hours later. 
Using a specially purified sample of amethopterin 
(Seeger et al. 1949), standard tubes were prepared 
160. 
containing 5 ml. each of a solution of the 
compound at a concentration of 1,000 mÓ /ml. These 
stock tubes were frozen at -4000., and a tube 
removed when new series of standards were required. 
By diluting this stock solution with distilled 
water standards containing 5, 10, 15, 20, 25, 30 
and 35 mó /ml. were prepared. New standards were 
prepared for each experiment as follows. Four 
Petri dishes containing the assay medium inoculatec 
with Streptococcus faecalis were taken and on each 
were placed in turn four penicillin assay discs. 
0.09 mi. of one of the prepared standard dilutions 
was delivered with an automatic penicillin pipette 
to each disc immediately it was placed on the assa' 
medium. Standard dilutions of 5, 10, 15 and 20 
mV/ml. were placed on discs on each of two plates, 
and dilutions of 10, 25, 30 and 35 A/ml. on the 
remaining two plates. The standard was duplicated 
for accuracy. For further accuracy, on to a 
single disc on each test plate was delivered 0.09 
of a standard solution of 10 mó /ml. amethopterin, 
three other discs being inoculated with the test 
solutions of various dilutions - ranging from 
1 -5 to 1 -40 depending on the tissue and its 
expected amethopterin content as determined by 
preliminary experiments. Discs were inoculated 
with full strength serum and dilutions of 1 -3 and 
1 -10. The standard and test plates were then 
161. 
incubated for eighteen hours and the diameter of 
the inhibition zone read with a Bermuda Colony 
Counter (American Optical Co.) containing an etched 
glass scale graduated in millimeters. A standard 
curve was obtained by plotting the diameter of the 
zone against the concentration of the standard 
solution. The content of amethopterin in the test 
solutions was then calculated from the standard 
curve. 
Results 
Serum Levels. Fig. 11 shows the level of 
amethopterin in the serum in six series of normal 
mice-: It will be observed that after the first 
thirty minutes following injection the levels are 
closely related. In all cases the serum 
concentration has reached or ap_:roximated zero in 
four hours. 
Tissue Concentration. Table 9 shows the 
,concentration of amethopterin in the tissues. It 
will be noted that much higher concentrations of 
amethopterin were assayable in the boiled specimens 
(B) in the case of the liver and to a lesser extent 
in the spleen. This can be readily explained by 
the fact that enzymatic freeing of folic acid and 
citrovorum factor (C.F.) from their conjugates was 
prevented by boiling. In the unboiled specimens (A) 
on the other hand, incubation resulting in freeing 
of folic acid and C.F. which reversed some or all 
SERUM LEVELS OF AMET HO PTERIN IN NORMAL, 
AK4 AND AK4R MICE AFTER I.V. INJECTION 
x Sis AT 0.5m9./k9 
400- 
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of the amethopterin activity. This was significant 
as it was an indication of the folic acid and CF 
content of the tissue and suggested that the 
highest concentration was present in the liver and 
kidneys. Owing to the small quantity of free folic 
acid and CF present in tissues (Dietrich et al. 195 
it was presumed that the boiled specimens gave an 
accurate estimate of the amount of amethopterin 
present in the tissues. It can therefore be 
observed that the majority of the compound was 
Present in the liver followed in sequence by the 
kidney and spleen, while no significant quantities 
were found to be present in the lung after one hour 
and at no time in the muscle. 
In view of the retention of relatively large 
Quantities of amethopterin in the liver and kidneys 
after four hours at which time it had approximated 
zero in the serum, the amount of the compound 
present twenty -four hours after injection was 
determined. As may be seen, readily assayable 
quantities, little different from those found afte 
four hours, remained. 
B. Tissue Distribution of Amethopterin in 
Leukaemic Mice. 
Young mice of the inbred Akm stock (as used i 
the previous investigation) were injected intra- 
?eritoneally with 0.1 ml. of a saline suspension of 
leukaemic spleen so diluted that 0.1 ml. contained 
165. 
one million cells. Leukaemia AK4, an acute strain 
causing the death of the animal in an average time 
of twelve days was used as amethopterin was known 
to have a definite therapeutic effect against this 
particular strain of leukaemia (Burchenal et al. 
1949 b), In addition other mice of the Akm stock 
were given AK4R leukaemia, a strain of leukaemia 
made resistant to amethopterin by passing leukaemic 
cells generation after generation through 
amethopterin treated mice (Burchenal et al. 1950 a). 
Two groups of mice were therefore prepared, one 
with amethopterin sensitive leukaemia and the 
other with amethopterin resistant leukaemia. The 
possible analogy is the human subject with leukaemia 
which is sensitive to treatment, and the one which 
has developed resistance to treatment with 
amethopterin. Both groups of mice had an advanced 
degree of leukaemia when used in this experiment, 
as evidenced by a markedly enlarged and easily 
palpable spleen, and a high leucocyte count. 
The experimental procedure was the same as for 
normal mice, each mouse being given 0.5 mg. /kg. 
amethopterin intravenously and thereafter 
sacrificing the animals at various intervals and 
assaying the tissues for their amethopterin content. 
Total concentration of the antimetabolite in the 
tissues was obtained by boiling the homogenates to 
prevent freeing of PGA and CF. from their conjugates. 
166. 
Results. 
1. Ak4 Leukaemic Mice (Sensitive). 
As may be observed in Fig. 11 the serum leve s 
of amethopterin in the Ak4 mice is consistently 
higher over the four hour test period than those of 
normal animals. 
Amethopterin could be detected in all tissues 
assayed throughout the four hour period (Table 10) 
In contrast to the normal animals higher 
concentrations of the antimetabolite were present 
in the spleen and readily assayable quantities wer; 
present in the lungs. 
2. AkiR Leukaemic Mice (Resistant Strain). 
The findings in this group of mice were 
similar to those of the Ak4 strain (Table 10)(Fig. 11) 
The serum levels were generally nigher than the 
normal animals and the antagonist was demonstrable 
in all tissues over the four hour period. Although 
the level of amethopterin in the serum during the 
first two hours appeared lower in the mice with 
Ak4R leukaemia, no obvious difference in 
concentration of amethopterin in the tissues of 
mice with the sensitive and amethopterin resistant 
strain of leukaemia could be detected. 
Discussion 
It has been shown by the experiment on normal 
mice that following the administration of 
amethopterin it became concentrated in folic acid 
167. 
1 Hour 2 Hours 4 Hours 
Ak4 Ak4R Ak4 Ak4R Ak4 Ak4R 
Liver 1397 (4) 1170 (4) 814 (4) 748 (4) 542 (4) 599 (4) 
(2 - 2.5 G.) 
Kidneys 213 (4) 197 (4) 168 (4) 163 (4) 167 (4) 126 (4) 
( .35 - .45 G.) 
Spleen 142 (4) 143 (3) 139 (3) 127 (4) 127 (4) 116 (4) 
( .35 - .6 G.) 
Lung 97.5 106 (4) 31 (3) 46 (4) 24 (3) 63 (4 ) 
( .2 - .3 G.) 
TABLE 10 Average concentration of Amethopterin in tissues of Ak4 and Ak4R 
mice following i.v. injection at 0.5 mg. /kg. expressed in 
me /organ (boiled specimens) . 
Figures in parenthesis denote number of mice tested. 
168. 
and CF containing tissues. In addition it was 
observed that the highest concentration of 
amethopterin was found to be present in the liver 
followed in order by the kidney and spleen. This 
was of interest in view of the fact that a 
similar distribution of folic acid and CF has been 
demonstrated in the rat, guinea pig and chick 
tissues by direct microbiological assay (Dietrich 
et al. 1952). This tissue selectivity of 
amethopterin was not unexpected in view of the 
known properties of this compound, and supported 
the view that the antimetabolite replaces the 
metabolite, in this case amethopterin, and folic 
acid and CF respectively, in the enzyme systems in 
which they are associated. It also was additional 
evidence that the main action of the folic acid 
analogues in suppressing the acute leukaemic 
process is by interfering with the utilisation of 
folic acid and CF. It was suggested from this 
study that in normal mice, following an injection 
of amethopterin, most of the compound is rapidly 
excreted or metabolised within foúr hours, the 
serum level by that time having reached or 
approximated zero. The remainder is concentrated 'n 
folic acid and CF containing tissues. The 
continued presence of amethopterin activity in the -e 
tissues after twenty -four hours or more indicates 
failure of the mouse tissues to complete the 
169. 
metabolism of amethopterin. 
The intravenous administration of amethopterin 
in mice with a strain of leukaemia (Ak4) known to 
be sensitive to amethopterin resulted in a more 
widespread distribution of the compound in the 
tissues and higher concentrations in the serum as 
compared with the normal tissues. Although the 
amethopterin content of the liver and kidney showed 
little change from that in the normal animal - wher- 
the concentration was found to be the highest - the 
concentration in the leukaemic spleen was six times 
that observed in the normal. Similarly, readily 
assayable quantities of amethopterin were present 
in the leukaemic lung after four hours. The 
suggested inference was that in the leukaemic 
animal a more widespread distribution of amethopte in 
occurred possibly as a result of the affinity of 
the leukaemic cell for amethopterin. It should, 
however, be remembered that the mice had advanced 
leukaemia and the possibility of the higher serum 
levels of amethopterin being due to impaired renal 
function cannot entirely be excluded. Burchenal 
et al. (1951a) have demonstrated the effect of renal. 
function on serum levels of amethopterin in human 
subjects. In the present study, however, if 
retention of the drug had occurred due to renal 
dysfunction one would have expected to find a 
higher concentration in the liver and kidneys, 
170. 
where as previously mentioned the total content of 
amethopterin was no higher than in the normal 
animal. 
Amethopterin was found to concentrate in the 
tissues of mice with Ak4R (amethopterin- resistant) 
leukaemia in a manner similar to that observed in 
the sensitive leukaemia. No indication that 
amethopterin was altered in any way by the 
resistant cell was observed. 
171. 
C. Retention of Amctho-oterin in Animal Ttssues. 
In the previous experiment it was shown that 
following the intravenous administration of 
amethopterin in normal mice at a single dose of 
0.5 mg. /Lg. the majority of the compound was rapidi 
excreted or metabolised within approximately four 
hours. The remainder was found to be concentrated 
mainly in those tissues (liver and kidneys) 
containing relatively high concentrations of folic 
acid and citrovorum factor. The detection of the 
anti -metabolite in significant áuantities (approx. 
6 per cent. of the injected dose) in these organs 
twenty -four hours following injection suggested a 
delay or failure in excretion, or in completion of 
its metabolism. As a consequence of this finding 
it was considered of interest to attempt to 
determine for what; period of time following the 
administration of amethopterin, using various 
dosage schemes, assayable amounts of antimetabolito 
remained in the tissues in the normal mouse. Also 
by implantation of amethopterin resistant leukaemi . 
cells intraperitonealiy into normal mice, 
previously given amethopterin, whether the resista 
cell affected the concentration and retention of 
the antagonist in the tissues. Finally metabolic 
studies in human subjects were performed in an 
attempt to detect any differences in the 
metabolism of amethopterin in the non- leukaeinic, 
172. 
leukaemic, and leukaemic patient who had become 
resistant to amethopterin therapy. 
(1) Normal Mouse Ti s sues. 
Materials and Methods. 
The mice used in this experiment were of the 
inbred Akm stock weighing approximately 20 G. All 
were young mice of approximately the same age. 
Groups of mice of different sexes were used. 
Previous to and throughout the experiment the mice 
-ere fed the standard Purina Laboratory Chow diet. 
For convenience of description the mice used 
in this study are best divided into five groups. 
Group 1 (31 mice) received amethopterin intra 
peritoneally at a dose of 3 mg. /kg. on alternate 
days for a total of three injections. Thereafter 
mice were sacrificed at intervals as shown in Tabi 
up to twenty -one days and blood collected and 
homogenates of the liver, kidneys, spleen and 
lungs prepared in a manner described in the previo 
experiment. All homogenates ere boiled immediate 
for five minutes to inactivate conjugase. Each 
specimen was thereafter centrifuged and the 
supernatant assayed for amethopterin activity by 
the plate assay technique also described previousl 
Group 11 (13 Dice) received 1 mg. /kg. intra- 
peritoneally on alternate days for a total of 
three injections. 




peritoneal injection of 3 mg. /kg. 
Group 1V (12 mice) was given 1 mg. /kg. intra- 
venously on alternate days for three injections. 
All mice in Groups 11, 111, and 1V, were 
sacrificed at intervals over the twenty -one day 
Period and the tissues assayed for amethopterin as 
for Group 1. 
Group V (18 mice) were each given amethopteri 
as for Croup 1. Seventy -two hours after the last 
injection two mice were sacrificed and the tissues 
assayed for the Tresence of anti- metabolite. 
Thereafter at daily intervals all the, remaining 
mice were given citrovorum factor intraperitoneall7 
at doses ranging from 0.5 to 30 mg. /kg. Mice were 
tilled daily, twenty -four hours after the last 
injecti ̂ n of CF, and tissues assayed for 
amethopterin as outlined previously. 
Results. 
Cc.ntrol mice not injected with amethopterin 
showed no evidence of any inhibitory substance in 
the tissues. 
Table 11 shows the concentration of 
amethopterin in mó /G. of wet tissues in the organs 
of mice of Group i - 1V. Throughout the twenty-on 
day period mice in these groups showed the presenc: 
of amethopterin in high concentration in the liver 
and kidneys. The levels remained remarkably 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































the concentration in the kidney over the test 
period, there was little evidence that the compound 
was being metabolised or excreted. The size of 
the dose and mode of administration bore no 
relationshi to the amethopterin concentration. 
Similar results were observed following a single 
injection of 0.5 mg. /kg. and also with a single 
dose of 20 mg. /kg. 
Apart from small Quantities of amethopterin 
of doubtful significance detected in the spleen 
and lung within seventy -two hours after the last 
injection, no assayable Quantity was present in 
the lung or spleen during the twenty -one day period 
The serum was of interest in that amethopterin 
was recovered in small amounts in all groups at 
intervals throughout the period of the experiment. 
The serum levels of Group 1 mice are shown in 
Fig. 12 and similar levels were detected in 
Groups 11 to 1V. Following the administration of 
CF to mice in Grouo V the serum level of 
amethopterin rose to significantly higher levels. 
In order to be assured that the serum level was 
relatively free of CF it was not tested for 
amethopterin in the majority of instances until 
twenty -four hours following the injection of CF. 
The actual amount of CF administered did not 
appear to bear any relationship to the height of 
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FIG. 12. Concentration of amethopterin in the serum, 
liver and kidneys of two groups of mice. (A) . methopterin 
3 mg /kg X 3 i.p., alternate days. (B) As for (A), followed 
by daily i.p. inj. of citrovorum factor. 
0 
177. 
_(2) Tissues of Uice with amethoiterin- resistant 
leukaemia (Aie R) . 
Materials and Iiethod. 
In view of the short survival time of mice 
with Airs R leukaemia it was impracticable by 
administering amethopterin to the animal with 
advanced leukaemia to observe whether it was 
retained in the tissues as in the normal animal. 
In order to determine the effect of the resistant 
leuka_emic cell on amethopterin it was decided to 
administer the compound to normal mice and later 
transplant Ak,R leukaemia to these animals. 
Six mice of the Aiïm breed were riven three 
injections of amethopterin intraperitoneally at a 
dose of 3 rag. /!gig. on alternate days. Fourteen days 
after the last injection all the mice were given a 
suspension of leukaemia spleen intraperitoneally 
from a mouse with advanced Ak4R leukaemia, in a 
manner similarly to that for transmitting sensitive 
Ake, leukaemia as described previously. When the 
mice had developed evidence of advanced leukaemia 
as shown by considerable sulenic enlargement, they 
were sacrificed, homogenates of the liver, kidneys, 
spleen and lung prepared, boiled for five minutes, 
and after centrifuging and diluting assayed for 
their amethopterin content. 
Results. 
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Av. Concn. Amethopterin 
6 Mice (m0G. 
Liver 
(Av. wt. 2 - 3 G.) 
Kidney 
(Av. wt. .4 - .6 G.) 
Spleen 
(Av. wt. .35 - .65 G.) 
Lung 







It will be observed that assayable quantities 
of amethopterin were still present in the liver, 
kidneys and spleen in all mice (Table 12): 
Taking into account the increased weight of the 
organs the concentration of amethopterin in the 
liver and kidneys was similar to that found in 
normal mice. That in the spleen was, however, 
considerably raised which again indicated the 
affinity of leukaemic tissue for the antimetabolite. 
There was thus no evidence to suggest the trans- 
plantation of Ak4R leukaemia into mice previously 
given amethopterin had any effect on the 
concentration of amethopterin in the tissues, which 
appeared to be retained in the mouse with resistant 
leukaemia in a manner similar to the normal animal. 
The resistant leukaemic cells did not appear to 
utilise or metabolise, at least detectable 
quantities, of the antimetabolite. The possibility 
that deamination to a weaker antagonist, 
179. 
N10- methyl Dteroyl- glutamic acid Çmethopterin), 
occurred could not ha *r ever be ruled out as this 
compound like amethopterin inhibits the growth of 
S. faecalis. 
(3) Amethopterin Excretion Studies in Leukaemic 
í&&:dion- Leukaemic Subjects 
In conjunction with Drs. Burchenal, Murphy, 
Ellison and Hutchison, a study of the excretion 
of amethopterin in human subjects was carried out 
at the same time as the animal studies were in 
progress. 
Materials and Methods. 
Twenty -seven patients witli acute leukaemia 
(of various ages, size and weight), some of whom 
later developed remissions on amethopterin 
treatment and some who were resistant to the anti - 
folies, and ten patients with advanced carcinoma, 
were given 0.05 mg. /kg. amethopterin intravenously, 
after ensuring that renal function was normal. 
The significance of impaired renal function had 
previously been pointed out by Burchenal et al. 
(1951a). Venous blood samples were thereafter 
collected at 5, 15, 30 and 60 minutes intervals 
and the blood allowed to coagulate. Serum was 
removed with a Pasteur pipette and diluted:. Full 
strength serum and 1 -3 and 1 -10 dilutions were 
found to be satisfactory for assay purposes. The 
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amethopterin content of the serum was then 
measured by means of the plate assay technique 
described previously (page 
In twenty -four leuïcaemic and non- leukaemic 
patients urine was collected throughout the six 
hour period following the administration of the 
drug, the patient being asked to empty the bladder 
at the end of this period. This short, six hour 
excretion test was performed. because Burchenal 
et al. (1951a) had previously demonstrated that 
when a 5 mg. dose of amethopterin was given orally 
to a normal human subject on an empty stomach, over 
90 per cent. of the total amount excreted was 
passed in the urine within six hours. Preliminary 
studies e:tending over twenty -four hours showed 
this also to be the case when amethopterin was 
given intravenously. The intravenous route was 
preferred in order to overcome any possible 
variations in absorption and to ensure a rapid 
uptake by the tissues and rapid excretion. 
The quantity of urine passed in the six hour 
Period was measured after which suitable dilutions 
(1 -50 to 1 -500) were prepared and the amethopterin 
content per ml. determined. The total amount of 
amethopterin excreted and the amount expressed as 
a percentage of the dose administered was then 
calculated 
The assay was performed on the day of the test 
181. 
in each case, the urine and blood samples being 
dept in a cold room at 4 °C. until reauired. 
Results. 
The serum levels, and percentge excretion 
at six hours are demonstrated graphically (Fig.13). 
It will be observed that the serum levels in the 
leukaemia patients closely followed the pattern 
observed in the control group. At the end of one 
hour in only three out of the total of thirty- seven 
_'ati eats were the serum levels still above 
50 mb /ml. In twenty -one of the total of twenty- 
four patients from both groups, the total excretion 
of amethopterin was found to be less than 60 per 
cent. of the injected dose. Considerable 
variation in the amount excreted was noted in both 
the leukaemia and non -leukaemic patients, ranging 
from 14 to 75 per cent. No obvious difference in 
rate of excretion between the leukaemia and control 
group was observed, nor did there a7pear to be any 
obvious difference between the antifolic- resistant 
and antifolic- sensitive acute leukaemias. For 
conclusive evidence a larger series should be 
studied, and normal individuals used as controls. 
The possible toxic -side effects associated with 
amethopteri n however precludes the latter, and the 
wide individual variation in excretion in both the 
leukaemia and control subjects indicates that either 
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very large series would have to be tested in order 
to demonstrate it. 
Discussion. 
It has been found that in normal human 
volunteers (iiurchenal et al. 1951a) only 40 to 57 
,er cent. of an oral dose of 5 mg. amethopterin 
was excreted in twenty -four hours, the majority 
within four to six hours. Studies in a series of 
thirty -seven leukaemic and non- leukaemic subjects 
showed a similar delay in excretion, thirty-four 
excreting less than 60 Per cent of the injected 
dose, 3vrend.seid (1952) also noted that variable 
amounts of arrminopterin were unaccounted for by 
renal excretion alone. It seems probable that the 
explanation for these findings may be similar to 
those found in the laboratory animal. 
It was evident from the previous experiments 
that a relatively high concentration of amethopteri 
persists in tissues of the normal mouse for a 
period of three weeks. Moreover, it appeared that 
within the dosage range used in these experiments 
the mouse could rapidly eliminate within twenty - 
four hours all the amethopterin in excess of a 
threshold amount which was retained in the liver 
and kidneys. The effects of very large doses of 
amethopterin on tissue retention were not studied 
as it was considered desirable to keep the dosage 
below the ranf'e which produces toxic manifestations 
184. 
(Ferguson et al. 1950) and within the chemotherapeutic 
range (''urchenal et al. 1949. The largest single 
dose given (20.0 mg.,/Lg.) was a.-_, rroxirnately one 
fifth of the acute L. D 50 dose while the nice in 
groups I and V received a dose (3 rnr. /leg.) comparable 
to that when given three times weekly prolongs the 
survival time of mice with transplanted leukaemia. 
Although small nuantities of amethopterin 
were found to be f r. eauently present in the serum 
there was little indication that any was being 
metabolised or e cereted after the first tenter -four 
hours and with the results of the previous 
experiments in mind (Table 9) probably after 
a beriod of four heurs following administration. 
Urine samples taken on several occasions at the 
time of sacrificing the animals failed to show 
the presence of r ethopterin. 
In keeping with the hypothesis that anti - 
metabolites function by excluding a structurally 
related metabolite from combination with its 
enzyme (Woolley 1952) and thus preventing the 
formation of an enzyme substrate complex, it was 
probable that the amethopterin retained for such 
long periods of time was incorporated ub to a 
relatively constant concentration in enzyme systems 
ordinarily associated with folic acid and CF and 
any excess was rapidly excreted, This incorporation 
appeared stable but not entirely irreversible as 
185. 
was shown by the rise in the serum level following 
the administration of C.F. (Fig. 12) 
The tissue concentration of amethopterin was 
however not affected to any extent by high doses of, 
C.F. which would explain the unsuccessful attempts 
to overcome the toxic effects of the folic acid 
antagonist in experimental animals (Higgins, 1949; 
Philips and Thiersch, 1949) and the leukaernic 
patient (Farber, 1949). The vitamin would appear 
unable to enter into body metabolic processes and 
is rapidly excreted. The work of Swendseid et al. 
(1952) in human subjects supports this concept. 
It was observed that none of the animals in 
Groups I - IV developed any evidence of folic acid 
and CF deficiency although retaining relatively 
high concentrations of amethopterin in the liver 
and kidneys for a period of three weeks. Studies 
in mice (Ferguson et al. 1950) have shown that 
the chronic L.D. 50 for amethopterin to be 1.9 mg./ 
kg. when given daily for five doses. This was of 
interest in view of the finding that a fortyfold 
variation in dosage of amethopterin (0.5 - 20.0 
mg. /kg.) when given in a single injection resulted 
almost identical concentrations of amethopterin 
in the liver and kidney twenty -four hours later. 
i 
Similar concentrations were noted following divided 
doses given on alternate days. Thus for folic acid 
and CF deficiency to occur an adequate increase 
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above the tolerated tissue concentration must 
presumably be obtained by administration of 
amethopterin at daily intervals. Another possible 
explanation might be the deamination of amethopterin 
to N10- methyl pteroylglutamic acid (methopterin) 
which is known to be a weaker antagonist ineffective 
as a therapeutic agent in leukaemia, but readily 
inhibits the growth of S. faecalis. Such a 
concentration of methopterin together with an 
adequate dietary intake of OF would possibly not 
lead to CF deficiency. 
By transplanting AkaR leukaemia to mice 
previously injected with amethopterin it was shown 
that the amethopterin resistant leukaemic cell 
had no effect on the concentration of the anti - 
metabolite.. This was of some importance for it 
suggested that the resistant cell did not apparently 
utilise amethopterin for its metabolism, which has 
previously been considered as a possible property 
of the amethopterin resistant cell. Whether or not 
the resistant cell may convert amethopterin to a 
weaker antagonist must however still be demonstrated. 
187. 
D. Identification of the Anti -metabolite in 
,souse Tissues foïlo}rri-ar administration of 
AmethoDteri n. 
The substance present in mouse tissues, after 
administration of amethopterin, with growth 
inhibitory _properties for Streptococcus faecalis ha 
to the present, been Presumed to be amethopterin. 
Because of the sugg::stion by many investigators 
that resistance to amethopterin in leukaemia may be 
due to conversion of the drug to a weaker antagonis 
(Page 61) it seemed_ of some importance to 
determine whether or not the anti-metabolite -oresen 
in normal mouse ti>._ues after injection of 
amethopterin, and similarly later in amethopterin 
resistant leukaemic mice was in fact amethopterin. 
It is well recognised that the antagonist activity 
of the folic acid analogues is increased by 
substitution of an amino Froup in position 4 of 
the pteridine ring and it seemed pos=,ible that 
deamination of amethopterin may occur in the mouse 
liver.. The deaminated derivative of amethopterin, 
methopterin (N10 methyl- pteroylglutamic acid) can 
s, 
inhibit the growth of Streptococcus faecalis but 
has no effect on the survival time of ALL mice 
(Burchenal et al. 1949b) nor is it able to modify 
the course of human acute leukaemia. 
It was therefore decided to attempt to identify 
the anti -metabolite -)resent in the liver of mice 
previously riven ame thopterin, using a combination 
188. 
of chromatograpiy and bio- autography. As a 
preliminary to this, the following two studies 
were carried out. 
1. Determination of Rf values of various Folic 
Acid. Analogues. 
Materials and Methods. 
Solutions of various analogues of folic acid 
were prepared as listed below. 
1. Amethopterin (4- amino -N10- methyl pteroyl 
glutamic acid) 
2. Aminopterin (4 -amino pteroyl glutamic 
acid) 
3. Methopterin (110 -meth l pteroyl glutamic 
acid 
4. Iodo - amethopterin 
5. Dimet -fol (9, 10- dimethyl pteroyl 
glutamic acid) 
6. A- Ninopterin (4- amino -9- methyl pteroyl 
glutamic acid) 
7. A- Denopterin (4- ar:-ino -9,10- dimethyl 
pteroyl glutamic acid) 
8. Bremfol ( Pteroyl 9- methyl glutamic 
acid) 
9. Amino -Anfol (4 -amino pteroyl aspartic 
acid) 
10. Anfol A (pteroyl aspartic acid) 
11. Amino- teropterin (4 -amino trigtutamic acid) 
Solutions 1, 2, 3, 4, 5, 6, '7, were prepared at 
oncentrations of 10 n/.01 ml., solution 3 at 
4/.01 0 /.Oî ml. , solution 9 at 100 W.01 ml., 
olution 10 at 3Ó /.O1 ml. and solution it at 
nil. 
189. 
Solvent System. Butyl Acohol (Butanol) and Acetic 
Acid, prepared by saturating butanol with water in 
separating flask, running off the butanol and to 
it adding 10 per cent. by volume of glacial 
acetic acid. The pH was taken and found to be 3.0. 
Paper Strip. Approximately 3" No. 1. Whatman paper 
Procedure. A fine pencil line (A) was drawn 5 ems. 
from one end of the paper strips, and on the centre 
of each was placed .01 mi. of the above solutions. 
The strips were then placed 'spot -end' lowermost 
in separate glass cylinders containing the solvent 
which reached a level of approximately 5 cms. from 
the bottom of the cylinder so that the lower end of 
the strips were just immersed in the solvent. The 
upper end of the strips were folded and fastened 
with a paper clip over glass rods resting over the 
mouths of the cylinders. 
The paper strips were allowed to remain for a 
Period of twenty -four hours until the solvent had 
moved high up the strips but had not reached the 
clip at the upper end. The strips were then 
removed and the upper level of the solvent flow 
marked immediately by pencil (B). After drying the 
strips were cut across at A and B and placed for 
five minutes on large Pyrex plates which contained 
ir ifco Folic Acid Assay agar plus PGA at 1 mi /ml. 
and seeded with S. Faecalis.. The position of each 





Bio- autographs of the three principal 




SOLVENT SYSTEM - Butanol pnd Acetic Acid. 
191. 
small Pieces of paper and after removal of the 
strips the elates were blaced in an incubator for 
a Period of sixteen to twenty -four hours. 
Results and Comments. (Table 13) 
Ali the test solutions were found to produce 
zones of growth inhibition. The Rf value for each 
folic acid analogue was determined by measuring 
(C) the ditance from the spot to the upper level 
of the zone of growth inhibition and (D) the 
distance from the spot to the maximum point of 
C 
solvent flow. Rf = D, The Rf values of the eleven 
folic acid analogues are presented in Table 
together with the approximate size of each zone of 
growth inhibition. 
It will be observed that it was possible to 
determine Rf values for the various analogues of 
folic acid by a combination of chromatography and 
bi o- autography. The inference, from this experiment 
was that, using a butanol- acetic acid solvent 
system, those analogues containing a methyl group 
in their molecule (samples 1, 3, 4, 5, 6, 7, 8) hay* 
similar Rf values much higher than those not 
containing a methyl group (samples 2, 9, 10, 11). 
Two separate zones of inhibition were noted in the 
case of Bremfol (Sample 8) suggesting the presence 
of an impurity. 
2. Separation of Ametho oterin from Citrovorum 
Factor in Sipple solution and from livers of 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Another preliminary experiment was to determii 
whether or not amethopterin could be separated 
chromatographically from growth factors present in 
mouse liver 
Materials and Methods. 
Solutions containing amethopterin and CF were 
prepared at concentrations tabulated below. In 
addition a normal mouse injected twenty -eight days 
previously with amethopterin at a dose of 3 mg. /rig. 
X 3, on alternate days, was sacrificed, the liver 
removed, weighed and muddled in 5 ml. distilled 
water, and boiled immediately and centrifuged. The 
concentration of antimetabolite in the supernatant 
of the liver sample :tires -then assayed by the plate 
technique. 
Three normal mice given amethopterin fourteen 
days previously at a dose of 3 mg. /kg. X 3, on 
alternate days, and thereafter given A 4R 
leukaemia by intraperitoneal transplantation of 
Ak,iR leukaemic cells were sacrificed when showing 
evidence of advanced leukaemia. The livers were 
removed, weighed, muddled and the homogenate boiled 
immediately and centrifuged as before and the 
antimetabolite content of the supernatant assayed. 
The chromatographic technique was similar to 
that described in the previous experiment. .01 ml. 
of the solutions containing amethopterin or 
mixtures of amethopterin and CF were placed on pape. 
194. 
strips and after drying developed for twenty -four 
hours in the butanol and acetic acid solvent 
system. 
With anowledg=;e of the content of anti- 
metabolite in each of the liver extracts it was 
possible to determine the volume containing an 
amount of between 7 to 10 m , a concentration known 
to give a good zone of inhibition This amount was 
placed on the paper strip, .01 ml. at a time with 
cool air drying between each application (hot air 
via a hairdrier resulted in a 'hard soot' and 
interfered with the chromatogram). Thereafter the 
strips were developed for twenty -four hours, using 
the butanol and acetic acid solvent system. 
After removal of the strips and drying, bio- 
autograms --ere prepared and the necessary 
calculations made as described. 
Materials. 
1. Amethopterin at 10 mi)./.01 mi. 
2. Amethopterin at 10 m / .01 ml. + CF at 
30 mh` /.01 ml. 
3. Amethopterin at 10 m4/.01 ml. + CF at 
60m' /.01ml. 
4. Normal Mouse Liver containing 308 mY 
antimetabolite /5 mis. distilled water. 
5. AkR Mouse Liver containing 355 m 
antimetabolite /5 mis. distilled water. 
6. AkaR Mouse Liver containing 526 m1( 
anfimetabolite/5 mls. distilled water. 
7. AkaR Mouse Liver containing 380 m ó 
anfimetabolite/5 mls. distilled water. 
195. 
Results and Comments. 
From this study it was evident that the 
-Presence of citrovorum factor did not interfere 
with the chromatographic and bio- autographic 
identification of the antimetabolite present in 
mouse liver after inoculation with amethopterin. 
The antimetabolite was found to have a similar Rf 
value to amethopterin and it was of considerable 
interest that the antimetabolite present in both 
the normal liver and the livers of mice with 
amethopterin resistant leukaemia had similar Rf 
values, using the butanol- acetic acid solvent 
system, (Table 14). As it had been observed 
previously, however, that folic acid analogues 
containing a methyl g-rou-, had similar Rf values 
the possibility that the antimetabolite was a 
weaker antagonist could not at this stage be 
excluded. In this connection deamination of 
amethopterin to methoi terin seemed possible and it 
Tan now decided to attempt to differentiate between 
these two substances, by the use of different 
solvent systems. From experience gained various 
modifications of technicue 7-:r. e to be employed in 
order to lead to a high degree of accuracy. One 
difficulty with regard to testing of the anti - 
i!etaboîite in liver samples was the need under the 
IN resent arrangements of putting a relatively large 







































































































































































































































































































tended to lead to a 'hard spot' and occsi onal 
i Li) irrJ nt of =' I r ';T. c,o.ic e:í11; 1't 1_..L`; the liver 
extract it was thought that this might be overcome. 
A large series of controls were also thought 
desirable. 
Identification of Anti -Metabolite in Normal Mouse 
Tissues Follo wing injection of .f-methooterin using 
using; three different solvent systems. 
Materials and Methods. 
A series of mice was injected i ntraferitoneal! 
with a iethopterin at a dose of 3 mg. /kg. These 
animals were sacrificed at half an hour intervals 
up to three hours then at four, five, seven, 
seventeen, te _ty -four, forty -eight, seventy hours, 
four, eight and fourteen days. Other mice not in 
this series were tested up to eight months after 
injection. The liver was removed from each animal 
and treated as previously mentioned, after which 
the supernatant was concentrated in vacuo to 
approximately 1 ml. 
As controls for this experiment homogenates of 
four normal livers were prepared. Amethopterin 
(0.51/G -) was added to the first preparation, 
methooterin (ú 1/G--) to the second, aminopterin 
(1Y/G-) to the third and to the fourth control was 
added a single preparation containing the three 
folic acid antagonists in the concentrations given 
above. These controls were boiled, clarified and 
c_oncentrat,ed like the test samples. .01 ml. of the 
198. 
liver concentrates were _laced on Eaton -Di Leman 
_To. 613 paper strips after :which the strips were r
developed for six to sixth.- -e1 tit hours in three 
different solvent systems; (A) 1 ar cent. 
aeueous (Wieland et al. 1952) , (3) 5 ?per 
cent. sodium citrate and iso -amyl alcohol (Wieland 
et al. 1952) and (C) 70 per cent. Iso- propanol, 
10 per cent. NE4OH, 20 per cent. distilled water. 
It should be mentioned that the paper strips were 
also buffered with 0.03 ,iaC 1P0_ . 
J 
After developing, the strips nere removed and 
air dried and placed on Pyrex -plates containing 
Difco Folic Acid Assay Agar plus folic acid at 
0.5 my /ml. seeded with S. faecalis for five minutes 
Thereafter the bio- autographs of the inhibition 
zones were observed after an incubation of sixteen 
hours. 
Results and Conclusions. 
With the technique described above it was 
possible to identify the antimetabolite which 
persisted in the mouse liver and to follow its cours 
in a series of mice. A bio- autograph of a series of 
liver samples and of the clinical amethopterin 
parenteral preparation) is presented in Fig. 14. 
Strip iio. 1 shows the separation of aminopterin, 
r:ethopterin and amethopterin. Strip No. 2 represent 
the particular sample of clinical amethopterin that 
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Fig. 14. Bioautographs of strips from alkaline iso- propanol system on 
S. faecalis (8043). 
Strip 1. .01 ml. of control liver concentrate which contained 
amethopterin, methopterin, and aminopterin. 
Strip 2. 100 m V of amethopterin, Lederle Lot No. 7 -8528. 
.01 ml. of liver concentrates following administration of amethopterin 
(3 mg. /kg.) . 
Strip 3. After 1 hr. 4.2 
5. 7 
6. 48 
7. 4 days 
8. 8 
9. 14 
10. 8 mo 
200. 
liver concentrates aminopterin was not detected 
after one hour and methopterin was present at seven 
hours but not at seventeen hours. It is po ible 
that these antifolics were excreted, but it is 
also possible that they cannot be detected because 
folic acid and CF appear to have approximately the 
same 2f values as aminopterin and methopterin 
respectively (Table 18) . The findin of three 
com_^onents in the ametho._Dterin molecule preparations 
complicates any metabolic study, but only the 
amethopterin content of tissues was considered since 
neither of the other two cony onents was detectable 
after seventeen hours. Amethopterin was detectable 
after fourteen days and in another series it could 
be identified by chromatography and bio- autography 
after seven months. 
Identification of amethopterin in a liver 
taken twenty -four hours after injection is 
demonstrated in Fig. 15: Strip 1 shows the three 
spots representing aminopterin, methopterin and 
amethopterin seen when these compounds were added 
to normal liver. Strip 2 shows the single spot 
found in liver of a mouse twenty -four hours after 
injection of amethopterin. When amethopterin was 
added to this liver preparation, only one spot was 
noted (Strip 3) but when methopterin (Strip 4) or 
aminopterin (Strip 5) was added a second spot 
appeared in addition to the original one representing 
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Fes. 15. Bioautographs of strips from alkaline iso- propanol system on 
S. faecalis (8043) . 
* Strip 1. .Ol ml. n.l.h. + 
.015 ml. n.l.h. + 
.01 ml. n.l.h. + 
¡ ** 






0.5 \,/g amethopterin (control). 
2 `, /g methopterin (control). 
1 /g aminopterin (control). 
hrs. after injection of amethopterin 
.01 ml. 1.c. 24 hrs. after injection of amethopterin 
(3 mg./kg.) + .01 ml. amethopterin control. 
.01 ml. 1.c. 24 hrs. after injection of amethopterin 
(3 mg. /kg.) + .015 ml. methopterin control. 
.01 ml. 1.c. 24 hrs. after injection of amethopterin 
(3 mg. /kg.) + .01 ml. aminopterin control. 
n.l.h. = normal liver homogenate 
** 
1.c. = liver concentrate 
202. 
amethopterin. Identical results were obtained in 
the iso- amyl alcohol and h2HPO4 systems. 
It was concluded that the inhibiting substanc 
present in the normal mouse liver twenty -four Tours 
to fourteen days after the administration of 
amethopterin having the same Rf value as 
amethopterin in three different solvent systems was 
in fact .amethopterin, which appeared to remain 
unchanged in the tissues. 
Identification of the Anti-metabolite in Tissues 
of LeuLaemic nice following the administration of 
Ametnopterin. 
The previous study revealed that the injected 
4-amino-N10-methyl pteroyl glutardic acid (Amethopterin) 
retained in the normal mouse tissues remained 
unchanged and if in fact any altered product of 
the antifolic was present it occurred in too small 
an amount to be detected by these methods, or it 
did not of "ect the growth of Streptococcus faecalis. 
The natural conseouence of the studies on 
normal mice was the investigation of the metabolic 
fate of amethopterin in the animal with sensitive 
and amethopterin resistant leukaemia, in the hope 
that it might lead to _knowledge concerning the 
mechanism of resistance. It has been previously 
shown that in mice given A14R, amethopterin 
resistant leukaemia, an antimetabolite was retained 
in the tissues following in'. :raperitoneaï injection 
of amethopterin, as in normal animals, and that this 
203. 
antimetabolite had a similar Rf value to 
amethopterin (Table 14) in the butanol- acetic 
acid solvent system. However, as the analogues of 
folic acid containing methyl groups appear to have 
similar Rf values (Table 13) in this solvent 
system, the possibility that deamination of 
ametho-oterin occurred to form inethopterin (N10- 
methyl pteroylglutamic acid), a weaker antagonist, 
could not be excluded. The main object of this 
present study was to show whether or not the 
resistant leukaemic cell had the ability to 
deaminate the antagonist, as several observers 
have considered this to be one of the possible 
mechanisms of resistance, and have suggested that 
aminopterin might be converted to utilisable folic 
acid by the resistant cell and amethopterin to the 
much weaker, and therepeutically inactive, 
metho pterin. 
Materials and Methods. 
In this study L 1210 (sensitive) and L 1210 /A 
(amethopterin resistant) leukaemia were used. 
These varieties of leukaemia obtained from Dr. 
Lloyd Law, of the National Institutes of Health, 
United States of America, result in the formation 
of a very large tumour at the locus of injection 
which off ers a good mass of "pure" leukaemic cells 
with which to study. Compared with the AK4 And 
AK4R leukaemias there is not so much involvement of 
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the spleen. 
Dice were injected with L 1210 and L 1210/A 
leukaemia and developed tumours on the eleventh and, 
thirteenth day respectively. At this time, 
amethopterin 3 mg. per Kg. was injected intra- 
peritoneally and twenty -four hours later the animal 
were sacrificed. The livers, spleens and tumours 
,Jere removed, and were homogenised separately in 
water. There were five L 1210 mice and four L 1210, 
mice in the experiment. The resulting suspensions 
were centrifuged and the supernatants concentrated 
under nitrogen to a volume of 0.5 ml. The samples, 
and standard solutions of amethopterin, methopterin 
and aminopterin were spotted on filter paper strips 
which had been soaked in 0.08 M. Na2HPO4 and dried. 
The solvent system consisted of 70 per cent. iso- 
propyl alcohol; 10 per cent. NIi4OH and 20 per cent 
H20. The strips were developed on agar plates 
containing the complete Flynn medium (Flynn et al. 
1951), PGA and seeded with S. faecalis 8043. 
The Study consisted of three experiments: - 
A. In the first experiment, 0.01 ml. of the sample 
were spotted and run for forty -eight hours, and the 
strips developed on plates containing 1 ml/m1. 
GA. Only one inhibition zone was noted on each 
strip, corresponding to the amethopterin control, 
except in the case of one spleen sample from an 
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Fi .1G a Bioautographs of strips from alkaline iso- propanol system on 
S. faecalis (8043). 
Strip 1. Standard solutions of amethopterin, methopterin and aminopterin 
(control). 
Strip 2, .01 ml. t.c. 24 hrs. after injection of amethopterin 
(3 mg. /kg.) r L 1210 ( amethopterin sensitive) leukaemia 
Strip 3. .01 ml. t.o. 
(3 mg./kg.) - 
Strip_4. .01 ml. 1.0.X 
(3 mg./kg.) - 
Strip 5, 
Strip 6. 
.01 ml. l.c. 
(3 mg./kg.) ° 
* 
.01 ml. s.c. 
(3 mg./kg.) m 
24 hrs. after injection of amethopterin 
L 1210 /A (amethopterin resistant) leukaemia. 
24 hrs. after injection of amethopterin 
L 1210 leukaemia. 
24 hrs. after injection of amethopterin 
L 1210 /A leukaemia. 
* 24 hrs. after injection of amethopterin 
L 1210 leukaemia. 
axial. .01 ml. s.c. 24 hrs. after injection of amethopterin 
(3 mg. /kg.) L 1210 /A leukaemia. 
t.c. = tumour concentrate 
x 
1.0. = liver concentrate 
** 
s.c.= spleen concentrate 
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contained two zones (Pig.16a) 
B. In the second experiment 0.03 ml. of the 
tissue samples were spotted, the chromatograms run 
for sixty -eight hours, and the strips developed on 
:dates containing 0.5 ml/M1. PGA. As before, only 
one zone corres:onding to amethopterin was 
observed for each strio, except in one case where 
two inhibition zones were noted. In this instance, 
however, the sample was from the spleen of an 
amethopterin sensitive leukaemia. 
C. In a final experiment, amethopterin and 
methopterin were added to liver and tumour extracts 
from one amethopterin sensitive and one amethopteria 
resistant leukaemic mouse which had been injected 
intraperitoneally with amethopterin, 3 mg. /Kg., 
twenty -four hours before being sacrificed. The 
extracts were concentrated and volumes spotted as 
shown in Fig. 16b the chromatograms run for 
forty -eight hours, and the strips developed on 
plates containing 1 0/ml. PGA. Where amethopterin 
was mixed with the extracts only one zone was 
observed, while the methopterin mixture gave two 
distinct zones, corresponding to those of 
amethopterin and methopterin. 
Comments. 
The results of this experiment indicated that 
most, and probably all, of the injected amethopterin 
remained unchanged in the livers, tumours and spleers 
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Fig. 16b Bioautographs of 
faecalis (8043) 
strips from alkaline iso- propanol system on 
. All mice given amethopterin (3 mg./kg.) 
24 hrs, previously. 
+ 0.5 /G. amethopterin - L 1210 leukaemia 
(amethopt erin sensitive). 
+ 2 ;/G. methopterin - L 1210 leukaemia. 
S. 
intraperitoneally 
Strip 1. .01 ml. t.c. 
.015 ml. t.c. Strip 2. 
Strip 3. .01 ml. t.c. + 0.5 /G. amethopterin m L 1210 /A leukaemia 
(amethopterin resistant). 
Strip 4. .015 ml. t.c. + 2 1/G. methopterin - L 1210 /A leukaemia. 
Strip 5. .01 ml. i.e. X + 0.5 \r/G. amethopterin L 1210 leukaemia. 
.,- 
Strip 6. .015 ml. 1.0. + 2 `/G. methopterin L 1210 leukaemia. 
Strip, .01 ml. 1.c. + 0.5 '< /G. amethopterin m L 1210 /A leukaemia. 
Starip 8. .015 ml. l.c. + 2 !/G. methopterin m L 1210/A leukaemia. 
x 
to. = tumour concentrate 
1.0. = liver concentrate 
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of animals with either amethopterin sensitive or 
resistant leukaemias. The method was probably not 
Quantitative enough to say for sure, but if any 
altered product of the folic acid analogue was 
present it occurred in too small an amount to be 
detected by the present methods, or on the other 
hand it did not affect the growth of S. faecalis. 
The fact that a considerable amount of amethopterin, 
was left in the tissues, was more than suggestive 
that it was not altered, or if it was altered 
enough amethopterin remained so that it could have 
been inhibitory. 
The use of two biological systems, mice and 
bacteria, leads to some difficulty in evaluation 
of these experiments, but the weight of evidence 
strongly favours the conclusion that the 
amethopterin resistant leukaemic cells do not in 
any way result in an alteration of the anti - 
metabolite. The importance of such a conclusion 
cannot be underestimated, for it indicates that 
resistance of leukaemic cells to folic acid 
analogues is not due to an increased ability of the 
resistant antagonist by way of deamination or 
demethylation, to form either a weaker antagonist 
or to convert the antagonist to utilisable folic 
acid. 
The second zone of inhibition which was noticed 
in two instances, in a spleen sample from L 1210 /A 
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mouse in Experiment A, and a spleen sample from an 
L 1210 mouse in Experiment B, was probably 
arAnopterin, which is .: nown to be present in small 
amounts in the amethopterin used for injecting the 
mice. 
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FOLIC ACID AND CITROVORUI.I FACTOR IN NORMAL, 
AND L: UK ,; MIC _:'LOUSE LIVER. 
Many observers consider that the folic acid 
activity (FA) of normal mouse liver tissue is 
largely due to its content of citrovorum factor 
(CF). Swendseid et al. (1951a) using mouse liver 
concluded that " under standard dietary 
conditions, folic acid is absent from the liver or 
present in very small amounts." May and his 
associates (May, M. et al. 1951) using a combinatio 
of paper chromatography and bio- autography Caine to 
similar conclusions. Others, however, provided 
evidence of the presence of FA in animal tissue 
(Dietrich et al. 1952, Wieland et al. 1952) . It is 
generally recognised that the folic acid vitamins 
are present in liver largely in conjugated forms 
(Mims et al. 1944; Dietrich et al. 1952) although 
small cuantities of free vitamin are also present. 
Swendseid et al. (1951a) considered this to be 
largely CF, whereas Dietrich et al. (1952) observed 
small quantities of free FA in rat, guinea pig and 
chick livers, frozen immediately upon removal to 
prevent conjugase activity, but under similar 
conditions no free CF. 
This study was undertaken in an attempt to 
determine any difference in the total amounts and 
distribution of FA and CF in the normal and 
leukaernic mouse liver. 
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:ïicrobi_olof ica.l assay was the method for 
quantitative determination of vitamin present in 
the liver tissue. An attempt has been made to 
determine the relative proportions of FA and OF 
present in both free and bound forms, a matter 
which always gives rise to doubts and difficulties. 
It has been demonstrated that the gro;Tth of 
Streptococcus faecalis on a medium deficient in FA 
is stimulated by the presence of either FA or CF, 
whereas the growth of Leuconostoc citrovorum 
responds only to CF. The assay with S. faecalis may 
therefore be used as a measure of the sum of the 
activities of FA and ulo whereas the L. britrovorui 
assay yields information solely relating to CF 
activity. Calculation of the FA activity alone 
would then appear straight - foulard but in view of 
the stimulation of growth of S. faecalis by FA and 
CF being variable, such an estimation of FA activity 
alone becomes difficult. Swendseid et al. (1951a) 
gpproached the problem by using CF to produce the 
standard curves and measuring the concentrations of 
itamin in terms of CF activity. In such an assay 
rocedure, in which CF was used as a standard, if 
he activity in the tissue was greater in stimulatin 
;rowth of S. faecalis than L. citrovorum, FA was 
onsidered to be present, whereas if the activities 
rere similar only CF was present. Girdwood (1951) 
sed a similar procedure in estimating FA and CF 
g 
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activity in human liver tissue. ïinder the 
conditions of asay re_orted here preliminary 
studies (Table 15) showed that the stimulation 
of rTowth of S. faecalis by FA was approximately 
equal to that produced by the same amount of 
synthetic CF (leucovorin, Lederle). It was 
therefore decided that the S. faecalis assay using 
FA for the standard curve should be used to 
determine the sum of the CF and FA activities. 
Undoubtedly the validity of the data from such 
differential assays rests to a great extent on the 
relative activity of folic acid and CF for the two 
test organisms. Snendseid et al. (1951a) reported 
that the growth stimulation of S. faecalis produced 
by 1 mg. of folinic acid was aiprroximately 
equivalent to that produced by 1.5 mg. of folic 
acid. Bond et al. (1949) stated that folinic acid 
did not a e<ar to be less active than folic acid in 
promoting growth of S. faecalis while Wieland et all 
concluded that leucovorin was only 50 -60 per cent. 
as active as FA, which was more in agreement with 
Cirdlwood's (1951) finding that 1.0 mg. of citrovorum 
factor was equivalent to 0.58 - 0.78 mg. of folic 
acid in stimulating growth of S. faecalis. Hitchin s 
et al. (1952a) observed that folic acid and 
citrovorum factor (synthetic "Leucovorin") had 
approximately the same growth stimulating DroDertie 
for S. faecalis, which corresponded to the finding 
CF FA 
S. faecalis assay S. faecalis assay 
(ó /Gm) (2( /kn) 
1 (a) .85 .84 
(b) 1.58 1.64 
(c) 2.71 2.54 
2 (a) .92 .88 
(b) .86 1.16 
(c) 1.60 1.54 
(d) 2.85 2.70 
3 (a) .63 .61 
(b) 59 56 
(c) .71 .76 
(d) 2.90 2.64 
TABLE 15. 
Comparison of assays using CF and FA to produce 
standard curves. Similar results indicate equal 
growth stimulating properties of synthetic CF 
(leucovorin) and F.A. 
(Homogenates of three separate mouse livers 
incubated for various periods of time) . 
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of the author in the present study. Although 
erroneous conclusion may have been arrived in 
differential assays for FA and CF owing to a lack 
of exact knowledge concerning the relative activity 
of CF and FA for the gro4rth of S. faecalis, it is 
-probable that the variable results obtained by 
several investigators may at least in part be due 
to individual conditions of assay. 
Another difficulty encountered in assay 
procedures such as this is the use of reference 
standards consisting of synthetic material of 
doubtful purity. In the present experiment, 
however, it was shown by chromatography and bio- 
autography that the synthetic CF contained no FA 
and had the same Rf value as naturally occurring 
CF. Indeed the synthetic and natural material 
appeared identical. 
Another possible source of error is the 
presence in liver of growth factors other than the 
folic acid vitamin. Thymidine can promote maximal 
growth of L. citrovorum but growth produced by 
thymidine is slow and unlikely to interfere with 
assays made after twenty hours. Thymine or 
thymidine may also promote the growth of 
S. faecalis and Wieland et al. (1952) have shown by 
chromatography several other factors which may 
stimulate S. faecalis and L. uitrovorum. 
`MI 5. 
Experimental. 
A. Microbiolllical Assay of FA and CF. 
Preliminary studies were carried out to 
determine the best assay procedure and it was 
concluded that assay of the clear supernatant after 
boiling the liver homogenate and centrifuging gave 
the best results. Chicken pancreas was found to be 
a good source of conjugase and liberated bound forms 
of vitamin satisfactorily. This method was 
therefore used in the estimation of 'total' growth 
factor, although autolytic enzymes by comparison 
seemed to be equally effective. Recovery of known 
quantities of CF and FA were found to lead to 
accurate results. (Table 16). 
The mice used in this experiment were (1) 
normal mice of the inbred Akm stock weighing 
approximately 20 Gm. and (2) Akm juice with advanced 
Ak4 or Ak4R leukaemia. The mice were made leukaemic 
in a manner similar to that described in a previous 
experiment (p. 164). All animals were maintained 
on a standard Purina Laboratory Chow Diet. 
The animals were anaesthetised with ether, 
decapitated and bled. The livers were quickly 
removed, weighed and homogenised in 10 mls. 
disodium phosphate - citric acid buffer at pH 7.0 
in a Potter -Elvehjem homogeniser (Potter and 
Elvehjem, 1936). The homogenate was transferred to 
a test tube and the muddling tube rinsed with 10 mis. 
Sample CF CF FA 
L. citravorum assay S. faecalis assay S. faecalis assay 
(má) (mó) (m?r) 
1 102 116 109 
2 No Growth 117 114 
3 49 108 108 
TABLE 16. 
Assa of solutions of known concentration of CF and FA. 
1. CF > 100 m r /Stock. 
2. FA 100 m?r /Stock. 
3. Mixed equal vols. CF and FA i.e. 50 mY each. 
buffer. The rinsings were then added to the 
homogenate yielding a 5 per cent. homogenate. The 
homogenate was then boiled immediately for five 
minutes to destroy autolytic enzymes. 10 mis. was 
transferred to another test tube and chicken 
pancreas added at a concentration of 100 mg. per 
Gm. of liver tissue. After covering liberally 
with toluene this sample was incubated for 
approximately twenty hours at 37°C. Thereafter it 
was autoclaved, centrifuged and the supernatant 
assayed for vitamin content. A further tube 
containing chicken pancreas alone in phosphate- 
citric acid buffer was incubated, autoclaved and 
centrifuged in a similar manner and assayed for its 
vitamin content, in order that the folic acid and 
OF content of a given quantity of chicken pancreas, 
be known for purposes of calculating the amount of 
bound vitamin present in the liver. 
The tube containing the remaining 10 mis. of 
5 per cent. boiled homogenate was centrifuged and 
the supernatant assayed. The assay values obtained 
for this sample was interpreted as representing the 
amount of the folic acid and CF present in the liver 
in free form. 
The assay procedures for folic acid and CF are 
outlined as follows: - 
Folic Acid. A series of test tubes were partly 
filled with a measured quantity of Difco folic aci 
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assay medium and graded dilutions of the treated 
liver. homogenates. After autoclaving the tubes 
were inoculated with the test organism - in the cas 
of folic acid - S. faecalis (ATCC 8043) and incubat 
for eighteen hours at 37°C. The turbidity of the 
tubes was then estimated in a Coleman photoelectric 
absorptionometer and compared with a standard curve 
prepared from readings of the turbidity caused by 
growth of the test organism in tubes containing 
known cuantities of folic acid - 0.2, 0.4, 0.6, 
0.0, 1.0, 1.5, 2.0, 4.0, 6.0 mY- folic acid per 
tube up to a concentration of 20 mY. The galvanome er 
reading; was set initially, and after each estimatio , 
at zero with the aid of an inoculated reagent blank 
The combined folic acid and CF activity ?resent in 
the liver samples could then be calculated. 
Citrovorum Factor. The assay procedure was 
essentially the same. The medium used was that 
sugested by Sauberlich and Baumann ( Sauberlich and 
Baumann 1948) with Leuconostoc citrovorum (ATCC 8Où1) 
as the test organism. The standard curve was 
prepared from tubes containing from 0.2 to 2.0 mY 
synthetic CF (leucovorin, Lederle). The CF activity 
in the liver preparations was then calculated. 
The assay with S. faecalis was used as a 
measure of the sum of the activities of FA and CF 
in the liver preparations as it had _previously been 
demonstrated that the growth of S. faecalis on 
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medium deficient in FA is stimulated by the 
presence of either FA or CF. CF alone was 
estimated as indicated previously by using 
L. citrovorum this responding only to CF. It was 
thus possible to calculate the amount of total 
(conjugate + free) and free FA and CF present in 
the liver. 
Results. (Table 17) 
Assay of normal mouse liver indicated that 
folic acid vitamins were present almost completely 
in conjugated forms and that growth activity in the 
incubated specimens was due almost completely to it 
CF content. The presence of traces of free FA and 
CF were detected. In the leukaemic mice conjugate 
CF was similarly predominant. The interesting 
finding was, however, the definite increase in free 
vitamin, both FA and CF and particularly FA, as 
compared with the normal. The mean total vitamin 
content of the normal liver was found to be 2.25 ' /Gn 
(standard error ± .306). A statistical analysis 
usin Students "t" test showed that in a comparison 
of the vitamin concentration in the normal and 
leukaemic livers t = 2.111, n= 18 p (.05. This 
indicated a barely significant increase in total 
rowth factor concentration per Gm. in the Ak4 liver 
=s compared with the normal, but in view of the 
eukaemic liver being approximately twice the weight 
1)].? the normal mouse liver the total concentration of 
Bioassay of Normal and Leukaemia Mouse Liver for Folic Acid (FA) 
and Citrovorum Factor (CF) 
Mouse CF zj/Gm. FA?t/Gm. 
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TABLE 17. 
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growth factor in the leukaemic liver was twice that 
of the normal, the increase being presumably due to 
the FA and CF present in the infiltrating leukaemic' 
tissue. 
Discussion. 
The findings for normal mice corresponded closely 
to that of Swendseid et alts. (1951a). They 
disagreed, however, with later workers, Dietrich 
et al. (1952), and Wieland et al. (1952) who 
detected a higher degree of FA activity in animal 
liver tissue. Wieland and his co- workers presented 
excellent evidence including bio- autographic 
studies indicating the presence of FA in the 
incubated specimens. Using similar techniques the 
author (Fountain 1952a) obtained similar evidence 
of the presence of FA activity in liver tissue. In 
the non -incubated specimens the growth stimulating 
activity seemed to be largely, if not wholly, due 
to FA. (Table 18) 
The interesting finding from this study was 
that although the total vitamin concentration per 
Gm. of the leukaemic liver showed only a minimal 
and barely significant increase to that in the 
normal liver a definite increase in free CF and FA 
was present. Using F1 mice (from C 58 male and Bagg 
albino female) and Line 1 leukaemia, Hutchinson and 
Burchenal (1954) later showed that whereas the CF 
concentration in the normal and leukaemic liver 
were similar, the total CF content of the leukaemic 
spleen was approximately three times that of the 
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A. Plate with No PGA - S.faecalis (8043) 
Sample 
Amount Solvent 
on strip Flow 
ml. oms. 
Distal Point Rf 
cros. 
1. CF - 10 m ' .01 27.8 11.0 .40 
2. CF - 10 my .01 29.0 11.8 .41 
3. PGA - 10 m ?i .01 25.2 5.2 .21 
4. PGA - 10 m6. .01 29.3 7.2 .25 
5. Normal liver .1 26.6 50 .19 
(Boiled) 




7. Normal liver ,05 28.9 5.5 .19 (Boiled) 
8. Normal liver 
.01 28.6 6.3 
.22 
(Incubated) 11.6 .41 
9. Normal liver 
+ Ameth opter in 1 ?l .01 28.6 10.3 .36 
(Incubated) 
B. Plate with No CF - L.citrovorum (8081) 
10. PGA - 10 má .01 28.5 NO GROWTH 
11. CF - 10 m21 .01 29.4 12.6 .43 
12. Normal liver .05 28.6 NO GROWTH 
(Boiled) 
13. Normal liver 
.01 28.6 9.6 .34 
(Incubated) 
14. Normal liver 
+ Amethopterin 1Z' .01 28.6 1205 .44 
(Incubated) 
TABLE 18. 
(See over page) 
TABLE 18. 
Rf values of synthetic folic acid and CF, and an attempt 
to demonstrate the FA and CF activity in normal liver tissue, 
using a combination of paper chromatography and bio- autography. 
Experimental details similar to those described previously 
(page 189) . Solvent system:- Butanol and acetic acid. Two 
sets of plates (A) containing Difco folic acid assay agar, 
inoculated with S. faecalis but not containing folic acid and 
(B) containing CF assay medium inoculated with L. citrovorum 
but no added CF. In the incubated specimens two areas of 
growth were observed giving a 'dumbell' appearance to the growth 
zone, the upper with an Rf value corresponding to synthetic CF 
and the lower to synthetic folic acid. 
KEY 
Samples 1, 2 and 11; CF - 10 me/.01 ml . 
3, 4 and 10; PGA - 10 mY /.01 ml. 
5, 7 and 12; Normal liver - boiled immediately 
after removal and homogenising to destroy autolytic 
enzymes. 
6, 8 and 13; Normal liver - incubated for 24 hours 
to liberate conjugated vitamins. 
9 and 14; Normal liver to which amethopterin 1 ó' 
added after homogenising. Incubated then for 24 hours. 
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normal tisue and free CF was hiffher in the 
leukaemic tissue. In view of the low content of 
vitamin in the normal spleen, as compared with the 
liver, assay of splenic suspensions probably gives 
a more accurate assessment of the relative 
concentrations of growth factor in leukaemic 
tissue. If, however, the increased size of the 
leukaemic liver in the present study (approximately 
twice normal) was due to its content of leukaemic 
tissue, the fact that the concentration per Gm. of 
vitamin was the same as for normal liver would 
sug. est the FA and CF activity in leukaemic tissue 
was a_-.. proximately equivalent to that in normal live 
Hutchinson and Burchenal (1954) comparing the 
CF content of Line 1 leukaemic tissue with that of 
Line 1/A (amethopterin resistant leukaemia) have 
shown that the free CF in the resistant leukaemic 
spleen was significantly higher than in the 
sensitive. Assay of five Ak4R livers showed a mean 
concentration of 3.88Y /G. (standard error ± .398) 
total growth factor, which using the Student "t" 
test shared a significant increase over the 
concentration in normal liver but comparing it with 
Ak4, sensitive, leukaemic tissue the Student "t" 
test failed to reveal any significant difference in 
concentration of total vitamin. 
The evidence of a high content of free and 
total vitamin in leukaemic tissue compared 
r. 
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favourably with the findings of Swendseid et al. 
(1951) who showed that leucocytes of patients with 
acute leukaemia contained five times the 
concentration of CF than the normal. The inference 
was that the increase in CF reflected the high 
metabolic activity in these tissues and it has been 
suggested that on this account they become more 
susceptible to the action of the folic acid 
antagonists. The possibility that resistance to 
the therapeutic action of the folic acid antagonists 
may in part be related to an increased synthesis of 
CF gained some sup')ort from the work of Hutchinson 
and Burchenal (1954). These workers went further 
and suggested that one of the actions of amethopterin 
was to block the conjugase activity of the leukaemic 
cells and that the conjugase of the resistant cells 
was less susceptible to the antagonist. Nichol 
(1954b) has shown, however, that although the 
resistant strain of S. faecalis had the ability 
to synthesise more than a hundred times the amount 
of CF from folic acid than the parent sensitive 
strain, resistant leukaemic tissue was unable to 
synthesise CF from synthetic folic acid more 
readily than the sensitive. The present study 
has also failed to demonstrate any increased CF 
activity in the resistant leukaemic tissue as 
compared with the sensitive. Further work is 
obviously necessary before any final conclusions 
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can be drawn relating to the possible role of 
increased CF synthesis as a mechanism of resistance 
to the folic acid antagonists. 
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UTILISATION OF CITROVORUM FACTOR (CF) 
IN THE LEUKAEMIC AND NON- LEUKAEMIC SUBJECT. 
The report by Swendseid et al. (1951) that in 
patients with acute leukaemia rapidly proliferating 
leucocytes have a content of CF five times that of 
the normal white cell and the findings of Swendseid 
et al. (1952a), and at a later date Girdwood 
(Girdwood, 1953), that leukaemia patients excreted 
less of a test dose of folic acid than normal 
individuals suggested an increased utilisation of 
folic acid and CF by the leukaemia cell as a 
consequence of their high metabolic requirements. 
With this in mind, in conjunction with Drs. Burchenal, 
Ellison, Murphy and Hutchinson, it was decided to 
investigate the utilisation and excretion of a test, 
dose of CF in the leukaemia and non -leukaemic child. 
Materials and Methods. 
A series of thirty -four leukaemia children of 
which the majority had received no treatment with 
the folic acid antagonists or other chemotherapeutic 
agents were tested. A small percentage had 
developed resistance to amethopterin after previous' 
haematological remissions. Fourteen non -leukaemic 
children with simple tumours, e.g. lipomata, were 
selected to act as control subjects. After drawing 
an initial venous blood sample u. at a dose of 
0.05 mg. /kg. was given by the intravenous route. 
Thereafter further specimens were obtained at five, 
fifteen, thirty and sixty minutes following 
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injection. The blood was allowed to coagulate and 
the serum separated by centrifuging at 5,000 revs. 
per minute for ten minutes. All urine passed 
following the injection of CF was collected for a 
period of six hours, the patient being asked to 
empty the bladder at the end of this time. All 
urine specimens were stored in brown bottles 
containing toluene and a phosphate buffer at pH 6.8. 
Assays for CF were carried out within the next 
seventy -two hours, the specimens being stored in a 
cold room at 4 °C. until required. 
Serum and urinary estimations of CF were 
carried out microbiologically in a manner similar 
to that described previously (page 218) using 
Leuconostoc citrovorum as the test organism. 
Results and Conclusions. 
The results are expressed graphically in 
Fig. 17. 
The 'fasting' serum levels of CF in both 
leukaemic and non -leukaemic subjects shared no 
significant difference and were within the range of 
l0 to 30 m) %mi. The rapidity of uptake of CF 
following intravenous injection was found to be 
similar in both leukaemic and control subjects, and 
after one hour the serum concentration of CF had 
returned to the 'fasting' level. Patients whose 
disease had become resistant to treatment showed 
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Estimation of the urinary excretion of OF 
six hours after administration in fifteen leukaemic 
and nine non- leukaemic children shoed less than 
32 per cent. excretion in both groups. No 
significant difference in excretion of CF was 
observed between the leu&aemic and non- leuka.emic 
groups. Students "t" test for analysis of small 
groups resulted in t = 0.772, p <.5, whi ch 
indicated an absence of any significant difference 
between the two groups, Study of a larger series 
and estimation of the twenty -four hour excretion, 
although the serum level returned to normal after 
one hour, might possibly reveal a difference but 
from the results obtained in the present series any 
considerable variation between the two groups 
would appear improbable. 
The conclusion arrived at as a result of this 
experiment was that the metabolic reouiree uts of 
the leukaemic :patients for exogenous CF were little 
or probably no different to that of the - le ;. e is 
subjects, These findings were of interest 
of those of Swenc? seid et al. (1952a) and Girdrmod 
(1953) who observed that leukae ;tic Mire . 
excreted less of a test dose of folio aoid than 
normal individuals. One can only deawe Tr m the 
present study that if the leuk:aemic oei1 uti1iees 
more OF than the normal leucocyte the in el 3 
demands are obtained from endogenous eourcee and 
231. 
that any tissue depletion is balanced by an 
increased synthesis from folic acid. 
232. 
EXP.ER=NT Ali 3 :]CT I0 N . S Ü ;II:TARY 
The concentration of amethopterin in the serwn, 
iver, kidneys, spleen, lungs and muscle of normal 
nice was ascertained at intervals following 
ntravenous injection of 0.5 mg. /Kg. of the compound 
The relative concentration of amethopterin in 
he tissues appeared to parallel the folic acid and 
F content viz. liver, kidneys and spleen in 
_escending order.. No significant quantity of 
methopteri n was found in the lungs or muscle. 
Ametho Merin was found to be still present in 
he liver and kidneys in relatively large quantities 
wenty -four hours after injection, although the 
erura level had reached or approximated zero in 
:our hours. 
i. A similar dose of amethopterin given intra- 
renously to Ak4 and Ak4R mice resulted in higher 
oncentrations in the blood and a more widespread 
- istribution in the tissues than in normal mice 
suggesting an affinity of the leukaernic tissue for 
amethopterin. The Possibility that this may, 
owever, have been due to impaired renal function 
'I .S mentioned. 
No significant difference in the distribution 
and concentration of amethopterin in the Ak4 and 
k4R leukaemic tissues was observed. 
6. Amethopterin given parenteraïly in various doses 
to normal mice resulted in the retention of a more 
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or less constant amount of amethopterin in the 
liver for a period of at least three weeks. A 
gradual slow decrease in the renal concentration of 
amethopterin was observed. 
7. CF at doses ranging from 0.5 to 30 mg. /Kg. 
intraperitoneally failed to have any detectable 
effect on the concentration of amethopterin in the 
liver and kidneys but caused a significant rise in 
the serum level of amethopterin. This stable 
incorporation of amethopterin was suggested as the 
likely explanation of the inability of large doses 
of the folic acid vitamins to overcome the toxicity 
of the folic acid analogues. 
8. Ak4R leukaemic cells did not appear to 
metabolise amethopterin in vivo, although the 
possibility that amethopterin might be converted to 
a weaker antagonist, N10- methyl pteroylglutamic 
acid (methopterin) was not eliminated at that stage. 
9. Amethopterin when given intravenously in doses 
of 0.05 mg. /Kra. to human subjects with acute 
leukaemia, including patients with amethopterin 
sensitive and resistant leukaemia, and to a control 
group with advanced cancer showed no difference in 
serum level pattern. In both groups less than 60 
per cent. was excreted in a six hour period. No 
obvious difference in the rate of excretion between, 
the two groups was observed, but a larger series 
was recommended before final proof could be obtained. 
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10. Rf values of various folic acid analogues 
were determined using a combination of paper 
chromatography and bio- autography. A butanol and 
^.cetic acid solvent system was used. 
11. Using a butanol- acetic acid solvent system 
analogues containing a methyl group in their 
molecule were found to have similar Rf values. 
12. Following preliminary studies the antimetaboli 
present in normal mouse tissues following the 
injection of amethopterin was identified by means o 
paper chromatography and bio- autography, using 
three different solvent systems. The antimetabolit 
was found to have the same Rf value as amethopterin 
in the three solvent systems, and it was concluded 
that amethopterin remained unchanged in the normal 
mouse tissues. 
13. Using mice with L 1210 and L 1210 /A leukaemia 
it was shown that amethopterin remained unchanged. 
in the livers, tumours and spleens of both 
amethopterin sensitive and amethopterin resistant 
leukaemias. 
14. It was concluded that resistance was not due 
to an increased ability to detoxify the antagonist 
oy way of deamination or demethylation. Certain 
drawbacks of the technique employed were mentioned. 
5. A method for estimating the folic acid and CF 
ctivity in mouse liver was described. 
5. Assay of normal mouse liver indicated that 
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folic acid vitamins were present almost completely 
in conjugated forms. Growth activity in the 
incubated specimens was due almost completely to 
its CF content. Traces of free FA and CF were 
detected. 
17. Using chromatographic and bio- autographic 
techniques evidence was obtained sup - sorting the 
concept that FA is present in mouse liver. 
18. An increase in free FA and CF, particularly 
FA, was observed in leukaemic liver (Ak4) as 
compared with the normal. 
19. The total FA and CF activity in the Ak4 liver, 
expressed as \ /Gm. liver tissue was approximately 
the same as in the normal liver. The total 
expressed as r /organ was approximately twice the 
normal. It was suggested that the increased total 
activity in the leukaemic liver was probably due to 
the high vitamin content of the infiltrating 
leukaemic tissue. 
20. No evidence was obtained to support the 
suggestion that resistance to the therapeutic action 
of the folic acid antagonists may be due to 
increased synthesis of CF. CF activity in the Ak4 
and Ak4R mouse liver showed no significant difference. 
21. Serum levels of CF following an intravenous 
test dose of CF at 0.05 mg. /Kg. were similar in 
both leukaemic and non -leukaemic children. 
22. The six hour excretion of CF following the test 
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dose showed n-. significant difference in a limited 
series of leukaemic and non. -leuk! emic children. 
It was concluded th ̂t there was probably no 
Increased demand for e zoenous C7 by leukaemic 
cells. 
237 . 
THE TREATMENT OF LEUKAEMIA 'li;IvIIA
AND SOP:IE ALLIED DISORDERS 
WITH 6- I,:ERCAPT O PUR I Tv E 
238. 
The discovery that antagonists of folic acid 
were able to induce remissions in a proportion of 
children with acute leukaemia, resulted in an 
intensive search for therapeutically active 
analogues of other nucleic -acid precursors. Of 
the purine and pyrimidine derivatives discovered to 
date the most therapeutically successful has been 
the new compound, 6- ITercaptopurine (6-NP). This 
substance was synthesised and developed by Hitching 
and his associates (Elion et al. 1951 and 1952, 
Elion and Hitchings 1953) during a comprehensive 
study of the roles of pyrimidine and purine bases 
in nucleic acid metabolism and at the same time in 
co- operation with the Sloan -Kettering Institute, Nei 
York, in an attempt to discover new compounds with 
anti -tumour activity. 
6- Mercaptopurine (Elion et al. 1952) is an 
analogue of the nucleic acid constituent adenine an 
the physiological purine base hypoxanthine and Jiff 
a 
only in chemical structure (Fig. 18) by 
substitution of an SH group for the amino and 
hydroxyl groups respectively. It is one of a large 
series of such analogues studied by Hitchings and 
his colleagues (Hitchings et al. 1945, 1950, 1950a, 
1952; Falco et al. 1951) and tested for 
chemotherapeutic activity in view of its property 
of interference with nucleic acid biosynthesis. It 



























chemotherapeutic agent with the demonstration by 
Clarke et al. (1953 and 1953a) that it inhibited th 
rowth of the Crocker mouse sarcoma 180 and 
resulted in an increase in survival time. An 
e_.tension of this observation by Sugiura (1953) 
disclosed that 6 -LP could significantly inhibit the 
E,,rowth of several other mouse tumours. Biesele (19 
reported growth inhibition of mouse tumours in 
tissue culture by 6 -_.P, while Law et al. (1954) 
observed an increased survival time of :Nice with 
transplanted acute lymphocytic leukaemia. Skipper 
(1x'54) also noted an increase in the life span of 
6 -LIP and amethapterin appeared to be synergistic 
with regard to anti- leukaemic activity. 
The toxic effects of 6 -LP in animals have been 
studied by Clarke et al. (1953a) and Philips et al. 
(1953) who observed hypoplasia of the bone marrow, 
damage to intestinal epithelium and evidence of 
liver necrosis following lethal doses of the drug. 
An interesting finding was the inability of adenine 
guanine, xanthine and hypoxanthine to protect mice 
against the lethal effects of 6 -LIP. 
The exact mechanism of action of 6 -IP in 
patients with leukaemia, remains unknown.. It has 
been shown by Ellen' et al. (1951 and 1953) by 
microbiological studies that the growth of 
Lactobacillus casei is inhibited by 6 -MP, and growt 
can be restored by any of the four ?hysiolog:ical 
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:; Urifle basis - adenine, guanine, xanthine and 
hypoxanthine. It has also been demonstrated that 
growth of Streptococcus faecalis (.ACC 8043) is 
inhibited by 6 -iTP and that this can be reversed by 
adenine, guanine, xanthine and hypoxanthine 
(Sullivan 1953). The conclusion drawn is that 
6-7P in bacterial systems acts as a purine 
antagonist, although definite proof of a similar 
mode of action in' animal tissues has not been 
demonstrated. 
Large amounts of folic acid or ci rovor= factcr 
are unable to prevent the toxicity of 6-EP in mice 
(Philips et al. 1953) or the therapeutic effect of 
3-MP on transplanted leukaemia in mice :Surchenal 
et al. 1953a). While there is no direct evidence 
that the mode of action against the leukaemic cell 
in. the human subject is the same as in bacterial 
systems or in animals, the weight of evidence, 
including the finding of activity in anti -folic 
resistant mouse and human leukaemias (Lahr 1953; 
úurchenal et al. 1953), suD)orts an anti -purine 
rather than an anti -folic acid mode of action. The 
finding by Law et al. (1954) that 6 -MP resistant 
mouse leul-zaemia has actually an increased sensitivity 
to ametho pterin lends further su_ port to this 
belief. 
By using a 6 -LIP resistant strain of 
lactobacillus case! Elion et al. (1953a) have 
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obtained information su gesting that 
hy- noxanthi.ne cointaining metabolite may be an 
i 11terneCí_iate in the conversion of adenine to 
r-uanine anC? that 6 -ï,'P may act by interfering with 
the conversion of this substance to a corresponding 
u^.nine containing'' substance. Hutchison (1954) 
used three strains of S. faecalis, S. faecalis :043 
S. faecalis'A (amethopterin resistant) and 
S. fa -calis /i'P (6-P resistant) , in an attempt to 
obtain information concerning the mode of action of 
5 -::-P in bacterial systems. The possibility that in 
these it i cro- organisms the metabolism of xanthine or 
closet, related compound was interferes_ with, 
was suggested. 
mhe metabolism. of 6-EP in animals and man has 
been investiated with the aid of radioactive 
isotopes. As a preliminary to studies in the human 
subject Elion et al. (1954) investigated the 
metabolic fate of MP in 1-Ace using C 14 and S 35 
labelled 6 -LP. They observed that the antimetaboli 
was rapidly metabolised with the excretion of 
i -t iouric acid and other unknown products. 
Following intraperitoneal injection the drug was 
found to be in highest concentration in the gut 
followed by kidney, liver, blood, lung, sternum, 
spleen and brain. Three hours after injection 
radioactive material was found to be incor ;orated 
into both the ribonucleic acid (P.iS ?A) and 
e 
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desoxyribonucleic acid (Di A) fractions of the 
nucleic acids. Hamilton and Elion (1954) and 
Hamilton, Ilion and Bases (1954) later studied the 
fate of 6 -HIP in human subjects with acute leukaemia 
and chronic myeloid_ leukaemia with the aid of 
intravenously administered S 35 labelled 6 -MP. 
The results in both types of leukaemia were 
essentially similar. A rapid metabolism of the 
drug° occurred, the urinary findings indicating a 
rapid and extensive transformation of 6-MP. As in 
the mouse 6 -IMP was found to be excreted partly as 
thiouric acid and unknown products but in contrast 
sulphate excretion was more prominent in man. From 
preliminary data these authors believe that, as in 
animals, 6 -1IP becomes incorporated into nucleic aci 
This is suggestive but not proof of the mechanism 
of growth inhibition Such studies as these are of 
considerable importance, for not only do they assis 
in determining the metabolism and site of action of 
chemotherapeutic agents, but may also increase our 
knowledge concerning the metabolism of nucleic acid 
The first report of the clinical use of 6 -P;iP 
was by Burchenal et al. (1953) who showed that good 
clinical and haematological remissions occurred in 
fifteen out of forty -five children with acute 
leukaemia and in another ten patients, partial 
remissions and clinical improvement were observed. 
The same authors described occasional remissions 
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in adult Patients with the disease, and encouraging 
results in patients with chronic myeloid leukaemia. 
Chronic lymphatic leukaemia did not a-opear to 
respond to 6 -._P thera,w and in thirty -five 
Patients with Hodgkin's disease, reticulum cell 
sarcoma and miscellaneous forms of cancer no 
improvement, at doses which produced bone marrow 
depression, was observed. Fountain (1954, 1955) 
also reported remissions in acute leukaemia 
following 6-11P therapy and notes_ the beneficial 
effects of "maintenance therapy" in chronic myeloid 
leukaemia. At a conference on 6- Mercaptopurine 
held by the New York Academy of Sciences in 1954, 
many investigators reported the effects of 
treatment of acute leukaemia with this new 
antimeta.bolite (Conference on 6- Mercaptopurine, 
1954). An analysis of the results show that of 
three hundred and twenty -four children treated with 
6-P by fourteen different investigators 60 per 
cent. showed clinical and haematological 
improvement, 35 per cent showing a complete 
disappearance of the clinical manifestations of 
the disease with a return of the blood picture to 
apparent normality. The effect of treatment on 
adults was less marked. Definite improvement was, 
however, observed in 40 Der cent of two hundred and 
four patients, but only 12 per cent developed 
complete remissions. Few patients with chronic 
ti4s 
RESULTS OF TREATMENT OF ACUTE LEUKAE'_:IIA TITH 6-r1L:RCAPTOPURINE 
A. CHILDREN 








Burchenal 87 41 16 30 
Bernard 34 11 5 18 
de Asúa 11 6 1 4 
Farber 60 9 19 32 
Pierce 22 6 7 9 
Rundles 8 3 2 3 
Hyman 22 7 6 9 
Foun tal.n 4 1 1 2 
Rosenthal 12 5 2 5 
R9/1 1 12 7 4 1 
Sawitsky 14 4 5 5 
Gaffney 23 10 9 4 
Petrakis 7 - 5 2 
Ill son 8 3 - 5 
324 113 (35 %) 82 (25 %) 129 (40 %) 
\60 %/ 
. ADULTS 
Burchenal 50 7 10 33 
Hall 25 3 11 11 
Bernard 8 - 1 7 
de Asúa 5 1 1 3 
Rundle s 10 2 6 2 
Hyman 12 2 2 8 
Fountain 5 2 1 2 
Rosenthal 35 1 12 22 
Hill 16 6 3 7 
Sawitsky 6 1 - 5 
Gaffney 13 - 2 11 
Petrakis 7 - 3 4 
Wilson 12 - 7 5 
204 25 (12jä) 59 (28 %) 120 (60 %) 
(Data compiled from a Symposium on 6- ?Iercaptopurine held in 
New York on April 30 and May 1, 1954, and published in the 




myeloid leukaemia treated with 6 -MP v,: ere reported. 
Most observers agreed that temporary improvement 
followed its administration but relapse tended to 
follow withdrawal of the drug. No details of the 
effect of maintenance therapy were reported. 
The present study is based on experience 
gained in the treatment of fifty patients between 
June 1953 and September 1955 (Table 20). Of these, 
twenty -eight had acute leukaemia, sixteen chronic 
myeloid leukaemia, two chronic lymphatic leukaemia, 
two multiple myeloma, one mycosis fungoides and one 
erythroderma secondary to an underlying reticulosis 
of undetermined type. 




CHRONIC MYELOID LEUKA EI,MIA 16 
CHRONIC LYMPHATIC LEUKAELIIA 2 
MULTIPLE I,YELOMA 2 
r.'YCOSIS PUNGOIDES 1 
RETICULOSIS of SKIN 
50 
TABLE 20 . 
LATI of TREATMENT 
Patients were unselected and included all 
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those whore the author was recuested to treat. Thos 
with acute leu;La.emia received no other form of 
chemotherapy prior to or as a supplement to 
treatment with 6 -'._P in the first instance. Follovri 
relapse the effect of other forms of therapy either 
alone or in combination with 6 -MP was observed in 
some instances. Of the sixteen patients with 
chronic myeloid leukaemia eleven had received no 
previous treatment, four had initially received 
deep x -ray therapy and one urethane. With the 
exception of one patient with mycosis fungoides who 
had several courses of x -ray treatment none of the 
other patients had received any other form of 
treatment prior to 6- mercaptopurine. 
Blood transfusions and antibiotics were 
prescribed as the need arose. 
The majority of patients received the initial 
course of treatment in hospital and clinical and 
haematological examinations were performed at 
frequent intervals, usually daily or on alternate 
days. In patients with acute leukaemia bone marrow 
examinations were performed initially and 
thereafter at intervals during treatment. Patients 
who improved sufficiently were later followed -up 
in the out- patient department and had blood 
examinations at weekly or fortnightly intervals. 
DOSAGE OF 6- M:RC_4PTOPURIhE. 
The dosage of 6 -MP was based on that suggested 
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UT Tiej: -e quj 4aGAG2Aoq '12GJGCLUiG"L90J 9CL -71-_IL07.0 41 
.seouonbGsuoo SUOTAU JTGq; 17Ut 'L:TUGc:0;.:2Q0O2Z.0J1_1; 
T)U-e eTuGdoo-LIGT 'eTIllaeuc :4.TAT49-e 1:,0Ja-ela GUOC, 
Jo uoTsseadaD GaGAs GO-0.0,1cT 0; oTcp2TT sT 
'09.3 
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treatment, often showed a hypoplast:ic picture. 
Me galoblastic erythro-?oiesis, which is an occasion 
seruel of treatment with the folic acid antagonists 
1C'_ the diamino- C7ichlori henl_Oyrimiäines, was not 
observed. 
Ulceration of the mouth, which commonly 
follows treatment with aminopterin and 
amethopterin, was not observed. 
Burchenal et al. (1953) have stated that 
gastro -intestinal symptoms may occur, but whereas 
occasional nausea, vomiting and diarrhoea have 
been seen (cases 12, 16 and 24) on no occasion were 
these symptoms definitely attributable to the drug 
and treatment had not to be interrupted on their. 
account. 
Experience to date has revealed no toxic 
symptoms consistently associated with 6 -LP, and the 
only danger to guard against is its depressant 
effect on the bone marrow With experience and 
careful regulation of dosage this in the author's 
experience should not give rise to anxiety. 
RESULTS OP TREATMENT. 
A. AOUTE LEUKAEMIA. 
It has become the custom to classify remissions 
occurring du.rin`; the course of treated acute 
leukaemia, complete or partial. Such a classificati 
is based largely on the degree of improvement of the 
bone marrow and Teri heral blood picture. The term 
on 
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'complete' remission in its strictest sense would 
seem incorrect as it is doubtful whether treat ,:ent, 
,.hich can only at present produce temporary 
improvement, ever co_-._. letel;r rids the bolo- of 
leukaemic cells, although clinically there may be 
no obvious evidence of the disease. The criteria 
on which a complete remission was based in this 
series consisted of - 
(a) a disappearance of all clinical evidence 
of disease and a return of the - patient to full 
activity. 
(b) a return of the peripheral blood "icture 
to normal, and 
(c) a return of the bone marrow to near 
normality with a disappearance of blast cells or a 
reduction to less than 10 per cent. 
In the case of patients with acute lymho- 
blstic leukaemia, as a remission developed, it was 
difficult to determine the difference between 
lymphocytes normally present in the bone marrow and 
leukaemic cells. It was therefore decided to 
consider patients with this type of leukaemia to be 
in full remission when (a) and (b) were present and 
when the bone marrow showed less than 30 per cent. 
lymphocytes and blast cells. 
A partial remission was said to be present whe 
considerable clinical and haematological improvemen 




In some instances, in the interest of the 
patient, repeated bone marrow punctures were not 
performed. Remissions in these cases were 
therefore based largely on clinical and peripheral 
blood findings. On no occasion, however, was a 
Patient said to be in complete remission without 
observing changes in the differential bone marrow 
nucleated cell count in keeping with this 
classification. 
Of the twenty- eight patients with acute 
leukaemia treated with 6 -IIP (Table 21), seventeen 
were children under the age of fifteen years and 
eleven were adults. Included was one infant with 
congenital leukaemia (case 19) and an adult with 
leukanaemia (case 23). Six of the children (cases 
1, 2, 3, 4, 5, 6), between the ages of two and ten 
years developed complete remissions while another 
six (cases 10, 1, 12, 13, 14, 15) showed 
improvement in keeping with a partial remission. 
Five failed to respond to treatment (cases 7, 18, 1 
20, 21), two of which (cases 18 and 19) died within 
a few days of starting treatment. 
Of the eleven adults, three developed complete 
remissions (cases 7, 8, 9), two partial remissions 
(cases 16, 28) while six (cases 22, 23, 24, 25, 26, 
27) failed to show any clinical or haematological 
improvement as a result of therapy. Two of the 
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Remissions No Response 
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failures (cases 25, 26) had courses of treatment of 
only eight days and three days respectively and in 
view of the known latent period before the drug 
becomes effective, were probably uninfluenced to 
any extent by treatment. 
The results in this relatively small series 
compares favour ably with those obtained by other 
workers. The figures suggest that approximately 
70 per cent . of children with acute leukaemia show 
clinical and haematological evidence of improvement, 
of varying degree and duration. Previously it has 
been mentioned that in a series of three hundred 
and twenty -four leukaemic children treated with 
and reported at a Conference on 6- Mercaptopurine 
(1954) , 60 per cent., were found to improve followin 
treatment. The less satisfactory effect of 
on the leukaemic Process in adults was also voiced 
at the above Conference. The results in the presen 
series support this finding, but suggest that 6 -LIP 
is an improvement over the folic acid antagonists 
in the treatment of adult acute leukaemia. 
In both children and adults a delay was noted 
before the drug became effective. This latent 
period was of variable duration but usually between 
seven and twenty- eight days. The first indication 
of a response to treatment was a fall in the 
leucocyte count to a leucopenic level. In two 
instances of aleu.kaemic leukaemia (cases 8 and 15) 
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further reduction in the white cell count did not 
follow treatment but both patients developed 
remissions, the leucocytes increasing as imì)rovemen 
occurred. It was of interest that patients with 
high initial white cell counts showed .responses 
earlier than those with normal or slightly raised 
counts. Thus, in case 16, the white cells fell 
from 60,000 to 6,800 per C.M. after ten days 
treatment; in case 13, from 250,000 to 30,000 per 
c.r11111. in five days; in case 12, from 13ír,600 to 
40,800 per c.r,m. in four days and after eleven days 
to 1,700 per c.iflil., and in case il, from 320,000 
to 3,000 per c.mm. in eight days. Ail these 
patients received the routine dosage of 6-MP. Many 
haematologists believe that a high leucocyte count 
in acute leukaemia is a sign of a poor immediate 
Prognosis and indicative of increased metabolic and 
mitotic activity. That this is probabl;; the case 
is sug bested by the susceptibility of these cells 
to 6 -MP as indicated above. Early in this therapeutic 
trial a male patient (case 9) with extremely acute 
myel o blast is leukaemia was given an initial "loadin. 
dose of 1 G. of 6-MP, in an attempt to increase the 
rate of action of the drug. The leucocyte count 
thereafter fell rapidly and after five days had 
fallen from 129,000 to 4,800 per C.mm. In the 
light of further experience it seems doubtful wheth:r 
the initial -high dose of 6 -MP was any more benefici.1 
FIG., 
(A) 
to . O 
ego 
(B) 
Sternal bone marrow of a child with 
acute lymphoblas tic leukaemia (Case 2) 
(A) before treatment, and (B) 5 weeks 
after the start of treatment with 
6 -me re aptopurine. 
258. 
than the routine dose. Another patient (case 26) 
was also given a "loading" dose of 6 -MP, but she 
died two days later without any effect of treatment 
being observed. 
A fall in the white cells to leucopenic levels 
indicated a reduction in the dose of 6 -MP or a 
temporary cessation of therapy. In some instances 
(cases 1, 7) the leucopenia persisted for up to 
three weeks after stopping treatment. 
A fall in the leucocyte count was almost 
invariably associated with a reduction in size of 
the spleen, liver, lymph glands and other 
manifestations of the disease. These changes were 
not, however, necessarily indicative of subsequent 
remissions, although frequently associated with 
symptomatic improvement. In patients developing 
remissions, haematological improvement also occurred. 
The onset of definite haematological improvement 
appeared at variable intervals after the start of 
treatment, ranging in children from fourteen to 
fifty -two days (cases 11 and 3 respectively) and in 
adults from sixteen to thirty -five days (cases 9 an. 
8). The average delay before both clinical and 
haematological improvement was observed in the 
seventeen patients - adults and children - who 
developed complete or partial remissions was 
approximately twenty -seven days. 
The bone marrow during the leucopenic phase wa. 
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generally hypoplastic. As improvement in the blood 
picture occurred, the percentage of blast cells in 
the bone marrow diminished accompanied by increased 
erythroid and myeloid activity. This was reflected 
in the peripheral blood by a rising haemoglobin and 
erythrocyte count, and an increase in platelets, 
together with a rise in the proportion of mature 
polymorphonuclear cells in the peripheral blood at 
the expense of leukaemic cells. The persistence of 
blast cells in the bone marrow and peripheral blood 
and an associated rise in the leucocyte count was 
an indication to increase the dose of 6 -MP. 
Table 22 indicates the extent of improvement 
observed in the seventeen patients responding to 
treatment. In some instances partial and complete 
haematological remissions were indistinguishable 
clinically. Fourteen of the seventeen showed complete 
regression of lymph nodes, hepatomegaly and 
splenomegaly, etc. In three (cases 12, 14, 16) a 
persistent splenomegaly remained and in another 
(case 10) cervical lymph node enlargement remained 
obvious. All experienced a definite increasing 
feeling of well being and returned at least 
temporarily to full activity. Several of the 
children went back to school. All remissions were 
associated with haematological improvement and in 
all but three (cases 15, 16 and 28) the haemoglobin 
rose to over 13.0 G. The platelet count rose from 
26J. 
TABLE 
Patients with Acute Leukaemia showing_ a Response to 6- Mercaptopurine 
Status before 6 -MF Therapy 6 -MP Therapy Status after 6 -MP Therapy 
Maximum Improvement 
Age Clinical Haematological Days , Total Dose Clinical Haematological (S) Dura- Follow up 
se 
Case (years) Type of Leukpeml, 
Leuastic 





Peripheral Blood Bone Marrow 
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x 10 a 
1 32 M Subacute (L) 6.0 1.9 4.8 1 6o 100/0 35 1.0 + + 14.5 67 214 23.6/30 9 16 wk. remission cn 
6 -LT. No ACTH 
response. 
S.T. 182 months. 
2 4 F Subacute (L) 5.9 1.9 9 11 64 91.6/6 57 4.07 + + 13.3 57 250 15/48 36 Sympt. improvement 
on 6 -2p . No ACTH 
response. 
S.T. 20-4 months + 
62 F Subacute (L) .2 1.51 12.4 5 - 95/1.5 52 1.525 -` + 14.8 70 266 26/28.4 38 + (Continues in 
remission. 
S .T . 122 months + 
4 22 F Acute (L) 2.8 945 3.8 2 - 100/0 33 1.95 + + 14.4 68 270 20/36 52 + (Continues in 
remission. 
S.T. 15 months + 
5 2 M Subacute (L) 4.48 1.4 3.2 24 90 88.5/0.5 35 1.325 + + 16.8 83 350 19.5/15.5 13 No response to 
6 -MP. 
6 10-2 F Subacute (L) 8.7 2.9 2.7 17 89 94.6/2.6 21 2.1 + + 15.5 68 250 30/44.2 10 
S .T . 62 months , 
No response to 
6 -ìßíP . 
S.T. 72 months. 
7 44 M Acute (Mo.) 8. 2.8 6.8 41 66 59/8.5 29 5.3 + + 13.3 80 250 0/29 7 No response to 
S.T. 5 months. 
8 62 F Subacute (L) 7.8 2.8 1.9 36 119 66.4/16.8 35 4.2 + + 14.6 67 275 20/34.8 33 No response to 
6 -MP. 
S.T . 15- months. 
9 41 M Acute (M) 11.8 3.8 129 2 35 85.2/0.4 16 3.0 + + 14.1 84 450 3.2/39.2 92 No response to 
6-MP. 
S.T. 5 months. 
10 9 F Subacute (L) 11.9 4.0 3.4 4 35 96/2.8 32 2.45 + ± 14.8 49 274 44/30 36 Response to ACTH 
(Lymph nodes +) S.T. 15z months. 
11 3 M Acute (L) 7.6 320 1 10 - 14 0.7 + + 11.8 65 220 - 22 No response to 
6 -MP or ACTH. 
S.T. 7* months. 
12 31 M Acute (L) 6.2 2.1 137.6 5 95 91.2J0.8 21 1,05 + ± 24.8 5 145 20/34.5 2?- No response to 
(Spleen +) 6-LT. 
S.T. 33 months. 
13 32 F Acute (L) 5.8 1.9 250 1 15 99/0 17 .675 + 13.2 78 250 - 4- No response to 
6-10. Improvement 
with 6 -MP + ACTH. 
B.T. 7 months. 
14 14 M Acute (L) 14.7 5. 0 24.6 5 1 210 78.8 10.0 / 14 2.1 + ± 14.7 68 3 00 21 2. /3 5 651- Improvement with 
(Spleen +) 6-MP + ACTH. 
S .T . 54 months . 
15 5 F Subacute (L) 11.9 3.8 2.4 39 275 96.8/2 21 1.05 + + 12.2 61 285 29/5 7Q No response to 
6-11P. 
S.T. 6- months. 
16 30 F Acute (Mo.) 6.9 2.26 9 21 101 84/2.4 21 2.3 + 11.1 42 180 28.5/14.5 2 No response to 
(Spleen +) 6 -MP. 
S.T. 4 months. 
28 34 F Acute (M) 5.1 1.4 1.0.0 11 30 95/0 13 2.6 + + 10.4 50 175 34/20 7 S.T. 44 months. 
S.T. 6 months. 
16 30 F Acute (Mo.) 6.9 2.26 69 21 101 84/2.4 21 2.3 + = 11.1 42 180 28.5/14.5 2 No response to 
(Spleen +) 6 -1iP. 
S.T. 4 months. 
28 34 F Acute (M) 5.1 1.4 40.0 11 30 95/0 13 2.6 + + 10.4 50 175 34/20 7 S.T. 44 months. 
KEY 
(1) Acute indicates severely ill patient with bleeding. 
Subacute indicates absence of severe symptoms, e.g. bleeding, and good 
general condition. 
(2) Mature polymorphonuclear cells. Remaining white cells, mainly lymphocytes 
or blasts. 
(3) In acute lymphoblastic leukaemia all lymphoid cells counted as leukaemic cells. 
(4) From start of therapy to appearance of haematological improvement. 
(5) Max. recorded improvement. 
(6) Duration of remission since response. 
(7)'; ST . - Survival Time since onset symptoms. 
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critical levels to within normal limits in all 
instances and in all but three patients the platele's 
rose to over 200,000 per c.mm. The proportion of 
mature _polymorphs in the peripheral blood increased 
in all patients. In fifteen the percentage rose to 
over 50 per cent., in the other two to 42 per cent. 
and 49 -oer cent. respectively (cases 16, 10). 
Leukaemic cells in the bone marrow decreased in 
numbers associated with a re- appearance of polymorp 
and erythrocyte precursors. The maximum recorded 
improvement in bone marrow cytology is shown in 
Table 22. 
Age and Remissions. 
From the data available children appear more 
likely to respond to 6 -MP therapy than adults 
(Table 21) . This is in agreement with other 
workers (Burchenal 1953; Conference on 6 -MP, 1954) 
Remissions of varying degree were observed, however 
in over one third of adult patients. 
Type of Leukaemia and Remissions. 
In a small series it is not possible to reach 
definite conclusion as to which cytological type of 
acute leukaemia responds best to treatment. Of the 
seventeen children, fifte n had lymlphoblastic and 
two myeloblastic leukaemia. Neither of the latter 
responded to treatment. Of the eleven adults, four 
had n?onoc rtic, six myeîoblastic and one lymphoblast c 
leukaemia.. Of the three complete remissions observed 
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in adults, one occurred in the patient with 
lymphoblastic leukaemia and the remaining two in 
patients with myeloblastic and monocytic leukaemia 
respectively. The impression gained was that the 
lymphoblastic type of leukaemia may be more 
susceptible to 6 -MP, and the higher incidence of 
this type in children may be a factor associated 
with the higher rate of remissions in children. 
On the other hand, the increased incidence of 
lymphoblastic leukaemia in children may explain the 
suggested higher incidence of remissions in this 
type of leukaemia. 
Duration of Remissions. 
The duration of the remissions was calculated 
from the time clinical and haematological 
improvement was first observed and was found to 
vary considerably (Table 22 ). The longest remissio 
was in a child (case 4) who up to the present, has 
been in complete remission for fifty -two weeks 
while another (case 3) is still in remission after 
thirty -eight weeks. Two children (cases 2 and 10) 
had remissions lasting thirty six weeks, while one 
adult, aged 62 years, (case 8) showed a clinical 
and haematological remission of thirty -three weeks 
duration. Of the remaining patients, four out of 
nine childre_l had rep issions lasting longer than 
ten weeks, but none of the three adults had 
remissions exceeding ten weeks duration. 
i 
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The effect of chemotherapy after relapse and in 
patients failing to show an initial response to 
6 -MP. 
Only one patient (case 1) developed a second 
complete remission on 6-MP therapy. Cases 7, 8, 9, 
10, 12, 15 and 16 all failed to respond to 6 -MP 
alone a second time, while case 2 obtained only 
some symptomatic benefit. A combination of 6 -MP 
and ACTH resulted in temporary improvement in case 
13 and 14 while one (case 10) responded to ACTH 
alone after becoming refractory to 6 -MP therapy. 
Five children and six adults failed to obtain 
any benefit from 6 -MP therapy. Two children (cases 
18 and 19) and two adults (cases 25 and 26) died 
within a week of starting treatment and were 
considered to have had inadequate courses of 
treatment. One child (case 17) rapidly developed a 
complete remission following ACTH therapy after 
failing to respond to prolonged treatment with 
6 -MP. The possibility that 6 -MP may have 
influenced the leukaemic process in this patient 
cannot altogether be ignored. ACTH was ineffective 
in one child and two adults (cases 20, 22 and 27). 
A total of nine patients, all of whom were 
resistant to 6 -MP therapy, were treated with ACTH 
or cortisone and it was of interest to note that 
in four a response to ACTH or cortisone occurred. 
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Although eleven patients, six adults and 
five children, failed to develop remissions as a 
consequence of 6 -MP therapy, some effect of treatme 
was noted in eight, viz. a reduction in leucocyte 
count and diminution in size of the spleen or 
other objective evidence of the disease. No 
symptomatic or haematological improvement was 
however observed. 
Survival time of acute leukaemia in the present 
series. 
Survival time may be measured from the onset 
of the first symptom or the date of diagnosis of 
the disease. As most of the large series recorded 
in the literature are measured in the former manner 
for comparative purposes the survival time in the 
present series has also been measured from the 
date of the onset of symptoms. 
The average survival time of the twenty -eight 
patients treated with 6 -MP was seven and a half 
months, the range being one week to twenty -one 
months. 50 per cent. were dead by the end of seven 
months and 75 per cent. by the tenth month. Six of 
Ithe twenty -eight patients survived longer than one 
year. Comparison of the group in which remissions 
developed with those who failed to respond to 
treatment is interesting. The average survival 
time in the former was 9.8 months as compared with 
.3 months in the latter. 45 per cent. of those 
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respondif_T to treatment were alive for longer than 
nine months compared with none in the group failing 
to show improvement, while all six patients 
surviving longer than one year had developed 
remissions following treatment. In conclusion it 
may be said that although those patients who fail 
to show a clinical and haematological remission 
probably survive no longer than untreated subjects 
(see page 75), patients responding to chemotherapy 
may have several more <<onths of useful, sym tom -fre 
life to loo forward to. 
B. CHRONIC LY LOID LEUKAEMIA. 
Improvement fol=lowing treatment with S -=;iP was 
assessed subjectively, objectively and with regard 
to haematological changes (Table 23). 
e.r. Sub ective improvement: increased. feeling 
of well being, increased activity, ao _petite and 
weight, etc. 
Objective improvement: diminution in size 
of the spleen, liver, lymph glands and other 
objtictive evidence of disease. 
Haematological improvement: a fail in the 
leucocyte count with diminution in proportion of 
primitive cells, a rise in the haemoglobin 
concentration and maintenance of a normal platelet 
count or rise from a subnormal level. 
Dósa.re 
The initial dosage of G -'._P was similar to that 
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employed in the treatment of acute leukaemia. As 
the leucocyte count fell to normal treatment was 
either sto-ped temporarily or reduced until the 
optimum maintenance dose of between 50 an d 150 mg. 
daily was obtained. Early studies showed that 
maintenance treatment with 6 -MP was essential in 
chronic myeloid leukaemia (cases 29 and 39). 
Results of Treatment. 
Of sixteen patients at various stages of the 
disease, including one in the terminal acute phase, 
a response of varying degree was observed in fiftee 
the other patient (case 43) dying of cerebral 
thrombosis within a week of starting treatment. 
Four of the remaining fifteen patients had 
previously received deep x -ray therapy and one 
urethane, -prior to 6 -MP. The other ten had no 
lorevious treatment. 
(a) Clinical improvement was observed in all but 
one of the fifteen patients. The patient failing 
to show any response (case 42) had previously been 
treated with x -rays and had reached a terminal 
refractory stager The spleen and liver were 
reduced in size and the leucocyte count fell from 
10,000 to 2,400 per c.mm. A refractory anaemia 
persisted, however, and there was no subjective 
improvement. Another patient (case 41), although 
showing temporary symptomatic improvement initially 
relapsed quickly and has since required repeated 
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29 49 M Fair. Vomiting. 9.0 3.3 128 300 - - 4.4 Well, working. 12.7 22.4 Good, working. 13.6 10.5 250 A/24+ + + + + Continues 
Spleen 8 ems. .05 -.1 Spleen 1 cm. Spleen 1 cm. P.68% satisfactorily. 
L.32% 
30 25 M Good. Spleen 14.5 4.6 75 220 X -rays - 3.5 Well, working. 12.2 11.8 Good, working. 16.0 12.8 190 A/12+ + + + Continues 
2 cros. .05 -.1 Spleen 1 om. Spleen 1 cm. P.82% satisfactorily. 
L.16% 
M. 2% 
31 9 M Poor. Weight 6.9 2.0 300 25 - 1 5.75 Good. Spleen 10.8 10.6 Good. At school 13.0 7.0 150 A/13+ + + + + Continues 





32 18 M Fair. Spleen 10.4 3.5 259 175 - - 4.4 Good, working. 15.4 14.6 Good, working. 14.8 12.6 225 A /13+ + + + + Continues 





33 42 F Poor. Severe 11.8 4.2 96 ' Urethane - __1202_ Fair. Chest 13.6 7.4 dell for 6 12.3 12.4 - D/7 + + + + Died of 
bronchitis. 
Spleen 12 ems. 
below costal 
margin. 
.05 -.1 improved. 








34 34 F Poor. 4.9 2.2 204 270 - 1 2.9 Good. Spleen 13.4 19.3 Good. Spleen 13.6 6.3 150 A/6+ + + + + Continues 
Haematemesis. .05 -.1 impalpable. impalpable. P.81% satisfactorily. 
Pain lt. abdomen L.19% 
Spleen to 
pelvis. 
35 62 F Poor. Pain lt. 8.3 3.3 275 - - 5.15 Good. Spleen 13.5 6.7 Good. Fully 14.6 11.2 305 A /7+ + + + + Continues 
abdomen. .05 -.1 1 cm. active. P.75% satisfactorily. 
Haematuria. L.25% 
Spleen 4 ems. 
above pubis. 
36 56 F Poor. Acute 8.2 2.3 152 225 X -rays 2 4.1 Good. Spleen 11.8 4.4 Relapsing. 12.3 27.3 - D/6 + + + + Died. 








15 ems. below 
costal mar gin . 
Blasts in bone 
marrow. 
37 58 F Fair. Liver en- 12.0 3.7 128 210 X -rays - Good. No 11.0 35.0 Good. Liver 13.6 24.1 260 A/l9 + + + + Refractory 





.D5 -.1 symptoms. 
Liver im- 
palpable. 




normal. 6 -MP 
continued. 
T.B. glands. 
38 48 F Poor. Mi tral 7.4 2.52 202 150 1 3.4 . Good. No 11.1 7.1 - - - - A /5+ + + + + Continues 





39 49 M Fair. Ulcer on 7.7 2.3 112 150 - 3 2.8 Fair. Ulcer healed. 8.1 50.4 - - _ - _ 4 + + - Temporary 
(Course i) leg. Spleen in - Spleen below benefit. No 
1 
pelvis. Liver 4cms. umbilicus. iíntenancA 
aDy. . or 
x-ray t. (Course ii)Poor. C.H.F. Spleen 
in pelvis. 3.2 
198 100 X-rays 2 2.4 Good. Symptom free10.0 
Spleen at umbili- 
35.1 Good. Spleen 1 
cm. Light work. 
12.2 40.8 
14.2% .2f
D /92 + + + + 
Relapsed y 9 .05 -.15 




mths . 6 -hip and 
myeleran in- 
effective. 
40 55 M Good. Spleen ha1f.10.9 3.4 58 - - 3.85 Good. Spleen 13.0 15.8 
- 
14.2 9.6 159 A /6+ 4. + + + Continues 
way to umbilicus. .05 -15 impalpable. p.76% satisfactorily. 
L.22% 
M. 2% Persistent 
41 48 M Fair. Spleen 2 7.5 2.5 364 200 - 1 4.8 Good,f ollowing 10.4 14.4 
A/5+ - + + - anaemia. 
cros . Liver at 
umbilicus. 




42 58 F Poor . CHF .Spleen 
I.-n Dubin. Lymph 
7.7 2.5 10 110 X -rays 1 2.4 Poor . Liver im- 
palpable. Spleen 
7.4 2.4 - - _ - D/3 
+ + - 
Died. 
39 I 491,t 
(Course i) 
Spleen 5cros .below 
costal margin. 
Fair. Ulcer on 7.7 
leg. Spleen in 
pelvis. Liver 4cros. 
(Course ii)Poor. C.H.F. Spleen 
in pelvis. 3.2 
40 55 11, 
41 48 L` 
42 58 F 
43 69 MI 
48 32 M 
Good. Spleen half10.9 
way to umbilicus. 
Fair. Spleen 2 
ems. Liver at 
umbilicus. 
7.5 
Poor. CHF.Spleen 7.7 
to pubis. Lymph 











































Fair. Ulcer healed. 8.1 
Spleen below 
umbilicus. 
Good. Symptom free 10.0 
Spleen at umbili- 
cus, liver not 
palpable. 





Poor. Liver im- 7.4 
palpable. Spleen 
10 cros. below lt. 











Good.. Spleen 1 


















nerapy. . or x-raya. 
Relapsed A- 
















KEY (TABLE 23) 
B.T. - Blood Transfusions. 
2. Dose of 6 -MP - "Stabilising" 
' itIaintenance" 
3. S.I. - Subjective Improvement. 
4. 0.I. - Objective Improvement. 
5. Rise in Hb. or maintenance of normal level. 
6. Duration of 6 -MP response, from time 
treatment started. 
7. For differential leucocyte counts see 
case reports. 
8. P - polymorphs; L - lymphocytes; 
My - myelocytes; M - monocytes. 
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blood transfusions. He had received no previous 
treatment and was considered a therapeutic failure. 
(b) Objective improvement was noted in all 
Patients treated. Cases 31, 32, 34, 39 and 42 had 
massive splenomegalies, the lower pole of the 
spleen extending below the pelvic brim. Following 
treatment the soleen became impalpable in two 
(cases 32 and 34), the tips just palpable in one 
and considerable reduction in size in the 
remaining two. One patient (case 37) who had 
previously received x -ray treatment and whose 
spleen had been removed previously, presented with 
a huge hepatomegaly with associated pain and 
discomfort. After 6 -EP therapy, the liver returned 
to a normal size, the symptoms cleared and she 
thereafter remained symptom-free with no clinical 
evidence of disease for a further nineteen months. 
Another patient (case 39) presented with an ulcer o 
the leg and was found to have a grossly enlarged 
spleen. Blood examination revealed the diagnosis 
of chronic myeloid leukaemia. After treatment with 
6 -MP the ulcer healed completely (Fig. 47) , and 
the spleen regressed in size. Clinical improvement 
may be said to have been complete, apart from 
slight occasional splenic enlargement, in ten out 
of fifteen '.patients (cases 29, 30, 31, 32, 34, 35, 
37, 38, 40, 48). All obtained the maximum expected 
benefit from treatment and returned to normal 
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activities, Case 29, a hospital porter, has not 
lost a day's work through sickness since 6 -LP 
therapy was begun over two years ago, the blood 
picture has been consistently normal and the only 
clinical evidence of leukaemia has been an 
occasionally palpable spleen. Cases 30 and 32 have 
not been array from work for a year and case 31, a 
boy aged nine years, returned to school following 
treatment and has now been in remission for over 
thirteen months. Cases 34, 35 and 37, all females, 
returned to full domestic duties. Others who have 
obtained considerable benefit from treatment may 
not have returned to full activities on account of 
other infirmities. Thus, case 38, has rheumatic 
heart disease and case 40 osteoarthritis. In 
neither, however, have there been any symptoms 
referable to leukaemia. The duration of individual 
responses to treatment is given in Table 
(c) Haematological Changes. 
Leucocytes. 6 -MP led to a fall in the white 
cell count in all fifteen patients. A delay in 
response of one to three weeks, comparable to that 
observed in acute leukaemia, was followed by a rapi 
fall in the number of leucocytes in the peripheral 
blood, a normal level being reached within a month 
of the start of treatment. The diminution in 
leucocytes coincided with a reduction in size of 
the spleen, liver and other objective evidence of 
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the disease. A fall to leucopenic levels occurred 
in some instances which led thereafter to the 
withdrawal temporarily, or reduction in dosage of 
the drug as the count fell towards normal. The 
white cells continued to fall for a period 
following the withdrawal of the drug but in 
instances where the drug was withheld too long 
(cases 29 and 39), the leucocytes were found to 
increase and evidence of leukaemia. became more 
obvious. This resulted in the prescribing of a 
maintenance dose of the drug. The optimum dosage 
for maintenance of a satisfactory clinical and 
haematological state varied from 50 to 150 mg. dail, . 
In three subjects (cases 37, 39 and 48) the most 
satisfactory improvement was observed when the 
leucocyte count was at higher than normal levels. 
At these levels (24 - 75,000 per c.mm.) the patient . 
were maintained symptom -free and with good 
h- e or lobin levels. 
The proportion of immature granular cells in 
the peripheral blood was observed to diminish as th 
number of leucocytes fell, and in several prolonged 
disappearance of immature cells from the peripheral 
blood was noted (Table 23). In one (case 29) the 
differential count has been consistently normal for 
over two years. 
Haemoglobin. One of the essential criteria of 
q-n__effective therapeutic a ent is its ability to 
272. 
produce a. rise in the haemoglobin level. In the 
present series definite improvement in erythro- 
poiesis and ha.emorlobin synthesis followed treatmei t 
with 6-MP in twelve ,patients. In one (case 30) th- 
initial haemoglobin level was within normal limits 
and was maintained at a normal level following 
treatment, In two further patients (cases 41 and 
42) no improvement occurred. I._ ten patients the 
haemoglobin level rose to normal levels, i.7J. over 
13.0 G., while in two a rise above 12.0 G. was 
observed. Seven patients required initial blood 
transfusions but in all but two (cases 41 and 42) 
the haemolobin level was improved following 
treatment with -MP. The rate of rise of 
haemoglobin varied and in some was difficult to 
estimate because of blood transfusions. In seven 
patients not receiving transfusions the increase 
averaged 3.2 G. during the first two months of 
treatment. In a11, the maximum haemoglobin level 
was not reached until three to five months after 
the beginning of treatment. In two (cases 30 and 
31) a temporary fall occurred within the first two 
Pionths . 
Platelets. Another es, ential property of a 
chemotherapeutic drug is that it should inhibit onl 
myeloid tissues and should not depress either 
erythrocyte or -- latelet d.eveiooment . It has been 
Siiowri that e ythro"loiesis i fresueiltly improved 
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pfter 6-MP therapy and, in the present series, 
thrombocytopenia has not been observed to follow 
6-TT tbr-ray. After six months continuous therapy 
one Patient (case 34) has shown a sliFht fall in 
the platelet count. mwo (cases 31 and 39) showed 
a definite increase fo11oinr treatment. In one 
patient particularly (case 31) was 7)latelet 
formation imoved by treatment, the count rising f 
25,000 per c.mm. to within normal limits. Other 
patients retained a normal count. 
PTTRO-,:= 7,=:2=PICT; LEUKS,ZidiA, 
Two patients (aced 73 and 56 years) (cases 44 
and 45) with chronic lymphatic leukaemia showed no 
clinical or haematolorzical evidence of improvement 
fo11owin,7 treatment with 6-EP. 
D. IIS'a:TLIJAKOUS G7.0UP. 
Two patients (cases 46 and 47) with .12.1tiple 
myeloma, and one with erythroderma considered to be 
due to a reticulosis of undetermined type, failed 
to benefit from a month's treatment with 6-MP. 
One patient with pycosis funFoides appeared to be 
tem-oorarily benefited. 
Discussion 
A study of the results obtained in this more 
sly: arts ills finf1inr, of Burchenal 
2.1i6. hi s cnTifles (T5f3) and of other workers in 
this field thr-lt Pay produce temporary 
remissions in a marcents,, of patients with acute 
"OM 
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leukaemia and modify the course of chronic myeloid 
leukaemia. Chronic lymTyziatic leukaemia, however, 
appears to be unaffected b7, it. 
Adults, as well as children, may be improved 
by which is of interest when one considers 
the ineffectiveness of the foli2 acid antaonists 
in 'dalt leukaemia. Five out of eleven adults 
with acute leukaemia were benefited in the preent 
series which compares favourably with the fiEure 
of 40 per cent. obtained from an analysis of the 
results of others (Conference on 1954) . A 
larFer series of patients must be treated before 
definite information can be obtained as to the 
morphological type of acute leukaemia likely to be 
most responsive to treatment with S-LP. All that 
can be said is that remissions have been observed in 
the lymphoblastic, myeloblastic and myelomonocytic 
types of leukaemia. Although the majority of 
rPrTlissions occurred in the acute lymphoblastic 
variety this may be explained by the hi:her 
incidence of this type in children, but the 
possibility that the lower. incidence of lymphoblastjc 
leukaemia in adults may be an explanation of their 
les successful response to treatment cannot at 
this stage be dismissed. There seems little doubt, 
aowever, that 5-YP is more versatile in its action 
than aminopterin and amethoterin, which are 
Eenerally accented as ineffective in adults and 
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most effective in acute lymphoblastic leukaemia. 
As with other present day chemotherapeutic 
agents used in the management of acute leukaemia 
(Fountain, 1954b), the remissions in patients who 
respond are only temporary. Second remissions are 
unusual, and the disease gradually becomes 
resistant to the drug. The absence of cross 
resistant to ACTH, cortisone and amethopterin 
(Burchenal et al., 1953) is important, for patients 
who have become resistant to 6 -MP may respond to 
other compounds. In the present series four out 
of nine patients who had developed resistance to 
6 -MP, showed varying degrees of clinical and 
haematological improvement following ACTH. It 
would therefore seem desirable at present to use 
these compounds in sequence. Because of its low 
toxicity, and the absence of associated added 
discomforts to the patient, an important 
consideration in the management of cases of 
leukaemia, 6 -MP seems the choice of treatment at 
the outset, followed after resistance develops 
by amethopterin and ACTH and cortisone. The latter 
will probably find their main value in the very 
acute case associated with severe haemorrhage, and 
in producing symptomatic relief in adults who fail 
to respond to the antimetabolites, as well as in th 
later stages of the disease in children. A combin- 
ation of antimetabolite and hormone therapy has bee 
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advised by several investigators on the grounds 
that a higher incidence of initial remissions occur 
se P°. e '71 ) . Others disagree with this mode of 
therapy, believiri that resistance to the two 
compounds is likely to occur at an earlier stage. 
By using' the various drugs available in the above 
sequence Burchenal et al. (1954b) have demonstrated 
a definite increase in survival time. If a true 
synergistic relationship existed between any of 
these compounds it may, however, be an indication 
for combined therapy but no evidence of such has, 
however, been demonstrated (Burchenal, 1954). The 
various reports of the additive effects of 
combinations of drugs in animal leukaemia sug e sts 
that this mode of therapy may eventually lead to 
better results in human subjects and with this in 
mind effective combinations should be sought for. 
In the hope that the rate of action of 6 -NP 
would be increased, an initial "loading" dose of 
1 G. in the first t wenty -four hours was given to 
one patient (case 9) with a high leucocyte count. 
Dramatic clinical and haematological improvement 
followed within the next four days. Another 
patient (case 26) , however, failed to respond 
rapidly to large doses and others with high initial 
leucocyte counts have shown a rapid response to 
routine doses of 6 -MP. It therefore seems doubtful 
Whether initial "loading" doses are any more 
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beneficial than routine therapy. 
Whether patients who experience a complete 
-: erdission should receive a daily maintenance dose 
of _T remains unanswered. Although the majority 
of patients in this series continued to receive 
treatment when in remission, it seems doubtful 
whether maintenance therapy does in fact greatly 
prolong the remission. In this respect, it might 
be mentioned that case ô, an adult aged 62 years, 
had a complete remission lasting seven months 
during which time she received no treatment. Some 
patients, however, seem to benefit by regular daily 
treatment, especially those whose response to 
therapy is incomplete (e.g. case 10) , and it is 
probably this observation that led to the use of 
maintenance therapy throughout this group of 
patients with acute leukaemia. 
Whether or not 6 -PP becomes accepted as a 
suitable agent Thr the treatment of chronic myeloid 
leukaemia remains to be seen. As with any other 
chemotherapeutic agent one must consider whether it 
is an effective substitute for the most widely 
accepted form of treatment at the present day, 
radiotherapy. Only a carefully controlled 
comparative study extending over several years 
would give an accurate answer to this Question. 
Iiorever, comparison of the survival rates, and the 
degree, and duration of remissions in patients 
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treated with 6 -IJP with those reported in the 
literature following irradiation will yield most 
of the desired information.. It is at present too 
early to compare the survival rates of patients 
treated with' 6-MP alone with those treated by 
radiotherapy alone, and until this analysis 
becomes possible one cannot advocate 6 -MP as a 
first line of treatment. The results reported do, 
however, suggest that 6 -MP may yield prolonged 
remissions in a large number of patients during 
which time a satisfactory clinical and 
haematological state may be maintained. The longes 
response observed so fa.i' is in case 29, a male 
who has continued satisfactorily for over two years 
Four other -patients have now been doing well for 
over a year. The degree of improvement in the 
thirteen patients, out of a total of fifteen 
responding satisfactorily to 6 -MP, appeared as good 
as any other form of treatment, the haemoglobin 
level rising spontaneously as the leucocyte count 
fell together with a disappearance of clinical 
evidence of the disease. 6 -PP would therefore 
appear to be a satisfactory substitute for 
radiotherapy if unavailable or contra -indicated. 
advantage it holds over external irradiation is its 
lack of toxic side- effects although administration 
of x -rays in the form of radio- active phosphorus 
has tended to overcome this difficulty. Other 
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advanta Tes of 6-EP would appear to be its 
simplicity of handling and administration, the ease 
with which the disease may be controlled with 
proper dosage and adeguate haematological 
supervision, and the absence of depression of 
-)latelet production. In addition, by the use of 
maintenance therapy, longer periods during which 
the patient may be clinically and haematologica.11y 
normal, may be obtained. A definite advance over 
x -ray treatment would be reached when a 
chemotherapeutic agent is found that will produce 
a rood r. es!)onse in patients who have either 
responded unsa.tisfctorily to x -rays from the start 
or who have reached the terminal refractory phase 
associated with unresponsive anaemia. It is true 
to say that no such com_` ounö has yet been found 
which will consistently bring about clinical and 
haematological inr rovement in the "radio- resistant" 
patient, and the discovery of such a drug would 
undoubtedly be a major advance in the treatment of 
chronic leukaemia. 6 -ìd°, like others may 
occasionally yield good results in the patient 
responding poorly to x -rays (case 39) but at other 
times is suite ineffective (case 42). 
The effectiveness of 6 - ?:'P must also be comroare 
with that of other chemotherapeutic agents. 
Individual preference still plays a large dart in 
Ithe choice of agent and there is no doubt that 
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experience in the handling of a particular drug, 
whether trea.tin acute or chronic leukaemia, leads 
to better results. The results obtained with the 
majority of present day agents are, in experienced 
hands, probably much the same. Certain compounds 
would, however, seem to have definite advantages 
over others, particularly when used by those not 
accustomed to handling them. Thus 6 -MP and 
myeleran, both of which are relatively non- toxic, 
are superior to arsenic, benzene, urethane and 
nitrogen_ mustard including TEï','I because of the lack 
of upsetting side -effects and the more readily 
controlled effects on the bone marrow, in addition 
to the longer remissions which may follow the use 
of maintenance therapy. Certain advocates of these 
other forms of treatment have, however, at times 
reported excellent results including Willïinson 
(1955a) who considers intravenously administered 
nitrogen mustard as the most satisfactory modern 
treatment of chronic myeloid leukaemia and able to 
Produce results equal to x -rays including an 
equally long survival time. On the whole, however, 
it is the author's opinion that myeleran and 
probably 6 -MP, when a longer trial has been studied 
are the treatment of choice, other than radiotherap; 
for the reasons previously mentioned, and 
particularly for the use of the general physician 
with no special knowledge of chemotherapy. At the 
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present stage, myeleran, which has undergone more 
extensive clinical trials (Galion 1953; 1955), in 
vier: of the prolonged improvement it may produce, 
its known effectiveness in some patients responding 
poorly to x -ray therapy, its apparently specific 
action on myeloid tissue in addition to its ease 
in handling and low cost, probably holds an 
advantage over other chemotherapeutic drugs. 
Whether or not 6-MP will be as effective remains 
to be seen. The results at the present time are 
encouraging and like myeleran prolonged remissions 
may follow its use, and it seems eouaily specific 
in its action on myeloid tissue. It is easy to 
handle and patients on maintenance therapy are 
genera_L_Ly seen at intervals of no less than a 
month at the out -patient clinic and experience 
suggests that patients may beseen at longer 
intervals without giving rise to anxiety. 6-MP 
is also an important contribution to the therapy of 
chronic myeloid leukaemia in that it may be 
effective in the acute terminal phase (case 36) 
(_urchenal et al. 1953) and is probably unique in 
being effective in both the acute and chronic form 
of leukaemia. 
Conclusions. 
It has been demonstrated that a new compound, 
6- merca-gtonurine, an antimetabolite allied to the 
folic acid analogues, has been discovered with whicl 
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dramatic remissions may be obtained in a percentage 
of cases of acute leukaemia. Unlike aminopterin 
and amethopterin, 6 -HP may be effective in adults 
and has a low toxicity. It can therefore be used 
with little danger of added discomfort to the 
patient - an important consideration in the 
management of cases of leukaemia. That the 
remissions are only temporary suggests the value 
of 6 -MP as a research compound will at present 
outweigh its clinical usefulness. However, with 
the knowledge that aminopterin and amethopterin, 
A.C.T.H. and Cortisone, and 6 -MP may all produce 
clinical and haematological remissions in acute 
leukaemia, it seems desirable to give patients the 
advantage of such chemotherapy. Symptomatic relief 
may be obtained (Fountain and Towers, 1955) and by 
sequential use these drugs may offer several months 
of useful life. A number of physicians, _lowever, 
are of the opinion that in the consideration of 
humanity, treatment should be limited to the relief 
of pain and distress, and in view of the eventual 
fatal outcome no attempt to induce remissions and 
prolong life should be made. Such an attitude is 
not likely to lead to therapeutic advances and can 
only lead to a demoralised patient, relative and 
doctor and in a broader sphere a negative 
therapeutic approach to many other forms of 
malignant neoplasms. Each physician must consider 
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these factors himself. In all cases of leukaemia 
in children the author has discussed the treatment 
and its shortcomings with the parents. Suffice it 
to say that, without bringing any pressure to 
bear, on no occasion has treatment been refused 
and never have the parents regretted the period of 
remission of the disease, however brief it may 
have been. 
Although the period of follow -u . of patients 
with chronic myeloid leukaemia treated with 6 -MP 
must be longer before the ultimate value of 6 -MP 
is known, initial observations suggest it may well 
hold a place in the management of the disease. 
Like chemotherapy as a whole it is relatively cheap 
easy to give and more readily available to the 
population as compared with radiotherapy. Moreover 
it is of low toxicity and therefore easy to control 
Whether it is recognised by the physician as an 
advance in treatment or not, the fact that chronic 
leukaemia in addition to the acute form, can be 
Controlled by an antagonist of a nucleic acid 
precursor is of considerable fundamental interest 




1. The results of treating fifty patients 
suffering from leukaemia or allied disorders with 
a -urine antagonist, 6- mercaptopurine, have been 
presented and discussed. 
2. Of twenty -eight patients with acute leukaemia 
seventeen responded to treatment. Complete 
clinical and haematological remissions followed 
treatment in nine patients. The results were 
compared with those obtained by other workers. 
3. Remissions were temporary and resistance to 
further therapy with 6 -MP eventually resulted. 
The duration of remissions varied from a few weeks 
to over a year. 
4. Children responded better to 6 -MP than adults, 
but 6 -MP seemed more effective in adults than the 
folic acid antagonists. The lymphoblastic type of 
leukaemia appeared to respond best to treatment 
but remissions were also observed in patients with 
myeloblastic and monocytic leukaemia. 
5. No cross resistance between 6 -MP and ACTH 
and cortisone was observed. 
6. The survival time of patients who developed 
remissions on the average appeared to be longer 
than those who failed to respond to treatment. 
7. Sixteen patients with chronic myeloid leukaemi4 
were treated with 6 -MP. The effect of maintenance 
therapy in the majority resulted in prolonged 
clinical and haematological improvement. 
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8. Two patients with chronic lymphatic leukaemia, 
two with multiple myeloma, and one with reticulosis 
of the skin did not respond to treatment, while 
one patient with mycosis fungoides obtained some 
improvement. 
9. 6 -MP is of low toxicity and no serious 




Case No. 1. 
A boy, aged 3;L- years, was admitted to a 
children's ward at the General Infirmary, Leeds, 
on June 20, 1953. He gave a history of pains in 
the legs of five months' duration. Five weeks 
before admission he was diagnosed as having mumps 
and from that time his condition rapidly 
deteriorated. His appetite became poor and pain 
in the legs prevented him from walking. 
Increasing pallor was noticed by the parents and 
the temperature at times was elevated. 
On admission he was found to be severely 
anaemic and enlarged lymph glands, 2 to 1 cm. in 
diameter, were palpable in cervical, 
and inguinal regions. Numerous small scalp 
tumours up to 5 mm. in diameter were observed. 
The skin, throat and mouth appeared healthy and 
the liver and spleen were not palpable. There 
was no pyrexia. 
Blood studies were in keeping with a 
dia gnosis of acute lymphoblastic leukaemia. Six 
days after admission, on the day treatment with 
6 -MP was started the blood findings were as 
follows: haemoglobin 6 G., red cells 1,900,000 
per c.mm., reticulocytes 1.9%, platelets 60,000 
per c.mm., white cells 4,800 per c.mm. 
Differential white cell count: blast cells 17%, 
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lymphocytes 83%. On tibial puncture the bone 
marrow was found to be highly cellular and 
replaced by lymphoid cells of which 56% were 
:primitive cells with the characteristics of 
lymphoblasts, while the remainder were more or 
'less mature lymphocytes. 
Progress and Treatment (Figs. 20 & 21) 
A transfusion of packed red cells was given 
on June 26, which elevated the haemoglobin to 
13.5 G. On the same day treatment with 6 -MP was 
instituted, and 50 mg. of the drug was given by 
¡mouth daily for nine days. On July 5, the dose 
was increased to 75 mg. daily for five days and 
during the following two days a further 75 mg. 
was administered. 6 -MP was discontinued on 
July 11, after a total of 0.9 G. had been given. 
,During the course of treatment the child's 
condition remained good, pain in the legs was not 
a striking symptom, and he remained afebrile. A 
diminution in size of the lymph nodes and scalp 
tumours were first observed on July 5, at which 
time the leucocyte count was 2,800 per c.uun. On 
'July 14, the glands and scalp tumours were 
,impalpable, the white cell count having fallen 
to 650 per c.mm. (polymorphs 11%, lymphocytes 89 %) 
and the haemoglobin 9.6 G. A tibial puncture on 
July 17 showed a hypocellular marrow with 20% 
blast cells, 57% lymphocytes, 18% myeloid cells 
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and 3% erythroid cells. Leucopenia persisted for 
approximately three weeks and was followed by 
haematological remission. 6 -MP, 25 mg. daily, 
for four days, was given when the white cell count 
began to rise, but was discontinued when it became 
clear that haematological improvement was 
occurring. On July 27, the child developed a 
boil in the gluteal region and for eleven days 
Penicillin (Distaquaine) 300,000 units b.d. was 
given. The infection remained localised, there 
was no pyrexia and a satisfactory response to 
penicillin treatment was obtained. 
Although not considered highly significant 
at the time, the appearance of polymorphonuclear 
'cells in the peripheral blood on July 14, three 
days after treatment was withdrawn, was probably 
the first sign of haematological remission. Three 
days later bone marrow examination revealed the 
presence of returning granulopoiesis and 
erythropoiesis, which was mirrored in the 
periph ral blood thereafter by a rising haemoglobin ! 
and an increase in granular cells. An increase in 
the platelet count was also observed at this stage 
and by July 28 had risen to 169,000 per c.nim. On 
August 1, the white cell count was 4,000 per c.nim. 
of which 55% were polymorphs and 45% lymphocytes, 
and tibial puncture revealed a fail in the number 
of blast cells in the bone marrow to 6.4%. 
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Lymphocytes 17.2%, myeloid cells 46.4% and 
erythroid cells 30.0;6 7;ere present r:nd the marrow 
still showed a diminished cellularity. The 
presence of erythroid elements was reflected in 
the rising haemoglobin and red cell count, which 
on August 5, had reached 12.2 G. and 4,000,000 
per c.mm. respectively. 
The patient was discharged home in apparently 
normal health on Ault 11. Physical examination 
revealed no abnormality, his azypetite was good 
and he regained full activity. His weight had 
increased 6y over four pounds. He remained in 
full clinical and haematological remission for 
nine weeks when relapse occurred. He was re- 
admitted to hospital on Oct. 2, 1953, and 
following a second course of treatment with 6 -MP 
lasting ten weeks, he again developed a complete 
remission. This remission, during which a daily 
maintenance dose of 25 mg. 6 -P was prescribed, 
lasted four months. He had now become resistant 
to 6 -MP and treatment with A.C.T.H. was instituted. 
No definite haematological improvement occurred, 
however, and his condition gradually deteriorated 
and death resulted on August 4, 1954. 
ost- morte_ examination was not perfor_?ed. 
Comment. 
A child aged 3 years developed a remission 
following 6 -Mp therapy. Following relapse a 
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a second remission lasting four months followed 
further treatment with 6 -I'vP. Thereafter he was 
resistant to treatment. 
He survived 13,1- months from the time of 
diagnosis, or lai months from the ons.::t of 
symptoms. 
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Case No. 2. 
A female child, aged 4Z years, was admitted 
to the Leeds General Infirmary on February 10, 
1954, with a history of increasing pallor, nains 
in the lumbar region and legs, lassitude and 
loss of weight of six weeks' duration. 
On admission she was found to be anaemic and 
several lymph glands about z cm. in diameter were 
palpable in the cervical, axillary and inguinal 
regions. The spleen and liver were not palpable 
and there was no bleeding. The temperature was 
99°F. 
Blood examination gave the following findings: 
haemoglobin 5.9 G., red cells 1,900,000 per c.mm., 
reticulocytes 3 %, platelets 64,000 per c.mm., 
white cells 9,000 per c.mm., differential white 
cell count:- blast cells 19 %, lymphocytes 69; , 
neutrophils 115, myelocytes 1 %. 
Sternal bone marrow showed almost total 
replacement by large, deeply staining primitive 
cells having little cytoplasm and deeply staining 
nuclei. Many of the cells contained nucleoli. 
The differential cell count was as follows: blast 
cells 89.6%, lymphocytes 2.0 , myeloid cells 1.6 %, 
erythroid cells 6.0, other cell types 0.8. 
The peripheral blood and bone marrow cytolo?y 
was in keeping with a diagnosis of acute 
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lymphoblastic leukaemia. 
Progress and Treatment (Fig. 22) 
Treatment with 6 -MP, 50 mg. daily, was 
begun immediately on February 10. A transfusion 
of packed red cells was given on February 11, 
which raised the haemoglobin to 13.8 G. and 
produced considerable clinical improvement. The 
temperature settled within forty -eight hours and 
the patient's general condition remained good. 
She was very active and played normally. The 
blood picture was, however, slow in improving. A 
leucopenia developed two days after the start of 
therapy and pa rsisted for two months. 6-11P., 
25 or 50 mg. daily, was continued during this 
period when the leucocytes fluctuated between 
2 -4,000 Der c.mm. By Liarch 15, approximately five 
weeks after the introduction of treatment, the 
platelet count had risen to 150,000 per c.inïn. and 
the bone marrow showed a definite improvement: - 
blast cells 31 %, erythroid cells 35.2, myeloid 
cells 28.8%, lymphocytes 4.8, Leukaemic cells 
were still the predominant cell, however, in the 
peripheral blood. Two weeks later, as her 
general condition was so good, she was discharged 
home and thereafter was observed as an out -patient. 
Clinical examination on discharge (March 30) 
showed slight anaemia and a few small cervical 
95 
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It was not until April 29, after eleven v ee Ls 
of treatment, that the haematological evidence of 
a complete remission appeared.. The bone marrow 
on that day gave the following differential count: - 
myeloid cells 37 %, erythroid cells 4ó¡i, 
lymphocytes 5%, smear cells 10;x. Apart from the 
high proportion of smear cells the bone marrow was 
apparently normal. The haemoglobin which to this 
time had tended to fall now rose to a normal level, 
the platelet count reached a normal figure and the 
distribution of leucocytes in the peripheral blood 
improved. On May 13, blood examination gave the 
following results:- haemoglobin 13.3 G., red cells 
per c.mm., white cells 4,500 per c.min., 
differential white cell count:- polymorphs 57%, 
lymphocytes 39 %, monocytes 4 %, platelets 250,000 
per c.irin. 
She was now given a maintenance dose of 
25 mg. 6 -MP daily. She started school and remained 
in apparently normal health until November, 1954, 
the only suggestion of the disease being a few 
persistent small cervical lymph glands and at times 
a slight preponderance _:f lymphocytes in the 
peripheral blood. It was not thought necessary to 
carry out further bone marrow examinations during 
this period. 
298. 
On iovember 22, she was admitted again to 
hospital complaining of pains in the legs, 
difficulty in walking and lassitude. She was 
pyrexial, anaemic and enlarged lymph glands were 
again obvious. The blood picture was as follows: - 
haemoglobin 7.5 G., white cells 2,900 per c.mm. 
(neutro_ohils 34 %, lym_hocytes 66%) , platelets 
195,000 per c.mm. Bone marrow : - blast cells 
39.6 %, lymphocytes 49.2;x, myeloid cells 6.8 %, 
erythroid cells 4.0 %, other cell types 0.4%. 
After an initial blood transfusion, 6 -MP was 
increased to 50 mg. daily. Symptomatic 
improvement followed and the temperature settled 
after two weeks. She was allowed home on 
December 18, the blood still showing evidence of 
leukaemia but symptom free. In mid -January, 1955, 
however, she required a further blood transfusion. 
As no further benefit was being afforded by 6 -MP, 
A.C.T.H. therapy was given in March. No 
haematological improvement resulted and in May, 
1955, she was again admitted to hospital. Further 
courses of 6 -MP and .A.C.T.H. were prescribed with 
little effect on the blood picture and repeated 
transfusions have been necessary. 
Comment. 
A child, aged 42 years, with acute 
lymphoblastic leukaemia responded slowly to 
299. 
treatment with 6 -MP. After almost three months 
continuous therapy a complete remission occurred. 
She was maintained in good health, returned to 
school and carried out normal activities for 
thirty -six weeks after the initial response to 
6 -MP. Relapse then occurred and 6 -MP failed to 
bring about haematological improvement a second 
time, although she obtained temporary symptomatic 
relief. r _.C.T.H. was later prencribed with little 
beneficial effect. 
She has survived 19 months since the diagnosis 
was made, or 20 months since the onset of symptoms 
300. 
Case No. 3. 
A 62 year old female child was admitted to 
Wakefield General Hospital on November 2, 1954, 
with a history of increasing pallor and loss of 
energy of five weeks' duration, and more recent 
breathlessness on exertion. 
On admission the temperature was 102 °F. She 
was very anaemic, and bruises were present over 
the arms and back, and lymph glands were palpable 
in the cervical, axillary and inguinal regions. 
The spleen tip was just palpable. 
Blood examination gave the following result: - 
haemoglobin 5.2 G., red cells 1,510,000 per cu.mm., 
white cells 12,400 per c.min., differential white 
cell count:- neutrophils 5 %, lymphocytes 22 %, 
blast cells 73 %. The blast cells were considered 
to be lymphoblasts. They measured approximately 
10 -12 u in diameter and were almost entirely 
composed of nucleus, cytoplasm being very scanty. 
Nucleoli were present in several. 3 normoblasts 
of types B and C, were seen while counting 100 
white cells. 
Bone marrow was easily obtained from the 
sternum and was found to be abundantly cellular. 
95ó of the cells had the characteristics of 
primitive blast cells, granular and red cell 
precursors being almost completely absent. 
301. 
A diagnosis of acute lymphoblastic leukaemia 
was made. 
Progress and Treatment (Fig. 23) 
A transfusion of whole blood was given 
shortly after admission which raised the 
haemoglobin to 9.7 G., and produced symptomatic 
improvement. Treatment with 6 -MP, 50 mg. daily, 
was begun on November 8. The dose was reduced to 
25 mg. daily after four days due to a steadily 
falling leucocyte count, and on November 18, when 
the count was 2,800 per c.mm., to 12.5 mg. per day. 
Treatment was witheld for four days between 
November 27 and December 1, when the leucocytes 
fell below 2,000 per c.mril. During this period of 
6 -MP therapy the child was fairly well. She was 
out of bed and playing each day and rarely 
complained. The temperature, however, remained 
elevated between 99° - 100 °F., her appetite was 
poor and the spleen and lymph nodes were still 
palpable. The haemoglobin level gradually fell 
and although the leucocyte count was always low 
no improvement in the distribution of leucocytes 
in the peripheral blood occurred. After three 
weeks treatment therefore no clinical or 
haematological improvement had occurred. 6 -MP, 
12.5 mg. daily, was re- started on December 1 and 
the same dosage continued until December 8, when 
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it was increased to 50 mg. daily. Still no 
improvement in the blood picture had occurred and 
a further blood transfusion was necessary on 
December 9. On reviewing the case at this time 
the conclusion arrived at was that the dose of 
6 -MP prescribed had possibly been too small and 
that irrespective of the persistent leucopenia a 
higher dose would be given in the hope of inducing 
a remission. A week after increasing the drug to 
50 mg. daily the persistent temperature finally 
settled, the majority of the lymph nodes had 
disappeared, the spleen became impalpable and her 
appetite and general condition improved. Although 
the bone marrow on December 21 still showed 87% 
leukaemic cells, the peripheral blood by the end 
of December showed 46% mature polymorphs. This 
was the first time since treatment was started 
7i weeks previously that the percentage of 
polymorphs had risen over 12%. She was discharged 
from hospital on January 1, 1955. Two weeks later 
a further bone marrow still showed a preponderance 
of leukaemic cells. Continued improvement in the 
peripheral blood - a rising haemoglobin and 
platelets and a return of the leucocyte picture to 
normal - suggested a return of the bone marrow to 
nearer normality. This was confirmed by further 
marrow examination in early February when 
erythroid cells 28.4 %, lymphoid cells 20 %, were 
304. 
observed, the remainder of the cells being mature 
granular cells. For the following eight months 
she has been seen at regular intervals as an 
out -patient. Throughout this period she had 
attended school without a break. She is entirely 
symptom free and possesses apparently normal 
health. On July 12 blood examination showed: - 
haemoglobin 14.8 G., white cells 5,200 per c.mm. 
(polymorphs 70%, lymphocytes 27%, monocytes 3%). 
Bone marrow examination showed:- lymphocytes 31 %, 
myeloid cells 32 %, erythroid cells 35 %, other cell 
types 2%. She continues to have 50 mg. 6 -MP daily. 
Comment 
a 6 year old schoolgirl with acute 
lymphoblastic leukaemia developed a clinical and 
haematological remission after seven and a half 
weeks 6 -MP therapy. The delay in response was 
thought to be due to sub- optimal dosage. The 
remission continues thirty -eight weeks later, and 
she is being "maintained" on a daily dose of 50 mg. 
6 -MP. 
She has survived it months since diagnosis, 
or 12!6 months since the onset of symptoms. 
305. 
Case No. 4. 
A female child aged 2-i years was admitted to 
Wakefield General Hospital on July 31, 1954, with 
a 6 weeks' history of vomiting, pyrexia and 
"swelling of the glands ". A diagnosis of 
glandular fever was made by her doctor but the 
gradual development of severe anaemia, constant 
tiredness, anorexia, loss in weight and finally 
the appearance of extensive impetigo necessitated 
her transfer to hospital for further investigation. 
On admission she was found to be extremely 
anaemic. Ecchymoses were present on the arras and 
legs and impetigo was observed affecting the 
circumoral region, right temple, right pinna and 
external auditory meatus. The left eye was 
infected, swollen and closed, and numerous 
enlarged lymph glands were palpable in the 
cervical, axillary and inguinal regions. The 
liver and spleen were not palpable. The 
temperature was raised to 101 °F. 
Blood examination gave the following findings:- 
haemoglobin 2.8 G., red cells 945,000 per c.mm., 
white cells 3,800 per c.mm., differential white 
cell count : - polymorphonuclear cells 2%, lymphoid 
cells 98%. The majority of the latter cells were 
primitive blast cells. 
Bone marrow obtained from the iliac crest was 
306. 
found to be highly cellular and composed entirely 
of blast cells. No cells of the erythroid or 
granular series were present. 
The marrow and peripheral blood Picture 
indicated a diagnosis of acute lymphoblastic 
leukaemia (aleukaemic type). 
Progress and Treatment (Fig. 24) 
A transfusion of packed red cells was given 
immediately, raising the haemoglobin to 7.0 G. 
Penicillin 250,000 U. 6 hourly i.m., and Ung. 
Hydrarg. Ammon. dil. locally to the impetiginous 
areas on the face and head, and Guttae Penicillin 
to the infected eye were also prescribed. 
6 -MP was begun on August 1, at a dose of 
100 mg. daily. It was hoped by giving this larger 
initial dose that improvement might be hastened. 
Five days later the dose was reduced to 50 mg. 
daily. The impetigo and infection of the left eye 
cleared rapidly with local treatment. 
Haematological improvement was not observed, 
however, until almost five weeks after 6 -MP 
therapy was started when the peripheral blood 
showed the presence of 30% mature polymorphe. 
During this period she developed chicken -pox with 
widespread skin sepsis and two further blood 
transfusions were necessary. On both occasions 
the transfusion wound became septic and there was, 
307, 












PACKED RED CELLS 
FROM 420 mis. BLOOD 
OCT ' NOV DEC ' JAN FEB ' MAR APR ' MAY 
1954 1955 
9 G.C. AGED 2YRsAC.LYMPHOBLASTIC LEUKAEMIA 
FIG. 24. 
308. 
apart from a week in mid- August, continuous fever. 
On September 3, the temperature settled and 
clinical improvement coincided with haematological 
improvement. By September 16, the bone marrow 
showed:- blast cells 36%, myeloid cells 39¡x, 
erythroid cells 23 %, other cell types %; the 
haemoglobin was 9.0 G., and rising without further 
recourse to transfusion. The skin infection was 
clearing rapidly and she was up and walking about. 
A few shotty glands were still present in all 
regions. 
She continued to do well and on September 28 
was discharged from hospital symptom free and fully 
active. The haemoglobin had risen to 11.0 G. and 
the bone marrow showed a further reduction in 
lymphoid cells to 20%. Erythroid cells numbered 
36%, myeloid cells 43% and monocytes 1%. 
A maintenance dose of 50 mg. 6 -MP daily was at 
first prescribed but this was reduced to 25 mg. 
daily on October 26. 
When last seen in the out- patient department, 
fifty -two weeks after the onset of the remission, 
she was still well and in apparently normal health. 
Since her discharge from hospital the haemoglobin 
has remained over 13.0 G. and apart from an 
occasional slight 1rrphocytosis the blood film has 
shown no suggestion of leukaemia. Further bone 
309. 
marrow studies have not been carried out. 
Comment 
A 2.1 year old female child with acute 
lymphoblastic leukaemia developed a complete 
clinical and haematological remission under 
treatment with 6 -MP. Five weeks elapsed before 
treatment became effective and she continues in 
normal health fifty -two weeks after the onset of 
the remission, and 13¿ months after the diagnosis 
was made. She is taking a maintenance dose of 
25 mg. 6 -MP daily. 
She has survived 13? months since diagnosis, 
or 15 months since the onset of symptoms. 
310. 
Case No. 5. 
A male child, aged 2 years, was admitted to 
St. James's Hospital, Leeds, on January 25, 1955. 
A history was obtained of 'influenza' a month 
previously following which he remained pale and 
debilitated. The parents noticed the pallor 
increasing and on this account sought the advice 
of their doctor. 
On admission he was found to be extremely 
anaemic, slight enlargement of the inguinal lymph 
glands were detected and the spleen was palpable 
2 ems. below the costal margin. The liver edge 
could just be felt. Systematic examination was 
otherwise negative and the temperature was normal. 
Blood examination gave the following results: - 
haemoglobin 4.48 G., red cells 1,400,000 per c.mm., 
reticulocytes 0.6 %, white cells 3,200 per c.mm., 
differential white cell count:- blast cells and 
lymphocytes 70%, polymorphonuclear cells 24%, 
myelocytes 1%, monocytes 4 %, Tinck cells 1%. 1 
nucleated red cell per 100 white cells was present, 
and many of the lymphocytes were seen to be 
immature. A platelet count carried out shortly 
after treatment was started was 90,000 per c.mm. 
Bone marrow obtained from the iliac crest was 
found to be extremely cellular and the 
differential cell count was as follows:- blast 
311. 
cells 87.0 %, myeloid cells 11%, erythroid cells 
0.5%, lymphocytes 1.5 . A diagnosis of acute 
leukaemia probably of lymphoblastic type was made. 
Progress and Treatment (Fig. 25) 
On January 28, a transfusion of packed red 
cells was given which raised the haemoglobin to 
normal and produced considerable symptomatic 
benefit. Treatment with 6 -MP 50 mg. daily was 
started on February 1, and a few days later in 
view of his excellent clinical condition he was 
allowed home. When seen as an out -patient on 
February 23, he was found to be symptom free and 
fully active. Clinical examination was negative, 
the liver and spleen being now impalpable. The 
blood picture, however, was still typical of 
leukaemia:- haemoglobin 12.4 G., platelets 
35,000 per c.r:m.., white cells 2,700 per c.mm., 
differential count:- neutrochils 7 %, monocytes 
3%, lymphocytes 90%. In view of the low leucocyte 
count 6 -MP was reduced to 12.5 mg. daily. Two 
weeks later, the haemoglobin had fallen to 7.1 G. 
Other feature of the blood picture, however, 
suggested improvement, the platelet count now 
being normal at 350,000 per c.mm. and the bone 
marrow findings:- blast cells 7.5, myeloid cells 
51.0 %, erythroid cells 5.5%, lymphocytes 26%, 
monocytes 10 %. 
312. 
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Continued improvement in the blood picture 
followed. The haemoglobin rose without blood 
transfusions to over 14.8 G., and the blood film 
returned to apparent normality. A further bone 
marrow examination at the end of March showed only 
19.5% lymphoblasts and lymphocytes. 
On May 2, three months after treatment with 
6 -MP was instituted, blood examination showed 
haemoglobin 16.8 G., white cells 9,600 per c.mm., 
differential count:- polymorphonuclear cells 79%, 
lymphocytes 17 %, monocytes 4%. He was symptom free 
and clinical examination was negative. He 
continued to take 6 -MP 12.5 mg. daily, and 
continued in apparently normal health until the 
first week of June, 1955. Clinical and 
haematological relapse then occurred, and in spite 
of continued 6-MP therapy he died on July 8, 1955. 
Comment. 
A male infant with acute lymphoblastic 
leukaemia developed a complete remission under 
treatment, mainly as an out -patient, with 6-MP. 
His clinical condition was good from the outset and 
improvement of the blood picture was first noticed 
five weeks after the start of treatment The 
remission lasted thirteen weeks. 
He survived 5' -, months following diagnosis, or 
6 months since the onset of symptoms. 
314. 
Case No. 6. 
A girl aged 102 years was admitted to 
Seacroft Hospital, Leeds, on April, 3, 1955, with 
an illness which started on Christmas Day, 1954, 
while en route by ship to Canada with her parents. 
Her initial complaint was low back pain which 
persisted for three days. On landing at Halifax, 
Nova Scotia, she felt improved and early in 
January she started to attend school. A 
recurrence of the low back pain occurred and she 
was noticed to be becoming progressively paler. 
She lacked energy, lost her appetite and became 
pyrexial. A diagnosis of rheumatic fever was made 
and as a result of failure to respond to 
salicylate therapy was admitted to Hamilton 
General Hospital, Ontario, on February 24, 1955. 
Further investigations, including two sternal 
marrow examinations revealed her to have leukaemia. 
The parents were informed of the hopeless prognosis 
of the disease and returned to England by air on 
March 31, 1955. 
On admission she was found to be severely 
anaemic and complained of severe pain in the 
lumbar region on movement. The temperature was 
99°F. A few small lymph glands were palpable in 
the cervical region and in both groins. The spleen 
tip was just palpable. There was no purpura or 
T 
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other evidence of haemorrhage. 
Blood examination on admission was as follows: - 
haemoglobin 8.7 G., red cells 2,900,000 per c.inr., 
platelets 89,000 per c.mm., white cells 2,700 per 
c.mm. Differential white cell count:- lymphoid 
cells 79%, polymor;phonuclear cells 17 %, monocytes 
4%. Many of the lymphoid cells were immature and 
showed the characteristics of blast cells. A few 
normoblasts were identified. 
Bone marrow aspirated from the left iliac Gres' 
was found to be highly cellular, a differential cel 
count showing 94.6% blast cells, 2.2% myeloid cells, 
2.6% erythroid cells and 0.6% other cell types. 
A diagnosis of acute lymphoblastic leukaemia 
was made. 
Progress and Treatment (see Fig. 26) 
Treatment with 6 -MP wad begun on April 6, 1955, 
a dose of 50 mg. b.d. being prescribed. During the 
following three weeks no improvement occurred, she 
had recurrent attacks of pain in the back and joints 
and on April 18, the haemoglobin had fallen to 5.2 t 
A transfusion of concentrated red cells was given 
which raised the haemoglobin to 9.1 G. 
On April 27, the temperature returned to norma 
and the spleen was impalpable, the pain in the join 
and lumbar region cleared, her appetite improved 
and she was able to get up. The peripheral blood, 
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cells. The dose of 6 -MP was reduced to 25 mg. b.d. 
on April 30 and apart from a period of a week when 
it was increased to 25 mg. t.d.s. this dose was 
continued as mmintenance therapy. On May ll the 
haemoglobin had risen to 13.2 G., the white cell 
count was 4,700 per c.mm. and the differential 
count showed polymorphs 68 %, lymphocytes 28%, 
monocytes 4%. The platelet count was normal at 
250,000 per c.mm. A further bone marrow 
examination showed a reduction in cellularity and 
the following cell picture: blast cells 9.6 %, 
myeloid cells 23.8 %, lymphocytes 20.4;á, erythroid 
cells 44.2%, other cell types 2%. When seen a 
month later she was fully active and symptom free. 
The haemoglobin had risen to over 14.6 G., the 
peripheral blood picture a geared normal and there 
was no clinical evidence of le ukaemia. She 
continued in full remission for ten weeks. On 
July 6, she complained, however, of pains in the 
limbs and the blood picture revealed evidence of 
relapse. She was re- admitted to hospital and 
found to be resistant to further 6 -MP therapy. A 
downhill course followed and she died on August 
7, 1955. 
Comment 
A 10i year old girl with acute lymrohoblastic 
leukaemia developed a complete remission following 
treatment with 6 -MP. The remission, during which 
318. 
the child was in normal health with no acparent 
clinical or haematological evidence of leukaemia, 
lasted for ten weeks. She failed to respond a 
second time to treatment. 
She survived for 5;- months after the diagnosis 
was made, or 7? months after the onset of symptoms. 
319. 
Case No. 7. 
A 44 year old baker was admitted to St. 
James's Hospital, Leeds, on June 9, 1953, with a 
four weeks history of pain in the lumbar region, 
sweating and dyspnoea on exertion. On admission 
widespread ecchymoses were found and two small 
skin tumours, the size of a farthing, were 
observed in the region of the xiphisternum. Sacral 
oedema was present and the liver and spleen were 
palpable 6 ems. and 5 ems. respectively below the 
costal margins. The temperature was normal and 
no other abnormalities were detected on physical 
examination. A radiograph of the chest was normal 
and a biopsy of one of the skin tumours showed it 
to be due to leukaemic infiltration. 
His blood count on June 11, was as follows: - 
haemoglobin 8.5 G., red cells 2,800,000 per c.mm., 
reticulocytes 1%, platelets 66,000 per 
white cells 6,800 per c.mm. Differential white 
cell count: blast cells 11 %, myelocytes 11%, 
neutrophile 30j, eosinorhils 11%, basophils 1 %, 
lymphocytes 22%, monocytes 14%. On sternal 
puncture the bone marrow showed: blast cells 59%, 
myeloid cells 12%, erythroid cells 8.5%, lymphocyte 
15%, other cell types 5.5%, Megakaryocytes were 
scanty. Many of the primitive blast cells were of 
a monocytoid type, the appearance suggesting a 
320. 
mo-oncytic leuhaemia. 
Treatment (Figs. 27 & 28) 
Treatment with 5-1.,T was begun on June 15, 
ano IL given daily by mouth for seven days. 
On June 22, the patient became severely dyspnoeic 
due to a large left sided pleural effusion. Two 
pints o7r haemorrhagic fluid were removed, and the 
dose of the drug increased, to 200 mg. daily. A 
transfusion of whole blood, was given on the fifth 
of treatment elevating the haemoglobin to 
10.5 CLI. TTO 31.17:mge in the clinical or 
haematological state occurred during the first 
three wecus cf treatment. On July the patient 
stated be was feeling much better, the pain in the 
luMbar region had disappeared and his appetite 
fri,Troved. 
Physical anamination showed no change, 
hOlVf....T, in the size of the liver and spleen and a 
large 7leurai effusion was still present. Blood 
ezamination shoved the haemoglobin to have fallen 
end a further transfusion of whole blood was 
performed. The leucocyte count was 4,200 per c.mm. 
and the prIELIts 85,000 per c.mm. Thereafter the 
white cell cil=t continued to fail and treatment 
TE.E discontinue:: an July 14, When the white cells 
reacned Icar c.lam.; a total dose of 5.3 G 
.7Lf 5.-lahad. been given. The patient was now 
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FIG. 28. Case No. 7. Radiograph of chest (a) before 
treatment, and (b) after treatment with 6 -MP, showing 
diminution in size of pleural effusion and mediastinal 
lymph nodes. 
323 _ 
symptom fre, the liver had become impalpable and 
the spleen had regressed so that the lower pole 
could only be felt on deep infiltration. The 
remaining skin tumour over the sternum had 
disappeared. Fluid was still present in the left 
pleural cavity and a further two pints were 
removed on July 13. A sternal puncture on July 14 
revealed a hypoceîlular bone marrow and a diminution 
in blast cells to 10%. Erythroroiesis was depressed 
but normoblastic in type and there was a relative 
increase in lymphocytes:- myeloid cells 38¡x, 
erythroid_ cells 3.5 , lymphocytes 44°x, other cell 
types 4.5 . 
The platelet count three days after treatment 
was stopped rose to 192,000 per c.mm. and 
thereafter remained within normal limits. 
Leuco-oenia e rsisted for two weeks and the 
leucocyte count then rising to a normal level. A 
fail in haemoglobin to 7.5 G on July 23 
necessitated a transfusion of packed red cells, 
and thereater a satisfactory haemoglobin level was 
maintained without further recourse to blood 
transfusions. On July 29, physical examination 
revealed the tip of the spleen to be palpable, 
otherwise no abnormality could be detected. Blood 
examination gave the following results: 
haemoglobin 11.5 G., red cells 3,80,000 per c.mm., 
324. 
reticulocytes 1 %, platelets 250,000 per c.mm., 
white cells 5,700 per c.rnrn. Differential white 
cell count: neutrophils 78 %, eosinophils 2%, 
lymphocytes 16 %, monocytes 5. The sternal bone 
marrow was still hypocellular but the differential 
cell count showed considerable improvement, blast 
cells being 3.6;x:, myeloid_ cells 47.6 %, erythroid 
cells 16.4%, lymphocytes 13.6 %, and degenerate 
cells 18.8 %. 
The patient was discharged home on August 1, 
with instruction to attend for follow -up 
examination as an out --,patient. A maintenance 
dose of 6 -MP was not prescribed. For seven weeks 
after therapy was discontinued he was symptom free 
and carried out normal activities. There was no 
clinical evidence of leukaemia. A radiograph of 
the chest one week after discharge was normal. The 
haemoglobin remained above 12.0 G. and the 
leucocyte count, differential and platelet counts 
were normal. A sternal puncture carried out on 
August 25 showed a relatively normal bone marrow 
appearance. In early September he began to 
complain of a cough and dyspnoea on exertion, and 
examination revealed a reaccumulation of fluid in 
the left pleural cavity. In addition the skin 
tumour re- appeared over the lower sternum, the 
liver and spleen became palpable and the blood 
325. 
again showed the characteristic changes of acute 
leukaemia. Treatment with 6 -MP was again 
instituted but the disease was now found to be 
completely refractory and the patient died on 
October 8, 1953. 
Post -mortem. The significant findings were 
extensive glandular infiltration in the thorax 
and abdomen, blood- stained effusions in both 
pleural cavities and early broncho- pneumonia. In 
addition a large mass of leukaemic tissue was 
observed on the front of the sternum and small 
plaques were present on the parietal pleura. The 
liver showed discrete leukaemic infiltrations 
around bile ducts in both lobes, some attaining 
the size of one inch in diameter. There was no 
diffuse infiltration of the liver. The spleen 
showed no definite macroscopic evidence of 
leukaemia. The kidneys Presented an unusual 
appearance in that a rim of leukaemic tissue about 
" wide was present beneath the capsule into which 
haemorrhage had occurred. At certain .points the 
tissue dipped into the renal_ cortex forming small 
diffuse niasses about 2" in diameter. In addition 
very large infiltrations in several of the 
medullary papillae were observed. Leukaemic 
infiltration was also observed in the wall of the 
-bladder and in the myocardium. Microscopically 
326. 
the visceral infiltrations were found to be 
composed of very primitive cells in keeping with 
the ante -mortem diagnosis. Histological evidence 
of leukaemia was also observed in the spleen. 
Comment 
A 44 year old male with acute monocytic 
leukaemia developed a dramatic clinical and 
haematological remission following treatment with 
6 -MP. Evidence of the disease, including a 
pleural effusion, skin tumours and hepato- 
splenomegaly completely disappeared for seven weeks 
when relapse occurred. 
He survived 4 months after diagnosis, or 
5 months after the onset of symptoms. 
327. 
Case No. 8. 
A 62 year old housewife was admitted to the 
General Infirmary, Leeds, on July 23, 1953, with a 
ten weeks history of increasing pallor, lassitude, 
loss of appetite and dyspnoea on exertion. During 
this period she noticed some distension of the 
abdomen developing, together with flatulence and 
tenderness in the left hypochondrium, but no 
abdominal pain. For three weeks she had been 
troubled with night sweats which were severe and 
soaked her bed clothes. 
On admission the temperature was 100.4 °F. 
She was found to be anaemic and lymph glands up to 
12 cms. in diameter were palpable in the axillae 
and groins. The liver was palpable 5 ems. and 
the spleen 12 cms. below the costal margin. 
Slight sacral oedema and crepitations at both lung 
bases were also detected. There were no other 
abnormalities on physical examination. A 
radiograph of the chest suggested that the right 
half of the diaphragm was raised and associated 
with slightly increased pulmonary markings in the 
right lower lobe. 
Blood findings were as follows:- haemoglobin 
7.8 G., red cells 2,800,000 per c.mm., platelets 
119,000 per c.mm., white cells 1,900 per c.iir. 
Differential white cell count: polymorphs 36 %, 
328. 
monocytes 2 %, lymphocytes 62%. Nucleoli were 
observed in a percentage of the lymphocytes. 
On sternal puncture the bone marrow was found 
to be moderately cellular and 66.4% of the cells 
were of the lymphoid series, about half being 
lymphoblasts. The remaining cells were equally 
divided between the myeloid and erythroid series. 
The picture was consistant with a diagnosis of 
aleukaemic lymphatic leukaemia. 
Progress and Treatment. (Fig.29) 
The patient received a transfusion of packed 
red cells three days after admission and 6-MP in 
doses of 200 mg. daily, was begun on August 7. 
No change in her condition occurred during the 
following nine days, her main complaints being 
abdominal distension, flatulence, anorexia, 
sweating and general weakness. A painful sore on 
her nose also appeared. On August 17 she stated 
that she felt better and that her appetite was 
improving. Physical examination at that time 
revealed no change, but four days later the spleen 
had diminished in size, and the feeling of 
abdominal distension had lessened. The sacral 
oedema had disappeared and the infection of the 
nose was healing. The dose of 6-MP was reduced to 
100 mg. daily on August 24, and finally 
discontinued seven days later; a total of 4.2 G. 
had been given. At this stage the spleen was 
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impalpable and liver edge could be felt only on 
deep inspiration. A few small, fleshy glands 
remained in the axillae. Physical examination 
was otherwise negative, the temperature was normal 
and the patient symptom free. 
Unlike the patients described previously no 
significant reduction in white cells followed the 
administration of the drug, and at no stage did 
the count fall below the initial figure. An 
improvement in the distribution of leucocytes in 
the peripheral blood was, however, observed within 
ten days of the start of therapy. A steady rise in 
haemoglobin occurred, but there was no significant 
increase in platelets at this stage. On 
completion of treatment the blood findings were as 
follows: haemoglobin 11.2 G., red cells 3,700,000 
per c.rnm., platelets 100,000 per c.mm., white cells 
3,100 per c.nm. of which 65% were polymorphs. The 
bone marrow showed a diminished cellularity. Very 
few lymphoblasts comprising only 1.2% of the marrow 
cells were seen; 33.6% of the cells were 
lymphocytes. Erytiropoiesis was active and 
normoblastic, 34.0% of cells being of this series. 
The remainder were developing granulocytes. 
The patient was discharged on September 5 
feeling well. She was seen again as an out - patient 
ten days later, improvement having been maintained. 
The haemoglobin had risen to 12 G. and the platelet 
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count to 275,000 per c.mm. A further bone marrow 
examination revealed only 20% blast cells, and 
lymphocytes, 34.8% being red cell precursors and 
the remainder granular cells. Thereafter she 
remained in good health with an apparently normal 
blood picture for a period of 7 months. During 
this time she was fully active, carrying out her 
household duties and living a normal life. 
Maintenance therapy was not given during the 
period of remission and following relapse in 
April 1954 the disease was refractory to further 
treatment with 6 -MP. A gradual downhill course 
occurred and she died on August 23, 1954. 
She survived a period of 13 months following 
diagnosis, or 15 months after the onset of 
symptoms. 
332. 
Case No. 9. 
An adult male aged 41 years was admitted to 
the Leeds General Infirmary on April 7, 1954. His 
history was of increasing dyspnoea, lassitude and 
loss in weight of six weeks' duration. For four 
days he had repeated epistaxes and noticed a rash 
on the legs. 
On admission he was found to be pale and 
showed signs of weight loss. Enlarged lymph glands 
were present in the cervical, axillary and inguinal 
regions and a purpuric eruption was present over 
both lower limbs. The trachea was displaced to 
the right and there were signs of an extensive 
pleural effusion on the left side. There was no 
splenomegaly. 
A chest x -ray confirmed the presence of fluid 
in the left pleural sac and also shored a large 
mediastinal mass. 
Blood examination on April 3 was as follows: - 
haemoglobin 11.8 G., red cells 3,800,000 per c.mm., 
platelets 35,000 Per c.mm., white cells 129,000 
per c.mm. A blood film showed only 2% 
polymorphonuclear cells. A few typical myelocytes 
were present but the majority were leukaemic blast 
cells which showed very fine granules on peroxide 
staining. On sternal puncture the bone marrow 
showed: blast cells 85.2%, myeloid cells 0.4%, 
333. 
erythroid cells 0.4, lymphocytes 13.2. 
A diagnosis of acute myeloblastic leukaemia 
was made. 
Progress and Treatment (Fig. 30) 
In view of the patient's extremely critical 
condition an attempt was made to induce an early 
response to 6-MP by giving a large initial dose. 
1 G. of 6 -MP was given over the 24 hour period on 
April 8, followed by 200 mgm. daily for five days. 
The haemoglobin fell rapidly after admission and a 
transfusion of whole blood was necessary on April 
12, raising the haemoglobin to 10 G. The white 
cells fell to 4,800 per c.mm. in five days with 
considerable clinical improvement. The leucocyte 
count having fallen to 2,000 per c.211. on April 14 
the dose of 6 -MP was reduced to 100 mg. daily and 
eventually discontinued ten days .:.titer when the 
count was 600 per c :m. During this period 
clinical improvement continued, the enlarged lymph 
glands disappeared, the dyspnoea was relieved and 
the mediastinal mass and ,pleural effusion 
diminished in size as shown radiologically. 
Paracentesis had not been carried out. On May 1, 
blood examination gave the following results: 
haemoglobin 12.2 G., -.platelets 450,000 per c.mm., 
white cells 5,400 per c.mm., differential white 
cell count: polymorphs 65¡, lymphocytes 34, 
<564. 
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monocytes 1 %. Sternal bone marrow: blast cells 
3.2%, myeloid cells 44.4 %, lymphocytes 12;, 
erythroid cells 39.2%, other cell types 1.2;x. 
He was discharged from hospital fully active 
and in aDparently normal health on May 8, on a 
daily maintenance dose of 100 mg. 6 -MP. On May 31, 
a further bone marrow examination revealed an 
apparently normal picture. Chest x -ray at this 
time, apart from some minor pleural thickening, 
showed the lung fields to be clear. Further 
diminution in the width of the mediastinal shadow 
had also occurred. 
He remained in complete clinical and 
haematological remission until June 28, when he 
started to complain of anorexia, nausea, and 
skeletal pain. Widespread purpura and glandular 
enlargement was observed and the blood picture 
showed evidence of haematological relapse: - 
haemoglobin 14.8 G., platelets 85,000 per c.rnii., 
white cells 41,500 per c.mm., differential white 
cell count:- polymorphs 16 %, blast cells 84 %. 
He was re- admitted to hospital but in spite of 
intensive therapy with 6 -MP went downhill rapidly 
and died on July 17, 1954. A post -mortem was 
not performed. 
Comment 
A case of acute myeloblastic leukaemia 
336. 
showing a dramatic response to 6-MP therapy. A 
complete remission resulted - the duration from 
the onset of clinical and haematological 
improvement being nine and a half weeks. On 
relapse he was completely resistant to further 
treatment with 6-MP. 
He survived 3 months following diagnosis, 
or 5 months after the onset of symptoms. 
337. 
_Case No. 10. 
Miss P.P., aged 9 years, was transferred from 
another hospital to Leeds General Infirmary on 
July, 12, 1954. Four days previously a diagnosis 
of acute lymphoblastic leukaemia had been made 
and a blood transfusion was given. 
She gave a history of pains in the back and 
legs with difficulty in walking for three months. 
She had been noticed to be becoming increasingly 
pale and during the week prior to admission had 
been troubled with epistaxis. 
On admission she was found to be slightly 
anaemic and several lymph glands were palpable in 
the cervical, axillary and inguinal regions. There 
was no evidence of bleeding, purpura, or 
splenomegaly or other abnormality on physical 
examination. The temperature was normal. 
Blood examination gave the following findings: 
haemoglobin 11.9 G., red cells 4,000,000 per c.mm., 
platelets 35,000 per c.mm., white cells 3,400 per 
c.mm. Differential white cell count:- lymphoid 
cells 96 %, neutrophils 4 %. Many of the lymphoid 
cells were immature blast cells. Sternal bone 
marrow examination was in keeping with the 
diagnosis of acute lymphoblastic leukaemia, 96c, 
being lymphoid cells, the majority having the 
characteristics of blast cells. 1.2% myeloid 
cells and 2.8% erythroid cells were also present. 
338. 
Progress and Treatment 
Treatment with 6 -MP, 100 mg. daily, was begun 
on the day of admission. A rise in temperature 
three days later, associated with a discharging 
right ear, necessitated giving penicillin. She, 
however, did not complain and her general 
condition was good, the only clinical indication 
of disease being anaemia and enlarged cervical 
lymph nodes. No improvement in the blood picture 
occurred for several weeks. Two weeks after 
admission the haemoglobin had fallen to 6.5 G. 
and the peripheral blood showed 92% leukaemic cells 
The leucocyte count had been low from the outset 
and on July 29, when 1,700 per c.nm., the dose of 
6 -MP was reduced to 25 mg. b.d. The count 
thereafter fluctuated between 1 -2,000 per c.mm. 
for a further three weeks. An improvement in the 
peripheral blood was observed on August 13, almost 
five weeks after the start of treatment. At this 
time the presence of polymorphonuclear cells in 
substantial numbers (34%) was noticed for the first 
time. The temperature, which had persisted for 
four weeks, had settled and she was symptom free. 
On August 19, blood examination was as follows: 
haemoglobin 7.5 G., red cells 2,500,000 per c.mm., 
platelets 274,000, white cells 3,200 per c.mm. 
Differential white cell count: polymorphs 44%, 
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monocytes 2¡, lymphocytes 54 %. A further bone 
marrow examination showed:- lymphoid cells 44 %, 
myeloid cells 26 %, erythroid cells 30%, a 
percentage of the lymphoid series being blast cells 
In view of the clinical and haematological 
improvement she was discharged home on August 21, 
1954, on a maintenance dose of 25 mg. 6 -MP daily. 
She was seen on August 30, when the haemoglobin 
had risen to 11.8 G. without further transfusion. 
Thereafter she was maintained symptom free for 
the fallowing thirty -six weeks and she was able 
to attend school and carry out full activities. 
During this time the haemoglobin level was 
consistantly normal. The differential leucocyte 
count, however, frequently showeda slight 
preponderance of lymphocytes and the platelet 
count tended to be subnormal. A few lymph glands 
persisted also in the neck. 
On April 18, 1955, she began to complain of 
pains in the legs and abdomen and loss of energy. 
The blood picture showed haemoglobin 11.8 G., white 
cells 5,700 per c.mm. of which 85% were lympho- 
blasts. The dose of 6 -MP was thereafter increased 
to 75 mg. daily but no improvement occurred in the 
following three weeks. She was re- admitted on 
May 14, 1955, to hospital. On admission a blood 
transfusion was required which raised the 
340. 
haemoglobin to 10.5 G. Platelets were 12,000 
per c.mm. and there was epistaxis. Over 90% of 
the white cells in the peripheral blood were 
lymphoblasts and the spleen was enlarged. 6 -MP 
was stopped on admission and A.C.T.H., 25 I.J. 
i.m. 8 hourly prescribed. A marked drop in 
leucocytes occurred followed by clinical 
improvement, a rise in the platelet count and 
mature leucocytes in the peripheral blood. 
Further transfusions were not required. On June 
16, the blood showed: haemoglobin 12.6 G., white 
cells 2,700 (polyrnorphs 72;x, lymphocytes 28 %) , 
platelets 150,000 per c.mm. The bone marrow still 
showed a marked preponderance of leukaemic cells 
but she was discharged home the next day. A.C.T.1 -ï. 
was stopped and 6 -MP 20 mgs. daily given as 
maintenance therapy. When seen at the medical 
out -patient department on June 27, further 
improvement had occurred and the haemoglobin had 
risen to 14.8 G. The differential count was 
normal but platelets remained low at 130,000 per 
c.mm. Improvement was, however, short lived, and 
she proved completely refractory to further 
treatment and died in late July, 1955. 
Comment 
A case of acute lymphoblastic leukaemia in 
a 9 year old girl who responded satisfactorily and 
341. 
almost completely to 6 -MP therapy. For thirty - 
six weeks following treatment she lived a normal 
life. There was no anaemia during that time and 
the only evidence of the underlying disease was 
a slight preponderance of lymphocytes in the 
peripheral blood, a generally rather low normal 
platelet count and a few enlarged cervical lymph 
nodes. 
After relapse temporary im-Drovement, both 
clinical and haematological ,followedtreatment with 
A.C.T.H. 
She survived a period of l2;- months after 
the diagnosis of acute leukaemia was made, or 
l5 =? months after the onset of symptoms. 
342. 
Case No. 11. 
A male child aged 3 years was admitted to 
Pontefract General Infirmary on March 2, 1955, with 
a history of swelling of the parotid glands and 
increasing pallor of two weeks' duration. 
On admission the temperature was raised to 
100 °F. He was found to be anaemic and numerous 
bruises and petichiae were present over the lower 
limbs. There was bilateral parotid enlargement 
and a right sided facial palsy. The spleen and 
liver were enlarged and lymph glands were palpable 
in the cervical, axillary and inguinal regions. 
Ulceration of the gums was also observed. 
Blood examination gave the following results: - 
haemoglobin 7.6 G., white cells 320,000 per c.mm. 
A blood film showed practically all the leucocytes 
to be blast cells. Platelets were absent. 
A diagnosis of acute leukaemia was made. 
Progress and Treatment 
6 -LP, 50 mg. daily, was started on March 3, 
and increased to 100 mg. daily on March 8. On 
March 11 a blood transfusion was given which 
raised the haemoglobin from 5.2 G. to 8.1 G. A 
rapid fall in the leucocyte count occurred and on 
March 11 had reached 3,000 per c.mm. 6 -Pam was 
reduced at this stage to 50 mg. daily. Two weeks 
after the start of treatment he was feeling greatly 
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improved, the facial swelling had subsided and the 
facial movements improved. The spleen and liver 
were impalpable and the lymph nodes smaller. The 
haemoglobin was rising and the peripheral blood 
contained 32% mature polymorphs. The temperature, 
however, persisted. By March 29 he was symptom 
free and the blood picture was: haemoglobin 
11.1 G., white cells 6,500, differential count: 
neutrophils 65%, lymphocytes 35%. Thereafter he 
remained well with no clinical evidence of disease 
apart from a persistent slight anaemia. He was 
maintained on 25 mg. 6 -MP daily and the remission 
lasted twenty -two weeks. He was then found to be 
refractory to treatment with 6 -MP and also A.C.T.H. 
and he died on September 26, 1955, just less than 
seven months after the diagnosis was made. 
Comment 
A child aged 3 years responded dramatically to 
treatment with 6 -MP. Considerable clinical and 
haematological improvement occurred but the 
haemoglobin level never completely reached normal. 
He continued in remission twenty -two weeks after a 
satisfactory response to 6 -MP therapy was first 
noted. 
He survived a period of 6 months following 
diagnosis, or 74 months after the onset of symptoms. 
344. 
Case No. 12. 
A male child aged 3 years 9 months was 
admitted to the Leeds General Infirmary on 
October 2, 1954, with a history of loss of energy 
and increasing pallor of 2 months' duration and 
night sweats and distension of the abdomen for 
2 weeks. 
On admission his temperature was 100 °F, and 
he was sweating profusely. Anaemia was evident 
and there was bruising of the right forearm. 
Lymph gland enlargement was present in the 
cervical, axillary and inguinal regions and there 
was hepato -splenomegaly. The liver extended 
3 -4 ems. and the spleen 8 cros. below the costal 
margins respectively. There were no other 
abnormal findings. 
Blood examination gave the following findings: 
haemoglobin 6.2 G., red cells 2,100,000 per c.111111.1 
platelets 95,000 per c.nz_., white cells 137,600 
per c.mm., differential white cell count: 
polymorphonuclear cells 5 %, lymphocytes 15 %, 
blast cells 80 %. Three nucleated red cells per 
100 WBC's were observed in the blood film. 
Sternal bone marrow was found to be highly 
cellular, the differential cell count being as 
follows: blast cells 84.8%, lymphocytes 6.4 %, 
myeloid cells 7.6 %, erythroid cells 0.8 %. 
3458 
A diagnosis of acute lymphoblastic leukaemia 
was made. 
Progress and Treatment (Fig. 31) 
A blood transfusion was given on October 7 
which raised the haemoglobin to 12.2 G. and 
treatment with 6 -MP, 50 mg. daily, was begun on 
the following day. Four days later the leucocyte 
count had fallen to 40,800 per c.mm. but the 
clinical picture was unchanged. By October 19, 
after eleven days of 6 -MP therapy, the white cells 
were 1,700 per c.mm., 23% of which were mature 
? polymorphs, the remainder being leukaemic cells. 
The child was now lively and active, the sweating 
had cleared and the temperature had almost settled. 
The liver and spleen were reduced in size. 
Improvement continued and after three weeks 
treatment with 6 -MP he had regained normal 
activity, there was no fever, the enlarged liver 
and lymph glands had disappeared and the only 
clinical evidence of the disease was the spleen 
which was just palpable. Blood examination was 
as follows: haemoglobin 13.0 G., platelets 
140,000 per c.mm., white cells 4,900 per c.mm., 
differential leucocyte count: polymorphs 49 %, 
lymphocytes 48%, monocytes 3%. A sternal bone 
marrow showed only 20% blast cells, the remainder 
of the cells being approximately equally divided 
between myeloid and erythroid precursors. 
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The copenia had persisted for a week when 
irrespective of continued treatment the leucocyte 
count returned to normal. The haemoglobin level 
rose to normal without further transfusions and 
he was allowed home on October 30, on a 
"maintenance" dose of 50 mg. 6 -MP daily. 
The improvement was, however, short lived 
for on November 15 he was re- admitted to hospital 
in status epilepticus. The fits which began on 
the day of admission had been preceded by 
intermittent attacks of vomiting of six days 
duration. This had been considered to be due to 
the 6 -IVIP which had been stooped three days 
previously. Clinical examination revealed a 
right sided hemiplegia and slight splenic 
enlargement. The peripheral blood picture was 
satisfactory; haemoglobin 14.5 G., white cells 
6,400 per c.mm. (polymorphs 75%, lymphocytes 
24%, monocytes 1%). The fits stopped one hour 
after admission and his general condition improved. 
He was symptom free, apart from weakness of the 
right leg during the next four days. On November 
20, he complained of right sided headache and was 
obviously drowsy, but temporary improvement again 
occurred. However, on November 22, he developed 
persistent vomiting, gradually became comatose 
and died on November 24. 
The cerebro- spinal fluid was examined on two 
348. 
occasions and showed: 
November 15, 1954: cells 1,800 per c.mm. (polys 
80%, lymphs 20%), protein 
198 mg. %, chloride 720 mg.%, 
sugar 70 mg.%, culture sterile. 
November 22, 1954: cells 3,720 per c.mm. ( lymphs 
100%), protein 290 mg.%, 
chloride 710 mg.%, sugar 
70 mg.%. 
From November 15 -24 the clinical picture 
other than the haematological complications 
showed no apparent change. The blood showed a 
gradually developing anaemia, the leucocyte count 
rose with the re- appearance of 8% leukaemic cells 
indicating early relapse. 6 -MP was re- started on 
November 20 with no effect. Further bone marrow 
studies were not performed. 
The nature of the neurological manifestations 
and its relationship to the underlying leukaemic 
process was obscure. Leukaemic deposits in the 
meninges or localised bleeding was a considered 
possible explanation. 
The relevant post -mortem findings are briefly 
mentioned below. 
1. Slight enlargement of the paratracheai, 
retropancreatic and mesenteric lymph nodes. 
2. Enlargement and leukaemic infiltrn:tion of 
spleen and kidneys. 
349. 
3. Petechial haemorrhages and a little fresh 
haemorrhage in the epidural space overlying the 
upper cervical segment. No evidence of leukaemic 
infiltration in the meninges. 
4. On sectioning the brain intense 
generalised capillary congestion was observed. 
The petichial haemorrhages were confined to the 
meninges and the underlying grey matter was 
normal. No visible leukaemic infiltration was 
present. The spinal cord was normal. 
Histology. 1. Infiltration by lymphoid cells 
of liver, kidney, spleen, pancreas, thyroid and 
lymph nodes. 
2. Considerable meningeal 
infiltration by lymphocytic cells, mainly 
perivascular and infiltrating adventia. The cortex 
showed similar infiltrates around vessels in grey, 
but more especially around veins in white matter. 
Similar infiltrates throughout basal ganglia. 
Section from spinal cord also showed similar 
changes. 
Comment 
A 34 year old boy with acute lymphoblastic 
leukaemia responded dramatically to 6 -MP therapy, 
with a return of the peripheral blood picture to 
apparent normality. The remission was not complete 
as the spleen, although markedly reduced in size, 
350. 
remained palpable. Approximately two weeks after 
discharge from hospital he was re- admitted with 
bizzare neurological complications and died in 
coma nine days later. The peripheral blood showed 
early indications of relapse prior to death. 
Post -mortem revealed widespread infiltration of 
viscera by leukaemic cells. Deposits in the brain 
and leptomeninges suggested that that was the cause 
of the neurological features. 
He survived 14 months following diagnosis, or 
34 months after the onset of symptoms. 
351. 
Case No. 13. 
A 3,1- year old female child was admitted to 
Pontefract General Infirmary on November 29, 1954, 
with a history of mumps, diagnosed a month earlier, 
listlessness, increasing pallor, epistaxis, 
anorexia and recent vomiting. 
On admission she was found to be anaemic and 
the temperature was elevated to 99.8 °F. Widespread 
ecchymoses and petichiae were present mainly on the 
limbs and lymph node enlargement could be felt in 
the cervical, axillary and inguinal regions. The 
spleen was palpable 4 ems. below the costal margin 
and the liver edge could just be felt. 
Blood examination gave the following findings: 
haemoglobin 5.8 G., red cells 1,900,000 per c.mm., 
white cells 250,000 per c.rnm. Platelets 15,000 
per c.mm. The blood film showed less than 1% 
mature polymorphonuclear cells, virtually all the 
leucocytes being primitive blast cells. 
Bone marrow obtained from the iliac crest 
showed 99% lymphoid cells, the majority of which 
were blast forms. 
A diagnosis of acute 1ymphoblastic leukaemia 
was made. 
Progress and Treatment, (Fig. 32) 
A blood transfusion was given on December 2, 
which raised the haemoglobin to 7.8 G. 6 -MP, 
352. 
50 mg. daily, was begun on December 4. Five days 
later the leucocyte count had fallen from 250,000 
to 30,000, the child was feeling happier and there 
was a reduction in size of the spleen and lymph 
glands. On December 14, after ten days treatment, 
the white cells were 2,000 per c.mm. and the dose 
of 6 -NIP was reduced to 25 mg. daily. A further 
transfusion was given on December 17 and 
thereafter a sustained rise in the haemoglobin 
level occurred without further recourse to blood 
transfusion. The temperature had settled by 
December 21, the purpuric skin eruption had faded, 
the spleen tip was just below the costal margin 
and the liver could not be palpated. The 
peripheral blood picture was also greatly 
improved - 43% of leucocytes being mature 
polymorphs. The child was very lively, running 
about and playing normally and on January 4 she 
was well enough to be discharged home. Clinical 
examination now failed to reveal any evidence of 
leukaemia. Blood examination was as follows: - 
haemoglobin 11.8 G., platelets 110,000 per c.um., 
white cells 5,500 per c.mm. (polymorphs 79 %, 
lymphocytes 17%, monocytes 4 %). A maintenance dose 
of 50 mg. 6 -MP daily was prescribed and she was 
instructed to attend the out -patient clinic at 
regular intervals. She remained in apparently 
353. 
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normal health without any indication of the 
underlying disease apart from an occasional mild 
anaemia (haemoglobin range 11.2 to 13.2 G.) until 
February 11, a period of eight and a half weeks 
since the beginning of the remission. The spleen 
could then be again palpated and a few lymph 
glands were becoming obvious in the neck. She did 
not complain and was allaued to remain at home. 
Two weeks later on February 25 the leucocyte count 
had risen to 22,000 per c.mm. and the percentage 
of mature granular cells in the peripheral blood 
Thad 
fallen to 44 %. The spleen and glands were 
considerably enlarged and there were a few 
ecchymoses to be seen. 6-MP was increased to 75 mg 
per day and in view of her few symptoms she was 
allowed to stay at home. She failed to return for 
her appointment a week later and when next seen on 
March 25 was severely anaemic, the spleen extended 
into the left iliac fossa, the liver edge was 
palpable 2 -3 ems. below the right costal margin and 
there was widespread purpura. The temperature was 
99 °F. Blood examination was as follows: 
haemoglobin 5.2 G., white cells 250,000 per c.mm. 
(polymorphonuclear cells 1%, blast cells 
The dose of 6 -PIP was increased to 100 mg. daily 
and A.C.T.H. 75 T.J. daily in 8 hourly doses of 
25 I.U. i.m., was prescribed in addition. After 
355. 
twelve days (Ap r.6) the leucocytes had fallen to 
5,000, and the clinical evidence of leukaemia was 
much reduced. The dose of 6 -MP and A.C.T.H. was 
now reduced to 50 mg. and 50 U. daily 
respectively and an improvement in the 
distribution of leucocytes in the peripheral blood 
followed, 43% polymzorphs being present by April 13. 
The haemoglobin, however, failed to rise and 
further transfusions were necessary. 
Although clinical and haematological 
improvement occurred it was only short lived. 6 -MP 
and A.C.T.H. were continued but irrespective of 
this relapse occurred, the leucocyte count on 
April 23 rose to 240,000 per c.mm. By increasing 
the dose of 6 -MP and A.C.T.H. it was again possible 
to temporarily reduce the total white cells and 
for two weeks improve the differential leucocyte 
count. The anaemia was persistent, however, and 
transfusions were again necessary. The fall in 
the white cell count was not associated as 
previously with such a marked reduction in the 
evidence of leukaemia elsewhere, i.e. lymph glands, 
spleen, etc. and the child's condition gradually 
deteriorated with bleeding from the mucous 
membranes and renal tract, and she died on June 16. 
Comment 
A 3k year old female child with acute 
356. 
lymphoblastic leukaemia developed a clinical and 
haematological remission lasting eight and a half 
weeks while under treatment with 6 -MP. Relapse 
then occurred and temporary improvement of two 
weeks duration followed combined therapy with 6 -MP 
and A,.C.T.H. Further tree ment with increased 
doses of the two drugs again reduced the 
leucocyte count and improved briefly the 
differential cell count but failed to produce 
any clinical improvement. 
She survived 64. months following diagnosis, 
or 7 months after the onset of symptoms. 
357. 
Case No. 14. 
Master R.W., aged 14 years, was admitted to 
the Leeds General Infirmary on February 7, 1955. 
His main complaints were cough and progressive 
dyspnoea of three weeks' duration. For two weeks 
he had noticed swellings, first in the left 
axilla and then in the right cervical region. His 
appetite had deteriorated and on one occasion he 
had vomited. 
On admission he was found to have a good 
colour. Numerous enlarged cervical and axillary 
lymph glands about z cm. in diameter were palpable. 
The spleen was enlarged 4 cms. below the left 
costal margin and the liver edge extended 3 cms. 
below the right costal margin. Signs suggestive 
of pleural effusion were present at the left base. 
The temperature was normal. X -ray of the chest 
confirmed the presence of a pleural effusion and 
in addition showed massive enlargement of the 
mediastinal lymph glands. (Fig. 33a) 
Blood examination on admission gave the 
following findings: haemoglobin 14.7 G., red cells 
5,000,000 per c.mm., platelets 210,000 per c.tuuu., 
white cells 24,600 per c.mm. Differential white 
cell count : - neutrophils 51%, lymphocytes 49%. 
The blood film showed that many of the lymphocytes 
were immature having the appearance of lymphoblasts 
358. 
A sternal bone marrow examination confirmed the 
diagnosis of acute lymphoblastic leukaemia, 78.8¡ 
of the cells being lymphoid cells the majority 
primitive blast cells. Myeloid cells 11.2% and 
erythroid cells 10.0% were also observed. 
Progress and Treatment (Figs. 33 & 34) 
6-MP was begun on February 11, a daze of 
150 mg. daily being prescribed. No change in his 
clinical condition occurred during the next 
thirteen days. During this time he complained of 
severe stabbing pain in the left chest and dyspnoea 
on exertion and the physical findings remained 
unaltered. On February 24, the lymph glands, liver 
and spleen were reduced in size and he began to 
feel better. The chest pain cleared and the 
breathlessness became less. On February 28, a 
further chest x -ray showed considerable reduction 
in size of the mediastinal glands and the effusion 
was much less. 
After an initial rise in the leucocyte count 
to 67,000 per c.mm. on February 15 a gradual fall 
occurred and on February 25 it was 4,200. The 
haemoglobin level had also fallen at that time to 
10.4 G. The dose of 6 -MP was reduced to 50 mg. 
daily on February 28 and after a week's 
convalescence he was discharged home on March 7, 
symptom free and fully active. On March 4 (fig.33b 
Fig. 33. Case No. 14. Radiograph of chest (a) 
before 
treatment and (b) after treatment with 6 -MP, showing 
clearance of pleural effusion and almost complete 
disappearance of mediastinal lymph nodes. 
360. 
.a further x -ray revealed clearing of the pleural 
effusion and a return of the mediastinam to almost 
normality. Blood examination on larch 5 was as 
follows: haemoglobin 10.5 G., platelets 300,000 
_cer c.mm., white cells 4,000 per c.mm., 
differential white cell count : - neutrophils 68, 
lymphocytes 31 %, monocytes 1%. A further bone 
marrow examination showed a less cellular picture 
with the following differential cell count: 
lymphocytes and blast cells 21 %, erythroid cells 
32.5 %, myeloid cells 45.5 %, other cell types 1.0%. 
A maintenance dose of 50 mg. 6 -MP daily was given 
and he remained in good health for a period of six 
weeks. The differential leucocyte count remained 
normal and a gradual rise in the haemoglobin 
occurred. Some evidence of the disease persisted, 
however, for a chest x -ray on March 28 still 
showed some enlargement of mediastinal glands, and 
the spleen remained palpable. On April 23, he was 
re- admitted to hospital in relapse. He was 
extremely dyspnoeic with marked enlargement of the 
mediastinal and cervical lymph glands. 
Splenomegaly was also prominent. The blood 
picture shaved haemoglobin 14.6 G., p]atelets 
235,000 per c.mm., white cells 22,400 pr c.mm., 
differential white cell count: lymphoid cells 69%, 
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362. 
primitive types. 6 -MP, 150 mg. daily, and A.C.T.H. 
25 mg., 6 hourly, was prescribed during the next 
fourteen days with marked symptomatic benefit. 
The dyspnoea was relieved and the enlarged 
mediastinal lymph nodes and splenomegaly again 
regressed. The peripheral blood picture when 
discharged on May 12 showed:haemoglobin 9.3 G., 
red cells 3,180,000 per c.mm., platelets 270,000, 
white cells 3,600 per c.mm. Differential white 
cell count:- neutrophils 57 %, lymphocytes 43%. A 
bone marrow examination revealed the following 
cellular distribution:- lymphoid cells 570, 
myeloid cells 18%, erythroid cells 25 %. 
Treatment with 6 -MP daily and A.C.T.H. gel 
25 mgs. twice weekly, was continued at home. The 
haemoglobin rose to 11.5 G. in the following two 
weeks but relapse soon followed. He was again 
admitted to hospital on May 29, and found to be 
completely refractory -to further therapy. 
Irrespective of treatment the leucocytes rose to 
288,000 per c.mm., and he died on June 23. 
Comment 
A youth aged 14 years with acute lymphoblastic 
leukaemia responded dramatically to 6 -MP therapy 
initially. Respiratory distress, a consequence 
of superior rrediastinal obstruction from glandular 
enlargement was relieved, and both clinical and 
363. 
haematological improvement occurred. Relapse 
followed some six weeks later. A combination 
of 6 -MP and A.C.T.H. produced temporary benefit 
but a rapid deterioration followed and death 
ultimately occurred. 
He survived 4j months following diagnosis, 
or 54 months after the onset of symptoms. 
364. 
Case No. 15. 
Miss A.B., aged 5 years, was transferred from 
another hospital to Leeds General Infirmary on 
March 30, 1954. Her main complaints were loss of 
appetite, lassitude and weight loss for three 
months. For a month prior to admission her 
parents had noticed she had "swollen glands" in 
her neck. 
On admission the temperature was found to be 
normal. There was slight anaemia and numerous 
hard, cervical lymph glands 2 -1 cm. in diameter 
were palpable. The tip of the spleen was just 
palpable. No other abnormal findings were 
detected. 
Blood examination gave the following results: 
haemoglobin 11.9 G., red cells 3,300,000 per c.mm., 
platelets 275,000 per c.mm., white cells 2,400. 
Differential white cell count:- polymorphonuclear 
cells 39%, lymphoid cells 61%. The blood film 
showed a high percentage of the lymphoid cells to 
be immature blast cells. 
Sternal bone marrow examination gave the 
following differential cell count: blast cells 
96.3%, myeloid cells 2.0%, erythroid cells 2.0;x;. 
A diagnosis of acute lymphoblastic leukaemia 
(aleukaemic type) was made. 
Progress and Treatment (Fig. 35) 
6 -MP, 50 mg. daily, in divided doses of 25 mg. 
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each, was started on March 30. No change in her 
clinical condition occurred during the following 
two weeks. On April 14, a further bone marrow 
examination showed no significant change in the 
haematological picture, 84% of the cells being of 
the lymphoid series. A week later, on April 21, 
definite improvement was observed. She was feeling 
well and was fully active. The spleen was 
impalpable and the cervical lymph nodes reduced in 
size. The bone marrow picture was improving: - 
lymphoid cells 58.5%, myeloid cells 24.5% and 
erythroìd cells 17 %. 
She was discharged home on April 23, 1954, on 
50 mg. 6 -MP daily and thereafter her progress was 
followed as an out -patient. Ten days later the 
peripheral blood picture showed haemoglobin 12.2 G. 
red cells 4,200,000 per c.mm., differential count: - 
polymorphs 61 %, lymphocytes 38 %. The bone marrow 
now showed 29% lymphoid cells all of which 
appeared mature. Myeloid cells constituted 66% of 
all marrow cells, red cells being scanty at 5 %. 
She remained in apparently normal health 
during the next six weeks. The blood picture never 
completely returned to normal. There was a 
persistent anaemia and the platelet count fell 
after three weeks. The differential leucocyte 
count remained normal until clinical relapse was 
observed on June 14. She failed to respond to 
367. 
further treatment and died on July 13, 1954. 
Post -mortem examination was not carried out. 
Comment 
A child aged 5 years with acute 1yrnphoblastic 
leukaemia developed a partial remission following 
6 -MP therapy l,sting seven and a half weeks. 
She survived 3:, months after the diagnosis 
of acute leukaemia was made, or 6 months 
following the onset of symptoms. 
368. 
Case No. 16. 
A female aged 30 years of Belgian nationality 
was admitted to St. James's Hospital on December 
19, 1953. Her main complaints were of increasing 
veakness and lassitude of 2 months' duration, 
nausea and occasional vomiting for 1 month, and 
dizziness and dyspnoea on exertion for 3 weeks. 
or two weeks prior to admission she noticed that 
she bruised very easily. 
On admission she was found to be very anaemic, 
-cchymoses were present over the arms and lymph 
lands were palpable in the cervical and axillary 
regions. The liver extended 2 ems. and the spleen 
ems. below the costal margins. The right tonsil 
vas inflamed but the tenroerature was normal at 
7.8 °F. 
Blood examination gave the following findings: 
aemoglobin 6.9 G., red cells 2,260,000 per c.mm., 
latelets 101,000 per c.mm., white cells 69,000 per 
.mm., differential white cell count:- blast cells 
nd primitive monocytoid cells 58%, polymorphonuclea 
ells 21%, lymphocytes 18 %, monocytes 3%. There 
ere 2 nucleated red cells per 100 white cells. 
Sternal bone marrow was found to be highly 
ellular, in which the predominant cells were blasts 
nd primitive monocytoid cells, peroxidase negative. 
he differential cell count was as follows: blasts 
369. 
and primitive monocytoid cells 84 %, myeloid cells 
9.6%, erythroid cells 2.4%, lymphocytes 2.4 %, 
other cell ,types 1.6. 
A diagnosis of monocytic leukaemia, probably 
Naegali type, was made. 
Progress and Treatment 
No change had taken place in her condition 
when treatment with 6 -IvïP, 200 mg. daily, was begun 
on December 26, a week after admission, and the 
blood picture was essentially unaltered, the 
haemoglobin being 6.1 G., and leucocytes 60,000 
per c.r:m. of which the majority were primitive 
cells. In the following week approximately 2.5 
litres of blood were transfused but the haemoglobin 
level rapidly fell and by January 5 was 7.4 G. 
The leucocytes had fallen to 6,800 per c.mm. on 
January 5, the spleen was reduced in size and the 
liver impalpable. Her clinical condition, however, 
had deteriorated. She was febrile and troubled 
with diarrhoea and nausea. Penicillin was 
prescribed and the dose of 6-MP reduced to 100 mg. 
daily A further transfusion of approximately 
2.5 litres of blood was given which only raised 
the haemoglobin to 9.1 G. 6 -MP was stopped on 
January 7, after a total of 2.3 G. had been given, 
in view of the leucocytes having reached 2,500 
per c.mm. The diarrhoea rapidly cleared and by 
370. 
January 12 definite clinical and haematological 
improvement was observed, the bone marrow showing 
considerable progress in maturation. Blast cells 
:ere 25 %, myeloid cells 48.5 %, erythroid cells 
14.5%, lymphocytes 4.0 %, monocytes 3.5¡, and other 
cell types 4.5%, 6 -MP, 50 ing. daily, was re- 
started on January 12, in order to try and further 
improve the clinical and haematological state. The 
temperature settled, the spleen and lymph glands 
regressed, the platelet count rose to 180,000 per 
c.nni. and the haemoglobin, without further 
transfusion, to 11.1 G. The distribution of 
leucocytes in the peripheral blood also improved 
with an increase in percentage of mature cells. A 
few leukaemic cells remained however and in spite 
of continued 6 -LP relapse soon occurred. The 
leucocyte count rose to 41,000 per c.mm. on January 
25, and leukaemic cells in the marrow and periphera= 
blood increased. The temperature rose, and a 
widespread purpuric eruption appeared together with 
severe menorrhagia. She developed a dental abscess 
and irrespective of increased doses of 6-MP she 
rapidly deteriorated and died following a cerebral 
haemorrhage on February 16, 1954. Autopsy was not 
performed. 
Comment 
A 30 year old woman with monocytic leukaemia 
371. 
improved both clinically and haematologically 
following a course of 6 -MP therapy. Improvement 
was short -lived lasting no more than two weeks 
and further treatment proved of no value. 
She survived 2 months following diagnosis, 
or 4 months after the onset of symptoms. 
372. 
Case No. 17. 
A boy aged 14 years was admitted to St. 
James's Hospital, Leeds, on February 5, 1)54, with 
a two weeks' history of lassitude, anorexia, attack 
of dizziness and vomiting. On three occasions 
during the week prior to admission he had coughed 
up blood. 
On admission the temperature was 100.4 °F. He 
was very anaemic, lymph glands were palpable in 
the cervical, axillary and inguinal regions and 
the spleen was palpable 11 cms. below the left 
costal margin. A purpuric eruption was present 
over both lower limbs and the left chest. 
Blood examination gave the following results: 
haemoglobin 4.1 G., red cells 1,410,000 per 
platelets 79,000 per c.rnm., white cells 29,000 per 
c._rm. Differential white cell count:- blast cell 
92;x, lymphocytes 6%, neutro_ hils 1 %, metamyelocyte 
1%. 
Bone marrow aspirated from the left iliac 
crest was found to be extremely cellular. 96% of 
the cells ;-;ere myeloblasts, the remainder being 
polymorphs and normoblasts. 
Progress and Treatment (Fig. 36) 
Transfusions of whole blood were given on 
February d, and again on February 12, which raised 
the haemoglobin to 12.8 G. 6 -MP, 100 mg. daily, 
s 
373. 
was started on February 9. By February 26 no 
clinical or haematological improvement had occurred 
and the dose (of 6 -MP) was increased to 150 mgs. 
daily. The leucocyte count had fallen to 4,000 
per c.mm. on March 2, three weeks after the start 
of treatment and by March 9 was 1,000 per c.m. 
6 -MP was then stopped. The spleen was reduced in 
size being 8 ems. below the costal margin. The 
bone marrow however still showed 95.5% of blast 
cells. Although two further blood transfusions 
were given during the following three weeks, the 
spleen became impalpable and the lymph nodes 
reduced in size. By March 29, approximately three 
weeks after discontinuing treatment, the proportion 
of mature polymorphonuclear cells had risen to 414 %.; 
Platelets, which previously had been almost non- 
existent, rose to 69,000 per c.mì. The patient was 
feeling much improved, was eating better and the 
temperature was normal. Bone marrow examination, 
however, again showed a marked preponderance of 
leukaemic cells. It was therefore decided to be in, 
treatment with A.C.T.H., 25 units 5 hourly, on 
April 2. Three days later the blood count was as 
follows: haemoglobin 13.3 G., red cells 4,500,J0'0 
per c.mm., platelets 123, ?00 per c.mm., white cells 
3,000 per c.mm., differential count. : - ,- Iyultorp s 
72 %, lymphocytes 28 %. No abnorm: _. cells Here 
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the splenomegaly with reduction in size of lymph 
'lands and clinical improvement followed. Although 
an increase in polymorphonuclear cells and platelet 
in the peripheral blood occurred the bone marrow 
showed little change. Three days after treatment 
with A.C.T.H. was started considerable clinical 
and haematological improvement was observed. 
Whether this was due to A.C.T.H. or to a 
continuation of the improvement following 6 -MP 
therapy is difficult to ascertain. Thereafter 
after a temporary set -back the patient remained in 
apparently normal health for a period of four and 
a half months after A.C.T.H. therapy was 
instituted. 
He survived. 77 months after the diagnosis was 
made, or 8 months following the onset of symptoms. 
377. 
Case No. 18. 
A female child aged 2 years was admitted to 
the Leeds General Infirmary on October 14, 1953. 
She was well until seven weeks previously when she 
developed diarrhoea which persisted for three 
weeks. She never picked up, however, and was 
listless, her appetite was poor and she became 
increasingly pale. Repeated epistaxis occurred 
during the two weeks prior to admission and for 
five days slept almost continuously. 
On admission the temperature was 101 °F. She 
was found to be well nourished but extremely 
anaemic. Bruising was marked over the right iliac 
crest and both calves, and numerous petichiae were 
observed in the mouth and lips. Lymph glands were 
palpable in the cervical, axiilary and inguinal 
regions and the liver and spleen rrre enlarged. 
Fine crepitations were audible over both lung 
bases. 
Blood examination gave the following results: 
haemoglobin 5.3 G., platelets 33,000 per c.mm. , 
white cells 65,000 per c.mm. A differential white 
cell count showed that 100% of cells were of the 
lymphoid series and over half were blast forms. 
A diagnosis of acute lymphoblastic leukaemia 
was made,. 
378. 
_progress and Treatment 
A blood transfusion was given immediately 
following admission which raised the haemoglobin 
to 14.7 G. Bleeding from the nose continued and 
she remained drowsy. On October 15 the leucocytes 
had fallen to 2,900 per c.mm., with no change in 
the differential cell count. 6-MP, 50 mg. daily, 
was started on October 16, but no clinical or 
haematological improvement occurred and she died 
in coma five days later. It was thought probable 
that she had intra- cranial bleeding, but autopsy 
was not performed. 
C omnient 
A female child of 22 years with acute 
lymphoblastic leukaemia died seven days after 
admission and five days after starting 6 -MP 
therapy. A fall in the leucocyte count from 
65,000 to a leucopenic level occurred within 
twenty -four hours of admission and prior to 
beginning treatment with 6 -P. A blood transfusion 
was considered a possible cause of this fall in 
the white cells. 
She survived one weep after diagnosis, or 
2 months following the onset of symptoms. 
379. 
aase No. 19. 
A female infant was born on May 1, 1954, 
weighing 6 lbs. 13 ozs. The baby was rather 
shocked at birth and was given Corarnine and 
Lobeline with gradual improvement. On the eighth 
day the baby developed a 'sticky eye' and was put 
on Penicillin. On the following day the eye was 
better but the umbilicus was noticed to be rather 
inflamed. The cord was still attached and the 
base was about 1" in diameter. The baby was given 
Chloroniycetin, in addition to Penicillin, with 
improvement. Chemotherapy was discontinued on 
the eighteenth day. On the twenty -sixth day the 
cord had still not separated and there was still 
some inflammation. The temperature rose again 
and the abdomen became distended and tympanitic. 
The possibility of intestinal obstruction was 
suggested and a laparotomy was performed. At 
operation no obstruction or inflammation was seen. 
Free fluid was present in the abdomen and the 
spleen was greatly enlarged. The abdomen was 
closed and in view of the splenomegaly blood 
examination was performed. 
Blood examination (May 28, 1954) gave the 
following results: haemoglobin 7.6 G., white 
cells 290,000 per c.mm. The blood film showed 
almost all the leucocytes to be primitive blast 
380. 
sells. The impression obtained was that this was 
acute myelobïastic leukaemia. 
In view of the history probably extending 
from birth it was considered that this was a 
case of congenital leukaemia. The mother's 
blood revealed no abnormality apart from a mild 
anaemia (haemoglobin 12.2 G.). 
Progress and Treatment 
6 -IIP, 5D mg. daily, in divided doses was 
begun immediately. The dose, based on the 
child's weight, was high but this seemed warranted 
in view of the acuteness of the disease. 
Treatment, however, was ineffective and the 
child died twenty -four hours later. 
Comment 
A case of congenital acute leukaerAa, 
probably of myeloblastic type, died twenty -four 
hours after treatment with 6 -MP was begun. The 
duration of treatment was too short to produce 
any effect. 
She survived only one day following diagnosis 
and approximately one month after the onset of the 
disease. 
381. 
Case No. 20. 
A male child aged 2 years was admitted to 
Pontefract General Infirmary on December 20, 1954, 
with a history of lassitude, fever, difficulty in 
walking and progressive enlargement of the abdomen 
of two weeks' duration. 
On admission the temperature was 102°F., he 
was very anaemic and breathless and numerous 
petichiae were present over the limbs and trunk. 
Lymph glands were enlarged in the cervical, 
axillary and inguinal regions and the spleen was 
palpable. 
Blood examination was as follows: haemoglobin 
6.7 G., red cells 2,200,000 per c.mm., platelets 
50,000 per c.rnm., white cells 13,600 per c.nnn., 
differential white cell count: lymphoid cells 90 %, 
polymor._Dhonuclear cells 5%, metamyelocytes 4%, 
monocytes 1%. 
Bone marrow obtained from the left iliac crest 
was found to be almost entirely replaced by leukaem_ 
blast cells. Granular and red cell precursors were 
virtually absent. 
A diagnosis of acute lymphoblastic leukaemia 
was made. 
Progress and Treatment 
An immediate transfusion of packed red cells 
was given which raised the haemoglobin to 11.4 G. 
c 
382. 
6 -MP, 50 mg. daily, was started on December 22. 
The leucocyte count fell to 2,000 per c.n-im. after a 
,week and thereafter remained low. No improvement 
in the distribution of leucocytes in the peripheral 
blood, however, occurred, the haemoglobin fell and 
further transfusions were necessary on December 30 
and January 6. No clinical improvement resulted 
from treatment with 6 -MP, haemorrhages into the 
skin, eyes, mouth and urinary tract developed and 
on January 6, after fifteen days therapy, 6 -MP was 
stopped and A.C.T.H. gel 10 units i.m. 12 hourly 
was given. This also was ineffective, the 
temperature rose to over 104 °F. and the patient 
died on January 11, 1955. An autopsy was not 
Performed. 
Comment 
A child aged 2 years with extremely acute 
leukaemia failed to respond to treatment with 6 -MP 
and later A.C.T.H. The acuteness and rapid 
downhill course of the disease, and the shortness 
of the course of treatment were possible reasons 
for the failure of treatment. 
The survival time was 3 weeks following 
diagnosis, or 11 months after the onset of symptoms. 
383. 
Case No. 21. 
A a year old girl was admitted to the Leeds 
General Infirmary on August 13, 1954, with a 
history of attacks of nausea and pain in the left 
gluteal region for five weeks. For one week she 
had com nlained of severe pain in the legs with 
difficulty in walking and tiredness. 
On admission she was found to be pale, but 
quite happy and co- operative and did not complain 
of rain. She was afebrile. A few bruises were 
evident on the legs but the spleen could not be 
palpated. Small glands were present in the 
groins but none in the cervical or axillary 
regions. 
Blood examination gave the following findings: 
haemoglobin 10.7 G., red cells 3,500,000 per c.mm., 
white cells 8,200 per c.mm. Differential white 
cell count : - neutrophile 7 %, lymphoid cells 95%. 
Many of the latter cells were immature. A 
platelet count two weeks after admission was 
200,000 per c.mm. Tibial bone marrow on August 23 
was of normal cellularity and 99% of cells were 
lymphoid cells, many of which had the 
characteristics of lymphoblasts. 
A diagnosis of acute lymphoblastic leukaemia 
was made. 
384. 
Progress and Treatment (Fig. 37) 
When first seen, over two weeks after 
admission, her condition was unchanged and it was 
evident that the leukaemic process was running a 
clinically subacute course. Occasional attacks of 
pain and lassitude were her only symptoms and 
clinical examination, apart from anaemia, 
revealed no definite evidence of the underlying 
disease. 6 -1:îP, 50 mg. daily, was begun on August 
31. A month later no haematological improvement 
had been observed. The leucócytes had fallen to a 
leucopenic level, and a gradual fall in haemoglobin 
had also occurred. Her condition, however, remaine 
fairly good, apart from occasional leg pains, 
slight bruising and an occasional rise in 
temperature. 6 -MP was increased to 100 mg. daily 
on October 1, as a result of (a) a failure to 
respond on the lower dose after thirty days 
treatment and (b) the leucocyte count beginning to 
rise irrespective of therapy. No clinical or 
haematological improvement, however, occurred. A 
blood transfusion was given on October 20 when the 
haemoglobin had fallen to 8.3 G. and in view of 
her satisfactory general condition she was allowed 
home on October 21. Thereafter she attended as an 
out -patient and 6 -MP therapy was continued. The 
leukaemic process remained resistant to treatment, 1 
d. 
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the haemoglobin level fell slowly and platelets 
also became less numerous. She had few complaints 
apart from occasional pain. She was re- admitted 
to hospital on January 12, 1955, because of severe 
anaemia and given another blood transfusion. 
Clinical examination at this time showed anaemia, 
marked tenderness on pressure over the right femur 
with limitation of movement of the hip joint, and a 
shallow ulcer on the soft palate. There was no 
splenomegaly or lymphadenopathy. Following 
transfusion she felt much improved and was again 
allowed home. A gradual downhill course followed, 
however, and she died on March 4, 1955. 
Comment 
A girl aged 64 years, with acute lymphoblastic 
leukaemia was treated with 6 -MP almost continuously 
for five months. The disease ran a clinically 
subacute course in that symptoms were relatively 
mild, but no haematological improvement resulted 
from treatment. 
She survived approximately seven months 
following dia nosis, or 8i months after the onset 
of symptoms. 
387. 
Case No. 22. 
A female aged 53 years was admitted to St. 
James's Hospital on November 1, 1954, with a 
history of recurrent haematuria and bleeding from 
the bowel with increasing anaemia for one month. 
On admission she was found to be severely 
anaemic, the liver was enlarged 4 cms. and the 
spleen 3 ems. below the respective costal margins, 
and a few enlarged lymph glands were present in 
the cervical region. Prolapsed haemorrhoids were 
observed. There were no skin haemorrhages and the 
temperature was norihal. 
Blood examination gave the following findings: 
haemoglobin 4.5 G., red cells 1,300,000 per c.mm., 
platelets 45,000 per c.mm., white cells 11,400 per 
c.mm. Differential white cell count:- blast cells 
90%, promyelocytes 1, myelocytes 1 %, lymphocytes 
7 %, monocytes 1 %. Sternal bone marrow was 
hypercellular and the differential cell count 
showed 46.5% blast cells, myelocytes and 
polymorphonuclear cells 9 %, lymphocytes 4 %, 
erythroid cells 40.5 %. 
The blast cells had the staining characteris- 
tics of myeloblasts and a diagnosis of acute 
myeloblastic leukaemia was made. 
Progress and Treatment 
An immediate blood transfusion was given which 
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raised the haemoglobin to 9.0 G. and produced 
symptomatic improvement. 6 -:P, 150 mg. daily, was 
started on November 9 and continued until December 
1, when the leucocytes had fallen to 2,000 per 
c.mnl. On a reduced dose of 50 mg. 6 -MP 
leucopenia persisted for 3 weeks, the liver and 
spleen became smaller but no improvement in the 
distribution of leucocytes in the peripheral blood 
occurred, the platelets remained low and repeated 
bleeding from the lower bowel necessitated further 
blood transfusion to maintain the haemoglobin at a 
satisfactory level. A.C.T.H. 40 I.U. intra- 
venously in 500 mls. of saline given over a period 
of 8 hours was given on three consecutive days, 
and followed by A.C.T.H. gel 40 U. intra- 
muscularly twice daily for 7 days. There was no 
effect on the clinical or haematological picture. 
On December 30, the dose of 6 -MP was raised again 
to 150 mg. daily but apart from again producing 
a fall in the leucocyte count, it was 
ineffectual. After repeated haemorrhages, she 
passed into coma on January 22, and died the same 
day. Post -mortem examination was not performed. 
Comment 
A 53 year old female with acute myeloblastic 
leukaemia failed to obtain benefit from treatment 
with 6-MP over a period often weeks. The only 
389. 
effect of the drug was a fall in the leucocyte 
count and reduction in size of the liver and 
spleen. Treatment with A.C.T.H. also had no 
effect on the leukaemic process. 
She survived 24 months after diagnosis, 
or 3ç months following the onset of symptoms. 
390. 
Case No. 23. 
A female aged 47 years was admitted to St. 
James's Hospital, Leeds, on January 6, 1955, with 
a two months' history of tiredness, lassitude, 
nervousness and "thumping noises" in the head. 
Over the same period she had become progressively 
paler and had complained of dyspnoea on exertion, 
flatulence and heartburn. Menstruation had latterl 
become scanty. 
On admission the temperature was 98.0 °F. She 
was severely anaemic and a few small lymph glands 
were present in the right posterior triangle of the 
neck. There was no enlargement of the liver or 
spleen or evidence of bleeding. The right breast 
was the seat of chronic mastitis. 
Blood examination gave the following findings: 
haemoglobin 3.16 G., red cells 1,020,000 per c.nm., 
reticulocytes 1 %, P.C.V. 10 %, M.C.V. 103 cu., 
M.C.H.C. 26 %, platelets 50,000 per c.mm., white 
cells 9,500 per c.mm. Differential white cell 
count : - blast cells 24 %, myelocytes 3 %, 
polymorphonuclear cells 44 %, lymphocytes 21 %, 
monocytes 7 %, Tunck cells 1 %. 4 nucleated red 
cells per 100 white cells were observed. 
The sternal bone marrow was moderately cellular 
and obtained with difficulty. The differential cell 
count was as follows:- blast cells 42.4%, myeloid 
cells 33.6%, lymphocytes 5.6, plasma cells 2.85', 
erythroid cells 14.4%, other cells 1.2%. Erythro- 
poiesis was mainly megaloblastic. 
Other investigations included a Rehfuse Test 
Meal which showed the presence of free H01., serum 
bilirubin, direct 0 mgm.%, total 0.365 mg. %, 
plasma proteins 5.75 G.%, A/G ratio 1.4 :1, 
Alkaline phosphatase 10.4 units. Bence -Jones 
Protein - absent. Blood urea 41 mgms.%. X -ray 
chest and pelvis - normal. Faecal urobilinogen 
233 mg. %. 
Progress and Treatment 
The probable diagnosis was considered to be 
acute leukaemia with myeloblastic erythropoiesis 
(leukanaemia) but in view of the possibility of the 
blast cells in the bone marrow being atypical 
megaloblasts it was decided to try the effect of 
Vitamin B22 and folic acid. Vitamin B12 (Cytamen) 
100 mgms. was given on alternate days for a 
fortnight with no effect on the clinical or blood 
picture. Folic acid 20 mgn. daily was then 
prescribed and continued for several weeks. It 
failed, however, to have any effect on erythro- 
poiesis, no reticulocyte response occurred and 
repeated blood transfusions were necessary. 
Further bone marrow studies after both Vitamin B12 
and folic acid showed no alteration in the cell 
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picture - erythropoiesis remaining essentially 
megaloblastic. 
It was decided to start 6 -MP, 150 mg. daily, 
on April 29. Blood examination at that time 
showed: haemoglobin 7.4 G., white cells 50,000 per 
c.mm., platelets 30,000 per c.mm. The peripheral 
blood contained 89% blast cells and the bone marrow 
86.4 %. Clinical examination was unaltered, the 
white cells had fallen to 10,500 after ten days and 
after one month's treatment were 4,200 per c.mm. 
There was still a preponderance of leukaemic cells, 
however, and the platelet count remained low. Bloo 
transfusions were also still required. At her 
request she was transferred to a convalescent home 
on May 24 and advised to continue to take 6 -MP, 
100 mg. daily. When seen two weeks later her 
condition was unaltered and no haematological 
evidence of a response to treatment was observed. 
6-MP had no effect on the leukaemic process in 
his patient, who died on July 12, 1955. 
omment 
A patient with leukanaemia showed no response 
nitially to Vitamin B12 and Folic Acid. 
Thereafter 
-MP therapy was instituted but no clinical or 
aematological improvement occurred following a two 
Tionths course. 
She survived a period of 6 months following 
iagnosis, or 8 months after the onset of symptoms. 
Case No, 24. 
A male patient aged 78 years was admitted to 
St. James's Hospital on November 9, 1953, with a 
history of generalised pruritus of one year's 
duration. More recently he had been troubled 
with increasing dyspnoea on exertion and had 
noticed himself becoming paler. 
On admission he was afebrile and the only 
significant finding was severe anaemia. There was 
no lmiphadenopathy, hepatomegaly or splenomegaly. 
The skin was dry but there was no eruption. 
Blood examination gave the following findings: 
haemoglobin 7.0 G., red cells 2,00,000 per c.mm., 
platelets 58,000 per c.mm., white cells 4,900 per 
c.mm. Differential white cell count : - blast cells 
11%, neutrophils 29%, eosinophils 10%, monocytes 
30 %;, lymphocytes 18%, Tinck cells 2%. 
Sternal bone marrow was poorly cellular and 
showed: blast cells 27 %, myeloid cells 31,5%, 
erythroid cells 25%, monocytes 4 %, other cell 
types 2.5%. Many of the white cell precursors had 
a normocytic appearance and a diagnosis of 
monocytic leukaemia of Naegali type was made. 
Próress and Treatment 
A blood transfusion was given on the day of 
admission which raised the haemoglobin to 9.3 G. 
6 -MP, 200 mg. daily, was begun on November 28, 
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after a further transfusion owing to a fall in 
haemoglobin to 7.1 G. Treatment was continued 
until December 17 when the leucocytes reached a 
level of 1,400 per c.mm., haemoglobin 7.5 G., 
platelets 68,000 per c.mm. The peripheral blood 
still showed 30% blast cells and irruuature 
monocytoid cells and blast cells were the 
predominant cell in the hypoplastic bone marrow. 
The leucocytes continued to fall to 650 per c.mm. 
on December 21. At this time he developed a 
severe soreness of the throat and was given a 
further transfusion which initially gave rise to 
rigors and shock with a pronounced fall in blood 
pressure. The temperature rose, he developed 
diarrhoea, pain in the legs, breathlessness, 
dryness and cracking of the lips, and a monilia 
infection of the mouth, and eventually died from 
bronchopneumonia on January 5. The white cell 
count remained severely depressed being 1,200 per 
c.mm. the day prior to death and no improvement in 
the differential leucocyte picture occurred. A 
rise in platelets to 225,000 per c.mm. on 
December 30 was the only improvement observed in 
the blood. Post -mortem showed a right lower lobe 
bronchopneumonia, cystitis and bilateral 
pyonephrosis, cor pulmonale and advanced emphysema. 
There was no naked eye evidence sugs..e stive of 
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leukaemia in the liver, spleen or other viscera. 
None of the lymph glands were enlarged and the 
bone marrow was pale and slightly gelatinous but 
not characteristic of leukaemia. 
Histology of lymph_ glands from the mediast inum 
and lesser curvature of stomach showed extensive 
but patchy reticulo- endothelial reaction, with 
bizarre multinucleated giant cells. The 
architecture of the glands was not completely 
destroyed and there was some trabecular fibrosis. 
No fixation of eosinophils in the glands was 
noted. The liver showed mild portal cirrhosis 
but no leukaemic infiltration. Sections from 
other sites were not unfortunately taken. 
Comment 
An unusual and difficult case of an elderly 
man with a peripheral and bone marrow picture of 
monocytic leukaemia who failed to benefit from 
treatment with 6-MP. The only effect of treatment 
was a lowering of the leucocyte count, although 
latterly the platelets did rise to a normal level. 
Post- mortem revealed, together with other 
pathologies, Hodgkin's disease. 
It is suggested that the essential lesion was 
Hodgkin's disease with subsequent monocytic leukae 
The absence of evidence of the latter at autopsy i 
.difficult to explain. Histological examination wa 
ia. 
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not complete, however, and the possibility that 
the absence of leukaemic cells may have been a 
consequence of 6 -MP therapy suggests itself in 
view of the profound terminal depression of the 
leucocytes in the peripheral blood and bone marrow. 
Ike survived 14 months after the diagnosis was 
made. The survival time from the onset of 
symptoms was difficult to ascertain in view of 
the difficulty in obtaining a satisfactory history. 
Case 1o. 25 
A 50 year old female was admitted to the 
Brotherton Wing of the Leeds General Infirmary on 
October 26, 1953, with a history of night sweats, 
dyspnoea, recurrent purpura and increasing pallor 
of six months' duration. A week before admission 
she noticed haernaturia. 
On admission she was anaemic and purpura was 
Present over the face, neck, limbs and trunk. 
Ulceration of the lips and a large swelling in the 
right submandibular region was present. Lymph 
glands were palpable in all areas and the spleen 
was enlarged. The temperature was 100.40. 
Blood examination revealed: haemoglobin 
9.9 G., red cells 3,600,000 per c.rrm., platelets 
33,000 per c.mm., white cells 44,800 per c.mm. 
Differential white cell count:- polymorphonuclear 
cells 3¡, blast cells 96%. The blast cells were 
peroxidase positive and many had a monocytoid 
appearance. The sternal marrow was hypercellular, 
75% of cells being primitive blasts and 25% of 
the myeloid series. 
A diagnosis of monocytic leukaemia of 
Naegali type was made. 
Progress and Treatment 
A transfusion of concentrated red cells was 
given on November 2, and 6 -MP, 200 mg. daily, was 
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begun on the following day. The leucocyte count 
fell from 38,000 to 5,000 per c.rnm. in the 
following seven days, the spleen became impalpable 
and the mass in the neck smaller. Her clinical 
condition, however, remained unchanged, the 
temperature persisted and further transfusions 
were necessary. She finally succumbed from a 
right lower lobe pneumonia on November 11. 
Comment 
Acute leukaemia affecting an adult female 
who died of intercurrent infection a week after 
the start of treatment with 6 -MP. A fall in the 
leucocyte count and regression of leukaemic 
tissue was observed to follow therapy. 
She survived 2 weeks following diagnosis, 
or 6 months after the onset of symptoms. 
399. 
Case No. 26. 
A female patient aged 53 years was admitted to 
the Leeds General Infirmary on May 31, 1954, with a 
ten days history of epistaxis, purpura, haematuria, 
fever and pains in the back and limbs. 
On examination the temperature was 102.6 °F., 
she was severely anaemic and there was marked 
ulceration of the mouth and throat, widespread 
purpura was evident affecting the limbs, trunk and 
buccal cavity. Small cervical, axillary and 
inguinal lymph glands were palpated, the abdomen 
was distended but no enlargement of the liver or 
spleen could be detected. 
Blood examination gave the following result: 
haemoglobin 8.7 G., red cells 3,500,000 per c.rrmm., 
platelets 71,000 per c.nin., white cells 358,600 per 
c.mm. The majority of the leucocytes were 
primitive blast cells, but a percentage were 
promyelocytes and myelocytes. 
Sternal bone marrow was hypercellular, the 
predominant cells being poorly differentiated 
leukaemic cells of the myeloid series. Less than 
1% of mature polymorphonuclear cells were seen and 
no red cell precursors could be found. 
A diagnosis of acute myeloblastic leukaemia 
was made. 
4UU. 
Progress and Treatment 
In view of the extremely acute nature of the 
disease 6 -MP, ï Gm., was given in the 24 hour 
period following admission, together with a 
transfusion of concentrated red cells. 6-MP, 
200 mg., daily, was thereafter prescribed. No 
beneficial effect was observed, however, she had 
repeated convulsions and death occurred on June 3. 
Post -mortem examination revealed the 
characteristic findings of acute leukaemia, with 
massive haemorrhage in the left temporal lobe and 
smaller haemorrhages in the corona radiata, pons 
and cerebellum. 
Comment 
A 53 year old woman with acute myeloblastic 
leukaemia was given 1 G. 6 -MP in 24 hours. This 
failed to control the leukaemic process and she 
died three days after admission. 
She survived 3 days following diagnosis, or 
14 days after the onset of symptoms, 
401. 
Case No. 27 
A male patient aged 42 years was admitted to 
St. Luke's Hospital, Bradford, on December 21, 
1954, with a history of attacks of shivering and 
aching in the limbs and failing health of one 
month's duration. He had an attack of tonsillitis 
in early December followed by 'gastritis' which 
was associated with severe vomiting and lasted 
five days. 
On admission the temperature was raised to 
101.6 °F. He was found to be pale, a few palpable 
lymph glands were present in the cervical and 
inguinal regions and the spleen tip could just be 
palpated. There was no evidence of bleeding. 
Blood examination gave the following findings: 
haemoglobin 6.4 G., red cells 2,000,000 per c.mm., 
white cells 46, OO per c.mm., differential white 
cell count : - blast cells 56%, promyelocytes 16%, 
myelocytes 9 %, polymorphonuclear cells 3 %, 
lymphocytes 13 %, monocytes 3 %. 
Bone marrow examination was not performed. 
A diagnosis of acute myeloblastic leukaemia 
was made. 
P_ra ress and Treatment 
6 -MP, 200 mg. daily, was begun on December 
24. Penicillin was also prescribed and a 
transfusion of 840 mls. whole blood was given on 
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admission. A week after starting treatment the 
leucocytes fell to 10,300 per c.mm. A further 
transfusion was "five:_ at this time which raised the 
haemoglobin to 11.1 G. By January 3, the white 
cells were 1,400 per c.mm., the differential 
being unchanged. 6-MP was stopped but within three 
days a rising leucocyte count necessitated re- 
starting treatment at a dose of 150 mg. daily. He 
was, however, feeling much better, the temperature 
had settled, the spleen was impalpable and he was 
symptom free and he was allowed up. Clinical 
improvement was short- lived, however, the anaemia 
was persistent and the blood continued to show 
evidence of leukaemia. Towards the end of January 
he started to complain of dysphagia and the 
temperature and leucocyte count rose irrespective 
of continued 6 -MP therapy. A.C.T.H., 50 units 
6 hourly, was given for one week in addition to 
6-MP without any effect on the leukaemic process 
although the dysphagia did clear. Cortisone, 
100 -200 mgm. daily, was given for a month. The 
temperature settled for a week and the leucocytes 
fell to 800 per C.E. , but no clinical or 
haematological improvement followed. Repeated 
blood transfusions were given, but failed to 
prevent a downhill course, with sloughing necrotic 
lesions in the throat and mouth, gluteal abscesses, 
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cellularity of the right arm, and death occurred 
on April 8, 1955. 
Post -mortem revealed a right upper lobe 
pneumonia and widespread infiltration of all 
tissues with leukaemic cells. 
Comment 
A 42 year old male with acute myeloblastic 
leukaemia failed to respond to 6 -MP. A fall in 
the leucocyte count with regression of the 
enlarged spleen was noted initially together with 
clinical improvement of short duration. No 
response to A.C.T.. or Cortisone was observed. 
He survived 3- months after diagnosis, or 
44 months following the onset of symptoms. 
Case No. 2g. 
A female aged 34 years was admitted to St. 
Luke's Hospital, Bradford, on February 26, 1955, 
complaining of tiredness, general debility and 
dysonoea on exertion of three weeks' duration. 
On admission she was very anaemic and the 
temperature was 100.6 °F. Palpable lymph glands 
were present in the neck and groin and the spleen 
extended to below the umbilicus. 
Blood examination gave the following findings: 
haemoglobin 5.1 G., white cells 40,000 per c.mm., 
platelets 30,000 per c.mm. Differential leucocyte 
count:- blast cells 48%, promyelocytes 13%, 
myelocytes 3%, metamyelocytes 6 %, polymorphonuclear 
cells 11 %, lymphocytes 19%. 2 nucleated red cells 
per 100 white cells were observed. 
A diagnosis of acute myeloblastic leukaemia 
was made. Bone marrow examination was not 
performed at this stage. 
Progress and Treatment 
Initiai blood transfusions resulted in a 
temporary rise in haemoglobin. 6 -MP, 200 mg. 
daily, was begun on March ìï, when the haemoglobin 
was 6.9 G., white cells 24,000, platelets 31,000 
per c.mm. The differential white cell count still 
showed a preponderance of leukaemic cells. No 
change was observed during the following two weeks. 
405. 
On March 24, the leucocytes feil to ,,000 and six 
days later were 2,000 per c.r:-. The differential 
count was, however, unchanged and bone marrow 
showed 95% myeloblasts. Her clinical condition 
showed a regression in size of the spleen and 
lymph glands but the temperature remained elevated. 
6 -MP was stopped on March 30 and the white cells 
continued to fall. On April 5, they were 640 per 
c.mm. The count remained low for several days and 
on April 15 it was 600 pr c.mm. The spleen was 
now impalpable and the lymph glands much less 
obvious. The haemoglobin, however, remained low 
at 5.7 G., and she developed an ulcerated throat 
for which penicillin was prescribed. 
She was transferred to another hospital on 
April 19, 1955. The sore throat improved and the 
temperature gradually settled. Definite improvemen 
in the differential leucocyte count occurred with 
an increase in the percentage of mature polymorpho- 
nuclear cells. The haemoglobin level had risen 
without further transfusion and the enlargement of 
the lymph glands and spleen had subsided completely 
She felt well in herself and was discharged home 
on the 7th May. The bone marrow showed a 
reduction in blast cells to 34%. 6 -MP was witheld 
and when seen at the out- patient department on May 
19 the haemoglobin was 10.4 G. The differential 
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leucocyte count still showed 50% polymorphonuclear 
cells but myelocytes and a few blast cells could 
be observed. She was feeling well, and refused to 
be admitted to hospital for further treatment at 
that time. On June 22, she was, however, re- 
admitted in pronounced clinical and haematological 
relapse and she died following what appeared to 
be a cerebral haemorrhage on June 24. 
Comment 
A 34 year old woman with acute myeloblastic 
leukaemia developed both clinical and haematologica 
improvement after treatment with 6 -MP. The 
beneficial effects of therapy lasted, however, 
only seven `,reeks. 
The survival time following diagnosis was 
4 months, or 4 months after the onset of symptoms. 
407. 
Case No. 29. 
A 49 year old hospital porter had been in good 
health up to the day prior to admission to the 
Leeds General Infirmary on September 25, 1953. At 
that time he experienced a sudden attack of pain 
in the left side of the abdomen associated with 
vomiting. A past history of peptic ulceration 
with perforation in 1945, and partial gastrectomy 
in 1949, led to his innediate admission to hospital 
On admission he was found to be a pale, thin 
man, in obvious pain and who vomited repeatedly 
during the examination. A large rubbery, mobile 
lymph gland the size of a walnut was present in the 
left axilla and the spleen was palpable 8 ems. 
below the lift costal margin. No other 
abnormalities were found on clinical examination. 
Blood examination was in keeping with a 
diagnosis of chronic myeloid leukaemia and was as 
follows: haemoglobin 9.0 G., red cells 3,3D0,000 
per c._ni. , reticulocytes 2%, platelets 300,000 
per c.Yrxn., white cells 128,000 per c.mm. 
Differential white cell count: myelocytes 2%, 
metamyelocytes 17¡x, neutrophils 79%, eosinophils 
15, lymphocytes 1%, An occasional nucleated red 
cell was observed on examination of the peripharal 
blood film. Sternal puncture revealed a 
hyper. cellula r bone marrow, with a marked 
408. 
preponderance of granular cells, 93.6 being of 
this series. 
Progress and Treatment (Fig. 38) 
Treatment with 6- J,P was begun on September 28 
and continued until October 23, a total dose of 
4.4 G. being prescribed. Within 43 hours of 
admission the abdominal pain and vomiting ceased 
but some tenderness over the left upper abdomen 
Persisted for about one week. The blood picture 
remained unaltered for just over 3 weeks, when on 
October 21, the white cell count fell to 60,000 
per c.rnin. Two days later it was 44,000 per c.min. 
at which time treatment was stopped. Coinciding 
with the fall in the leucocyte count, the spleen, 
which during the first three weeks of treatment had 
increased in size, became smaller. He was 
discharged home on October 28 and thereafter his 
progress was followed, at regular intervals, at 
the out -patient department. His condition remain 
satisfactory, the haemoglobin level rose to 11.2 G. 
and he returned to work during the following 
month. On November 30 the spleen was much larger 
and the white cell count had risen to 56,000 per 
cmm. He was feeling well, hauever, and he 
continued won,:ing. 6- MP was re- started at a dose 
of 100 mg. daily and after a period of three 
weeks clinical and haematological improvement was 
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was 9.9 G. and the leucocyte count 26,400 ÌD r c.mm. 
In view of the previous experience and that 
of others it was obvious that relapse would follow 
within a month or six weeks of stopping treatment 
and a daily maintenance dose of 6 -MP seemed 
necessary if a satisfactory clinical and 
haematological state was to be continued for any 
length of time. 
A dose of 13O mg. or 50 mg. 6 -MP daily was 
thereafter prescribed as maintenance therapy. On 
this basic dosage scheme the patient has remained 
in good health. He has not lost a day's wort: for 
over two years. The spleen has been almost 
invariably palpable 1 -2 cm. below the costal margin:, 
the leucocyte count satisfactory, and the 
haemoglobin level after a slow initial rise has 
remained at a normal level. 
Co_rment 
A male aged 49 years with chronic myeloid 
leukaemia res ..onded well to -: ?. The evidence of 
disease rewressed and the b:_ od picture returned 
to normal. By the use of maintenance therapy he 
has continued in good health with a normal blood 
picture for over two years. 
4111, 
Case No. . 30 , 
A male aged 25 years was referred to the 
medical out -patient department of the Leeds 
General Infirmary on October 7, 1953. He had been 
discharged from Her majesty's Forces three weeks 
previously, suffering from chronic myeloid leukaemi 
and had received a course of deep x -ray therapy 
immediately prior to discharge. He was symptom 
free and was about to begin work. 
On examination his colour was good, there was 
no l mphadenopathy and the only abnormal finding 
was a palpable spleen about 1 -2 ems. below the 
left costal margin. 
Blood examination gave the following findings: 
haemoglobin 13.3 G., red cells 4,6 0,000 per c.mm. , 
platelets 210,000 per c.mm., white cells 23,700. 
Differential white cell count: myelocytes 2%, 
metamyelocytes 8%, polymor: nonuclear cells 72%, 
lymphocytes 15¡, monocytes 3 %. 
Progress and Treatment (Fig. 39) 
In view of his satisfactory clinical and 
haematological state, and recent radiotherapy, no 
further treatment was indicated. He was seen at 
monthly intervals and for the following eleven 
months he remained in good health, and carried out 
his job without interruption. The haemoglobin 
level was a1. trays above normal and the spleen was 
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just palpable. A gradual slow rise in the 
leucocyte count occurred. On September 1, 1954, 
the haemoglobin was 14.5 G., and the white cells 
75,200 per c.mm., the spleen had also begun to 
increase in size at this time and although he was 
still symptom free it was decided to attempt to 
improve the blood picture by chemotherapy. 6 -MP, 
2DJ0 mg. daily, as an out --patient, was started on 
September 6. Seven days later the dose was reduced 
to 150 mg. daily. Three weeks after the start of 
6-MP therapy, on September 27, the leucocyte count 
was 14,600 rer c.=.. and the tip of the spleen was 
just palpa.ple. On a maintenance dose -of 50 or 100 
mg. 6-MP daily he continued in good health a year 
later with a normal haemoglobin and platelet count. 
The leucocytes have been maintained at a 
satisfactory level throughout. On September 5, 
1955, clinical examination showed the spleen to be 
palpable 1 cm. below the costal margin and was 
otherwise negative. Examination of the blood on 
the same day gave the following findings: - 
haemoglobin 14.6 G., white cells 11,200, Platelets 
190,000 per c.mrn. 
Comment 
A male aged 25 years with chronic myeloid 
leukaemia responded satisfactorily to deep x -ray 
treatment. Eleven months later evidence of 
414. 
haematological relapse was a ._ earing and tretment 
ith 6 -i:-ìP started. The leucocyte count returned 
to normal after three weeks and thereafter his 
clinical and haematological state has been 
consistently normal over a poriod of twelve months. 
415. 
Case No. 31. 
A male child aged 9 years was admitted to 
St. James's Hospital, Leeds, on July 31, 1954, with 
a 5 months' history of loss in weight, progressive 
dyspnoea on exertion and lassitude. 
On admission he was found to be extremely pale 
and thin. Many bruises were present on the laver 
limbs. Several small lymph glands were palpable in 
the groins and neck. The spleen was enormously 
enlarged, the lower pole reaching almost to the 
symphysis pubis. The liver was palpable 4 cms. 
below the right costal margin. 
Blood examination gave the following results: 
haemoglobin 6.9 0-., red cells 2,000,000 per c.mm., 
reticulocytes 1 %, platelets 25,000 per c.mm., white 
cells 300,000 per c.: ü. Differential white cell 
count:- myeloblasts 4%, promyelocytes 6%, 
myelocytes 27%, metamyelocytes 30%, polymorphonucle 
cells 31%, ly monocytes i %, monocytes 1%. Sternal 
bone marrow was hypercellular, the myeloid -erythroi 
ratio 26 to 1 and blast cells numbering only 1.6 %. 
A diagnosis of chronic myeloid leukaemia was 
made. 
Laress and Treatment (Fig. 40) 
A transfusion of packed red cells was given 
which raised the haemoglobin to 9.6 G. and treatmen 
With 6 -MP, 100 mg. daily, was started on August 7. 
r 
416. 
ido clinical or haematological change occurred for a 
period of two weeks. On August 21, the spleen had 
regressed and the leucocyte count fallen to 
125,000 per c.mm. Treatment was continued and ten 
days later the leucocyte count was normal. He was 
feeling well, fully active and clinical evidence of 
disease, although still present, showed a marked 
regression. By September 7, the liver edge was 
almost impalpable, the spleen half way between the 
costal margin and the umbilicus and a few glands in 
the groins just pal-aable. The haemoglobin level wa 
rising without further transfusion and the leucocyt 
count was at a satisfactory level. Platelets, 
however, were still scanty but apart from a few 
bruises no bleeding occurred. The dose of 6 -MP was 
reduced to 50 mg. daily on September 7, and quite 
unexpectedly, oneweek later, a relapse occurred, t- 
leucocyte count rose to 300,0.:0 per c.mm., the 
haemoglobin started to fall and the spleen and 
liver increased in size. He had no complaints, 
however, apart from a septic thumb. Penicillin 
intramuscularly was prescribed and much bruising 
resulted. The dose of 6 -MP was increased to 150 mg. 
daily on September 21, Clinical and haematological 
improvement was observed on September 28, two weeks 
after the relapse began and one week after raising 
the dose of 6 -MP. The dose of 5 -MP was thereafter 
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418. 
reduced to 100 mg. daily on September 30, and on 
October 12 to 50 mg. daily. He was now well and 
returned home, the white cells numbering 10,600 
per c.riim. , and the haemoglobin having climbed to 
10.8 G. A month later the haemoglobin had reached 
13 G. and the platelets 210,00 per c.nm. Since 
that time he has been followed as an out -patient. 
He returned to school shortly after discharge from 
hospital, the spleen at times has been impalpable, 
but generally felt a few ems. below the costal 
margin. The blood picture has remained satisfactor 
exce :: -t for a fluctuation in the number of platelets 
On April 27 blood e: :amination was as follows: - 
haemoglobin 14.4 G., white cells 14,000 per c.:f ., 
platelets 150,000 per c.mr . He continues to be 
maintained on 50 mg. 6 -MP daily and is in good 
health, fully active and attending school, thirteen 
months after 6 -MP therapy was instituted The 
blood picture on August 17, 1955 was: haemoglobin 
13.1 G., white cells 13,500 and platelets 185,000 
per c. cï:_. 
Comment 
A boy of nine years with chronic myeloid 
leukaemia responded successfully to treatLent with 
6- =P. Clinical and haematological improvement 
resulted and thirteen months after 6 -11P therapy was 
instituted he continues in good health and at schoo 
419. 
Regression of the liver and spleen and lymph 
nodes with a fall in the leucocyte count, and 
spontaneous rise in the haemoglobin, followed 
initial therapy. After a temporary relapse he 
has been maintained satisfactorily on 50 mg. 6 -MP 
daily. The blood picture has been consistently 
good and the platelet count, at the outset 25,000 
per c.mm., rose to normal levels following treatment. 
420. 
Case No. 32. 
A male aged 18 years was admitted to the 
Leeds General Infirmary on July 30, 1954, with a 
history of general debility of two years' duration 
and recurrent attacks of pain in the le ft 
hypochondrium for six months. 
On admission lymph glands were palpable in 
the right side of neck and both axillae. The 
spleen was greatly enlarged, the lower pole being 
palpable in the right iliac fossa. The liver was 
palpable 3 cms. below the right costal margin. No 
other abnormality was found. 
Blood examination on August 6, 1954, gave the 
following results: haemoglobin 10.4 G., red cells 
3,500,000 per c.rm -., platelets 175,000 per c.mm., 
white cells 259,200 per c.mm. Differential white 
cell count:- blast cells 2%, myelocytes 35%, 
metamyelocytes 7%, neutrophils 51 %, lymphocytes 5 %. 
A diagnosis of chronic myeloid leukaemia was 
made. 
Progress and Treatment (Fig. 41) 
6 -MP, 200 mg. daily, was started on August 6, 
and continued until August 25, when the dose was 
reduced to 100mg. /50 mg. on alternate days. The 
leucocyte count was now 78,400 per c.mm., the 
spleen considerably reduced in size, the lower 
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422. 
normal at 300,000 per c.mm. The leucocyte count 
continued to fall and b: September 2 had reached 
8,000 per c.mm. By this time the patient was 
symptom free and the spleen had further regressed 
in size and the liver was impalpable. He was 
discharged on September 8 on a dose of 100 mg./ 
50 mg. 6 -MP on alternate days. On September 27, 
as a result of a rise in the leucocyte count to 
36,800 Der c.mm., 6 -MP was increased temporarily 
to 100 mg. /150 mg. on alternate days and later to 
100 mg. daily with the desired results. Thereafter 
he was put on a maintenance dose of 50 mg. 6 -MP 
daily. He returned to work almost immediately 
after discharge from hospital and has continued to 
do so without interruption. Over one year after 
treatment was instituted, he remains in good health 
He has been seen on the average once per month, at 
the out -patient department, and the blood picture 
on each occasion has been satisfactory. On 
September 5, 1955, the haemoglobin was 13.9 G. 
and white cells 10,100 per c.mm., and the spleen 
was impalpable. Since October, 1954, he has 
continually received 50 mg. 6 -hìIP daily as 
maintenance therapy. 
Comment 
A male aged 18 years with chronic myeloid 
leukaemia responded satisfactorily to treatment 
423. 
?with 6 -MP, and on maintenance therapy remains 
well and doing a full day's work thirteen months 
after treatment was instituted. The blood picture 
is normal, and there is no clinical evidence of 
disease. 
424. 
Case No. 33. 
A female aged 42 years was admitted to the 
Leeds General Infirmary on January 25, 1954, with 
severe bronchitis of four months' duration and for 
which she had been in hospital in November, 1953. 
She was known to have had chronic myeloid leukaemia 
since November, 1952, and had since been treated 
with urethane. She had remained fairly well during 
the following year, the haemoglobin remained at a 
satisfactory level and the white cells ranging from 
35- 75,000 per c.mm. The lower pole of the spleen, 
however, was always 2 -6 ems. below the umbilicus 
and had at times given rise to discomfort. 
On admission she was found to be slightly 
anaemic and the spleen was palpable 2 cros. below 
the umbilicus. There was no lymphadenopathy. 
Raies were audible over both lung fields and air 
entry was diminished at the bases. She was 
extremely breathless, febrile and troubled with a 
severe cough. Much purulent s_ utum wasbeing 
expectorated. 
Progress and Treatment 
Urethane therapy was continued for the next 
six weeks, during which period she had recurrent 
attacks of intense dyspnoea responding only to 
oxygen therapy and she was maintained in a tent 
-almost permanently for five weeks. A variety aC 
425. 
antibiotics were given in an effort to supprems 
the respiratory infection. 
It was decided to treat the leukaemia with 
6 -MP in March, 1954, and treatment was begun on 
March 6, at a dose of 200 mg. daily. The blood 
picture at that time was:- haemoglobin 11.8 G., 
red cells 4,200,000 per c.mm., white cells 96,000 
per c.mm., differential white cell count: - 
myelocytes 5 %, metamyelocytes 26%, polymorphonucle 
cells 68 %, lymphocytes 1%. The spleen was palpabl 
12 ems. and the liver 6 cms. below the costal 
margins. Two days after 6 -MP was started the 
breathing became easier and the respiratory 
infection began to clear. 
The leucocyte count fell gradually and after 
reducing the dose to 150 mg. daily on March 11, 
6 -MP was stopped on March 17, after a total dose 
of 3.05 G. had been given. The leucocyte count on 
March 29 was normal at 6,000 per c.mm. and a daily 
maintenance dose of 50 mg. 6 -MP was prescribed. 
The liver and spleen were considerably reduced in 
size and on April 2 the liver was impalpable and 
the spleen extended 5 cros. below the 1Eft costal 
margin. 
Her chest condition recurred in a lesser 
degree and persisted for fourteen days, up to 
April 12. She was discharged home a week later 
r 
426. 
and in vie7. of a rising white count advised to 
take 6 -MP, 100 mg. /50 mg. on alternate days. 
During the next six months, apart from 
occasional pain in the chest, she remained well, 
the blood picture was satisfactory, and the only 
clinical evidence of leukaemia was the spleen 
which was persistently 3 -5 cms. below the costal 
margin. 
On October 3, 1954, she was admitted as an 
acute emergency in marked respiratory distress. 
She was febrile and anaemic, and the spleen had 
become much bigger. The liver was also enlarged. 
A blood examination showed: - haemoglobin 7.5 G., 
white cells 39,000 per c.mm., differential: 
myelocytes 51%, metamyelocytes 2%, neutrophils 30 %, 
lymphocytes 1%. 3 normoblasts per 100 white cells 
were present and much polychromasia and 
basephilic stippling was observed. Treatment with 
6 -MP, 150 mg. daily, antibiotics and oxygen was 
given but she succumbed to the respiratory 
infection, four days after admission, on October 
12, 1954. 
Post -mortem revealed evidence of chronic 
myeloid leukaemia in the bone marrow, liver 
(1930 grammes), spleen (1970 grammes) and 
mediastinal lymph glands. A fleshy mass 4 cm. 
x 2.5 cm. was found extending round behind the 
427. 
manubrium and histologically ;-ras found to be 
A su_opurative bronchitis and considerable 
pulmonary oedema was also observed. 
Summary and conclusion 
A female, aged 42 years, with chronic myeloid 
leukaemia was treated for sixteen months with 
urethane. Thereafter she was found to respond to 
6 -MP and was maintained in a satisfactory clinical 
and haematological state for six months. For six 
months prior to 6-MP treatment, she had severe 
suppurative bronchitis. It seemed doubtful whether 
the 6 -LIP was related to the temporary improvement 
in the chest condition. Antibiotics, prolonged 
oxygen therapy and nursing care apart from the 
change in season were more likely explanations. 
Death from respiratory infection occurred 
seven months after 6 -MP therapy was instituted 




A female aged 34 years was admitted to the 
Leeds General Infirmary on March 8, 1955, 
complaining of pain in the left hypochondrium of 
one week's duration: Three days prior to 
admission she began to feel weak and complained of 
faintness and on the day of admission vomited 
about a oint of dark red blood. 
On admission she was found to be anaemic and 
the spleen was enormously enlarged, the lower pole 
extending below the brim of the pelvis on the left 
side and the right border 4 cms. to the right of 
the umbilicus. A few small glands were palpable 
in both inguinal regions and in the left axilla. 
Blood examination gave the following results: 
haemoglobin 4.9 G., red cells 2,200,000 per c.mm., 
colour index 0.7, platelets 270,000 per c.mm., 
white cells 204,000, differential White cell count: 
blasts 1%, myelocytes 11 %, metamyelocytes 21%, 
polyliiorphs 60 %, lymphocytes 6%. Bleeding time 2 
minutes, clotting time 4 minutes. A blood film 
showed 2 nucleated red cells per 100 white cells. 
A diagnosis of chronic myeloid leukaemia was 
made. 
Pro ress and Treatment (Fig. 42) 
A transfusion of whole blood was given on 
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430. 
Treatment with 6 -MP, 200 mg. daily, was started on 
March 11. Six days later she was feeling improved, 
no further haematemesis had occurred and the 
leucocyte count had fallen to 129,600 per c.mm. 
On March 23, the spleen was considerably smaller 
and the dose of 0 -MP was reduced to 100 mg. daily. 
On March 20, the white cells had fallen to 
10,300 per c.mm. and a maintenance dose of 100 mg. 
and 50 mg. 6 -11P on alternate days was prescribed. 
The spleen was now 5 ems. below the left costal 
margin. 
She was discharged home on April 6, 1955, 
sy7Jtom free. When seen at the out- patient clinic 
two weeks later the haemoglobin had risen to 12.3 G 
without further blood transfusion, the white cell 
count was normal at 6,800 per c.mm., the 
haemoglo.)in 13.5 G., and the spleen was impalpable. 
A barium meal x -ray revealed no abnormality 
in the oesophagus, stomach or duodenum. 
She has continued in good health and the 
blood picture has remained satisfactory up to the 
present date. On September 12, 1955, the 
haemoglobin was 13.6 G. and white cells 6,300 
per c. -gin. The spleen was impalpable. 
Comment 
A female aged 34 years with chronic myeloid 
leukaemia responded satisfactorily to 6 -MP therapy. 
431. 
The blood picture returned to normal and an 
enormously enlarged spleen became impalpable. On 
maintenance therapy she continues in good health 
six months later. 
432. 
Case No. 35. 
A female patient, aged 62 years, was admitted 
to Leeds General Infirmary on February 25, 1955. 
She gave a history ofvvague symptoms of ill- health 
extending over a year with recurrent attacks of 
-pain in the left loin of three months' duration. 
During the twenty -four hour period before 
admission haematuria was observed. 
On admission she was found to be anaemic, 
underweight and confined to bed. A few lymph 
glands were palpable in the cervical and axillary 
regions and the spleen extended almost to the 
;,pubis. 
Blood examination was as follows: haemoglobin 
8.3 G., red cells 3,310,000 per c. , white cells 
275,200 per c.rrun., differential white cell count: 
myelocytes 21 %, metamyelocytes 29%, polymorpho- 
nuclear cells 41%, lymphocytes 9%, 3 nucleated red 
cells per 100 white cells were present in the 
peripheral blood. 
A diagnosis of chronic myeloid leukaemia was 
made. 
Progress and Treatment (Fig. 43) 
Treatment with 6 -EP, 200 mg. daily, was begun 
on the day of admission. No significant changes 
in the clinical or blood picture during the first 
week of treatment. On March 8, the leucocytes had 
Hb. WßC. 
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434 
fallen to 10:.;,000 and six days later the spleen 
was definitely becoming smaller and the patient 
felt much better and was walking about the ward. 
On March 18, the leucocytes had fallen to 35,600 
per c.mm., and the dose of 6 -MP was reduced to 
100 mg. and 50 mg. on alternate days. The 
haemoglobin was starting to rise and at this time 
was 9.9 G. She was now strong enough to return 
home with a view to follow -up at the out -patient 
department. When next seen on March 28, the spleen 
had receded to the umbilicus and the white cell 
count was normal. On the same dose of 6 -MP 
continued improvement followed and when seen on 
May 2 the haemoglobin had risen to 13.5 G., and by 
June 6, to 14.5 G. The white cell count has 
remained within normal limits, the spleen has been 
remarkably reduced in size and she has.put on 
weight and returned to a full and active life. 
When last seen on September 5, 1955, the spleen 
tip was just palpable, haemoglobin 14.1 G., and 
white cell count 10,800 per c.mm. 
Comment 
A patient with chronic myeloid leukaemia 
responded satisfactorily to 6 -MP therapy. She 
regained her normal strength and became symptom 
free, the leucocytes fell to normal and the 
haemoglobin without blood transfusion rose from 
435. 
8.3 G., on admission, to 14.5 G., approximately 
three months later. The spleen, which had given 
rise to discomfort and pain before treatment, was 
considerably reduced in size. Seven months after 
treatment was instituted the blood picture is 
normal and the spleen tip just palpable. She has 
received a maintenance dose of 6 -.:P of 50/100 mg. 
on alternate days. 
436. 
Case No. 36 
A 56 year old housewife with a history of 
chronic myeloid leukaemia of seven years' duration, 
for which she had received several courses of deep 
x -ray therapy, the last in October, 1953, was 
admitted to St. James's Hospital, Leeds, on 
December 18, 1953. Her main complaints were 
repeated attacks of vomiting, a dragging sensation 
in the left side of the abdomen, loss of weight, 
sweating and epistaxis for which she had been 
confined to bed for three weeks prior to 
admission. 
On examination she was extremely ill, sweating 
profusely and clinically anaemic. The spleen was 
firm and tender and extended 15 ems. below the 
left costal margin and the liver was palpable 
2 ems. below the right costal margin. 
Blood examination showed the following finding 
haemoglobin 8.2 G., red cells 2,300,000 per c.mm., 
platelets 225,000 per c.mm., white cells 152,000 
per c.mm. Differential white cell count: blast 
cells 8.5 %, myelocytes 25.5%, metamyelocytes 8.0 %, 
polymorphs 38.5 %, lymphocytes 17.5 %, monocytes 2%. 
The sternal bone marrow was hypercellular and 
showed blast cells 74.0 %, myeloid cells 21.6%, 
erythroid cells 3.2%, lymphocytes 0.8%, other 
cells 0.4%. The blood findings were characteristic 
437. 
of the acute terminal phase of chronic myeloid 
leukaemia. 
Progress and Treatment (Fig. 4.4) 
Treatment with 6 -MP, 200 mg. daily, was 
instituted on December 18, 1953, and on December 23 
a blood transfusion was given which elevated the 
haemoglobin to 11.3 G. A fall in the leucocyte 
count was observed after three days treatment and 
after two weeks a level of 13,000 had been reached, 
the patient was feeling stronger, the vomiting had 
ceased and there was no sweating. No abdominal 
discomfort was complained of, the liver was now 
impalpable and the spleen was 9 ems. below the left 
costal margin. The dose of 6 -MP was reduced to 
100 mg. daily on January 2, and continued until 
January 14, when treatment was stopped. A total 
of 4.1 G. of 6 -MP had been given in twenty seven 
days. At this stage the white cells had fallen to 
300 per c.mIL. and the haemoglobin to 7.5 G., and 
the spleen was just palpable. A further blood 
transfusion was given on January 22 which raised 
the haemoglobin to 11.7 G. On the same day bone 
examination showed considerable 
haematological improvement- blast cells 8.5 %, 
myeloid cells 47.5%, erythroid cells 18.5 %, 
lymphocytes 24 %, other cells 1.5 %. She was now 
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leucopenia persisted for a month no complications 
resulted. The haemoglobin was maintained at a 
satisfactory level without further recourse to 
blood transfusions and clinical examinations failed 
to reveal any of the usual findings of leukaemia. 
On February 2, she was discharged home with a view 
to follow -up as an out-patient. Two weeks later 
on February 15, she was symptom free and carrying 
out a full day's domestic duties. Blood 
examination gave the following results: - 
haemoglobin 12.0 G., red cells 4,000,000 per c.mm., 
platelets 200,000 per c.mm., white cells 4,400 per 
calm. (polymorphs 80¡, lymphocytes 20%). She was 
thereafter put on a daily maintenance dose of 6 -MP 
of 50 mg. and remained in excellent health until 
the last ;reek of May, a matter of four anda half 
months following the cessation of the initial 
course of treatment. Relapse then occurred and 
the disease was found to be completely resistant 
to further treatment with 6 -MP, and she died on 
June 26, 1954. 
Post -mortem revealed widespread leukaemic 
infiltration. The bone marrow of the left femur 
and lumbar vertebrae was soft and opaque pinkish 
and the spleen was enlarged (840 G.). The dark 
red cut surface showed recognisable Malphigian 
bodies. The lymph nodes were not noticeably 
440. 
enlarged. Superficial ulceration of the soft 
palate and isolated areas of sloughing necrosis 
and ulceration of the mucosa of the small intestin 
was observed, with a moderate number of mucosal 
petechiae. The liver was enlarged (2350 G.), 
smooth, brick red and showed whitish mottling. 
Both kidneys showed alternating red and white 
streaking of the cortex, and the left renal pelvis 
contained numerous orange coloured, minute, 
calculi. The right lung showed pronounced oedema 
and the myocardium fatty change. On microscopic 
examination there were proliferating leukaemic 
cells in the bone marrow, and there were leukaemic 
infiltrations in the renal cortex and portal tracts 
Comment 
A 56 year old female in the acute terminal 
phase of chronic myeloid leukaemia showed a 
remarkable response to 6 -MP therapy. The clinical 
and haematological state returned to normal, and 
she remained in good health for nearly five months 
when relaDse occurred. She was then found to be 
resistant to further therapy with 6 -MP. 
441. 
Case No. 37 
A spinster aged 58 years was diagnosed as 
having chronic myeloid leukaemia in March, 1952. 
She received no treatment during the following 
year but due to the considerable enlargement and 
discomfort of the spleen a splenectomy was 
performed in April, 1953. Thereafter deep x -rays 
were given with temporary improvement. On 
December 4, 1953, she was admitted to the General 
Infirmary, Leeds, complaining of tiredness, loss of 
a._Tetite, abdominal pain and distension, and 
swelling of the ankles. 
On clinical examination the liver was enlarged 
12 cms. below the right costal margin and small 
discrete lymph glands were palpable in the axillae 
and inguinal regions. There was no obvious 
clinical anaemia. 
Blood examination revealed the following 
findings: haemoglobin 12.0 G., red cells 3,700,0)0 
per c.1:1i. , platelets 210,000 per c.mm., white cells 
128,000 per c.mm. Differential white cell count: 
myelocytes 3¡, metamyelocytes 12%, neutrophils 84%, 
lymphocytes 1 %.. 
Progress and Treatment (Fig. 45) 
6 -MP, 2DO mg. daily, was begun on December 5. 
A delay of nine days elapsed before treatment 
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count had fallen to 39,600 per c.mm., the patient 
was feeling improved and the liver was reduced in 
size, being palpable 6 cms. below the right costal 
margin. Treatment was now discontinued, a total of 
2.6 G. having been given and she was discharged 
home, with instructions to attend the out- patient 
clinic for follow -up examination. No further 
improvement occurred during the following week and 
on December 23, treatment with 6 -MP was re- started 
at a dose of 100 mg. daily. On December 30, she 
was feeling much better and had put on seven pounds 
in weight. The liver was, however, still 6 cms. 
below the right costal margin and the white cells 
had risen to 91,200. Increasing the dose of the 
drug to 150 mg. resulted in a fall of the leucocyte 
count to 15,400 by January 11, when the liver edge 
was just palpable and she was symptom free. The 
haemoglobin on this date as 13.5 G. and pbtelets 
250,000. No immature white cells were observed in 
the peripheral blood, but a preponderance of 
granular cells was present. 
This Patient was maintained on a daily dose 
of 6 -MP of 50 or 100 mg. for nineteen months during 
which time she was in good health, symptom free and 
fully active. No objective signs of disease re- 
a geared and the blood picture was satisfactory, 
the white cells remaining in the region of 30,000 
444. 
per c.mm., together with a normal haemoglobin 
level. In May, 1955, she developed enlarged lymph 
glands in the neck with absecess formation. 
Biopsy of a gland showed it to be the seat of 
tuberculous infection. Anaemia developed but the 
leucocyte count and the absence of other findings 
on clinical examination suggested that the 
leukaemic process w-.s still under control. Blood 
transfusion, surgical operation and anti - 
tuberculous treatment was undertaken with 
improvement. She was later discharged home, and 
continued to take 6 -MP. 
445. 
Case No. 38. 
A female, aged 48 years, was admitted to St. 
James's Hospital, Leeds, on March 17, 1955, with 
congestive heart failure. A history of heart 
trouble since childhood was obtained. 
On examination on admission she was found to 
be anaemic. Oedema of the ankles and sacrum was 
present and she was fibrillating. A mid -diastolic 
murmur was audible in the mitral area, in keening 
with mitral stenosis. The liver was enlarged 
6 ems. below the right costal margin and the spleen 
was palpable 5 cms. below the left costal margin. 
Examination of the blood gave the following 
findings: haemoglobin 7.4 G., red cells 2,520,000 
per c.mm., colour index 0..98, platelets 150,000 
per c.mm., white cells 202,000 per c.mm. 
Differential white cell count:- blasts 4%, 
promyelocytes 10%, myelocytes 29%, metamyelocytes 
28%, neutrophils 25%, basophils 1%, lymphocytes 3 %. 
2 normoblasts per 100 white cells were observed. 
A diagnosis of chronic myeloid leukaemia was 
made in addition to rheumatic heart disease and 
congestive heart failure. 
I12 ress and Treatment 
The heart failure responded satisfactorily to 
digitalis, diuretics and a low salt diet. 
Treatment with 6 -MP was started on March, 31, 
446. 
following a transfusion of packed red cells. An 
initial dose of 200 mg. daily was given, but 
reduced four days later to 100 mg. daily. After an 
initial delay of eleven days, improvement occurred 
with reduction in size of the spleen and liver, a 
fall in white cells and maintenance of a satisfacto 
haemoglobin level. Progress was interrupted by a 
severe attack of Herpes Zoster which was associated 
with much pain. On April 20, the leucocytes had 
fallen to 24,000 per c.mm. She was now convalescin 
and on April 30 was allowed home with a view to 
follow -up as an out -patient. The blood picture on 
discharge was: haemoglobin 10.5 G., white cells 
8,000 per c.ITLI. (Dolymorphs 74%, lymphocytes 20 %, 
monocytes 6%) pitelets 130,000 per c.mm. The liver 
was impalpable and the spleen 2 cros. below the 
costal margin. A maintenance dose of 100 mg. and 
50 mg. 6-MP on alternate days was recommended. 
When seen at the out- patient clinic two months 
later she was feeling well and able to carry out G 
her domestic duties. The haemoglobin was 11.8 G. 
and white cells 16,300. The same maintenance dose 
was prescribed and when seen on August 13, 1955, 
she was symptom free apart from occasional post - 
herpetic pain. The haemoglobin level had risen to 





A 48 year old female patient with chronic 
myeloid leukaemia responded satisfactorily to 
6 -MP therapy. Clinical evidence of the disease 
regressed, associated with a fall in leucocytes 
and a rise in the haemnolo bin level,, The 
ir._pr-over .er.t continues five :_ c ith s after the 
institution of treatnment. 
448. 
Case No. 39. 
A male, aged 49 years, was admitted to the 
Leeds General Infirmary on July 24, 1953, with a 
history of recurrent ulceration of the left leg, 
loss in weight and general ill health of fourteen 
months' duration. 
On admission the temperature was 101.4 °F., 
he was anaemic and lymph glands, 1 -2 ems. in 
diameter, were palpable in the cervical, axillary 
and inguinal regions. The spleen was enormously 
enlarged, occupying the whole of the left side of 
the abdomen, the lower pole extending into the 
pelvis. The liver edge was palpable .6127 cms. below 
the right costal margin. An ulcer measuring 
4 ems. x 2 ems. was present over the medial aspect 
of the left calf. 
Blood examination gave the following result: 
haemoglobin 7.7 G., red cells 2,300,000 per c.mm., 
platelets 150,000 per c.mm., white cells 112,400 
per c.mm. Differential white cell count:- blast 
cells 1%, promyelocytes 45, myelocytes 42%, 
metamyelocytes 7%, óolymorphonuclear cells 33%, 
lymphocytes 13%. Sternal bone marrow revealed 
changes in keeping with the diagnosis of chronic 
myelogenous leukaemia, erythropoiesis being 
markedly depressed. 
A biopsy taken from the edge of the leg ulcer 
449. 
showed leuka.emic infiltration to be prevent in both 
dermis and subcutis. 
Progress and Treatment (Fig. 46) 
- 6 -TT, 200 mg. daily, -:fas begun on August 7, and 
continued unt il August 20, when a total dose of 
2.8 G. had been given. The patient's clinical 
status at the start of treatment showed no change 
from that on admission eleven days earlier and a 
swinging temperature persisted. The white cells 
had risen to 160,400 per c.mm. On August 20, the 
spleen showed a reduction in size and the leucocytes 
had fallen to 20,8';0 per c..m. A fall in the 
haemoglobin to 5.2 G., iìowever, was also observed 
and a blood transfusion was necessary. The 
leucocytes continued to diminish in number and on 
August 25 were 9,800. By this time he was feeling 
stronger, his a .petite had improved and the 
temperature had settled. The leg ulcer was healing 
(Fig, 47), the liver edge had almost receded under 
the costal margin and the spleen had now reached a 
point midway between the pelvis and umbilicus. The 
white cells continued to fall for thirteen days 
after treatment was stopped, and on September 2 
were 1,700 Per c.,t_.. A further blood transfusion 
was given on that date raising the h.aemo-iobin to 
8.9 G. The pltelet count was normal at 209,000 
per c.._:i. The leucocytes had risen to normal awe <:ì: 
450. 
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FIG. 46. 
Note the relapse when treatment was stopped, indicating the 
necessity for continuous (maintenance) therapy. 
FIG. 47. Case No. 39. Photograph of left calf showing 
healing of ulcer following treatment with 6 -MP. 
452. 
later, the clinical evidence of the disease 
continued to regress and after a further 
transfusion he was discharged home on September 12. 
In view of his home being a considerable distance 
from Leeds he was not sen again until September 28 
The leg ulcer had now completely healed, but the 
spleen was enlarging again and the white cells had 
risen to 80,000 per c.mm. After a second short 
course of 6 -MP, 50 mg. daily, the leucocytes again 
fell but in view of the persistent anaemia, and 
marked splenic enlargement he was referred after 
further blood transfusions to the Radiotherapy 
Department for the benefit of deep x -ray treatment 
on November 2, 1953. Treatment with deep x -rays 
was given in November and December, 1953, and 
February and March, 1954. Only temporary 
symptomatic improvement followed with a fall in 
white cells and a slight reduction in size of the 
spleen - which at its best always reached the 
umbilicus. The refractory anaemia continued and 
transfusions were required during this period. 
He was re- admitted to hospital on June 1, 195 
with profound anaemia, congestive heart failure, 
massive splenomegaly, lymphadenopathy and 
hepatomegaly. The haemoglobin was 3.2 G., white 
cells 198,400, platelets 100,000 per c.mm. Blood 
._transfusions were given on admission, digitalis, 
453. 
diuretics and a low sodium diet. In view of the 
poor response to deep x -rays it was decided to try 
the effect again of 6- IMP. In view of his poor 
condition an initial dose of 1 G. 6-MP was given 
during the 24 hour period on June 2. On June 3, 
the white cells had fallen to 51,200 per c.mm. 
6 -IMP, 200 mg. daily, was continued until June 9, 
when the white cells were 7,900 per c.mm., and then 
discontinued. The clinical evidence of leukaemia 
(lymph glands, spleen and liver) started to regress 
but a further blood transfusion was necessary on 
June 14, which raised the haemoglobin to 9.3 G. 
His general condition now improved, the signs of 
heart failure cleared and he was allowed up. On 
June 17, a maintenance dose of 6-MP, 100 mg. and 
50 mg. on alternate days was prescribed, and nine 
days later he was judged fit enough to return home. 
When seen on July 5, the spleen had receded almost 
to the umbilicus and the haemoglobin level had been 
maintained. A slight rise in white cells to 36,800 
led to an increase of 6 -MP to 100 mg. daily. He 
was thereafter seen at monthly intervals. The 
leucocytes remained at a satisfactory level and the 
haemoglobin, although never reaching the normal 
figure, climbed to 12.1 G. He was symptom free, 
fully active and the spleen which had previously 
extended into the pelvis was now just palpable on 
454. 
inspiration. This happy state continued for nine 
and a half months, during which time he carried out 
a light job. On March 28, 1955, the haemoglobin 
began to fall and he was given a blood transfusion. 
The spleen started to enlarge again and he 
complained of weakness, anorexia, and general ill 
health. 6 -MP, 150 mg. daily, was continued but 
further improvement did not occur. Further 
transfusions were necessary in early May, but only 
temporary improvement followed, and he died in 
June, 1955 Latterly Myeleran was prescribed but 
it proved ineffective. 
Comment 
A 49 year old male patient with chronic 
myeloid leukaemia showed a response to an initial 
single course of 6 -MP. There was clinical 
improvement; a chronic ulcer of the leg with 
leuka_emic infiltration healed, the spleen, liver 
and lymph glands regressed in size and his general 
condition improved. A refractory anaemia persisted 
however. Relapse occurred just over a month after 
stopping 6 -MP therapy, and it was later decided to 
try the effect of deep x -rays. Four courses in the 
following seven months only resulted in temporary 
clinical improvement after ech course, a fall in 
leucocyte count and a reduced size of the spleen. 
The anaemia persisted and further transfusions 
455. 
were reouired., A second course of 6 %4 followed 
by maintenance treatment gave considerable relief. 
For the first time since diagnosis the haemoglobin 
rose spontaneously to over 12 G., the spleen 
receded to the left costal margin and he regained 
almost normal health. ITo transfusions were 
necessary for over nine months when relapse 
occurred. Thereafter the disease proved refractory 
to treatment with 6 -MP and Myeleran. 
456. 
Case No. 40. 
A male, aged 55 years, was admitted to the 
Leeds General Infirmary on May 21, 1955, with a 
history of dyspnoea on exertion of one year's 
duration, intermittent claudication for three 
years and pain in the right shoulder for eight 
months. 
On admission he was found to be anaemic, bhe 
spleen was palpable mid -way between the left costal 
margin and the umbilicus, but there was no 
glandular enlargement. Pulsations were absent in 
the arteries of the legs and feet and movement 
around the right shoulder joint was considerably 
restricted. 
Blood examination gave the following findings: 
haemoglobin 10.9 G., red cells 3.5 million per 
c.mm., white cells 58,400 per C.1TEI. Differential 
white cell count showed:- myelocytes 6%, 
metamyelocytes 14%, neutrophils 64 %, eosinophils 
1%, basophils 7%, lymphocytes 8.. 
A diagnosis of chronic myeloid leukaemia was 
made. 
Progress and Treatment 
Treatment with 6 -MP was started on May 25, a 
dose of 150 mg. daily being prescribed. No effect 
of therapy was noted for over two weeks, but on 
457. 
June 13, the spleen had become impalpable and the 
leucocyte count was 14,700 per c.mra. The 
haemoglobin level, however, remained unchanged. A 
maintenance dose of 100 mg. and 50 mg. 6 -MP on 
alternate days was given which has controlled the 
leukaemic state up to the present time. When seen 
on September 5, 1955, the haemoglobin had risen to 
13.0 G. and the white cells were 15,800 per c.mm. 
The spleen was impalpable and his only complaint 
was a persistent pain in the right shoulder. 
Comment 
A male patient with chronic myeloid leukaemia 
after treatment with 6 -MP showed a fail in the 
leucocyte count, a disappearance of splenomegaly, 
and gradual rise in haemoglobin level. On 
maintenance therapy he continues to do well five 
months after the start of treatment. 
458. 
Case No. 41. 
A male aged 48 years was admitted to the 
Leeds General Infirmary on April 27, 1955, with a 
history of lassitude, dyspnoea on exertion and 
swelling of the ankles of six weeks' duration. 
On examination on admission he was found to 
be anaemic, the spleen was enlarged 4 cros. below 
the umbilicus and the liver 6 ems. below the right 
costal margin. A few shotty lymph glands were 
palpable in both inguinal regions. 
Blood examination gave the following results: 
haemoglobin 7.5 G., red cells 2,500,000 per c.mm., 
white cells 364,800 per c.mm., differential count: 
myelocytes 27 %, metamyelocytes 25%, polymorphs 515, 
lymphocytes 2%. 
A diagnosis of chronic myeloid leukaemia was 
made. 
Progress and Treatment (Fig. 48) 
6 -MP, 200 mg. daily, was started on April 30, 
1955. No change in the clinical or haematological 
state occurred during the next twelve days. On May 
12, the leucocytes had fallen to 118,400 per c.mm., 
but the haemoglobin was low at 7.3 G. and he was 
conseauently given a transfusion of packed red cell 
which raised the haemoglobin to 9.0 G. on May 16. 
By May 23, the leucocyte count was normal at 11,600 
Hb WBC 
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per c.mm. (polymorphs 83%, lymphocytes 15%, 
monocytes 2 %). The patient was not complaining, 
the liver was impalpable and the spleen had 
regressed considerably being now 3 ems. below 
the left costal margin. 67MP was reduced to 50 mg. 
daily on May 24 on which day he was discharged home 
When seen at the out- patient clinic on June 6, the 
haemoglobin had risen to 12.7 G., he was symptom 
free and had started to work again as a miner. 
Unfortunately, in spite of increasing the 
maintenance dose of 6 -MP to 100 and 50 mg. on 
alternate days the leucocyte count rose, he again 
became anaemic and the spleen increased in size. 
He had no complaints, however, and it was decided 
to continue 6 -MP therapy at doses of 100 to 150 mg. 
daily. An improvement followed and by July 7 the 
leucocytes had returned to normal. During the 
following three months he has worked only 
intermittently and a refractory anaemia has 
persisted, the highest haemoglobin level attained 
being 10.4 G Blood transfusions have been 
necessnry, but the leucocytes have remained within 
normal limits. 
Comment 
A 48 year old male patient with chronic 
myeloid leukaemia showed a poor response to 6 -MP 
461. 
therapy, The clinical evidence of the disease 
regressed and the leucocytes returned to normal, 
but a refractory anaemia persists five months 
aft..r treatment tiras begun. 
462. 
Case No. 42. 
A female, aged 58 years, was admitted to Leeds 
General Infirmary on February 4, 1954. A diagnosis 
of chronic myeloid leukaemia had been made one year 
previously. Improvement lasting two months had 
followed a course of deep x -ray treatment in April, 
1953, but another course of treatment in December, 
1953, had little effect on the patient's general 
health. Her main complaints now were dyspnoea on 
exertion, swelling of the ankles and abdomen, and 
loss of energy which had confined her to bed. 
On admission oedema of the ankles and sacrum 
was present, enlargement of the neck veins, massive 
enlargement of the spleen down to the pubis, and 
lymphadenopathy and the liver was palpable below 
the right costal margin. 
Blood examination was as follows: haemoglobin 
7.7 G., red cells 2,500,000 per c.iin., platelets 
110,000 per c.mm., white cells 10,000 per c.mm., 
differential white cell count:- myelocytes 22 %, 
polymorphs 22%, lymphocytes 21`,x, monocytes 9 %. The 
sternal bone marrow showed a preponderance of 
myeloid cells, 79.5% being of that series with 
14.1% lymphoid and 6.4% erythroid cells. 
Progress and Treatment 
Treatment with 6 -MP was begun on February 6 
463. 
and continued until February 17, a total dose of 
2.4 G. being given. The congestive heart failure 
responded gradually to treatment with digitalis, 
diuretics, etc. 6 -MP failed, however, to have the 
desired effect. A fall in the leucocytes first 
observed nine days after the start of treatment 
was associated with considerable reduction in size 
of the liver, spleen and lymph glands, but no 
improvement in her general condition occurred. 
She developed severe bed sores ?which healed very 
slowly, and the haemoglobin failed to rise 
necessitating repeated blood transfusions. As no 
further benefit from treatment was expected she was 
allowed to return home on April 14, 1954. Although 
6 -LIP therapy was not given after the initial course 
the leucocyte count remained extremely low. Two 
months after treatment was stopped, being only 
2,300 per c.=. On My 13, she was re- admitted 
with advanced congestive heart failure and died a 
few hours later. 
Post -mortem revealed the characteristic 
changes of chronic myeloid leukaemia and congestive 
heart failure. 
Coi,ment 
An adult female with chronic myeloid leukaemia 
who failed to improve after deep x -ray therapy also 
464. 
showed no benefit from treatment with 6 -I«P. A 
fall in the leucocyte count with diminution in size 
of the spleen, etc. occurred but her general 
condition was not affected and the haemoglobin 
failed to rise. The white cells, initially low, 
fell to a leucopenic level and failed to rise 
before discharge two months later. 
465. 
Case No. 43. 
A 69 year old male was admitted to the Leeds 
General Infirmary on December 3, 1953, with a 
history of dyspnoea on exertion of six months' 
duration, cough and recent haemoptysis. 
On admission there were signs of congestive 
heart failure, enlarged lymph glands were palpable 
in the neck and massive hepato- splenomegaly, the 
liver edge being 15 cms. below the right costal 
margin and the tip of spleen 26 cros. below the left 
costal margin. Purpura was present on the legs. 
The blood findings were typical of advanced 
chronic myeloid leukaemia: - haemoglobin 10.5 G., 
platelets 85,000 per c.mm., white cells 198,400 
Per c.nm . Differential white cell count: blast 
cells 14%, myelocytes 41%, metamyelocytes 19%, 
newt rophi l s 26%. 
Progress and Treatment 
200 mg. daily, was begun on December 5. 
On the evening of December 6, he suddenly collapsed 
and died a few hours later of a cerebro- vascular 
accident. Autopsy showed the presence of chronic 
myeloid leukaemia, a right anterior cerebral 
haemorrhage and a lung abscess situated in the 
right lower lobe. 
466. 
Comment 
A male aged 69 years with advanced chronic 
myeloid leukaemia died following a cerebral 
haemorrhage a day following the start of 6 -MP 
therapy. 
467. 
Case No. 44. 
An adult female, aged 56 years, was admitted 
to the Leeds General Infirmary on February 5, 1954, 
complaining of dyspnoea on exertion, palpitations 
and increasing pallor for six months. In October, 
1953, a diagnosis of chronic lymphatic leukaemia 
was made at another hospital, the leucocyte count 
at that time being 51,000 per c.mm. of which 92% 
were lymphocytes. In December, 1953, the haemoglob 
had fallen to 3.7 G. and a blood transfusion was 
given. A further transfusion was given in 
January, 1954. 
On admission she was found to be anaemic and 
numerous petichael haemorrhages were observed. 
Lymph glands were palpable in the cervical, axillar 
and inguinal regions. The spleen was enlarged 
10 cms. below the left costal margin. 
Blood examination gave the following findings: 
haemoglobin 10.2 G., red cells 3,500, .00 per c.mm., 
platelets 32,000 per c.rnm., white cells 70,200 per 
c.rrnn. Differential white cell count:- neutrophils 
4 %, lymphocytes 96 %. Bleeding time 102 minutes. 
Bone marrow examination showed:- lymphocytes 
94.8 %, blast cells 2.8 %, myeloid cells 2.4 %. No 
red cell precursors or megakaryocytes were seen. 
A diagnosis of chronic lymphatic leukaemia 
n 
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in the terminal stage was made. 
Progress and Treatment 
6 -MP, 200 mg. daily, was started on February 5 
and continued for nineteen days without any effect 
on the clinical or haematological picture. Repeate 
blood transfusions were necessary and latterly 
A.C.T.H., 25 mg. 6 hourly, intramuscularly, was 
given in addition without effect, other than 
reducing the leucocyte count from 76,800 per c.mm. 
on February 19 to 17,600 per c.mm. three days later 
The patient died on February 24 and post- mortem 
revealed findings characteristic of chronic 
lymphatic 1eukaemia. 
Comment 
A total dose of 3.8 G., 6 -LP, given over a 
period of nineteen days to a patient with advanced 
chronic lymphatic leukaemia, failed to produce any 
clinical or haematological improvement. 
469. 
Case No. 45. 
A female, aged 73 years, was admitted to the 
Leeds General Infirmary on December 3, 1953, with 
a history of pain across the front of the chest, 
cough, dysDnoea and sweating cf two days duration. 
OA admission the temperature was 101.4 °P., 
and signs of consolidation were present over the 
right upper chest. The spleen was enlarged 2 cms. 
below the left costal margin, and lymph glands 
were palpable in the cervical and inguinal regions. 
A radiograph of the chest showed evidence of 
consolidation of the uïmer lobe of the right lung 
in keeping with lobar pneumonia. 
Blood examination gave the following results: 
haemoglobin 15.3 G., red cells 4,900,000 per c.mm., 
platelets 170,000 per c.mm., white cells 24,000 
per c.mm. Differential white cell count: - 
polymorphonuclear cells 11%, lymphocytes 89%. 
Sternal bone marrow showed 55.8% lymphocytes, 
35.8% myeloid cells, 8.4;x, erythroid cells and other 
cell types 0.8%. 
A diagnosis of chronic lymphatic leukaemia 
was also made. 
Progress and Treatment 
Penicillin rapidly controlled the pneumonic 
process. In view of a rising leucocyte count 
(51,200 per c.rnm.) and falling haemoglobin (12.2 G. 
470. 
it was decided to try the effect of 6 -MP, starting 
on December 11. A total dose of 3.8 G. was given 
which failed to produce any improvement in the 
distribution of leucocytes in the peripheral blood, 
the splenomegaly remained unchanged and the 
lymphadenopathy persisted. The leucocytes fell 
to 12,400 per c.mm. by December 31, but over 90% 
were lymphocytes, and as the count remained around 
20,000 per c.mm. during the following five months, 
without further treatment, it seemed likely that 
the initial rise may have been associated in some 
way with the infection and the fall not due to 
6 -MP but a consequence of the clearing of the 
pneumonic process. 
It was decided in view of the patientts 
excellent condition not to press further treatment 
and possibly produce complications due to bone 
marrow depression. 
Comment 
A case of chronic lymphatic leukaemia failed 
to show any haematological or clinical improvement 
when treated with 6 -MP. 
471. 
Case No. 46. 
A 63 year old female was admitted to St. 
James's Hospital, Leeds, on January 19, 1954, with 
a history of back pain of ten months' duration. 
For six months she had noticed a lump on the head 
which was gradually increasing in size. 
On admission she was found to be anaemic and 
a large soft swelling, 7.5 cms. in diameter, was 
present over the left parietal region. There was 
no splenomegaly or lymphadenopathy. 
Blood examination gave the following findings: 
haemoglobin 7.4 G., red cells 2,370,000 per c.nim., 
white cells 5,400 per c.r_un. (oolymorphs 50%, 
lynx hocytes 41%, monocytes 9 %) , platelets 295,000 
per c.rul. 
Sternal bone marrow showed a preponderance 
of plasma cells. 
Other investigations were as follows: B.S.R. 
(westergren) 150 in 1 hour, plasma proteins 11.9 G. 
(Alb. 4.25 G., Glob. 7.65 G.%), alkaline 
phosphatase 5.5 units. X -ray of skeleton showed 
generalised decalcification and also punched out 
areas in keeping with a diagnosis of multiple 
myelomatosis. 
Progress and Treatment 
Treatment with 6 -MP, 200 mg. daily, was begun 
on January 23, 1954. Thereafter weekly clinical, 
aematological and biochemical examinations were 
erformed. No improvement occurred and she died on 
ebruary 14, 1954, after three weeks' treatment. 
Comment 
A case of multiple myeloma failed to show any 
clinical, haematological or biochemical improvement 
after three weeks' treatment with 6 -MP. 
473. 
Case No. 47. 
A female aged 64 years was admitted to an 
orthopaedic ward at St. James's Hospital, Leeds, on 
January 8, 1954, with a history of recurrent pain 
in the lurrbar- sacral region and left sciatica of 
sixteen months duration. 
On admission there was evidence of dorso- 
lumbar kyphosis, wasting of the left thigh and 
calf muscles and an absent left ankle jerk. The 
temperature was 98.6 °F. and she was anaemic. There 
was no splenomegaly. 
Blood examination gave the following findings: 
haemoglobin 8.1 G., red cells 2,700,000 per c.mm., 
platelets 200,000 per c.mm., white cells 5,000 per 
c.mm. (poll morphs 65%, lymphocytes 32%, monocytes 
3%) . The sternal bone marrow showed the presence 
of 30% plasma cells, many of which appeared 
immature. Other investigations included: x -ray of 
skull, which showed multiple punched out areas; 
-Plasma proteins 12 G. (Alb. 3.2 G.%, Glob. 8.8 G. %; 
urine - negative for Bence -Jones proteose; 
alkaline Dhosphatase 5.0 units; E.S.R. (westergren; 
10 mm. in 1 hour. 
Apart from the inexplicably low E.S.R. the 
findings were characteristic of multiple 
myelomatosis. 
474. 
Progress and Treatment 
It was decided to try the effect of 6 -MP and 
treatment was begun on January 26, 1954, a dose of 
200 mg. daily being prescribed. Thereafter 
clinical e..amination and a conrr31ete haematological 
and biochemical investigation was carried out at 
weekly intervals. No improvement occurred. 
Definite evidence of depression of marrow function 
was observed and on February 17 the peripheral 
blood picture was as follows: haemoglobin 4.2 G., 
white cells 2,200 per c.mn. , platelets 96,000 per 
c.rmn. Irrespective of blood transfusions, the 
patient rapidly went downhill andafter developing 
purpura died on February 21, 1954. 
Comment 
A case of multiple myeloma showing no 
response to 6 -MP therapy. Profound depression of 
marrow function occurred and jeath occurred one 
month after starting treatment. 
475. 
Case No. 46. 
A 32 year old male was admitted to the Leeds 
General Infirmary on July 11, 1955, with a history 
of recurrent pain in the left shoulder and loss of 
energy of four months duration. 
On admission his colour was good, and the 
temperature was normal. The lower pole of the 
spleen was palpable one inch below the umbilicus 
and the right border extended across the mid -line. 
There was no hepatomegaly, but a few enlarged 
lymph glands were present in the inguinal and 
axillary regions. 
Blood examination gave the following results: 
haemoglobin 11.5 G., red cells 4,200,000 per c.mm., 
white cells 262,400 per c.mm. A blood film showed 
numerous myelocytes and metamyelocytes. 
A diagnosis of chronic myeloid leukaemia was 
made. 
Progress and Treatment 
6-MP, 200 mg. daily, was begun on the day of 
admission. No response occurred for fourteen days 
when the leucocyte count fell to '73,600 per c.l m. 
He was feeling well and was discharged on a 
maintenance dose of 100 mg. 6-MP daily. When seen 
at the out- patient clinic on August 12, after one 
month's treatment, the leucocyte count had fallen 
476. 
to 23,400 per c.rnm., but by September 5, the 
count had risen to approximately 100,0)0 per c.mm., 
and the spleen extended to the umbilicus, and he 
was feeling depressed. Thereafter a maintenance 
dose of 100 mg. and 150 mg. 6 -MP on alternate days 
was given. With this regime he has been maintained 
in good health. The spleen became much smaller, 
the haemoglobin rose and he has had no further 
pain. The leucocytes have been consistently above 
normal, but in view of his good general health no 
attempt to inhibit the leukaemia process further 
was considered advisable. 
When last seen on November 28, 1955, four and 
a half months after the start of treatment he was 
well and doing a full day's work. The haemoglobin 
was 13.5 G. and the leucocyte count 32,000 per 
c . mm. 
Comment 
A patient with chronic myeloid leukaemia 
showed a satisfactory response to 6 -MP therapy. 
The symptoms cleared, the leucocyte count fell, 
the haemoglobin level rose and the spleen became 
smaller following treatment. 
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CASE RECORD NUMBERS 
CASE NUMBER HOSPITAL RECORD NUMBER 
1 LEEDS GENERAL 276510 
INFIRMARY 
2. do. 305675 
3. WAKEFIELD GENERAL 34752 
INFIRMARY 
4. do. 33962 
5. ST. JAMES' 55/001434 
LEEDS 
6. SEACROFT 556686 
LEEDS 
7. ST. JAMES' 53/8231 
LEEDS 
8. LEMS GENERAL 30806 
INFIRJ ÏARY 
9. do 308384 
10. do. 313659 
11. PONTEFRACT GENERAL M 30771 
INFIRMARY 
12. LEEDS GENERAL 334809 
INFIRMARY 
13. PONTEFRACT GENERAL M 28791 
INFIRM,'íARY 
14. LEEDS GENERAL 341725 
INFIRMARY 
15. do. 258234 
16. ST. JAMES' 53/18002 
LEMS 
17. do. 54/1891 
18. LEMS GENERAL 301556 
INFIRïáIARY 
19 WAKEFIELD GENERAL 33138 
INFIRMARY 
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23. do. 55/6149 
24. do. 53/13736 
25. LE DS GENERAL 301789 
INFIRMARY 
26. do. 309887 
27. ST. LUKE'S 54/15417 
BRADFORD 
28. do. 51/5379 
29. LEEDS GEN MAL 117672 
INFIRMARY 
30. do. 283611 
31. ST. JAMES' 54/011200 
LEEDS 
32. LEEDS GENERAL 304911 
INFIRMARY 
33. do. 177864 
34. do. 340973 
35. do. 338231 
36. ST. JAMES' 53/17797 
LEEDS 
37. LEEDS GENERAL 227067 
INFIRMARY 
38. ST. JAMES' 55/4249 
LEEDS 
39. LEMS GENERAL 285586 
INF I RMARY 
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CASE NUMBER HOSPITAL RECORD NUMBER 
40. LEEDS GENERAL 
INFIRMARY 
253676 
41. do. 347511 
42. do. 270808 
43. do. 304902 
44. do. 303547 
45. do. 296747 
46. ST. JAMES' 53/16145 
LEEDS 
47. do. 54/408 
48. LEEDS GENERAL 360624 
INFIRMARY 
49. do. 289506 
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